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Abstract
Tumour metastasis represents the most lethal aspect o f  cancer. It involves initial attachment of 
cells to the extracellular matrix (ECM), degradation o f the ECM and subsequent migration and 
detachment o f cells from the ECM. This process depends on alterations in the expression of many key 
players including cell adhesion molecules (CAM s) and proteolytic enzymes such as the matrix 
metalloproteinases (MMPs). The MMPs are a large family o f proteases collectively capable of degrading 
the entire ECM. CD44 is a multifunctional transmembrane adhesion molecule, which also plays a key 
role in cell signalling. The interactions between CAMs and MMPs are crucial therefore in controlling 
tumour cell invasion and metastasis and this study aimed to elucidate these interactions.
W e have established a panel o f human colon cancer cell lines including a primary human colon 
adenocarcinoma cell line SW 480 and its lymph node metastatic derivative, SW 620. The SW 480 cells 
have been stably transfected with the cD N A  for MMP-7 (SW 480M 7) and MMP-9 (SW 480M 9). When 
the in vitro invasive activities o f the cell lines were compared, the SW 620 cells and the MMP transfected 
cells were more invasive than their parental SW 480. The SW 480M7 cells were more migratory in 
comparison to SW 480 cells and interestingly, the SW 620 were less migratory. MMP-9 expression 
increased when the SW 480M 9 cells were grown on H A and collagen. In addition, SW 480M 9 cells 
cultured in the presence o f a CD44 activating antibody resulted in a time dependent increase in MMP-9 
activity and increased invasion. The SW 480M 9 cells were shown to be the most adherent to plastic, HA  
and fibronectin and the SW 480M 7 were slightly less adherent. The increased HA adhesion in the 
SW 480M 9 correlated with increased 80kDa and 120kDa CD44 expression.
cD N A  microarray analysis was used to identify additional metastasis associated genes by 
examining and comparing differential gene expression profiles in these cell lines Analysis o f gene 
expression data revealed that 233 genes were significantly up regulated and 208 genes were down 
regulated in the SW 620 when compared to the SW 480. Over expression o f MMP-7 and MMP-9 in the 
SW 480 cells also caused differential expression. Following literature searches on the gene lists, 5 genes 
of biological interest were chosen for further analysis and validation. Selected genes were the cysteine 
protease, cathepsin C, caveolin 1, the nuclear receptor, peroxisome proliferative activated protein gamma 
(PPARy), the ECM component tenascin C and asparagine synthetase. These clones were sequenced from 
the cD N A  library to verify their identities and real time PCR analysis confirmed the fold changes in 
expression. Using a fluorescent assay, enhanced cathepsin C enzymatic activity in the SW 620 cells was 
confirmed. A  PCR-based method was also used to monitor the expression profiles o f particular 
alternatively spliced tenascin C isoforms in the cell lines studied. An initial pilot study was conducted to 
examine expression o f  these genes in matched samples o f normal and tumour colon tissue. RNA was 
extracted from tissues o f varying Dukes’ classification and expression was examined by real time PCR.
This study identified potential new biomarkers o f colorectal metastasis, and examined the 
involvement o f  many key players in this process. This study demonstrated that interactions between 
CD44 and MMPs were important in controlling tumour cell invasion. It is hoped that this work will help 
elucidate the exact mechanisms o f  such interactions as well as highlighting their importance in the 
metastatic process. Further study on these biomarkers and interactions would validate their use as novel 
markers and therapeutic targets in metastatic colorectal disease.
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Chapter 1
An introduction to tumour invasion and metastasis
1.1 Tumour invasion and metastasis
Metastasis represents the most lethal aspect of cancer and is the cause of 90 % of 
cancer deaths (Hanahan and Weinberg, 2000). This is usually because it is difficult to 
treat patients when the cancer is at this late stage. The metastatic spread of cancer cells 
from their site of origin enables them to escape the primary tumour mass and colonise 
new terrain in the body. Figure 1.1 gives a graphical representation of the overall 
process. Metastasis is a multi-step process that involves local area invasion at the 
primary site, followed by intravasation of tumour cells to either the blood or lymphatic 
vessels, thus accessing the general circulation. After circulating in the vascular systems, 
tumour cells arrest and extravasate at distant organs where they establish secondary 
tumours.
PRIMARY
TUMOUR METASTASES
Intravasation Extravasation
Figure 1.1 The multistage process of metastasis. (Figure adapted from 
w w w .m a.h w .ac .u k /~ tea / research.htm l. 17 September 2004)
The process of metastasis therefore involves the participation of numerous 
biomolecules in a variety of intricate cellular functions including altered cell adhesion, 
proteolysis and migration. It is not clear how the cancer cell coordinates these events 
but it is clear that the components of the tumour microenvironment are involved in 
contributing to tumour cell progression (Lynch and Matrisian, 2002). Apparently, 
normal bystanders such as fibroblasts and endothelial cells are conscripted by cancer 
cells to serve as active collaborators in their neoplastic agenda.
Groups of certain key players are involved in the main events of metastasis. 
These include the extracellular matrix (ECM), the cell adhesion molecules (CAMs) and 
proteolytic enzymes such as the matrix metalloproteinases (MMPs) (Bogenrieder and
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Herlyn, 2003). Figure 1.2 illustrates how these molecules are employed in the 
molecular mechanisms of tumour metastasis. These key players are implicated at 
almost every stage in the metastatic cascade. It is clear these groups of biomolecules 
have roles in metastasis but quite what these roles are, remains unclear. This chapter 
will introduce these key players.
A T T A C H M E N T
Tumour Cell 
Endothelium
{  Basement
MembraneP R O T E O L Y S IS
v & -
Secretion of ECM 
degrading 
enzymes
M IG R A T IO N
'X _x-
Figure 1.2 K ey even ts in  tum our c e ll in vasion . B efore tum our ce lls  breech the 
b asem en t m em brane they m ust first adhere to  and degrade the E C M  prior to their 
m igration  and intravasation into the circulation . (F igure adapted from
w w w .m a .h w .a c .u k /~ tea / research .htm l. 17 Septem ber 2 0 0 4 )
1.2 The extracellular matrix
Most cells in multi-cellular organisms are in intimate and often in 
permanent contact with either the surface of other cells or with the complex networks of 
structural macromolecules, termed the ECM. The ECM is an insoluble non-cellular 
material present between cells throughout the body of multi-cellular organisms. This 
extracellular superstructure is composed of a complex mixture of secreted molecules 
(Ruoslahti, 1996). The principal components of the ECM are; glycoprotcins, such as 
collagen IV, laminin, fibronectin, proteoglycans and glycosaminoglycans, such as 
hyaluronic acid (HA). These molecules assemble into the extracellular matrix once 
secreted.
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There are three major functions of the ECM. Firstly, it provides structural 
support and tensile strength. Secondly, it provides substrates for cell adhesion and cell 
migration. Thirdly, the ECM is a functional microenvironment that regulates cellular 
differentiation and metabolic function, for example by modulation of cell growth by 
binding growth factors (Park et al., 2000). The ECM is therefore no longer solely 
thought of as a static structural support for cells. The ECM plays a key role in 
maintaining normal tissue homeostasis between epithelial cells and their 
microenvironment and neighbouring cells, such as fibroblasts and endothelial cells. 
ECM-cell interactions trigger signalling cascades with broad affects on a variety of 
cellular functions including survival, differentiation and proliferation (Giancotti and 
Ruoslahti, 1999). The ECM also provides mechanical support for the migration of 
tumour cells. Furthermore, during tumour invasion soluble ECM proteins released due 
to their cleavage by proteolytic enzymes can stimulate cell migration. Matrix proteins 
such as fibronectin, collagen (type 1 and IV) and vitronectin have been shown to induce 
motility (Woodhouse et al., 1997).
1.3 Cell adhesion molecules in metastasis
A key group of biomolecules that participate in metastasis are the 
proteins involved in linking cells to each other and to their surroundings. The adhesive 
interactions of cells with their immediate environment are mediated by the receptor- 
ligand interactions of plasma membrane proteins termed CAMs. CAMs are a limited 
number of gene families including the integrins, the immunoglobulin superfamily, 
cadherins and selectins (Figure 1.3) (Rosales et al., 1995). Additional membrane 
components include syndecans and the CD44 protein. For the purpose of this study, 
only the integrins and CD44 will be discussed further in this chapter.
Interactions between the ECM and CAMs are key to tumour invasion and 
metastasis. Normal ECM-CAM interactions become deregulated during the metastatic 
process (Zetter, 1993). Throughout the entire metastatic cascade the tumour cells must 
undergo changes in adhesive preferences (i.e. from epithelial cells to endothelial cells to 
fibroblasts etc). These changes are dictated by specific interactions with the ECM and 
are caused by changes in CAM expression. Changes in adhesion interactions result in 
changes in the regulatory signals normally conveyed to the cells by the affected 
adhesion molecules.
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CadtViflns Ig Superfamlly Selecting Integrins
Figure 1.3 Structure o f  adhesion  receptor fam ilies . T h is figure sh ow s the general 
structures for the 4  m ajor C A M  fam ilies . Cadherins have 5 extracellu lar (EC ) sites  
and they interact w ith  caten in s v ia  their cy top lasm ic tail. There are m any m em bers 
in the Ig  superfam ily , all o f  w hich  share an im m u n oglobu lin  dom ain . S e lectin s are 
characterised by their short cy top lasm ic tail and E G F -lik e repeats. Integrins are 
h eterodim eric receptors con sistin g  o f  on e a  and on e P subunit linked non- 
cova len tly . A s  w ell as c e ll  -  c e ll in teractions, in tegrins are the m ain C A M  fam ily  
in v o lv ed  in c e ll-E C M  interactions. Integrins interact w ith  talin, a -actin in  and foca l 
ad hesion  k inase (F A K ) v ia  their cy top lasm ic tails. (A dapted  from  R osa les e t al.,
1995)
1.3.1 Integrins
The integrins are one of the major CAM families and it is only 17 years since 
they have been recognised as such (Hynes, 1987). Integrins are a group of at least 24 
bifunctional heterodimeric cell-surface glycoproteins formed by non-covalent binding 
of one of 18 a and one of 8 P subunits. Each subunit has a large extracellular domain 
(-1600 amino acids), a single membrane spanning region, and in most cases (apart from 
P4), a short cytoplasmic domain (20-50 amino acids) (Ruoslahti, 1991). Integrins act as 
receptors for ECM proteins, or for membrane bound counter-receptors on other cells.
Up to 24 integrin dimers have been found in nature, indicating that not all 
subunits can bind to each other (Hynes, 2002). Each integrin dimer has distinct ligand 
binding and signalling properties. The possible integrins are illustrated in figure 1.4. 
The pi integrin subunit can heterodimerise with 12 a subunits each with different ligand
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affinities, suggesting that the a subunits are involved with the ligand binding 
specificities of integrins. For example, in the pi-subunit ‘sub’-family, four integrins 
(a ip i, a2pi, a l ip i  and alOpi) bind collagens, five (a4pi, a5pi, a8pi, a9pi and 
aVpi) bind fibronectin and five (a ip i, a2pi, a3pl, a6pi, and a7pi) bind laminins 
(Humphries, 2000). Therefore, an individual integrin can recognize several distinct 
ECM proteins.
Figure 1.4 The Integrin Receptor Family. This figure illustrates integrin aP 
subunit associations, where 8 p subunits can assort with 18 a subunits to form 24 
distinct integrins that are considered in several subfamilies based on evolutionary 
relationships (colouring of a subunits), ligand specificity and, in the case of p2 and 
P7 integrins, restricted expression on white blood cells. This illustrates how the P4 
subunit can only bind with the a6 subunit. On the other hand, the P1 subunit can 
form heterodimers with 12 different alpha subunits. Asterisks denote alternatively 
spliced cytoplasmic domains. Figure adapted from (Hynes, 2002).
Integrins are involved in cell-cell and cell-matrix adhesion interactions. It is 
mainly via integrins that cells bind to and respond to the ECM. Successful binding to 
specific moieties of the ECM enables integrin-mediated transduction of signals into the 
cytoplasm that influence cell behaviour ranging from quiescence in normal tissue to 
motility, resistance to apoptosis and entrance into the active cell cycle. As well as a 
variation in adhesive properties, each integrin dimer also has unique biological 
functions and transduces different signals. Failure of integrins to form extracellular 
links can impair cell motility, induce apoptosis or cause cell cycle arrest. The roles of 
integrins in tumour cell progression are therefore immense and they are therefore prime 
targets for the development of therapeutic agents (Juliano and Varner, 1993).
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1.3.1.1 Integrin mediated signalling
In addition to their roles in adhesion to ECM ligands or counter-receptors on 
adjacent cells, integrins serve as transmembrane mechanical links from those 
extracellular contacts to the cytoskeleton inside cells. Integrin-ligand interactions are 
accompanied by the transduction of signals into intracellular signal transduction 
pathways mediating numerous intracellular events including proliferation, 
survival/apoptosis, changes in cell shape, motility, gene expression and differentiation 
(Schwartz, 1992). These signalling pathways are very similar to those emanating from 
growth factor receptors and some are coupled with them. In fact, the transduction of 
many growth factor and cytokine signals via their respective cell surface receptors is 
dependent on the anchorage of cells via the integrins (Schwartz et al., 1995). Some 
integrin-mediated signals are essential for cell survival. For example, integrin 
signalling via the PI3-kinase pathway is essential to block apoptosis and pi-containing 
integrin-ligand binding results in activation of the mitogen activated protein kinase 
(MAPK) pathway; also integrin signalling via ERK is essential for the stimulation of 
cell cycle progression (Morino et al., 1995). It is common in cancers for the control of 
these important pathways such as those that control cell proliferation to be lost, 
ultimately leading to uncontrolled growth.
1.3.2 CD44
Another cell adhesion molecule of interest to this study is CD44, a 
transmembrane glycoprotein expressed on the surface of a wide variety of cells that 
carries N- and O-linked sugars and glycosaminoglycan side chains. CD44 is the major 
cell surface receptor for HA in the ECM (Picker et al., 1989 and Ponta et al., 1998). 
CD44 is a multifunctional polymorphic cell adhesion molecule with proposed functions 
in adhesion, latent growth factor activation, invasion and migration (Lesley et al., 
1993).
1.3.2.1 CD44 structure
Ten exons of the CD44 mRNA are subject to alternative splicing (Figure 1.5), 
thus, generating different isoforms, containing inserts of varying sizes in the 
extracellular portion of the molecule (CD44 variants). It has been estimated that 45
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CD44 isoforms exist as a result of this alternative splicing (van Weering et al., 1993). 
The smallest and most common CD44 isoform, known as standard CD44 or CD44s, 
lacks any of the 10 variant exons and has a 248 amino acid extracellular domain with an 
apparent molecular weight of 80 kDa. The larger CD44 variants (CD44v) are similar to 
CD44s except they have sequences selected from the exons vl-vlO. The ‘stem’ 
structure is therefore enlarged by sequences that are encoded by the alternatively spliced 
variant exons. CD44 isoforms are also subject to such post-translational modifications 
such as glycosylations with the addition of O- and N- linked carbohydrates. The 
sequence encoded by exon v3 includes a heparin-sulphate site, a modification to which 
several heparin-binding proteins such as growth factors can attach (Yu et al., 2002).
Variant
Transcripts
TM
Variant u i «2 «a y i us y6 «7 na »9 mo I
E x o n -  1 2 3 4 5 5a 6 7 3 9 10 11 12 1314 15 16 17 1819
inooooooaaaH ooiiia
r v m __________a w ji
VWffL______
M w n _ _ _ _ _ i i u r o u u ]
WiJL_jroL_-JWJ]
Standard 
Forms 
(CD 44s)
CD44V7-10
CD44v 4-7
CD44v3,v 8-10
Figure 1.5 CD44 alternative splicing. Ten CD44 exons (vl to vlO) can be 
alternatively spliced giving rise to CD44 isoforms (CD44v) of varying structures 
and properties. None of these are expressed in standard CD44 (CD44s). TM - 
Transmembrane Domain. Figure adapted from Ponta et al., 1998.
All CD44 isoforms share highly conserved transmembrane (23 hydrophobic 
amino acids) and cytoplasmic (72 amino acids) domains (Isacke and Yarwood, 2002). 
CD44 binds hyaluronic acid through an amino terminal globular domain (Bajorath et 
al., 1998), which is separated from the plasma membrane by a ‘stem’ structure that 
contains proteolytic cleavage sites (Cichy and Pure, 2003 and Okamoto et al., 1999) 
(Figure 1.6).
Little is known about the mechanisms controlling the alternative splicing of 
CD44, but they are precisely regulated, with particular isoforms being expressed in
particular cell types and quite often a variety of isoforms exist within the same cell. 
Abnormal patterns and levels of variant CD44 expression are frequently associated with 
malignancy and are thought to represent a breakdown in this regulation (Gunthert et a l,  
1991 and Wielenga et al., 1998). CD44 and its splice variants are therefore often used 
as prognostic markers of tumour progression.
. rfh © Glycosaminoglycan addition
P h o s p h o ra te d  s e r in e s ^ -  N .,inkedcarbohyclrate acldition
^  161 O-linked carbohydrate addition
Figure 1.6 CD44 protein structure showing the HA binding domain and sites of 
glycosylation. Adapted from Ponta et al., 1998.
1.3.2.2 CD44 functions and signalling
The functions of CD44 are exerted through the ligation of HA in the ECM. 
CD44 has a variety of other ligands due to its various isoforms, these include 
fibronectin, laminin and collagen type I and IV (Naor et al., 1997). Phosphorylation at 
internal serine residues suggests a role for CD44 in signal transduction (Lesley et al, 
1993). The cytoplasmic tail of CD44 has been shown to interact with the actin 
cytoskeleton through association with the ERM (ezrin, radixin, moesin) family of 
adaptor proteins (Tsukita et al., 1994). ERM proteins function as molecular linkers 
between the plasma membrane and the actin cytoskeleton, and as such, have been 
implicated in a number of key physiological and pathological processes that involve 
cytoskeletal and membrane remodelling. These include cell-cell and cell-matrix 
adhesion interactions, cell motility, oncogenesis and apoptosis (Bretscher et al., 2002 
and Martin et al., 2003).
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1.4 The matrix metalloproteinases
The Matrix Metalloproteinases (MMPs) constitute a multigene family of over 
23 structurally and functionally related secreted and membrane bound proteolytic 
enzymes. The MMPs are endopeptidases that process a wide range of pericellular 
substrates and they are primarily distinguished from other classes of proteinases by their 
dependence on a zinc ion for activity. Other distinguishing parameters associated with 
the MMPs include the requirement for pro-domain cleavage for enzyme activation and 
the inhibition of their enzymatic activity by the tissue inhibitors of metalloproteinases 
(TIMPs) (Nagase and Woesner, 1999 and McCawley and Matrisian, 2001). Inactive 
pro-MMPs are secreted as latent zymogens and their activation occurs extracellularly. 
Most MMPs are secreted but six contain transmembrane domains and are expressed as 
cell surface molecules. Included in the wide range of targets of MMP activity are ECM 
proteins, cell adhesion molecules and cell surface receptors. Collectively the MMPs are 
capable of degrading the components of the entire ECM.
ECM homeostasis is key to maintaining normal cellular function and the MMPs 
can therefore be described as modulators of cell function. ECM breakdown and 
remodelling are essential for many normal biological processes (e.g. embryonic 
development, blastocyte implantation, organ morphogenesis, nerve growth, ovulation, 
hair follicle cycling, bone remodelling, wound healing, apoptosis etc.) and pathological 
processes (e.g. arthritis and cancer). MMP degradation of ECM proteins regulates the 
behaviour of cells by allowing cells to interact with their immediate surroundings. 
Several other ways MMPs regulate cell behaviour include the activation of latent 
growth factors or other proteinases or through the cleavage of cell surface molecules 
(McCawley and Matrisian, 2001 and Lynch and Matrisian, 2002).
1.4.1 MMP structure and function
Each of the 23 members of the MMP family has distinct and often overlapping 
substrate specifities, however together the MMPs can degrade the entire ECM. Eight 
primary MMP structures exist all of which share several domain motifs. These shared 
stretches of sequence homology give the MMP family a somewhat conserved overall 
structure (Stocker et al., 1995). These include a zinc-binding motif, a ‘Met turn’ and a
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“Cysteine Switch”. MMPs are therefore often grouped according to their modular 
domain structure (Figure 1.7).
SH
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PRO CAT Zn
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Pre PRO CAT zn H HEM
SH
| s-— s
Pre PRO F CAT Zn H HEM
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SH
s— s
Pre PRO F CAT 2n H HEM GP.I
Pre PRO F 1 CAT Zn CA 19
SH
1 s — s
Pre PRO CAT FN FN FN CAT Zi: H HEM
SH
i s-— S
Pre PRO CAT FN FN FN CAT Zr. CL H HEMH
Figure 1.7 The MMP Domain Structures. (A) Minimal domain MMPs, e.g. MMP- 
7/matrilysin and MMP-26. (B) Simple hemopexin domain-containing MMPs, e.g. 
MMP-1, -8, -13, -3, -10, -12, -20, -19 and MMP-27. (C) Furin-activated MMPs, e.g. 
MMP-11 and MMP-28. (D) Transmembrane MMPs, e.g. MMP-14, -15, -16 and 
MMP-24. (E) GPI-linked MMPs, e.g. MMP-17 and MMP-25. (F) Immunoglobulin­
like domain-containing MMPs, e.g. MMP-23. (G) and (H) Gelatin-binding MMPs, 
MMP-2/gelatinase A and MMP-9/gelatinase B respectively. Pre: leader/signal 
sequence, PRO: propeptide-domain with zinc-ligating thiol (SH) group, CA: cysteine 
array, CAT: catalytic domain, TM: transmembrane domain, Zn: zinc binding site, Ig: 
immunoglobulin-like domain, F: furin cleavage consensus sequence, FN: fibronectin 
type II inserts, H: hinge domain, CL: collagen-like domain, GPI: glycosyl 
phosphatidylinositol linkage signal, HEM: hemopexin domain. The hemopexin 
domain contains four repeats with the first and last joined by a disulfide bond (S-S). 
Adapted from (Brinckerhoff and Matrisian 2002).
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MMP-7 (matrilysin) and MMP-26 (endometase, matrilysin-2) are the simplest 
and smallest members of the MMP family (Figure 1.7), containing only the minimum 
number of domains required for secretion and activity. It was originally thought that 
MMP-7 represented the primordial form of MMP and additional domains were added 
by exon shuffling (Matrisian, 1992). However, an extensive analysis of the sequences 
and structures of the MMP family indicates that the assembly of the catalytic and 
hemopexin domains into multidomain enzymes was an early evolutionary event, 
suggesting that the simpler MMPs such as MMP-7 might have arisen from larger 
complexes (Massova, et al., 1998).
All MMPs have an N-terminal pre-domain, which directs their synthesis to the 
endoplasmic reticulum after which it is removed from the zymogen. Following the pre­
domain is a pro-peptide domain which has a conserved and unique sequence; Pro-Arg- 
Cys-Gly-(Val/Asn)-Pro-Asp. The cysteine residue within this sequence ligates the 
catalytic zinc, maintaining latency in pro-MMPs. It is only when the Cys-Zn2+ 
interaction is disrupted and the pro domain is subsequently removed that the MMP 
becomes active. This mechanism of activation is known as the ‘Cysteine Switch’ 
(Becker et al., 1995) and it produces active forms with lower molecular weights 
(Springman et al., 1990 and Birkedal-Hansen et al., 1993). The catalytic domain 
contains a zinc binding motif; His-Glu-X-X-His-X-X-Gly-X-X-His (where X represents 
any amino acid), and it also contains a conserved methionine residue which forms a 
distinct ‘Met turn’ structure (Nagase and Woessner, 1999 and Bode et al., 1993). The 
binding of Zn2+ to the metal binding site in the catalytic domain is essential for 
proteolytic activity (and explains the word ‘metallo’ in the name). Substrate and 
cleavage site specificity are mostly dictated by the catalytic domain as well as binding 
sites termed exosites located outside the catalytic domain (Overall, 2002). The 
understanding of the catalytic site structure is used in the design of drugs that inhibit 
MMPs.
As seen in figure 1.7, MMP-2 and MMP-9 (gelatinase A and B, respectively) 
have three cysteine rich fibronectin-type II repeats within the catalytic domain, which 
interact with collagens and gelatins (Allan et al., 1995 and Steffensen et al., 1995). 
MMP-9 has a unique type V collagen like insert at the end of its hinge region and its 
function is unknown. Figure 1.7 also shows domain compositions B, C, G and H to 
have a C-terminal hemopexin domain, which is joined to the catalytic domain via a
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hinge region. Though the function of this linker hinge region is unknown, it has been 
shown to be proline rich and using molecular modelling techniques, it has been 
hypothesised that it interacts with triple helical collagen (de Souza et al., 1996). All 
MMPs, with the exception of MMP-7 and MMP-26 contain a hemopexin domain which 
is also an absolute requirement for collagenases to cleave triple helical interstitial 
collagens, otherwise proteolytic activity can only occur via the catalytic domain on non­
collagen substrates (Clark and Cawston, 1989). The hemopexin domain also influences 
TIMP binding.
The membrane type matrix metalloproteinases (MT-MMPs) are comprised of 6 
family members. The first MT-MMP cDNA (MT1-MMP/MMP-14) to be cloned 
encoded a protein of 63 kDa with a transmembrane domain and was later identified as a 
specific activator of pro-MMP-2 (Sato et al., 1994). MT-MMPs contain a C-terminal 
hydrophobic stretch (transmembrane sequence or GPI anchor) that anchors the enzyme 
to the plasma membrane thus restricting its activity to the cell surface. MT-MMPs have 
varied substrate specificity and are capable of degrading fibronectin, laminins, and 
collagen types I, II and HI. Expression of MT1-MMP cDNA in MDCK epithelial 
kidney cells gave rise to enhanced cellular invasion through reconstituted basement 
membrane in vitro (Hotary et al., 2000). Five other MT-MMPs have since been 
identified and all six are listed in Table 1.1.
1.4.2 MMP substrates
Together, the MMP family can degrade all the components of the ECM. Each 
MMP has a unique yet slightly overlapping substrate specificity (Table 1.1). The 
MMPs are classified with respect to their protein domain characteristics but they were 
once classed into three subclasses according to their substrate specificity: 1) type I 
collagenases, 2) type IV collagenases and 3) stromelysins. Numerous MMP substrates 
have been tested and identified in vitro (Woessner and Nagase, 2000).
In addition to ECM components, MMPs can also cleave the pro-forms of other 
MMPs, and can activate and release latent and embedded growth factors. For example, 
MT1-MMP can activate pro-MMP-2 and MMP-9 has been shown to activate latent 
TGF-P (Sato et al., 1994 and Yu and Stamankovic, 2000) thus stimulating angiogenesis 
and invasion. These wider roles for MMPs are often implicated in malignant tumours.
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Table 1.1 Properties of the human matrix metalloproteinase family.
M M P Domain Enzym e Nam e M W k D a
(latent)
M W  kDa 
(active)
Substrates Activation o f other 
MMPs
M IN IM AL
M MP-7 M atrilysin, Pump-1, 28 19 Proteoglycans, laminin, fibronectin, 
gelatins, collagen IV, elastin, entactin, 
tenascin HBEGF, TN Fa, ß4 integrin
MMP-1, M MP-2, 
M MP-9
M M P-26 Endom etase 28 18 Collagen type IV, Fibronectin, Fibrin, 
Gelatin.
M MP-9
H EM O PEX IN
MMP-1 Interstitial coll age nase 55 45 Fibrillar collagens (types 1,0,111,VII,X), 
gelatin, proteoglycans, Pro-TN Fa
Unknown
M M P-8 Neutrophil collagenase 75 58 Collagens I, II, III. Unknown
M M P-13 ColIagenase-3 65 55 Collagen I, II, III, IV Unknown
M M P-12 M etalloelastase 53 45/22 Elastin, fibronectin, collagen IV. M M P-2, MMP-12
M M P-3 S trom elysin-1 57 45 Proteoglycans, laminin, fibronectin, 
collagen III, IV, V, X, gelatins. 
Plasm inogen
M M P-1, MMP-8, 
M MP-9
M M P -10 Strom elysin-2 57 44 Proteoglycans, fibronectin, collagen HI, 
IV, V, gelatins.
MMP-8
M M P -11 Stromelysin-3 51 44 Laminin, fibronectin (very weakly). Unknown
FIBRONECTIN
M M P-2 G elatinase A 72 66 Gelatins, collagens IV, V, VII, X, 
elastin, fibronectin. TN Fa
Unknown
M M P-9 G elatinase B 92 86 Gelatins, collagens IV, V, elastin. 
TG Fß2
Unknown
TR AN SM EM BR A NE
M M P-14 M T1-M M P 63 CD 44 M MP-2
M M P-15 M T2-M M P 72 U nknown Unknown
M M P-16 M T3-M M P 64 Unknown M MP-2
M M P -17 M T4-M M P 70 Unknown, TN F a Unknown
M M P-24 M T5-M M P 60 Proteoglycan ECM  com ponents. Unknown
M MP-25 M T6-M M P 62 Unknown M M P-2
M ISCELLANEOUS
M M P-19 RAS1-1 • - Gelatins, Aggrecan, cartilage. Unknown
M M P-20 Enamelysin 54 - Amelogenin, Aggrecan, cartilage. Unknown
M M P -21 Recently  cloned M M P - - U nknown Unknown
M M P-22 Recently cloned MMP - - Unknown Unknown
M M P-23 Recently cloned M M P 28 * Unknown Unknown
M M P-27 Epilysin 59 • Casein Unknown
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1.4.3 Regulation o f M M P activity
MMP activity is tightly regulated. Constitutive levels of MMP expression are 
normally quite low, with the enzymes being induced under various normal 
physiological circumstances when ECM turnover is required, for example during wound 
healing or bone remodelling. To accomplish their normal functions MMPs must be 
present in the right cell type at the right time in the right amount and at the right 
extracellular location. In addition they must be activated or inhibited appropriately. 
Several MMPs are regulated separately and are tissue specific. Differential patterns of 
expression largely dictate the biological function of individual MMPs and differences in 
their temporal, spatial and inducible expression often indicate their unique roles. The 
complex and tight regulation of MMPs occurs at the transcriptional and post- 
transcriptional level and at a protein level by their inhibitors and activators (Sternlicht 
and Werb, 2001).
1.4.3.1 Transcriptional regulation of MMPs
Most MMPs are closely regulated at the level of transcription through various 
stimulatory and suppressive factors that influence numerous signalling pathways (Fini 
et al., 1998). MMPs are regulated both positively and negatively at the transcriptional 
level by growth factors, cytokines, oncogenes, phorbol esters, integrin-derived signals, 
extracellular matrix proteins, cell stress and changes in cell shape (Fingleton and 
McDonnell, 1997, Birkedal-Hansen et al., 1993, Crawford and Matrisian, 1996, 
Kheradmand el al., 1998 and Sternlicht and Werb, 1999). Cytokines and growth factors 
that regulate MMP expression include interleukins, interferons, epidermal growth factor 
(EGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor 
(VEGF), tumour necrotic factor alpha (TNFa), TGF(3 and the extracellular matrix 
metalloproteinase inducer (EMMPRIN) (Fini et al., 1998). Many of these stimulate 
expression and/or activation of c-jun and c-fos proto-oncogene products, which 
heterodimerize and bind to activator protein-1 (AP-1) sites within the MMP promoters 
(Crawford and Matrisian, 1996).
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1.4.3.2 Post-transcriptional regulation o f MM P activity
Post-transcriptional control mechanisms are central to the regulation of MMP 
activity as all the soluble MMPs are secreted as latent zymogens that require activation 
through cleavage of the N-terminal pro-domain. The extracellular activation of most 
MMPs can be initiated by other already activated MMPs or by several serine 
proteinases that cleave peptide bonds within MMP pro-domains (Woessner and Nagase, 
2000). Plasmin, which is produced by the action of plasminogen activator on 
plasminogen, converts both pro-MMP-1 and pro-MMP-3 to their active forms (He et 
al., 1989). MT1-MMP has been shown to activate pro-MMP-2 using TIMP-2 as an 
activator by forming a trimolecular structure on the cell surface (Sato et al., 1994 and 
Seiki, 1999). Sequences have been identified in the pro-peptide of MT1-MMP that are 
specifically cleaved by the pro-hormone convertase furin (Yana and Weiss, 2000). This 
intracellular cleavage represents the initiating event in a cascade that leads to the 
activation of MMP-2 (Itoh et al., 2001). All these proteolytic events are tightly 
regulated in a cascade style system serving as a powerful and controlled mechanism co­
ordinating complete breakdown of the multiple components of the ECM.
1.4.3.3 The role of TIMPs in the regulation of MMP activity
Proteolytic inhibitors play an important role in controlling the overall proteolytic 
activity in tissues. The proteolytic activity of MMPs is specifically inhibited by a 
family of low molecular weight proteins: the TEMPs (Brew et al., 2000). There are four 
members in the TIMP family and they are produced by various cell types, including 
fibroblasts and endothelial cells. All TIMPs are secreted in soluble form with the 
exception of TIMP-3, which is bound to the ECM (Leco et al., 1994). TIMPs inhibit 
MMP activity by reversibly binding them in a 1:1 stoichiometric manner. TEMPs also 
play a role in the activation of MMPs as exemplified above with the activation of pro- 
MMP-2. This activation is dependent on TIMP-2 concentration, and only occurs at low 
concentrations because MT1-MMP activity is also inhibited by TIMP-2 (Strongin et 
al., 1995). Once generated, active MMP-2 is capable of auto-proteolysis, with further 
activation of the latent form. Such co-localisations may be a key mechanism for the 
regulation of MMP activity at the cell surface.
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1.4.4 MMP activity in cancer
The roles of MMPs in cancer cells are discussed in detail in Chapter 3. Briefly, 
MMP expression is found more in malignant cancers than in normal, benign or 
premalignant tissues, with the highest expression occurring in areas of active invasion at 
the tumour-stroma interface (Sternlicht and Bergers, 2000). A correlation exists, in 
virtually all types of cancer between increased MMP levels and poor prognosis, 
therefore MMP levels are used routinely as prognostic markers for how aggressive a 
particular tumour is (Murray et al., 1996 and Stetler-Stevenson et al., 1996).
17
1.5 Summary
Advanced metastasis represents a major hurdle in cancer treatment mainly 
because its molecular mechanisms remain unclear. Tumour metastasis is a multistage 
process involving many participants including CAMs and proteolytic enzymes. CAMs 
have roles to play in adhesion to the ECM, cell signalling and ligation of growth factors. 
Proteolytic enzymes such as the MMPs are crucial to ECM turnover, growth factor 
activation and angiogenesis making them and the CAMs potential biomarkers of tumour 
progression. The interactions between CAMs such as integrins and CD44 with the 
MMPs remain unclear. New insights into these interactions and the definitive roles of 
CAMs and MMPs in metastasis are needed for the development of successful therapies.
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1.6 T h esis  o v erv iew  an d  a im s
The primary aim of this study was to elucidate the complexity of tumour cell 
metastasis and highlight the individual and collective importance of the many 
participating biomolecules in this process. The research presented in this thesis 
examined the molecular mechanisms involved in colorectal tumour invasion and 
metastasis. The thesis has been divided into three main chapters.
• Chapter 3:
The aim of this study was to investigate the interactions between the cell adhesion 
molecule CD44 and the MMPs in regulating colon tumour cell invasion and 
migration. A panel of colorectal cancer cell lines were characterised based on 
their MMP and CAM expression profiles as well as their adhesive and in vitro 
invasive and migratory abilities. The effects of ECM components and the 
activation of CD44 on MMP activity and in vitro invasion were also examined.
• Chapter 4:
The aim of this study was to identify novel biomarkers of metastasis using cDNA 
microarray analysis. Gene expression profiles were examined in a panel of 
colorectal cancer cell lines of varying invasive and metastatic abilities. Following 
data analysis, expression changes contributing to tumour cell metastasis could 
easily be identified. Several differentially expressed genes were selected for 
further validation and analysis.
• Chapter 5:
The aim of this study was to further validate the importance of the genes 
identified in Chapter 4 by examining their expression in paired samples of normal 
and tumour colorectal tissues.
For convenience, this thesis has been divided into seven chapters. Chapter 1 
serves as a general introduction to the process of tumour cell metastasis as well as 
highlighting the roles of its main players. There is a common materials and methods 
section (Chapter 2) and bibliography (Chapter 8). Chapters 3, 4 and 5 each have their 
own introduction, results and discussion sections, while chapter 6 provides an overall 
summary of the thesis.
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Chapter 2
Materials and methods
2.1 Materials
All general-purpose chemicals and reagents used in experimental work were of 
analytical grade and were purchased from Sigma-Aldrich Inc., Dublin, Ireland.
All PCR primers were obtained from MWG Biotech, Ebersberg, Germany.
Anti-Actin antibody was obtained from Merck Biosciences, Nottingham, England.
Anti-CD44 antibodies, D2.1 and IM7.8.1 were obtained from Dr Aideen Long, Royal 
College of Surgeons, Dublin, Ireland and F10-44-2 was obtained from Biodesign, Saco, 
Maine, USA.
Anti-MMP-7 polyclonal serum was obtained from Prof. Lynn Matrisian, Vanderbilt 
University, Nashville, TN, USA.
Anti-MMP-9 (MAC96) and MMP-2 (GL8) antibodies were obtained from Dr. Andrew 
Docherty, Celltech, Slough, England.
Anti-ßl integrin antibody (W1B10) was obtained from Sigma-Aldrich Inc., Dublin, 
Ireland.
Anti ß-1 integrin antibody (AB 1937) was obtained from Chemicon Inc., Hampshire, 
United Kingdom
BCA reagent for protein determination was obtained from Pierce Chemicals, Rockford, 
Illinois, USA.
BHK cells transfected with the human MMP-9 cDNA (BHK 92) were obtained from 
Prof. Dylan Edwards, University of East Anglia, Norwich, England.
Biocoat Matrigel invasion chambers were obtained from Becton Dickinson Labware, 
Bedford, MA, USA.
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Blue/Orange Loading Dye (Cat # G1881) supplied by Promega, was distributed by 
Medical Supply Company, Dublin, Ireland.
Cell culture media and supplements including foetal bovine serum were supplied by 
Sigma-Aldrich Inc., Dublin, Ireland.
Cell freezing medium was obtained from Sigma-Alrdich Inc., Dublin, Ireland.
ColorBurst™ (Cat # C4105) electrophoresis marker was supplied by Sigma-Aldrich 
Inc., Dublin, Ireland.
Cy-3 and Cy-5 esters (Cat # PA23001, PA25001) were supplied by Amersham 
Biosciences Corp, NJ, USA.
DNA-free™ (Cat # 1906) was supplied by Ambion Inc., TX, USA.
G418 (geneticin) (Cat # US11379-lg) was supplied by Amersham Biosciences Corp, 
NJ, USA.
Glycogen (Cat # 9510) was supplied by Ambion Inc, Cambridgeshire, England.
L-glutamine, trypsin and penicillin/streptomycin were obtained from Sigma-Aldrich 
Inc., Dublin, Ireland.
MessageAmp™ aRNA system (Cat # 1750) including all the appropriate buffers and 
consumables, was supplied by Ambion Inc, TX, USA.
Microcon™ centrifugal filter devices were supplied by Amicon Ltd., Limerick, Ireland.
MMLV-RT supplied by Promega, was distributed by Medical Supply Company, 
Mulhuddart, Dublin, Ireland.
PBS tablets were obtained from Oxoid Ltd., Basingstoke, Hampshire, England.
Plastic consumables for cell culture, and 96-well plates were obtained from Sarstedt, 
Sinnottstown Lane, Drinagh, Co. Wexford, Ireland.
QIAquick PCR purification kit (Cat # 28106) including all the appropriate buffers and 
consumables was supplied by Qiagen Inc. CA, USA.
RNA Sample Loading Buffer (Cat # R4268) was supplied by Sigma-Aldrich Inc., 
Dublin, Ireland.
SuperScriptIM II Reverse Transcriptase was supplied by Invitrogen, CA, USA.
Supersignal West ECL detection kit was obtained from Pierce Chemicals, Rockford, IL, 
USA.
SYBR green and all real lime PCR reagents were obtained from Qiagen Inc. CA, USA.
Taq polymerase and other RT-PCR reaction components were purchased from Sigma- 
Aldrich Inc, Dublin, Ireland and Promega Corp, Southampton, England.
TRI-Reagenl1M (Cat #T9424) was supplied by Sigma-Aldrich Inc., Dublin, Ireland.
X-ray film was obtained from Amersham, Little Chalfont, England.
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2.2 Methods
2.2.1 Cell culture
All cells used in this study were adherent cell lines. The cell lines used were 
BHK92, SW480 (ATCC Cat # CCL-228), SW620 (ATCC Cat # CCL-227) and two 
transfected cell lines: SW480M7 (SW480 cells stably transfected with the cDNA for 
MMP-7) (Witty et al., 1994) and SW480M9 (SW480 cells stably transfected with the 
cDNA for MMP-9) (Murray et al., 2004). The SW480M7 cell line was received from 
Professor Matrisian’s laboratory (Vanderbilt University, Nashville, TN). This cell line 
has been previously studied (Witty et al., 1994) but it was important to re-characterise 
these cells as they had been frozen down since 1995. The SW480M9 cell line was 
developed by Dr McDonnell whilst on sabbatical in Memorial Sloan Kettering Cancer 
Center, New York, NY, USA. However, the cells had not been extensively 
characterised. All cells were maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) supplemented with 5 % (v/v) foetal bovine serum (FBS) [DMEM S5], 2 mM 
L-glutamine, 1 U/ml penicillin and 1 fig/ml streptomycin. Transfected cell lines were 
maintained in DMEM S5 media containing 600 fig/ml G418. All cells were incubated 
in a humid 5 % CO2 atmosphere at 37 °C in a Heraeus 6000 cell culture incubator. All 
cell culture techniques were performed in a sterile environment using a Holten HB225 
laminar airflow cabinet. Cells were routinely grown in 25 cm2 or 75 cm2 tissue culture 
flasks. Cell growth and morphology were monitored using an Olympus CK2 inverted 
microscope.
2.2.1.1 Subculturing of cells
Once cells had grown to confluency, as judged microscopically, they were 
subcultured by trypsinisation. Firstly, all growth media was removed and cells were 
rinsed twice with 3 ml PBS to remove any residual FBS, which contains a trypsin 
inhibitor (012 macroglobulin). 3 ml of fresh trypsin-EDTA (0.025 % (w/v) trypsin with 
0.02 % (w/v) EDTA in 0.15 M PBS, pH 7.4) was placed in each flask and incubated at 
37 °C for 5-10 min or until all the cells had detached from the growth surface. 3 ml of 
DMEM S5 growth medium was added to the cell suspension and the 5 ml was 
transferred to a sterile 25 ml universal container before being centrifuged at 2000 rpm 
for 5 min. Cells were resuspended in growth medium and an aliquot was kept for cell
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counting (see section 2.2.1.2). Cells were seeded at 2 x 105 -  1 x 106 cells/ml using 10 
ml growth medium per 75 cm culture flask and 5 ml per 25 cm flask.
2.2.1.2 Cell counts
A Naubauer haemocytometer slide was used to perform cell counts. Trypan 
blue exclusion dye was routinely used to determine cell viability. 20  jj,1 trypan blue was 
added to 100 jal cell suspension, mixed by vortexing, and the mixture left to incubate for 
2 min at room temperature. A 20 |xl sample of the mixture was applied to the counting 
chamber of the haemocytometer and the cells were visualised by light microscopy. 
Viable cells excluded the dye and remained clear while dead cells stained blue. Cells in 
the four outer quadrants were counted and an average obtained. The number of cells 
counted was determined as follows (average number of viable cells) x 1.2 (dilution 
factor) x 1 x 104 (area under coverslip) = viable cells/ml.
2.2.1.3 Cryopreservation: long term storage of cells
Long-term storage of cells was achieved by storing batches of cells in a Taylor- 
Wharton 35VHC cryofreezer (supplied by Cooper Cryoservice Ltd.) under liquid 
nitrogen at -196 °C. Cells to be stored were first grown until 80 % confluent, 
trypsinised, and resuspended at a concentration of 5 x 106 cells/ml in cell freezing 
medium (DMEM:FBS:DMSO; 45:45:10). 1 ml aliquots were transferred to cryovials 
and frozen at -20 °C for 30 min, -80 °C for 10 hr and finally under liquid nitrogen (-196 
°C) for long term storage. 1 vial from each batch was randomly chosen and thawed to 
check the viability of the stocks. For recovery, cells were first removed from liquid 
nitrogen storage and thawed rapidly using a 37 °C waterbath. Each 1 ml aliquot was 
mixed with 5 ml of DMEM S5 in a sterile 25 ml universal tube and centrifuged at 2000 
rpm for 5 min. The pellet was resuspended in DMEM S 5 at 1 x 106 cells/ml and 
transferred to culture flasks and incubated at 37 °C and 5 % CO2. An aliquot was also 
checked for cell viability as described in section 2 .2 .1.2 .
2.2.2 Isolation of total RNA from cell lines
RNA was isolated from cells when 80 % confluent. The growth media was 
removed and cells were washed twice with PBS. Once all PBS was removed, 1 ml of
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TRI-Reagent™ was added to one 75 cm2 flask of cells and left for 5 min at room 
temperature with occasional shaking. Once cells were lysed, as judged microscopically, 
the suspension formed was removed to a clean 1.5 ml microfuge tube, 200 jrl 
chloroform was added and the mixture was shaken, left at room temperature for 15 min 
and centrifuged at 13,000 x g at 4 °C for 15 min. The upper aqueous layer was 
transferred to a fresh 1.5 ml tube. Care was taken not to transfer the DNA and protein- 
containing lower- and inter-phase. 0.5 ml ice-cold isopropanol was added to the 
aqueous phase, shaken and left to stand on ice for 10 min before it was centrifuged at
13,000 x g at 4 °C for 10 min. The supernatant was removed and 1 ml of sterile 75 % 
ethanol was added to wash the pellet by gentle vortexing and centrifugation at 7500 x g 
for 5 min. The ethanol was removed and the pellet was allowed to air-dry for 5 min. 
Pellets were resuspended in 50 pJ 0.1 % DEPC treated H2O by heating at 60 °C for 15 
min. All RNA was stored at -80°C.
2.2.2.1 RNA quantitation and analysis
The absorbance values at 260 and 280 nm of a 1/100 dilution (5 |xl in 500 jd 0.1 
% DEPC treated H20 ) of total RNA were measured on a Shimadzu UV-160A 
spectrophotometer using a quartz cuvette. The absorbance value at 260 nm (A260) was 
multiplied by 4, to give the RNA concentration in |4g/(il (where 40 (ig of RNA has an 
absorbance value of 1 at 260 nm and because of the dilution factor used). The A 260/A 
280 ratio gave an indication of RNA purity, where a value of 1.8 was desirable, and a 
value greater than 1.8 indicated protein contamination, a value lower than 1.8 was 
indicative of organic solvent contaminants.
RNA integrity was assessed by agarose electrophoresis. A 1 % agarose gel was 
prepared by boiling the agarose in 1 X Tris Borate EDTA (TBE) (0.08 M Tris-HCl pH 
8.2; 0.04 M boric acid; 1 mM EDTA). After sufficient cooling, the gel was cast in a 
Hybaid Horizontal Gel Electrophoresis system. 1 |xl RNA loading buffer (62.5 % (v/v) 
deionised formamide; 1.14 M formaldehyde; 200 [xg/ml bromophenol blue; 200 (jtg/ml 
xylene cyanole; 1.25 X MOPS-EDTA-sodium acetate; 50 [ig/ml ethidium bromide) was 
mixed with 2 (xl RNA and heated at 65 °C for 10 min then cooled on ice prior to loading 
on the gel. The gel was run at 100 V in 1 X TBE. Before the dye front had run off the 
gel, the gel was stopped, removed and visualised on a UV transluminator. The presence 
of two and sometimes three strongly stained bands, representing the 28S, 18S and 6S
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subunits, signified intact RNA. Degradation could be seen as a smear running down the 
length of the gel.
2.2.3 Reverse transcription (RT)
1 |jg of total RNA (as prepared in section 2.2.2) was mixed with 1 (xl oligo dT 
(500 |xg/ml), the total volume was brought to 5 (il with sterile nuclease-free water, 
incubated at 70 °C for 10 min and then placed on ice. The following components were 
then added; 4 |j,l 5 X transcription buffer supplied with the enzyme (Promega), 1 jxl 
RNasin (40 units/|d), 1 |il dNTP mix (each at 10 mM), 8 |xl sterile water and 1 (il (10 
units/|j,l) murine Moloney leukemia virus reverse transcriptase (MMLV-RT). Repeated 
pipetting was used to mix and the sample was briefly centrifuged (~5 sec) to collect the 
sample at the bottom of the PCR tube. The reaction mixture was incubated at 37 °C for 
1 hr and heated to 95 °C for 2 min to inactivate the enzyme. The resulting cDNA was 
stored at 4 °C until required for PCR.
2.2.4 Real time PCR
Following reverse transcription, the following was added to 2 (xl of cDNA 
template; 12.5 (il SYBR Green master mix that contained Taq and dNTPs (Qiagen), 8.5 
|ll Dnase-free water, and 1 jj.1 each of forward and reverse primers. The sequences of 
the primers are listed in Table 2.1. Using a Rotor Gene™ 3000 multiplex system the 
reaction was held at 95 °C for 15 min followed by the following cycling conditions; 95 
°C; 20 sec, annealing temperature (Table 2.1); 30 sec, 72 °C; 30 sec. This cycle was 
repeated 45 times before being held at 60 °C for 1 min. Following cycling, to ensure 
specificity, melt curve analysis was carried out starting at 50 °C and ramping to 90 °C. 
One peak in the melt curve indicated no secondary, non-specific products were formed.
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Table 2.1 Details of the primers used for RT-PCR and real time PCR experiments.
Primers were chosen so that they amplified the target mRNA specifically and not DNA.
T arget P rim er Sequence Product
size
Annealing 
Temp (°C)
Reference
P Actin 5 ’ A T C  C T G  C G T  C T G  G A C  C T G  G C T  3 ’ 
5 ’ C T T  G C T  G A T  C C A  C A T  C T G  G T G  3 ’
682  bp 55 M urray  e ta l . ,  
2004
Asparagine
Synthetase
5 ’ C G C  C C A  G A T  T T T  C T T  C A A  T C  3 ’ 
5 ’ C C A  A A G  C A G  C A G  T T G  G T G  T A  3 ’
202  bp 56 M a e ta l . ,  
2003
Cathepsin C 5 ’ C C A  C A G  T C G  A A A  A A T  C C C  A A G  G  3 ’ 
5 ’ G T G  G T G  G T A  G A T  C C C  C T T  T T T  G  3 ’
549 bp 60 T okurik i, el  
al„ 2003
Caveolin 1 5 ’ G T C  A A C  C G C  G A C  C C T  A A A  C  3 ’
5 ’ T G T  C C C  T T C  T G G  T T C  T G C  A A G  3 ’
80 bp 60 U ray  e t a i ,  
2003
CD44 
C13 - C2a
5 ’ A A G  A C A  T C T  A C C  C C A  G C A  A C  3 ’
5 ’ C C A  A G A  T G A  T C A  G C C  A TT C T G  G 3 ’
m ultip le 56 V an  W eering  
e ta l . ,  1993
CD44v6 
v6 - C2a
5 ’ C A G  G C A  A C T  C C T  A G T  A G T  A C  3 ’
5 ’ C C A  A G A  T G A  T C A  G C C  A T T  C T G  G  3 ’
m ultip le 56 V an W eering  
e ta l . ,  1993
MMP-7 5 ’ T G T  A T C  C A A  C C T  A T G  G A A  A T G  3 ’ 
5 ’C A T  T T A  T T G  A C A  T C T  A C G  C G C  3 ’
341 bp 52 W itty  et al., 
1994
MMP-9 5 A T G  A G T  T C G  G C C  A C G  C G C  T G G  G C T  T  3 ’ 
5 ’ T  G C C  G G T  G A T  G A C  A C G  G A A  A C T  C A G  3 ’
329  bp 54 O nisto  e t al., 
1993
PPA R y 5 ’ A G T  G G G  G A T  G T C  T C A  T A A  T G C  C  3 ’ 
3 ’ A G C  T C A  G C G  G A C  T C T  G G A  T T C  5 ’
113 bp 56 P avan  e ta l. ,  
2003
Tenascin C 5 ’ G A G  A T T  T A G  C C G  T G T  C T G  A G G  T T G  3 ’
5 ’ G G T  A G C  C A T  C C A  G G A  G A G  A T T  G A A  G  3 ’
331 bp 70 N agata  e ta l . ,  
2003
Tenascin C 
8-18
5 ’ C A A  T C C  A G C  G A C  C A T  C A A  C G  3 ’ 
5 ’ C G T  C C A  C A G  T T A  C C A  T G G  A G  3 ’
m ultip le 58 A dam s et al., 
2002
Tenascin C 
9/17-18
5 ’ C A T  C C A  C T G  C C A  T G G  G C T  C  3 ’
5 ’ C G T  C C A  C A G  T T A  C C A  T G G  A G  3 ’
149 bp 58 A dam s e ta l . ,  
2002
Tenascin C 
9/16-18
5 ’ G C A  TC C  A C T  G A A  G C C  G A A  C  3 ’ 
5 ’ C G T  C C A  C A G  T T A  C C A  TG G  A G  3 ’
431 bp 58 A dam s e ta l . ,  
2002
Tenascin C 
8-14/16
5 ’ C A A  T C C  A G C  G A C  C A T  C A A  C G  3 ’ 
5 ’ T T C  G G C  T T C  T G T  C G T  G G C  3 ’
m ultip le 58 A dam s et al., 
2002
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2.2.5 Collection o f conditioned media
When cells had grown to 80 % confluency, all media was removed and cells 
were rinsed twice in 3 ml PBS before 5 ml serum free media (So) was added. The cells 
were incubated under standard conditions for 3 hr, thus starving the cells. The So media 
was then replaced with 5 ml fresh So and the cells incubated for a further 72 hr. 
Conditioned media (CM) was removed and centrifuged at 2,000 rpm for 5 min to 
remove debris. CM was concentrated using Microcon™ centrifugal filter devices with 
a 10 kDa cut-off. Briefly, 500 (j,l of CM was added to the filter and centrifuged at
10,000 rpm for 15 min. Following centrifugation, the retained media was recovered and 
protein concentration was determined using the bicinchoninic acid (BCA) assay 
(Pierce).
2.2.6 Bicinchonic acid (BCA) assay
The BCA assay was carried out to determine the total protein concentration in a 
sample. In this assay, Copper (Cu2+) reacts with protein under alkaline conditions to 
give Cu1+, which in turn interacts with BCA to produce a BCA-copper purple coloured 
complex that can be easily detected spectrophotometrically. Protein concentration was 
determined by preparing a standard curve from BSA standards ranging from 0.0 to 2.0 
mg/ml at 0.2 mg increments in distilled water. A BCA working solution was prepared 
using a commercially available kit, by combining 50 parts reagent A, an alkaline 
bicarbonate solution with 1 part reagent B, a copper sulphate solution. 200 (il of this 
solution was added to 10 |j,l sample or standard in a 96-well microtitre plate in triplicate. 
The plate was covered with aluminium foil and incubated at 37 °C for 30 min. The 
absorbance of each well was read at 560 nm using a Rosys Anthos 2010 plate reader.
2.2.7 SDS-PAGE
Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using the discontinuous system described by Laemmli (1970) using 10 % 
polyacrylamide gels and 3 % stacking gels prepared as follows:
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10 % Resolving Gel : 3.3 ml 30 % (w/v) Acrylamide containing 0.8 % (w/v)
bisacrylamide 
4 ml Distilled Water
2.5 ml 1.5 M Tris-HCl; pH 8.8 
100 pi 10 % SDS
100 (J.1 10 % Ammonium persulphate (freshly prepared)
20 jil TEMED
The resolving gel was poured, covered with a layer of 100 % ethanol and 
allowed to set before the stacking gel was cast.
3 % Stacking Gel : 0.8 ml (0.5 M Tris-HCl, pH 6 .8 ; 0.4 % (w/v) SDS)
0.5 ml 30 % (w/v) Acrylamide containing 0.8 % (w/v)
bisacrylamide 
2 ml Distilled water
33 (0.1 10 % Ammonium persulphate (freshly prepared)
20 \i\ TEMED
For western blot analysis 80 (ig of total protein was loaded on the gel. Samples 
were mixed 4:1 with sample buffer (2 % (w/v) SDS; 0.08 M Tris-HCl, pH 6 .8 ; 10 % 
(w/v) glycerol; 0.2 % (w/v) Coomassie Brilliant Blue; 1 M (3-mercaptoethanol) and 
boiled at 100 °C for 10 min. Samples were loaded, together with 10 (xl of coloured 
marker (see Table 2.2 for molecular weights) and the gel was run at a constant voltage 
of 100 V (-50 mA) in laemmli buffer (0.025 M Tris-HCl, pH 8.3; 0.19 M glycine; 0.1 
% SDS) using an Atto vertical mini-electrophoresis system until the blue dye front 
reached the bottom of the gel.
2.2.8 Western blot analysis
Following electrophoresis as described in section 2.2.7 the gels were then 
transferred to nitrocellulose. For each gel, one sheet of nitrocellulose and 4 sheets of 
Whatman-1 filter paper were pre-soaked in cold transfer buffer (0.025 M Tris, pH 8.3; 
0.192 M Glycine; 20 % (v/v) Methanol). Proteins were then transferred to 
nitrocellulose for 1 hr at 100 V at 4 °C. Transfer was confirmed by the presence of the 
colour marker on the nitrocellulose membrane and by the presence of protein bands
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when the blot was stained with a 0.1 % Ponceau S solution in 5 % (v/v) acetic acid for 
10 min at room temperature.
Table 2.2 Molecular weight distributions of protein marker used for western blots.
Band Colour M olecular Weight (kDa)
Violet 220
Pink 100
Blue 60
Pink 45
Orange 30
Blue 20
Pink 12
Blue 8
Following transfer, the blot was first rinsed in TBST (10 mM Tris, pH 8.0; 150 
mM NaCl; 0.05 % (v/v) Tween 20) to remove any Ponceau S, and then blocked using 5 
% dried milk in TBST for 2 hr at room temperature with gentle shaking and then 
incubated overnight at 4 °C with primary antibody diluted in the same blocking 
solution. The primary antibody dilutions used are listed in Table 2.3. Blots were 
washed three times for 15 min in TBST at room temperature with gentle rocking. Blots 
were then incubated at room temperature with gentle rocking for 2 hr with secondary 
HRP conjugated antibody, diluted in TBST. Secondary antibodies used are listed in 
Table 2.3. Blots were washed three times for 15 min in TBST and ECL (Pierce) was 
used to develop them. 1 ml of 1:1 H2O2 : Luminol mixture was poured over the blot. 
The blot was covered with a sheet of transparent acetate and under red light a sheet of 
Hyperfilm™ (Amersham) was placed over the blot for 5 min.
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Table 2.3 Details o f antibodies used for western blot analysis.
Target Primary Antibody Secondary Antibody Tertiary Component
MMP-2 GL8 (Celltech) 
1/2000
N A 9 3 1 (Amersham) Anti- 
M ouse HRP 
1/5000
n/a
MMP-7 Rat anti-human MMP-7 
Polyclonal sera 
used neat
B A -4000 (Vector) 
Biotinylated anti-Rat IgG  
1/15,000
SA-5004 (Vector) HRP- 
conjugated streptavidin 
1/20,000
MMP-9 M AC96 (Celltech) 
1/500
N A 931 (Amersham) Anti- 
M ouse HRP 
1/5000
n/a
CD44 D2.1
1/1000
N A 931 (Amersham) Anti- 
Mouse HRP 
1/5000
n/a
CD44v3 3G5 (R&D Systems) 
1/500
N A 931 (Amersham) Anti- 
Mouse HRP 
1/5000
n/a
CD44v6 2F10 (R&D Systems) 
1/100
N A 931 (Amersham) Anti- 
Mouse HRP 
1/5000
n/a
pi Integrin A B 1937 (Chemicon) 
1/10,000
P0448 (DAKO) 
Goat Anti-Rabbit 
1/2000
n/a
(J-Actin JLA20 (Merck) 
1/10,000
N A 931 (Amersham) Anti- 
M ouse HRP 
1/5000
n/a
The films were developed using a Hyper™ processor (Amersham). By lining up 
the film with the blot, bands were identified by molecular weight using the colour 
marker. Film was photographed using the Pharmacia Biotech Image Master system and 
images were analysed using Pharmacia Biotech Image Master ID Prime densitometry 
package for Windows.
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2.2.9 Zymography
Gelatinase activity was assessed in 50 ng total protein. 10 % acrylamide gels 
were prepared for MMP-2 and MMP-9 analysis. The following were the volumes used 
to prepare one gel;
Resolving Gel : 2.5 ml (1.5 M Tris-HCl, pH 8 .8 ; 0.4 % (w/v) SDS)
2.5 ml 3 mg/ml Gelatin stock
3.3 ml 30 % (w/v) Acrylamide containing 0.8 % (w/v)
bisacrylamide
1.7 ml Distilled water
33 (j,l 10 % Ammonium persulphate (freshly prepared)
20 |*1 TEMED
The resolving gel was poured, covered with a layer of 100 % ethanol and 
allowed to set before the stacking gel was cast.
Stacking Gel : 0.8 ml (0.5 M Tris-HCl, pH 6 .8 ; 0.4 % (w/v) SDS)
0.5 ml 30 % (w/v) Acrylamide containing 0.8 %(w/v) 
bisacrylamide 
2 ml Distilled water
33 n-1 10 % Ammonium persulphate (freshly prepared)
20 \ i l  TEMED
Once set, sample wells were washed with laemmli buffer (0.025 M Tris-HCl, pH 
8.3; 0.19 M glycine; 0.1 % SDS) to remove any excess ammonium persulphate. 
Samples containing 50 ng total protein were mixed 4:1 with sample buffer (15 % 
sucrose; 0.25 M Tris-HCl, pH 6 .8 ; 0.1 % (w/v) bromophenol blue). Samples were 
loaded together with a 20 (j,l aliquot of conditioned BHK92 media used as a positive
control. A molecular weight marker, the sizes of which are listed in Table 2.4 was also
loaded. Gels were run at a constant voltage of 100 V (-50 mA) in laemmli buffer. Gels
were run for - 2  hr or until the blue dye front had reached the bottom of the gel, during
this time the current dropped to -20 mA. The resolving gel was removed and washed 
twice in 2.5 % Triton-X 100 for 30 min and then rinsed in substrate buffer (50 mM Tris- 
HCl, pH 8.0; 5 mM CaCy before being submerged in the same buffer and incubated at
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37 °C for 48 hr in a sealed container. Following incubation the gels were stained with 
Coomassie blue (0.25 % in 6:3:1 water:propanol:glacial:acetic acid) for two hours with 
gentle shaking and destained using the same solvent system with gentle shaking until 
clear bands appeared. The gels were photographed using a Pharmacia Biotech Image 
Master system and images were analysed using Pharmacia Biotech Image Master ID 
Prime densitometry package for Windows.
Table 2.4 Molecular weight distributions of protein marker used for zymography.
Proteins Molecular Weight (kDa)
M yosin, rabbit muscle 205
ß-Galactosidase, E. coli 116
Phosphorylase b, rabbit muscle 97
Fructose-6-phosphate Kinase, rabbit muscle 84
Albumin, bovine serum 66
Glutamic Dehydrogenase, bovine liver 55
Ovalbumin, chicken egg 45
Glyceraldehyde-3-phosphate Dehydrogenase, rabbit muscle 36
Carbonic Anhydrase, bovine erythrocytes 29
Trypsinogen, bovine pancreas 24
a-Lactalbumin, bovine milk 14.2
Aprotinin, bovine lung 6.5
2.2.10 In vitro invasion assays
Biocoat Matrigel invasion chambers were used to investigate and compare the in 
vitro invasive activities of the cell lines used in this study. The 24-well invasion 
chambers were removed from -20 °C storage and allowed to come to room temperature 
for 10 min. The inserts were rehydrated by adding 250 (4,1 warm (37 °C) So to each 
chamber and left for 2 hr at room temperature. After rehydration the media was 
removed from the inserts and replaced with 500 |xl of a 5 x 105 cells/ml cell suspension 
in So. 750 jil of DMEM containing 20 % FBS (S2o) was added to the outer chambers 
and acted as a chemoattractant for the cells. The plates were then incubated for 24 hr in 
a 5 % CO2 humidified 37 °C incubator.
To investigate the effect of HA and CD44 activation on cell invasion, cells were 
seeded in serum free media containing 0.25 mg/ml HA in both upper and lower
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chambers. Cells were also allowed to invade in the presence of 50 (ig/ml CD44 
activating antibody Fi0-44-2 , CD44 blocking antibody IM7.8.1, or mouse IgG (Sigma) as 
a control.
Following incubation, non-invasive cells were removed from the upper chamber 
using cotton swabs soaked in PBS. Cells that had invaded through the membrane were 
fixed by soaking in methanol for 10 min. Cells were then stained in 0.75 % Mayers 
Haematoxylin solution for 5 min. The inserts were then washed several times in tap 
water to ‘blue’ the dye. The inserts were then dehydrated by soaking in a series of 
solutions of increasing ethanol concentration for two minutes each. 25 %, 50 %, 75 % 
and 100 % ethanol solution were used before the inserts were finally soaked in 100 % 
xylene solution. The membrane was carefully removed from the housing of the insert 
using a scalpel blade and mounted on a slide with the outside facing up using DPX 
mounting medium. Cells were visualised at 10 X magnification and the number of cells 
in 5 fields were counted and an average was obtained.
2.2.11 In vitro migration assays
The in vitro migratory capacities of cells was assessed using similar cell culture 
inserts to those used in section 2 .2 .10, with the exception that these inserts lacked the 
matrigel coating. Following trypsinisation and cell counts, 5 x 105 cells were added into 
the upper chamber of these inserts in 500 (4,1 serum-free media in triplicate. The inserts 
were then inserted into 24-well culture plates containing 750 (4,1 DMEM with 20 % FBS 
(S20) and allowed to incubate at 37 °C and 5 % CO2 for 24 hr. Following incubation, 
the migratory cells were enumerated by removing the inserts and staining and counting 
as outlined in section 2 .2 .10.
2.2.12 Cell adhesion assay
Separate wells of a sterile 96-well microtitre plate were coated overnight at 4 °C 
by adding 100 (4,1 of the following ECM components; hyaluronic acid (HA) 1 mg/ml or 
fibronectin 50 [4g/ml. Adhesion to plastic was also monitored using uncoated wells. All 
wells were washed twice with 100 (4,1 PBS and blocked with 100 (4,1 1 mg/ml BSA for 2 
hr at 4 °C. Following trypsinisation and counting of semi-confluent (-80 %) cells, 1 x 
105 cells in 100 (4l growth medium (S5) were added to each well and allowed to adhere
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for 90 min at 4 °C. Growth media and cells that had not adhered were removed by 
inverting and flicking the 96-well plate once. Plates were centrifuged at 150 x g for 5 
min to collect the adherent cells at the bottom of the well. Residual media was aspirated 
and 120 pi MTS (1/6 dilution) in S5 growth media was added to each well and incubated 
at 37 °C, 5 % CO2 for 2 hr. For % adhesion calculations 120 pi of the above MTS 
dilution was added to wells containing 1 x 105 cells which had not been inverted, these 
acted as controls for 100 % adhesion. After 2 hr, when a colour change (yellow to 
red/brown) occurred, the absorbance at 492 nm was read using a Rosys Anthos 2010 
plate reader. % adhesion was calculated and statistical analysis was carried out using 
Microsoft Excel.
2.2.13 Treatment of cells with antibodies and ECM components
Cells were passaged at least twice after thawing prior to any treatment. To 
investigate the effect of CD44 activation on MMP activity, cells were first grown until 
80 % confluent and the media was replaced with serum free media for 3 hr. Cells were 
then incubated with fresh serum free media containing 50 |ig/ml CD44 activating 
antibody F10-44-2 (Biodesign) or mouse IgG (Sigma) as control. Replicates were 
prepared and media and RNA were harvested at times 0, 6 , 24 and 48 hr. Cells were 
also treated with 0.25 mg/ml HA, 0.01 mg/ml Collagen type IV 10 mg/ml FN or 0.3 
(ig/ml anti-Pi-integrin stimulating antibody (W1B10, Sigma) in serum free media for 72 
hr. All harvested media was centrifuged at 2000 1pm for 5 min to remove debris. 
Supernatant was stored at 4 °C prior to further analysis. RNA was also harvested as 
described in section 2 .2.2  for further analysis.
2.2.14 Protein extraction from cells
Total cellular protein were extracted for the analysis of membrane bound cell 
adhesion molecules by western blot. Following trypsination of 1 x 107 cells, the cell 
pellet was resuspended in 100 pi lysis buffer (1 % Triton-X-100, 150 mM NaCl, 10 mM 
Tris-HCl; pH 7.0, 10 mM EDTA, 1 mM 4-(2-aminoethyl)-benzene-sulfonylfluoride 
(AEBSF), 0.8 (J.M Aprotinin, 20 pM Leupeptin, 40 pM Bestatin, 15 pM Pepstatin A, 14 
pM E-64). The mixture was placed on ice for 1 hr with occasional mixing. Samples 
were then centrifuged at 12,000 x g for 20 min to remove cell debris. The supernatant
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was aliquoted into clean microfuge tubes and protein concentration was determined 
using the BCA assay.
2.2.15 Polymerase chain reaction (PCR)
A 45 (0,1 PCR mix was prepared by adding 34.5 |il sterile nuclease-free water, 5 
jxl 10 X MgC^-free reaction buffer (supplied with the Taq polymerase enzyme), 2 (4.1 25 
mM MgCl2, 1 (J.1 dNTP mix (each at 10 mM), 0.5 |il Taq polymerase (5 U/(il), 1 |il 
forward primer and 1 (xl reverse primer to a sterile 0.2 ml PCR tube. All primers used 
were at 100 pmol/(il concentration and are listed in Table 2.1. 5 (xl cDNA as prepared in 
section 2.2.3 was added to this reaction mixture and the tube was briefly centrifuged to 
collect the sample at the bottom. Mineral oil was not required as the lid of the 
Eppendorf mastercycler used was heated to 105 °C to prevent condensation. The tube 
was placed in the thermocycler and programmed with an initial temperature of 94 °C for 
3 min, followed by 30 cycles consisting of the following sequential steps: 94 °C for 90 
sec (denaturation), annealing temperature, as listed in Table 2.1, for 3 min and 72 °C for 
3 min (elongation). The reaction was finally held at 72 °C for a further 7 min before 
tubes were removed and stored at 4 °C until further analysis.
2.2.15.1 PCR analysis of CD44 splice products
To analyse CD44 variant 6 expression C13 and C2a primers that anneal to the 
constant region of CD44 were used to carry out an initial PCR using the conditions 
listed in Table 2.1. 2 jxl of this reaction was then used as template for exon specific 
PCR, where the C2a primer was used as the reverse primer in conjunction with a primer 
specific for the variant 6 region.
2.2.15.2 Analysis of PCR products by agarose gel electrophoresis
A 1.5 % gel was prepared by boiling the required amount of agarose in TBE. 
The agarose was allowed to cool sufficiently and 1 (xl ethidium bromide (10 mg/ml) was 
added before the gel was poured and cast in a Hybaid horizontal gel electrophoresis 
system. 10 (xl of PCR product was mixed with 3 (4,1 DNA loading dye (Promega) and 
loaded onto the gel together with a 100 bp ladder. The gel was run at 100 V until the 
dye front had reached the end of the gel. The gel was removed and bands were
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visualised and photographed under UV using a Pharmacia Biotech Image Master 
system.
2.2.16 cDNA microarray analysis
cDNA microarray analysis was carried out at George Mason University (GMU), 
Virginia (VA), USA to simultaneously compare the expression of 40,000 genes in all 
cell lines used in this study.
2.2.16.1 Microarray fabrication
The microarrays used in this study were manufactured at GMU, VA, USA. 
Briefly, a microarray was constructed from 39,360 human cDNA clones (Research 
Genetics: l'tp://ftp.resgen.com/pub/sv librarics/RG Ms seq ver 06QI01.txt, 17
September 2004). The complete list of genes with accession numbers is published at 
http://www.gmu.edu/centers/genomics/keys, 17 September 2004. The microarray was 
distributed over two slides because of the large number of cDNA clones. A Beckman 
Biomek 2000 Laboratory Automation Workstation was used to amplify cDNA inserts 
directly from clones in culture using GF200F (5’- 
CTGC A AGGCGATT A AGTTGGGT AAC) and GF200R (5’-
GTGAGCGGATAACAATTTCACACAGGAAACAGC) universal primers. Selected 
aliquots of PCR amplifications were electrophoresed on agarose gels in order to monitor 
the yield and the specificity of the amplification reaction. Amplification products were 
purified using Multiscreen-PCR plates (Millipore), then dried and resuspended in 30 |xl 
of 3 X saline sodium citrate (SSC). Selected aliquots were monitored by agarose gel 
electrophoresis after purification. The collection of amplified cDNAs were printed on 
poly-L-lysine coated slides in a single replicate using Gene Machines OGR-03 
OmniGrid Microarrayer with SMP3 pins (Telechem International). Negative controls 
consisting of no-template PCR amplifications were also printed on the microarray as 
well as blank controls (areas on which nothing was printed but were quantified as 
normal spots). Blanks and negative controls were distributed in several sub-arrays to 
monitor different areas on the slide surface. Spotted slides were stored at room 
temperature under vacuum until further use.
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2.2.16.2 DNase treatment of RNA
Following isolation of total RNA from cells, contaminating DNA was removed 
using the Ambion DNA-free™ system. 25 pi (-40 pg) of total RNA, 1 pi DNase 1 (2 
units) and 2.5 pi 10 X DNase buffer were mixed gently and incubated at 37 °C for 30 
min. 5 pi DNase inactivation reagent was added, mixed and incubated at room 
temperature for 2 min. The mixture was centrifuged at 10,000 x g for 2 min to pellet 
the DNase inactivation suspension. The RNA supernatant was removed to a fresh tube 
and stored at -80 °C until further use. RNA quantitation and analysis was carried out as 
described in section 2.2.2.1.
2.2.16.3 RNA amplification
RNA was amplified using the Ambion MessageAmp™ aRNA system. This 
contained all the reagents and consumables required including buffers and purification 
cartridges. This method consists of reverse transcription with an oligo(dT) primer 
bearing a T7 promoter followed by in vitro transcription of the resulting DNA with T7 
RNA polymerase to generate hundreds to thousands of antisense RNA copies of each 
mRNA in a sample.
2.2.16.3.1 First strand synthesis
5 pg of DNase treated total RNA, isolated from cells as described in section
2.2.16.2 and quantitated as in section 2.2.2.1, was mixed with 1 pg of T7 oligo(dT) 
primer and the final volume brought to 12 pi with nuclease-free water. The mixture was 
vortexed and centrifuged briefly (-5  sec) to collect the sample at the bottom of the 
microfuge tube and heated at 70 °C for 10 min, then centrifuged briefly and placed on 
ice. The following were then added and mixed by gentle repeat pipetting; 2 pi 10 X 
first strand buffer, 1 pi ribonuclease inhibitor, 4 pi dNTP mix, and 1 pi reverse 
transcriptase to give a final volume of 20 pi. The mixture was then incubated at 42 °C 
for 2 hr and briefly centrifuged then placed on ice before immediately proceeding to the 
second strand synthesis step.
i
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2.2.16.3.2 Second strand synthesis
The following reagents were added (in order) to the above first strand synthesis 
reaction with mixing by gentle pipetting up and down; 63 (0,1 nuclease-free water, 10 (0.1 
10 X second strand synthesis buffer, 4 |o,l dNTP mix, 2 pi DNA polymerase, and 1 (o,l 
RNaseH. The mixture was briefly centrifuged then incubated at 16 °C for 2 hr after 
which it was stored on ice or at -20 °C before the cDNA purification step.
2.2.16.3.3 cDNA purification
cDNA filter cartridges were equilibrated with 50 pi cDNA binding buffer for 5 
min at room temperature. 250 pi cDNA binding buffer was added to the cDNA samples 
above and mixed by gentle vortexing. The cDNA sample/cDNA binding buffer mixture 
was applied to the equilibrated cartridge, which was firmly seated in its 2 ml wash tube 
and centrifuged for 2 min at 10,000 x g. The flow-through was discarded and 500 pi of 
ethanol-containing cDNA wash buffer was applied to the cartridge, which was replaced 
in the wash tube and centrifuged as above. The flow-through was discarded and the 
cartridge was replaced in the wash tube and centrifuged again to remove any trace 
ethanol. The cDNA filter cartridge was transferred to a 1.5 ml cDNA elution tube and 
10 pi of nuclease-free water (preheated to 50 °C) was applied to the centre of the filter 
and left at room temperature for 2 min before being centrifuged as above. The elution 
step was repeated to give an eluate of -16  pi containing dsDNA. The eluate was then 
placed on ice or stored at -20 °C before proceeding to the in vitro transcription step.
2.2.16.3.4 In vitro transcription to synthesise amplified RNA (aRNA)
The following was added with mixing by gentle pipetting to the 16 pi of the 
double stranded cDNA from the previous step; 4 pi ATP solution, 4 pi GTP solution, 4 
pi TTP solution, 4 pi CTP solution, 4 pi UTP solution, 4 pi T7 10 X reaction buffer and 
4 pi T7 enzyme mix. The mixture was centrifuged briefly to collect it at the bottom of 
the tube before being incubated at 37 °C for 12 hrs. 60 pi elution solution was added 
and mixed by gentle pipetting and vortexing.
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2.2.16.3.5 aRNA purification
Following in vitro transcription, all enzymes, salts and unincorporated 
nucleotides were removed from the aRNA sample. 350 |xl aRNA binding buffer was 
added and mixed thoroughly followed by the addition of 250 (0,1 100 % ethanol. The 
entire mixture was applied to an aRNA filter cartridge, which was placed in an aRNA 
collection tube and centrifuged for 2 min at 10,000 x g. The flow-through was 
discarded and 650 (0,1 of ethanol-containing aRNA wash buffer was applied to the 
cartridge which was replaced in the collection tube and centrifuged at 10,000 x g for 2 
min. The flow-through was discarded and the cartridge was centrifuged briefly to 
remove any trace ethanol. The cartridge was placed in a fresh collection tube. 50 |ol 
elution solution (0.1 M EDTA in nuclease-free water) preheated to 50 °C was applied to 
the centre of the cartridge and left for 2 min at room temperature before being 
centrifuged for 2 min at 10,000 x g. The elution was repeated with a second 50 (al 
aliquot of elution solution to give an aRNA solution of -100 (0,1. All aRNA was 
aliquoted and stored at -80 °C until further use. RNA quantitation and analysis was 
carried out as described in section 2.2.2.1.
2.2.16.4 Aminoallyl labelling of RNA
RNA was labelled with aminoallyl labelled nucleotides via first strand synthesis 
followed by a coupling of the aminoallyl groups to either Cyanine 3 or 5 (Cy 3/Cy5) 
fluorescent molecules.
2.2.16.4.1 Reagent preparation
A 50 X aminoallyl dNTP labelling mix was prepared with a 2:3 dUTP:dCTP 
ratio by mixing 5 |o,l dATP, dCTP, dGTP, 3 |xl dTTP and 2 (0,1 aa-dUTP (where each 
stock was 100 mM). The solution was stored at -20 °C.
2.2.16.4.2 First stand synthesis and aminoallyl labelling
2 (4.1 random hexamer primers (3 mg/ml) was added to 4 |og of DNase treated 
aRNA (as prepared in sections 2.2.16.2 and 2.2.16.3 and quantitated as in section 
2.2.2.1) and the final volume brought to 18.5 |ol with RNase free water. The sample
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was mixed well, incubated at 70 °C for 10 min, centrifuged briefly and then placed on 
ice. 6 (j.1 5 X first strand buffer, 3 (il 0 .1M DTT, 0.6 jxl 50 X aminoallyl-dNTP mix (as 
prepared above) and 2 jxl SuperScript™ II RT (200 U/|xl) were added, mixed and 
incubated at 42 °C for 15 hr. RNA was hydrolysed by the addition of 10 [xl 1 M NaOH 
and 10 (4.1 0.5 M EDTA. Samples were mixed and incubated at 65 °C for 15 min. The 
pH was then neutralised by adding 10 p.1 1 M HC1.
2.2.16.4.3 Reaction purification I: removal of unincorporated aa-dUTP
Amicon centrifugal filter devices were used to purify the aminoallyl labelled 
cDNA. 450 (4,1 of sterile water was added to the contents of the reaction and the entire 
mixture was applied to the filter, which was placed in a 1.5 ml tube and centrifuged at
12,000 x g for 8 min. The flow-through was discarded and the above wash step was 
repeated. The cartridge was inverted and spun at 12,000 x g for 2 min in a fresh 1.5 ml 
tube to collect the retentate. The samples were then dried using a speed vac.
2.2.16.4.4 Coupling of aa-cDNA to Cy dye ester
Aminoallyl labelled cDNA samples were resuspended in 4.5 |xl freshly prepared 
0.05 M NaHCC>3 , pH 9.0. 4.5 (4l of the appropriate Cy dye ester was added (i.e. Cy 3 
(green) to control and Cy 5 (red) to ‘treated’) and all tubes were wrapped in aluminium 
foil. The reaction was incubated for 4 hr in the dark at room temperature.
2.2.16.4.5 Reaction purification II: removal of uncoupled dye
A QIAquick PCR purification kit (Qiagen) was used to remove uncoupled dye. 
This kit included all buffers required for the procedure. 35 j4l 100 mM NaOAc pH 5.2 
was added followed by 250 jil PB (binding) buffer. The sample was applied to a 
QIAquick spin column in a 2 ml collection tube and centrifuged at 13,000 x g for 2 min. 
The collection tube was emptied and 0.75 ml of ethanol-containing PE (wash) buffer 
was added to the column and centrifuged for 2 min at 13,000 x g. The collection tube 
was emptied and the column was centrifuged for an additional minute at maximum 
speed. A coloured membrane (i.e. pink for Cy 3 or blue for Cy 5) at this stage indicated 
good labelling. The column was placed in a clean 1.5 ml microfuge tube and 30 (xl EB 
(elution) buffer was added to the centre of the column membrane and allowed to
42
incubate for 1 min at room temperature. The labelled cDNA was eluted by 
centrifugation at 13,000 x g for 1 min. The elution step was repeated with a fresh 30 (il 
of EB buffer using the same collection tube. The Cy dye labelled probes were then 
dried using a speed vac prior to hybridisation.
2.2.16.5 UV-crosslinking and prehybridisation of slides
Prior to hybridisation the spotted cDNAs were first rehydrated in a humidity 
chamber with 1 X SSC (0.15 M NaCl2; 15 mM Na3 C6 H 5 0 7 .2 H2 0 ), denatured at 95 °C 
for 4 min then UV cross-linked to the slide surface at 120 mJ. Slides were incubated at 
45 °C for 45 min in preheated prehybridisation buffer (5 X SSC, 0.1 % SDS, 1 % BSA). 
The slides were washed twice in Coplin jars containing MilliQ water by repeated 
dipping ensuring the entire slide was submerged. Slides were then submerged once in 
isopropanol, removed and allowed to air-dry. The water/water/isopropanol wash cycle 
was repeated with any slides that appeared smeared at this stage.
2.2.16.6 Probe hybridisation
Care was taken to expose Cy-labelled probes to as little light as possible. 
Labelled probes were resuspended in 23 (4,1 hybridisation buffer (50 % formamide, 5 X 
SSC, and 0.1 % SDS). Probes that originated from the same RNA and that were 
labelled the same were pooled together at this stage. A single aliquot from the pool of 
Cy3 labelled cDNA was combined with an independently labelled Cy5 in a total volume 
of 45 [4,1 for each slide, which was denatured at 95 °C for 3 minutes. A 22 mm x 60 mm 
microscope glass coverslip was placed on the prehybridised slide and positioned in a 
hybridisation chamber. The labelled probe mixture (45 |xl) was pipetted onto the slide 
surface at one end of the printed area and allowed to cover the entire print area by 
capillary attraction. Gentle tapping on the cover slip surface removed any bubbles 
underneath. 10 (4,1 water was added to the wells at each end of the chamber to ensure the 
atmosphere within remained humid during hybridisation. The chamber was sealed 
tightly and placed in a light proof incubator at 42 °C for 15 hr. Following hybridisation, 
the cover slips were removed and all slides were washed twice in 1 X SSC; 0.2 % SDS 
for 10 min at 45 °C followed by two washes in 0.1 X SSC; 0.1 % SDS for 10 min at 45 
°C and then two washes in 0.1 X SSC for 10 min at 45 °C. Slides were finally rinsed in 
MilliQ water and dried by brief centrifugation. Slides were scanned as soon as possible.
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2.2.16.7 Image acquisition and image processing
All hybridised slides were scanned using the confocal laser scanner ScanArray 
Express HT at 75 % photomultiplier tube, 75 % of laser power, and 10 [xm of pixel 
resolution. The wavelengths used were 550 nm (Cy 3) and 675 nm (Cy 5). Images 
were acquired by ScanArray Express 2.0 software (GSI Lumonics) and processed with 
Quantarray 3.0 software (Packard Bioscience) in order to measure the intensity and the 
local background for both Cy3 and Cy5 channels of each spot. This data was then 
further analysed as discussed in Chapter 4.
2.2.17 Protein extraction for the analysis of cathepsin C activity
To maintain cathepsin C activity trypsin was not used on the cells. All growth 
media was removed and cells were then rinsed in PBS. 1 ml of PBS was added to the 
culture flask and a cell scraper was used to remove cells into a 1.5 ml tube. The cell 
suspensions were then frozen and thawed three times to shear the cells. Cell 
suspensions were kept on ice while they were sonicated at 200 W with 1.5 sec intervals 
using a Sonics and Materials Inc VibraCell™ sonicator. The lysates were centrifuged at
13,000 x g for 10 min and supernatants were kept at -20  °C for further use.
2.2.18 Cathepsin C fluorescent substrate assay
This 96-well microtitre plate assay is based on the substrate specificity of 
proteolytic enzymes, where proteolysis of a specific synthetic substrate is monitored as 
fluorescence due to the liberation of a fluorescent leaving group. The leaving group 
used was the fluorescent molecule 7-Amino-4-methylcoumarin (AMC) which was 
conjugated to a Glycine-Arginine sequence. Gly-Arg is a specific substrate for 
cathepsin C.
In a white 96-well plate in triplicate 10 jal total cell lysis solution (as prepared in 
section 2.2.17) was added to 0.2 jj.1 10 mM Gly-Arg-AMC (in DMF), 4 p.1 0.1 M DTT 
and the final volume brought to 200 jil with 0.1 M sodium phosphate buffer, pH 6.0. 
Using the same 96-well plate a standard curve ranging from 0 to 10 jxM AMC was 
prepared by adding 195 (il standard to 5 [xl 0.1 M DTT. The plate was covered and
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in c u b a te d  a t 37  °C  fo r 6 0  m in . 5 0  |i l  10 %  (v /v )  a c e tic  a c id  w a s  a d d e d  to  e a c h  w e ll to  
te rm in a te  th e  re a c tio n . T h e  p la te  w a s  re a d  o n  a f lu o ro m e te r  w ith  an  e x c ita tio n  
w a v e le n g th  o f  3 7 0  n m  (s lit  w id th  10) a n d  an  e m is s io n  w a v e le n g th  o f  4 4 0  n m  (s lit  w id th  
2 .5 ).
2.2.19 Isolation of total RNA from tissue samples
T is s u e  s a m p le s  w e re  r e m o v e d  f ro m  - 8 0  °C  s to ra g e  an d  m o u n te d  o n  a  C M  1900 
C ry o s ta t  (L e ic a )  s e t  to  - 2 0  °C . 8 m ic ro n  s e c tio n s  w e re  re p e a te d ly  c u t in to  1 m l T R I1M 
re a g e n t a n d  a  f in e  g a u g e  n e e d le  w a s  u se d  to  fa c ili ta te  d is in te g ra tio n  o f  th e  tis su e . R N A  
w as th e n  is o la te d  as d e s c r ib e d  in s e c t io n  2 .2 .2  e x c e p t 1 (.d 5 m g /m l g ly c o g e n  and  
is o p ro p a n o l w e re  a d d e d  to  th e  a q u e o u s  p h a s e  to  p re c ip ita te  th e  R N A .
45
Chapter 3
The roles of MMPs and CD44 in colon cancer 
invasion
3.1 Introduction
ECM turnover and therefore proteolytic activity are key to tumour progression. 
Malignant cancers as opposed to benign neoplasms are characterised by their ability to 
cross tissue boundaries and spread to other organs of the body. Degradation and 
remodelling of the tumour microenvironment and the ECM, including the basement 
membrane through proteolysis of matrix proteins are essential steps in local invasion 
and metastasis. MMP degradation of ECM and cell associated proteins is essential for 
almost every step of metastasis; for example in aiding cells crossing ECM barriers and 
the epithelial basement membrane as well as facilitating intravasation and extravasation 
and colonisation at distant sites. Without the ECM-degrading MMPs, cancer cells 
would be unable to cross these matrix barriers that normally hinder their spread. MMPs 
are the main proteolytic enzymes associated with tumour progression and play a pivotal 
role in virtually all steps of cancer evolution, both early and late. The significant gaps 
in knowledge regarding the mechanisms underlying such contributions must be filled 
before the development of therapeutic MMP inhibitors (MMPIs) can proceed with a 
legitimate chance of success.
As well as physically removing the barriers for tumour progression, MMP 
activities have wider roles in tumour progression including growth factor and pro-MMP 
activation (Yu and Stamankovic, 2000 and Sato et al., 1994). MMP overexpression in a 
tumour therefore, is associated with a more aggressive phenotype. The contribution of 
the microenviroment to tumour progression is stressed by the fact that in epithelial 
cancers most of the upregulated MMPs are expressed by the neighbouring supporting 
stromal cells as apposed to the carcinoma cells (Werb, 1997 and Nelson et al., 2000). 
Malignant cells can consequently recruit this MMP activity and implement it in a 
variety of proteolytic tasks, i.e. from ECM turnover to the proteolytic release of latent 
ECM-bound growth factors. Increased levels of MMPs in a tumour occur due to their 
uncontrolled overexpression or because of diminished expression of the TIMPs. The 
TIMP family of secreted proteins inhibit the activity of MMPs through binding them 
selectively and reversibly in a 1:1 stoichiometric manner. The main MMPs associated 
with all aspects of tumour invasion (i.e. from intravasation to angiogenesis) are MMP-1,
3.1.1 MMPs in cancer and metastasis
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-2, -3, -7, -9, -12, -13 and -1 4  (Sternlicht and Bergers, 2000), with other MMPs having 
more discrete roles in the metastatic process.
MMP activity is implicated at all stages of cancer and metastasis including the 
early stages of tumour development. The exact roles of MMPs in early stage 
tumourigenesis are still unclear. However, MMP activity at the stages preceding 
invasion is thought to contribute to tumour growth rather than tumour initiation. One 
way for this to happen is through increased neovascularisation. MMPs play a key role 
in angiogenesis, an important part of tumour development where new capillaries are 
formed in response to angiogenic stimuli such as FGF and EGF (Fisher et al., 1994). 
The formation of tumour vasculature is crucial for tumour development. As the tumour 
grows in mass, a critical point is reached where further growth is prevented without 
angiogenesis occurring. MMP activity is involved in ECM degradation, thus allowing 
vascular endothelial cells to advance through the basement membrane in order to lay 
down new blood vessels (Stetler-Stevenson, 1999). Secreted MMP activity has been 
detected as a response of cultured endothelial cells to angiogenic stimuli (Fisher et al., 
1994). Studies using MMP inhibitors have shown that a reduction in MMP-2 activity 
results in reduced angiogenesis (Moses and Langer, 1991 and Brooks et al., 1998). The 
requirement for MMP activity during neovascularisation has implications for the growth 
of both the initial tumour and distant metastases.
3.1.1.1 MMP-7 in colon cancer and metastasis
MMP-7 (also known as matrilysin) expression is found in 90 % of colonic 
adenocarcinomas (Newel et al., 1994), where clinically, a correlation exists between 
expression and distant metastasis (Adachi et al., 1999). MMP-7 is sub-classed as a 
minimal domain MMP. At 28 kDa it is the smallest member of the MMP family and its 
active form has a molecular weight of 19 kDa. MMP-7 has the widest range of 
substrates, with the ability to degrade collagens, elastin, fibronectin, gelatin, laminin, 
tenascin, E-cadherin, proteoglycans and glycoproteins (Fingleton et al., 1999). The 
most distinctive aspect of MMP-7 expression patterns is the fact that it is expressed in 
the epithelial cells of tumours of gastrointestinal, prostate or breast origin, where as the 
majority of other MMPs are produced in the stroma. It is this aspect of MMP-7 that 
gives it its potentially novel functions (Wilson and Matrisian, 1996). MMP-7 is 
expressed in a variety of tumours including those of the breast, colon, prostate and lung.
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MMP activity is implicated at all stages of cancer even at the early stages of 
tumourigenesis (Fingleton et al., 1999). MMP-7 is thought to play key roles in both the 
growth of early colonic adenomas as well as their transformation into invasive cancers 
(Wilson et al., 1997). A significant amount of evidence has accumulated regarding the 
role of MMP-7 in the early stages of colorectal tumourigenesis. MMP-7 activity has 
been shown to be present in colorectal adenomas (Yamamoto et al., 1994). MMP-7 has 
also been found localised to the cytoplasm of colon adenoma cells, giving it possible 
intracellular functions in adenomas (Fingleton et al., 1999). In a model of colorectal 
tumour cell invasion, MMP-7 has been shown to be more important in the early stages 
of tumour formation, progression and growth as well as the later processes of metastasis 
(Witty et al., 1994). This study of the MMP expression profiles in two genetically 
matched human colon adenocarcinoma derived cell lines showed that the lymph node 
metastasis derived SW620 cell line expressed MMP-7 where the SW480 primary 
tumour cell line, derived from the same patient did not. In the Witty et al. (1994) study, 
over expression of MMP-7 in the SW480 cell line by cDNA transfection caused 
increased tumourigenicity and metastases when injected into nude mice, while MMP-7 
inhibition has also been shown to decrease metastasis (Hasegawa et al., 1998). 
Transgenic mice studies have also revealed the effect of MMP-7 overexpression on 
initial tumour establishment and growth (Rudolph-Owen et al., 1998). In this study, 
overexpression of MMP-7 led to enhanced tumourigenesis in a mouse breast cancer 
model. Furthermore, MMP-7 knockout mice that are null for MMP-7 have been shown 
to develop fewer tumours (Wilson et al., 1997) thus supporting the role for MMP 
activity in tumour establishment and growth. MMP-7 can therefore be considered to 
function as an oncogene since colorectal tumourigenesis is suppressed in mice lacking 
MMP-7 and tumourigenic potential is enhanced in cell lines overexpressing MMP-7 
(Ougolkov et al., 2002). One important downstream cellular function targeted by active 
MMP-7 is the suppression of Fas-mediated apoptosis and the subsequent promotion of 
cell survival. This is due to the MMP-7 mediated release of soluble Fas ligands from 
the cell surface (Mitsiades et al., 2001 and Powell et al., 1999). The expression of 
MMP-7 in primary tumours can therefore be monitored as a marker for progression.
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3.1.1.2 MMP-2 and MMP-9 in colon cancer and metastasis
Another group of MMPs that have extensive associations with colon cancer are 
the gelatinases. Gelatinase A (MMP-2) and gelatinase B (MMP-9) are the only 
members of the fibronectin domain sub-class of MMPs. MMP-2 and MMP-9 degrade 
denatured collagens (gelatins) and are specific for the degradation of type IV basement 
membrane collagen giving them essential roles in the processes of intravasation and 
extravasation. MMP-2 is secreted as a 72 kDa pro-enzyme and is activated to a 66 kDa 
form that degrades gelatin, collagens type I, III, IV, V, VII, X, VI and fibronectin. 
MMP-2 expression is widespread and is frequently elevated in malignant tumours. The 
expression of MMP-9 is also widespread with activity being described in malignant 
cells, neutrophils, and keratinocytes (Collier et al., 1988 and Wilhelm et al., 1989). 
MMP-9 is secreted as a 92 kDa zymogen and its active form has a molecular weight of 
86 kDa. MMP-9 cleaves gelatins, collagens type IV, V, XI, XIV, elastin and laminin. 
Increased expression of MMP-9 has been shown in colon adenomas when compared 
with normal mucosa, possibly representing an early change in progression from 
adenoma to carcinoma (Parsons et al., 1998). Another important observation is that this 
up-regulation was not seen in rectal tumours (Roeb et al., 2001). The major roles of 
MMP-9 in colon cancer are in ECM degradation and the subsequent migration and 
invasion of tumours. Inhibition of MMP-9 leads to impaired invasion and proliferation 
of tumour cells in a three-dimensional collagen matrix (Agrez et al., 1999).
3.1.1.3 MMPs and the ECM
The ECM plays a key role in regulating cell signalling and maintaining normal 
cell homeostasis. Degradation of the ECM at the site of adhesion can disturb these 
interactions thus modulating the signals to the cells. It has been shown that MMP-2 
degradation of a collagen matrix reveals hidden integrin adhesion sites (Montgomery et 
al., 1994). Integrins expressed on the cell surface of melanoma cells are then free to act 
as receptors for degraded collagen and signal for cell survival. MMP cleavage of matrix 
components releases soluble ECM fragments which have been shown to increase cell 
migration (Woodhouse et al., 1997 and Giannelli et al., 1997).
There is increasing evidence for a relationship between stromal cells and 
colorectal carcinoma cells in promoting MMP production in either tumour or stromal
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cells (Ornstein et al., 1999). It is well established that MMP-9 is produced in the 
stromal cells of colon cancers (Zeng and Guillem, 1996 and Nielsen et al., 1996). The 
observation that MMPs are largely produced by the stromal compartment surrounding 
the tumour tissue suggests that the tumour, by communicating with its surrounding 
environment, can stimulate MMP expression. This is often due to the MMP-mediated 
release of growth factors by either direct cleavage of bound cell surface growth factors 
or by their release from the ECM as a result of ECM turnover. As well as speeding up 
tumour proliferation, the bioavailability of such mitogens induces MMP genes, for 
example, MMP expression is often increased in response to members of the EGF and 
FGF families (McCawley and Matrisian, 2001). Tumours are known to produce 
cytokines and growth factors, including those with MMP-inducing ability (Birkedal- 
Hansen et al., 1993) and it is quite possible that these factors account for MMP 
production in the stromal compartment (Klein et al., 1997). Human colorectal cancer 
cell lines that did not express MMPs were shown to induce host MMP expression when 
transplanted into nude mice (McDonnell et al., 1999). MMP-7 has been shown to dock 
on the cell surface with CD44 where it can activate heparin bound epidermal growth 
factor (HBEGF), which also binds CD44, making it available to its cell surface receptor 
(Yu et al., 2002). This highly orchestrated mechanism illustrates how MMPs can finely 
control the tumour environment by utilising the host surroundings.
3.1.2 CD44 in cancer
CD44 expression has been identified on a variety of different tumour cells, 
including colon and breast (Gunthert et al., 1991, Choi et al., 2000, Herrlich et al., 1995 
and Bourguignon et al., 2002). Tumour progression is associated with abnormal CD44 
variant expression and by a generalised dysregulation of the splicing process leading to 
the expression of a multitude of CD44 isoforms in tumours of increasing malignancies 
(Jothy, 2003). O f particular interest are the CD44 variants CD44v6 and CD44v4-v7, 
which confer metastatic properties when overexpressed in vivo (Gunthert et al., 1991). 
Transfection of defined CD44 variants (v4 through v7, v6 and v7) converted non­
metastatic cell lines to cells that spread and colonised the lung in vivo where 
transfection with standard truncated CD44 (CD44s) was negative for metastasis 
(Herrlich et al., 1993). Colorectal tumour progression is associated with a decrease in 
CD44s expression and an increase in CD44v expression (Wielenga et al., 1993). In a 
study of the different stages of colorectal carcinogenesis, CD44v6 expression has been
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shown to be negative in normal colon epithelium and positive in 100 % of carcinomas 
and metastases (Mulder et al., 1994 and Herrlich et al., 1995). The functional roles for 
CD44v6 in the developed tumour are still unclear but one possibility is that it confers a 
growth advantage. Experimental animal studies have shown that an increase in CD44s 
expression prevents the establishment of metastasis (Pereira et al., 2001). 
Overexpression of CD44v6 has been observed more often in advanced colon cancers 
(Dukes’ stage C/D) compared with Dukes’ A/B, and it can therefore be used as a 
prognostic marker (Wielenga et al., 1993 and 1998). Interestingly, CD44 upregulation 
has been shown to be an early event, suggesting a role in tumourigenesis (Kim et al., 
1994).
The exact roles of CD44 in cancer have yet to be elucidated. The acquisition of 
a metastasising phenotype involves a large number of functions, but it is still unclear 
which function involves CD44. The remarkable and unusual property of CD44 in 
comparison with other adhesion molecules is that it mediates both cell-cell and cell- 
ECM interactions. Such varied adhesion interactions are required for the migration of 
tumour cells into the foreign stromal surroundings. Therefore, alterations in CD44 
expression can hypothetically aid the metastatic spread.
3.1.3 Integrins: roles in the transformed cell
Integrins are essential for tumour progression due to their capability to mediate 
specific physical interactions with the ECM and their ability to control signalling 
pathways especially those involved in cell movement. Cancer cells can switch the types 
of integrins they express, favouring ones that transmit pro-growth signals. On their 
travels, invading and metastasising cells experience changing tissue microenvironments 
and are presented with different matrix components. Successful metastasis therefore 
requires adaptation. Therefore, changes in integrin subunit expression in transformed 
cells are important in tumour progression (Juliano and Varner, 1993). As discussed in 
chapter 1, integrin signals influence cellular proliferation and differentiation as well as 
cell survival. They can, therefore directly or indirectly (via promoting growth arrest, 
differentiation and/or apoptosis) influence the growth of a tumour in vivo. For example, 
overexpression of the uv[)6 integrin, a fibronectin receptor, has been shown to enhance 
the proliferative capacity of SW480 colon carcinoma cells in vitro and in nude mice 
(Agrez et al., 1994).
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3.1.4 MMP interactions with cell adhesion molecules
Both altered matrix degradation and cell adhesion are vital factors in promoting 
tumour invasion. MMPs are thought to participate in both these processes via 
interactions with cell adhesion molecules.
MMP proteolysis of the ECM effects cell adhesion via the integrin family of cell 
adhesion molecules by changing the way integrins interact with the ECM. Several 
studies have shown a functional link between integrins and the MMPs. It has been 
shown that ligation of collagen by a2p i integrin on the surface of ovarian carcinoma 
cells results in tyrosine kinase signalling and the subsequent expression of MT1-MMP 
which activates pro-MMP-2 resulting in enhanced cell surface MMP activity 
(Ellerbroek et al., 1999). Increased avp i integrin expression leads to enhanced MMP-9 
secretion (Agrez et al., 1999). Individual integrins can bind several ECM proteins, with 
different interactions having different effects. For example, a4 [31-mediated adhesion to 
fibronectin induced the expression of MMP-2 and MMP-9 but upon a4pi-mediated 
adhesion to vascular cell adhesion molecule-1 (VCAM-1), only MMP-2 was induced in 
the same cells (Yakubenko et al., 2000). avf33 integrin will not bind native matrix 
collagen but it will bind proteolytically degraded collagen. av(33 expression and 
signalling confers an invasive advantage on cells (Cheresh, 1991). MT1-MMP can 
process the av subunit of the avP3 integrin leading to a C-terminal truncated dimer that 
is more efficient at promoting cell migration than the full-length avP3 (Deryugina et al., 
2002 and Ratnikov et al., 2002). Moreover, avP3 integrin can bind active MMP-2 at its 
C-terminus and target its activity on collagen (Brooks et al., 1996). This is a fine 
example of symbiosis between a cell adhesion molecule involved in cellular motility 
and an enzyme capable of basement membrane degradation. Tumour cell motility is 
stimulated by TGF-P1 through direct transcriptional activation of a3 integrin (Giannelli 
et al., 2002), which leads to acquired motility of tumour cells on a laminin-5-containing 
matrix. The presence of MMP-9 in this system leads to the cleavage and activation of 
TGF-P 1, giving it a key role in the signalling machinery responsible for cell motility 
and invasion (Yu and Stamenkovic, 2000). Certain integrins affect the transcription of 
various MMP genes. a2 p i overexpression has been associated with an increase in 
MMP-1 (interstitial collagenase) expression (Jones and Walker, 1997) and avp6 
integrin has been shown to induce MMP-9 in colon cancer cells (Niu et al., 1998). The
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P4 subunit of the a6p4 integrin is a specific receptor for laminin, and it is important in 
preventing tumour spread. Monoclonal antibody blocking of P4 integrin subunit 
activity resulted in enhanced MMP-2 expression and increased migration (Daemi et al.,
2000), providing evidence for the functional relationship between individual MMPs, 
cell adhesion, and cell invasion.
Both MMPs and CD44 are critical to the invasive process, and several studies 
have recently begun to define how these molecules interact with each other. 
Stimulation of CD44 has been shown to increase MMP-2 expression in human 
melanoma cells (Takahasi et al., 1999) and in lung carcinoma cells (Zhang et al., 2002). 
MMP-9 has also been shown to associate with CD44 on the surface of mouse mammary 
carcinoma and human melanoma cells thus enhancing invasion (Yu and Stamenkovic, 
1999). Invading cells therefore have a mechanism by which they can direct MMP-9 
activity to the area of invasion. MMP-9 is also free to activate other MMPs or growth 
factors in this tethered orientation (Yu and Stamenkovic, 2000). A recent paper has 
shown that CD44v3 can anchor MMP-7 on the cell surface and target its activity (Yu et 
al., 2002). CD44 can form a complex with MT1-MMP and both molecules co-localise 
on the cell surface at the cell migration edge. In this arrangement CD44 functions as a 
molecular linker between MT1-MMP and the actin cytoskeleton, linking the factors 
involved in cell motility such as matrix degradation, cell adhesion, morphology with the 
cytoskeleton (Mori et al., 2002). It has also been shown that MT1-MMP can directly 
cleave CD44 and promote cell migration in a pancreatic tumour cell line (Kajita et al., 
2001 and Cichy and Pure, 2003).
3.1.5 Therapeutic inhibition of MMPs
The ever growing information regarding the roles of MMPs in tumour 
development and progression have spurred the development of many synthetic matrix 
metalloproteinase inhibitors (MMPIs). Inhibition of MMP activity in tumours is 
desirable because it would ideally result in the inhibition of tumour growth, 
angiogenesis, invasion and metastasis. The key to the design of effective MMPIs is in 
understanding the roles and properties of individual MMPs. In this way, indiscriminate 
effects of such therapies on normal healthy tissue and subsequent side effects can be 
minimised. Originally, MMPI designs were based on small peptides that mimicked 
MMP substrates (Brinkerhoff and Matrisian, 2002). Based on the structure of collagen,
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the broad spectrum MMPI Marimastat (British Biotech, Oxford, UK) has been shown to 
significantly increase survival when administered to patients with early-stage, 
metastasis free disease (Whittaker et al., 1999 and Curran and Murray, 2000). 
Contributions of MMPs, especially MMP-7, to early stage tumourigenesis, suggest it 
may be beneficial to treat tumours at the early stages using MMPIs. Marimastat was 
not without side effects, with patients experiencing extreme joint pains. Trials on BAY 
12-9566, an MMPI developed by Bayer Pharmaceuticals were halted because the 
placebo performed better than it (Coussens el al., 2002). The fate of MMPI as a therapy 
lies in the hands of basic researchers. Further understanding of the exact roles of 
specific MMPs at different stages of tumour progression is needed. This would lead to 
more targeted therapies and would minimise side effects.
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3.1.6 Summary
CD44 and MMPs are among the many participants in tumour cell invasion and 
metastasis. MMPs have well-established roles in tumour cell invasion where MMP 
activity is involved in ECM turnover, neovascularisation and growth factor activation. 
Increased MMP-7 and MMP-9 activity have been associated with colorectal tumour 
progression. CAMs such as CD44 also have specific roles in the metastatic process. As 
well as mediating cell -  cell and cell -  matrix interactions, CAMs are also involved in 
cell signalling. Recent evidence has suggested CD44 may be involved in colorectal 
tumour cell invasion. Of particular interest are the CD44 splice variants, with splice 
variant expression having prognostic potential in colorectal cancer. Collaborative 
interactions between these biomolecules in the metastatic process have been unearthed 
by recent research into their functional relationships. While both these biomolecules are 
well-established participants in the metastatic process, their collective interactive 
functions are still unclear. Although the interactions between CAMs and MMPs in 
regulating tumour metastasis have yet to be completely elucidated, it is no longer 
suitable to consider these groups of biomolecules as acting in isolation. In this chapter, 
interactions between CD44 and MMPs in regulating invasion and migration in 
colorectal tumour cell lines were examined. The elucidation of such collaborative roles 
would validate their potential as either potential therapeutic targets or prognostic 
markers of colorectal metastasis.
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3.2 Results
3.2.1 Description of colon cancer cell lines used in this study
MMPs were overexpressed in colorectal cancer cells to investigate their roles in 
various aspects of tumour cell invasion. The main cell lines used in this study were the 
paired colon cancer cell lines SW480 and SW620. SW480 is a cell line established 
from a primary Dukes' stage B colon adenocarcinoma of a 50-year old male patient. 6 
months later a recurrent cancer was discovered in the same patient, with liver and lymph 
métastasés present. The SW620 cell line was derived from a lymph node metastasis 
(Leibovitz et al., 1976). These isogenic cell lines have been validated as a model of 
colorectal metastasis and therefore comparisons between them could provide new 
insights into the metastatic process (Hewitt et al., 2000). The non-metastatic SW480 
cell line was stably transfected with the cDNAs for MMP-9 and MMP-7 (Murray et al., 
2004 and Witty et al., 1994). The new cell lines have been termed SW480M9 and 
SW480M7 respectively.
3.2.2 Expression of MMPs in colon cancer cell lines
3.2.2.1 Expression of MMP-7 mRNA in colon cancer cell lines
The SW480M7 cell line was received from Professor Matrisian’s laboratory 
(Vanderbilt University, Nashville, TN). This cell line has been previously studied 
(Witty et al., 1994) and was referred to as SW480 (Mut6) in this paper, for convenience 
the name SW480M7 has been adopted for this thesis. It was important to re­
characterise these cells as they had been frozen down since 1995. The expression of 
MMP-7 in these cells was monitored by western blot and real time PCR analysis.
Firstly, total cellular RNA was isolated as described in section 2.2.2 and its 
integrity was assessed prior to RT-PCR as described in section 2.2.2.1. RNA is easily 
degraded by RNases. Unlike most nucleases, RNases are resistant to autoclaving but 
can be inactivated by DEPC when it is added to solutions at a final concentration of 0.1 
%. Therefore all solutions for RNA work were DEPC treated and gloves and disposable 
plastics were used at all times. To help prevent RNA degradation by endogenous 
RNases, all RNA procedures were carried out quickly and on ice. RNA was examined
I
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for degradation by running an aliquot of each isolated RNA sample on a 1 % agarose 
gel (Figure 3.1). The presence of 28S, 18S and 6S RNA ribosomal subunits were 
typical of undegraded RNA. Isolated RNA was quantified by measuring its absorbance 
at 260 nm (40 pg RNA had an OD of 1). RNA purity was assessed using the 
absorbance value for each sample at 280 and 260 nm to calculate its A260/A280 ratio. 
RNA samples had ratio values between 1.6 and 1.8, which indicated they were free of 
DNA, protein and organic solvent contaminants.
28 S 
18S
6S
Figure 3.1 An aliquot of total RNA was analysed for degradation by agarose gel 
electrophoresis. The presence of 28S, 18S and 6S ribosomal sub-units was typical 
of undegraded RNA.
To show MMP-7 overexpression in the SW480M7 at the level of transcription, 
real time PCR as outlined in section 2.2.4 was carried out on RT reactions. Real time 
PCR is a sensitive and reproducible technique that gives a quantitative expression value. 
Real-time PCR quantitates the initial amount of template more specifically, sensitively 
and with greater reproducibility than normal quantitative PCR, which detects the 
amount of final amplified product. This is because real-time PCR monitors the 
fluorescence emitted during the reaction as an indicator of amplified product formed 
during each PCR cycle (i.e. in real time) as opposed to the endpoint detection by 
conventional quantitative PCR methods, thus allowing the real-time progress of the 
reaction, especially its exponential phase, to be viewed. Although real-time PCR 
removes the need for electrophoresis of the PCR products, it does not detect the size of 
the product. The system is based on the detection and quantitation of a fluorescent
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reporter, w here the signal increases in  direct proportion to  the am ount o f PC R  product 
in  a reaction. SY B R  green, a double stranded D N A  binding dye that binds m inor 
grooves and w ill no t b ind  ssD N A  w as used. The real-tim e system  was used for 
com parative gene expression analysis, norm alising  w ith beta-actin  levels.
dF2/d2C
expression in SW480, SW620, SW480M7 and SW480M9 cells. The data from this 
curve (Table 3.1) was used to normalise MMP-7 and MMP-9 expression data. The 
colours used are summarised in Table 3.1.
Table 3.1 P-actin real tim e PC R  com parative concentration expression data. ‘T ake-off’ 
refers to  the cycle in  w hich  the reaction  en tered  the exponential phase. The com parative 
concentration data w as used  to  norm alise M M P-7 and M M P-9 real tim e PCR 
expression data.
Colour Name Takeoff Comparative Concentration
SW480 Actin 16.6 1.00E+00
■ SW480 Actin 16.5 1.06E+00
SW480 Actin 16.7 9.46E-01
SW620 Actin 13.0 7.25E+00
SW620 Actin 15.2 2.16E+00
SW620 Actin 14.7 2.84E+00
SW480M7 Actin 15.8 1.55E+00
SW480M7 Actin 15.9 1.47E+00
SW480M7 Actin 15.8 1.55E+00
SW480M9 Actin 16.1 1.32E+00
■ SW480M9 Actin 15.7 1.64E+00
■ SW480M9 Actin 17.0 8.02E-01
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T he constitu tively  expressed cytoskeletal protein  P-actin was used  as a control. 
The P-actin real tim e PC R  data obtained from  each cell line is sum m arised in Table 3.1 
and w as used  to norm alise M M P-7 and M M P-9 expression data. Follow ing real tim e 
PCR, m elt curve analysis was carried  out on all reactions by  heating from  50 °C to 100 
°C w hile m onitoring  fluorescence. A s can be seen from  Figure 3.3 all P-actin reactions 
resulted  in  only one m elt curve peak indicating that only one PC R  product was form ed 
in the reaction and that the prim ers and conditions used w ere specific for p-actin 
am plification.
dF2/d2C
obtained from this reaction (Table 3.2) was normalised using p-actin data. The 
colours used are also summarised in Table 3.2.
R eal tim e PC R  was carried on all sam ples for M M P-7 (Figure 3.4). The data 
obtained is listed  in  Table 3.2. A s can be seen from  Figure 3.5 only  one peak was 
obtained for the m elt curve analysis o f all reactions, indicating specificity.
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Table 3.2 C om parative concentration data  obtained from  the M M P-7 real tim e PCR 
reaction.
Colour Name Takeoff Comparative Concentration
■ SW480 MMP7 35.8 1.00E+00
■ SW480 MMP7 24.1 9.34E-01
■ SW480 MMP7 36.2 8.56E-01
■ SW620 MMP7 30.0 9.48E+00
■ SW620 MMP7 31.1 6.19E+00
■ SW620 MMP7 32.4 3.74E+00
■ SW480M7 MMP7 29.5 1.15E+01
■ SW480M7 MMP7 29.2 1.29E+01
■ SW480M7 MMP7 29.4 1.20E+01
■ SW480M9 MMP7 33.8 2.17E+00
■ SW480M9 MMP7 28.8 1.51E+00
■ SW480M9 MMP7 33.4 2.54E+00
each reaction indicated the reaction was specific.
In  order to  m ake quantitative com parisons betw een the cell lines used the 
com parative concentration values obtained  from  the M M P-7 real tim e PC R  reactions 
(Table 3.2) w ere norm alised using the P-actin real tim e PC R  data. It can be seen from  
F igure 3.6 that SW 480M 7 expressed the m ost M M P-7 at the m R N A  level w ith the 
SW 480 cells producing barely  detectable levels. Interestingly, the SW 620 cells and the 
SW 480M 9 cells produced sim ilarly  low  am ounts.
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Figure 3.6 Overexpression of MMP-7 in SW480M7 cells. Real-time PCR was 
used to compare the levels of MMP-7 expression in cell lines. P-actin was used for 
normalisation.
3.2.2.2 Expression of MMP-7 protein in colon cancer cell lines
C onditioned  m edia w as collected  from  cells as described in section 2.2.5 and 
p ro tein  concentration  was determ ined  using  the B C A  assay as described in section 
2.2.6. U sing a specific anti-M M P-7 antibody, M M P-7 overexpression in SW 480M 7 
cells w as show n by  w estern b lo t analysis o f 50 pg total protein (F igure 3.7). A lthough 
no positive  control was used, M M P-7 identity  was confirm ed by  its 28 kD a m olecular 
w eight. M M P-7 expression was not detected  in  either the parental SW 480 cells, the 
SW 620 cells o r the SW 480M 9 cells.
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Figure 3.7 MMP-7 overexpression in SW480M7 cells was determined using 
western blot analysis.
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3.2.2.3 Expression o f MMP-9 mRNA in colon cancer cell lines
The SW 480M 9 cell line was developed  by  D r M cD onnell w hilst on sabbatical in 
M em orial S loan K ettering C ancer C enter, N ew  York, NY , U SA . H ow ever, the cells 
had not been  extensively  characterised. M M P-9 expression in  all four cell lines was 
assayed by  real tim e PC R , gelatin zym ography  and w estern blot. Total cellular RN A 
was isolated  and analysed. Figure 3.1 show s SW 480M 9 R N A  to be intact. Real time 
PC R  w as carried  out as outlined in  section  2.2.4.
dF2/d2C
3.3. The comparative concentration values obtained (Table 3.3) were normalised 
using p-actin real time PCR data (Table 3.1).
Table 3.3: M M P-9 real tim e PC R  com parative concentration data.
Colour Name Takeoff Comparative Concentration
■ SW480 MMP9 22.5 1.00E+00
■ SW480 MMP9 22.5 1.00E+00
■ SW480 MMP9 21.3 1.84E+00 .
■ SW620 MMP9 22.3 1.11E+00
■ SW620 MMP9 22.4 1.05E+00
■ SW620 MMP9 22.0 1.29E+00
SW480M7 MMP9 22.1 1.23E+00
SW480M7 MMP9 22.1 1.23E+00
SW480M7 MMP9 21.5 1.67E+00
■ SW480M9 MMP9 18.9 6.27E+00
■ SW480M9 MMP9 19.2 5.38E+00
■ SW480M9 MMP9 19.2 5.38E+00
A s can be  seen from  Table 3.3 the SW 480M 9 cells had the earliest ‘take-off’ 
tim e and the h ighest com parative concentration  values. A  m elt curve w as carried out 
after the PC R  reaction to  conclude the reaction  was specific (Figure 3.9). One m ajor
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peak at 94 °C indicated  one product w as form ed. W hen norm alised, the data clearly 
show ed SW 480M 9 cells expressed the h ighest am ounts o f M M P-9 m RNA . M M P-9 
expression in  SW 480M 9 cells was five tim es h igher than  that o f  the parental SW 480 
cells at the  m R N A  level. There w ere no  significant differences in  M M P-9 expression 
betw een the  SW 480, SW 620 and SW 480M 7 cells (Figure 3.10).
SW480 SW620 SW480M7 SW480M9
Figure 3.10 Overexpression of MMP-9 in SW480M9 cells. Real time PCR was 
used to determine levels of MMP-9 expression in the cell lines studied. MMP-9 
expression data was normalised using (3-actin real time PCR data.
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3.2.2.4 Expression of M M P-9 protein in colon cancer cell lines
G elatinase activity  in  colon cell lines was studied by  analysing conditioned 
m edia (CM ) using  gelatin  zym ography, w hich  is sim ilar to sodium  dodecyl sulphate 
polyacrylam ide gel electrophoresis (SD S-PA G E) except the substrate, gelatin is 
incorporated  into the polyacrylam ide gel. Z ym ography is an extrem ely  sensitive 
m ethod and has the ability  to detect p icogram  quantities o f gelatinase activity (K leiner 
and S tetler-Stevenson, 1994). Incorporation o f gelatin  into the gel allow s detection of 
gelatinase activ ity  specifically. Proteolytic  enzym es such as the M M Ps are easily 
characterised  by  digestion o f  the substrate  and by  their m olecular w eight. M aintenance 
o f enzym atic activities is crucial and therefore care m ust be taken, e.g. precise buffer pH 
values are im portant and over-heating o f  gels m ust be avoided.
50 jxg o f  total protein  was assessed for gelatinase activity as described in section 
2.2.9. It can be seen from  F igure 3.11 that the SW 480M 9 cells secreted the highest 
levels o f M M P-9 in  com parison w ith  the  parental SW 480 cells, w hich did not produce 
any m easurable am ounts o f  the enzym e. Low  levels o f M M P-9 activity  were also 
detected in the SW 620 cells. M M P-9 w as identified  by  its m olecular w eight and its 
identity  was also confirm ed by  w estern  b lo t analysis. U sing an M M P-9 specific 
antibody, M M P-9 w as only detected in  SW 480M 9 cells by  w estern b lo t analysis 
(Figure3.12).
97 kDa 
84 kDa
Figure 3.11 Gelatin zymography was used to show MMP-9 activity in the 
SW480M9 cells.
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Figure 3.12 Western blot analysis was used to confirm MMP-9 overexpression in 
SW480M9 cells. MMP-9 was undetected in the other cell lines used.
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3.2.3 The in vitro invasive activities o f the cell lines studied
Invasion  is a  key  process in  tum our m etastasis and therefore the differences in 
invasion betw een  the m etastatic SW 620 cells and non-m etastatic SW 480 cells were 
m onitored. S ince E C M  degradation is key  to  tum our cell invasion, the effect o f M M P 
over-expression on in vitro invasion through m atrigel coated m em branes was also 
exam ined. T he in vitro invasion assay m im ics the  behaviour o f  invasive cells as they 
m igrate th rough the basem ent m em brane. M em branes at the bo ttom  o f  the 24 w ell cell 
culture inserts u sed  contained 8 |xm pores that w ere coated w ith a layer o f  m atrigel 
artificial basem ent m em brane com plex. This layer occludes the pores o f  the m em brane 
b locking non-invasive cells from  m igrating  through the m em brane. In contrast, 
invasive cells w ere able to  m igrate th rough the m atrigel-coated m em brane.
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Figure 3.13 10X microscopy of invasive cells using the in vitro assay. This figure 
gives an example of what was observed when invasive cells (red arrow) that had 
invaded through the 8 |xm pores (black arrow) were counted at 10X magnification. 
Line = 50 |xm.
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SW480 SW620 SW480M9 SW480M7
Figure 3.14 Comparison of in vitro invasion of cell lines. 5 x 105 cells were 
allowed to invade through matrigel for 24 hr and the invading cells were counted in 
five 10 X fields.
The assay was carried out as outlined in section 2.2.10. Invasive cells were 
counted at 10 X magnification (Figure 3.13) and invasive cells were expressed as an 
average cell count per 10 X magnification field (Figure 3.14). The SW480 cells showed 
little invasion in comparison to the SW620, SW480M7 and SW480M9 cells, which 
were significantly (p < 0.005) more invasive. The SW620 and SW480M9 were 
respectively twice and three times more invasive than the parental SW480. SW480M7 
cells were 9 times more invasive than the parental SW480 cells.
3.2.4 The in vitro migratory capacities of the cell lines studied
For the determination of the in vitro migratory abilities of the cell lines studied, 
the same cell culture inserts as those used in the invasion assays were used without the 
matrigel coating. In this case, the ability to degrade the basement was not required and 
motile cells could pass freely through the membrane to the lower chemoattractant- 
containing chamber.
SW480 SW620 SW480M9 SW480M7
Figure 3.15 In vitro migratory capacities of cell lines. Cell migration was assessed 
by allowing 5 X 105 cells to migrate for 24 hr.
MMP overexpression increased the migratory capacity of the transfected cell 
lines in comparison to the parental SW480 cells (Figure 3.15). The migration of 
SW480 cells increased with MMP-9 overexpression and more so with MMP-7 
overexpression. However, the parental SW480 cells were significantly (p<0.005) more 
migratory than the SW620.
3.2.5 Comparison of cell adhesion to ECM components
To investigate the adhesion of cells to ECM components, adhesion assays were 
carried out in the presence of HA and FN as described in section 2.2.10. Adhesion is a 
key event in the metastatic process where by cells must first adhere to the ECM prior to 
its degradation. Increased cell-cell signalling and contact is also mediated by increased 
expression of cell adhesion molecules.
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Figure 3.16 The adhesion of cells on plastic, hyaluronic acid (HA) and fibronectin 
(FN).
SW480M7 cells were overall the most adhesive cells, with no significant 
differences in their adhesion to plastic, fibronectin or hyaluronic acid. The SW480M9 
cells showed the most adherence to FN and HA (Figure 3.16) when compared to the 
adhesion of the same cells on plastic. All percentage adhesion values were significant 
(p < 0.005).
3.2.6 Effect of ECM components on MMP protein expression
To investigate the effect of ECM components on MMP expression, cells were 
cultured in the presence of HA, FN, type IV collagen and a pi-integrin activating 
antibody as outlined in section 2.2.13.
After treatment, neither the SW480, SW620 or SW480M7 cells showed any 
increase in MMP-9 expression levels (Figure 3.17). The SW480M9 cells showed no 
increase in MMP-9 activity in the presence of FN or the pi-integrin-stimulating 
antibody and a slight increase when grown on type IV collagen. Growth of the 
SW480M9 cells on HA greatly increased the levels of MMP-9. Densitometric analysis 
of the gel clearly showed this increase (Figure 3.18).
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Figure 3.17 Effect of ECM components on MMP-9 activity. Cells were treated 
with fibronectin (FN), collagen type IV (Col IV), pi integrin stimulating antibody 
and hyaluronic acid (HA). Untreated cells acted as a control.
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Figure 3.18 The effect of ECM components on MMP-9 activity in the SW480M9 
cells. Densitometry was performed on the resulting zymography gel and it showed 
hyaluronic acid to have the greatest enhancing effect.
3.2.7 Effect of ECM components on MMP-9 mRNA expression
RNA from SW480M9 cells was also harvested and analysed for MMP-9 
expression by real time PCR. Firstly, P-actin PCR was carried out.
iF2/d2C
Figure 3.19 P-actin real time PCR comparative concentration curve. The data 
obtained and the colours used are summarised in Table 3.4.
Table 3.4: |3-actin (Act) real time PCR data for SW480M9 cells treated with
fibronectin (FN), hyaluronic acid (HA), p i integrin antibody and collagen (Coll). This 
data was used to normalise the MMP-9 real time PCR data.
Colour Name Takeoff Comparative Concentration
SW480M9 Plastic Act 16.0 1.11 E+00
SW480M9 Plastic Act 16.1 1.11E+00
■ SW480M9 Plastic Act 15.8 2.02E+00
■ SW480M9 FN Act 16.4 1.15E+00
■ SW480M9 FN Act 16.7 1.14E+00
■ SW480M9 FN Act 16.8 1.35E+00
SW480M9 HA Act 15.6 1.00E+00
■ SW480M9 HA Act 15.6 1.00E+00
■ SW480M9 HA Act 15.6 1.00E+00
■ SW480M9 P-1 Act 15.4 1.13E+00
■ SW480M9 p-1 Act 15.3 1.20E+00
■ SW480M9 p-1 Act 15.3 1.20E+00
■ SW480M9 Coll Act 16.6 1.34E+00
■ SW480M9 Coll Act 16.7 1.24E+00
■ SW480M9 Coll Act 17.3 1.07E+00
The P-actin PCR reactions were tested for specificity by carrying out melt curve 
analysis. The one resulting peak (Figure 3.20) indicated that the conditions were 
specific.
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peak at 89 °C that indicated one product was formed in the reaction.
The P-actin PCR data was used to normalise the comparative concentration data 
obtained from MMP-9 real time PCR reactions carried out on RNA harvested from the 
cells treated with various ECM components.
dF2AI2C
Figure 3.21 Comparative concentration of MMP-9 in SW480M9 cells treated with 
various ECM components. Real time PCR was carried out on RNA from 
SW480M9 cells. The data obtained and the raw data is listed in Table 3.5.
Figure 3.21 shows the comparative concentration curve for the MMP-9 reactions and 
Table 3.5 gives the raw data obtained.
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Table 3.5 MMP-9 real time PCR raw comparative concentration data for SW480M9 
cells treated with fibronectin (FN), hyaluronic acid (HA), p i integrin antibody and 
collagen (Coll).
Colour Name Takeoff Comparative Concentration
■ SW480M9 Plastic M9 16.0 1.00E+00
■ SW480M9 Plastic M9 16.1 1.00E+00
■ SW480M9 Plastic M9 15.8 1.26E+00
■ SW480M9 FN M9 16.4 1.26E+00
■ SW480M9 FN M9 15.7 1.34E+00
■ SW480M9 FN M9 16.8 1.34E+00
■ SW480M9 HA M9 15.6 9.43E-01
■ SW480M9 HA M9 16.6 1.00E+00
■ SW480M9 HA M9 15.6 1.00E+00
■ SW480 (3-1 M9 16.4 1.00E+00
■ SW480 p-1 M9 15.3 1.43E+00
■ SW480 p-1 M9 15.3 1.56E+00
■ SW480M9 Coll M9 16.6 1.01E+00
■ SW480M9 Coll M9 16.7 1.22E+00
■ SW480M9 Coll M9 17.3 1.17E+00
Again, melt curve analysis was performed to ensure only one amplified product 
was obtained in the PCR reactions. One peak indicated the reaction was specific for 
MMP-9 amplification (Figure 3.22).
Figure 3.22 The above melt curve indicated that the MMP-9 real time PCR 
reaction was specific.
The plot of normalised expression showed MMP-9 levels to increase slightly 
upon treatment with ECM components (Figure 3.23). None of the treatments resulted in 
a significant increase in MMP-9 mRNA expression.
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Figure 3.23 The effect of ECM components on MMP-9 mRNA expression as 
shown by normalised real time PCR expression data. P-actin data was used to 
normalise the MMP-9 data.
3.2.8 Effect of CD44 activation on MMP protein activity
Since CD44 is the major cell surface receptor for HA, the SW480M9 were 
treated with an anti-CD44 monoclonal antibody F I0-44-2. Instead of blocking its 
activity, F10-44-2 activates CD44, mimicking the ligation of HA in the ECM and 
subsequently activating its associated intracellular signalling pathways. CM from 
antibody treated cells was collected at timed intervals and analysed for MMP expression 
by zymography and western blot analysis.
MWMBHK92 H20  Ohr- Ohr + 6 h r- 6hr+ 24h r-24h r +48h r-48h r +
97kD a-K  
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Figure 3.24 The effect of crosslinking CD44 on MMP-2 and MMP-9 activity. 
SW480M9 cells were treated with CD44 activating antibody (+) or with mouse 
IgG as a control (-). Conditioned media was analysed for gelatinases at times 0, 6, 
24 and 48 hr by zymography.
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Zymography showed that within 6 hr of treatment with the CD44-activating 
antibody, cells showed a slight increase in 92 kDa MMP-9 activity (Figure 3.24) when 
compared with cells treated with a control mouse IgG. This difference in activity was 
more apparent after 24 and 48 hr. Interestingly, activation of pro-MMP-9 to its active 
88 kDa form was more apparent after 24 and 48 hr. 72 kDa MMP-2 activity was also 
detected after 24 and 48 hr of CD44 activation. These observations were confirmed by 
western blot analysis (Figure 3.25) with specific MMP-2 and MMP-9 antibodies.
BHK92 H 20  Ohr- Ohr + 6hr - 6 h r+  2 4 h r -  24hr + 4 8 h r- 48hr +
Figure 3.25 MMP-2 and MMP-9 western blot analysis of conditioned media from 
SW480M9 cells treated with CD44 activating antibody (+) or with mouse IgG as a 
control (-).
3.2.9 Effect of CD44 activation on MMP-9 mRNA expression
RNA from the cells treated for 0, 6 and 24 hours was also collected for real time 
MMP-9 PCR analysis. P-actin real time PCR was first carried out on these samples to 
allow the normalisation of later results.
dF2AJ2C
Figure 3.26 P-actin real time PCR comparative concentration curve for all samples 
from all time points. The data obtained and the colours used are summarised in 
Table 3.6.
As can be seen from the comparative concentration curve for P-actin expression 
(Figure 3.26) the curves for all samples fall on top of one another indicating very 
similar amounts of expression in these samples.
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Table 3.6 p-actin real time PCR was carried out to normalise the data obtained from 
MMP-9 PCR.
Colour Name Takeoff Comparative Concentration
■ 0- actin 15.3 1.00E+00
■ 0- actin 14.6 1.40E+00
■ 0- actin 14.6 1.40E+00
■ 0+ actin 14.6 1.40E+00
0+ actin 14.2 1.70E+00
0+ actin 13.8 2.07E+00
■ 6- actin 15.0 1.16E+00
■ 6- actin 14.8 1.27E+00
■ 6- actin 15.2 1.19E+00
■ 6+ actin 15.0 1.16E+00
■ 6+ actin 14.9 1.21 E+00
■ 6+ actin 14.6 1.40E+00
24- actin 14.9 1.21 E+00
24- actin 14.3 1.62E+00
24- actin 14.4 1.55E+00
■ '24+ actin 14.8 1.27E+00
■ 24+ actin 14.7 1.22E+00
■ 24+ actin 14.8 1.27E+00
Performing a melt curve tested the specificity of the P-actin real time PCR 
reaction. One peak indicated that only one product was formed and that no non-specific 
products were formed (Figure 3.27).
only one product was formed with a denaturing temperature of 89 °C.
76
dF2/d2C
Figure 3.28 MMP-9 real time PCR for samples treated with F10-44-2 antibody or 
with mouse IgG as a control. The data obtained and the colours used are 
summarised in Table 3.7.
Table 3.7 MMP-9 real time PCR data for samples treated with F 10-4 4 -2  (+) or with 
mouse IgG (-) as a control over 0, 6  and 24 hr.
Colour Name Takeoff Comparative Concentration
■ 0- M9 16.9 1.00E+00
0- M9 15.8 1.58E+00
■ 0- M9 16.6 1.13E+00
0+ M9 19.2 1.40E+00
■ 0+ M9 18.5 1.60E+00
■ 0+ M9 19.1 1.32E+00
■ 6- M9 18.6 9.94E-01
■ 6- M9 18.7 8.74E-01
■ 6- M9 18.1 9.08E-01
■ 6+ M9 18.0 9.03E-01
■ 6+ M9 18.0 8.33E-01
■ 6+ M9 17.7 7.17E-01
■ 24- M9 16.9 1.00E+00
■ 24- M9 16.8 1.04E+00
■ 24- M9 17.5 1.18E+00
■ 24+ M9 17.3 9.17E-01
■ 24+ M9 17.7 8.17E-01
■ 24+ M9 17.1 9.20E-01
Following P-actin PCR, MMP-9 PCR was carried out on the same samples. The 
resulting curve is shown in Figure 3.28 and the data obtained is listed in Table 3.7. The 
melt curve shows that the conditions were specific for MMP-9 amplification in all 
reactions because only one peak was obtained (Figure 3.29).
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indicated that the conditions used in the reaction were specific.
The MMP-9 real time data was normalised with p-actin data and the results were 
plotted in Figure 3.30. There was no significant difference in MMP-9 expression 
between cells treated with F 10-4 4 -2  antibody and the control.
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Figure 3.30 Normalised MMP-9 real time PCR expression data for SW480M9 
cells treated with or without F10-44-2 antibody over 0, 6  and 24 hours.
3.2.10 Analysis of CD44 expression in colorectal cancer cell lines
Due to the increased adhesion of the SW480M9 cells on HA and the enhancing 
effect of HA and CD44 stimulation on MMP-9 activity, the expression of CD44 protein
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was examined. All cell lines studied expressed the 80kDa CD44 (Figure 3.31) often 
referred to as CD44s or standard CD44.
t-- O'
oac o<N
o
oc
o
oc
VC
£
cn cn ir. C/I
*—  120 kDa
mm m m + m
g f
■*—  80 kDa
 __ -—  Actin
Figure 3.31 The expression of CD44 in the cell lines studied, p-actin was used as 
a loading control.
The SW480M9 cells expressed the highest levels of CD44s compared to the 
SW480, SW620 and SW480M7 cells. Interestingly, the metastatic SW620 and the 
more invasive SW480M9 showed expression of a 120kDa variant of CD44 with 
SW480M9 showing highest levels of expression.
Attempts to identify the 120 kDa CD44 variant by western blot analysis using 
antibodies that detect the V3 and V6 isoforms gave negative results.
3 .2 .11  A n a ly s is  o f  C D 4 4  m R N A  ex p ressio n  in  co lo recta l ca n cer  ce ll lin es
RT-PCR was carried out as outlined in section 2.2.15.1 using primers that anneal 
to either end of the constant region of the CD44 gene (Figure 3.32). This PCR reaction 
resulted in multiple bands with different expression profiles in each sample. SW620 
cells possessed a band at 516 bp that was not seen in any of the other samples.
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Figure 3.32 PCR of the CD44 constant region resulted in multiple bands as a result 
of variant exon splicing.
RT-PCR was then carried out using primers specific for CD44 isoforms 
containing the V6 alternatively spliced exon. The results (Figure 3.33) showed that all 
cells except SW620 expressed the CD44 isoform containing v6 through vlO. All cells 
also expressed the CD44 isoform containing v6 through v8.
Figure 3.33 CD44 v6 RT-PCR revealed the SW620 cells to have a different v6 
isoform expression profile in comparison to the other cell lines studied.
These differences in CD44 expression may help explain the increased adhesion 
of SW480M9 to HA as well as the effect HA had on MMP-9 activity in these cells.
3.2.12 Expression of p i integrin in colorectal cancer cell lines
Because of its well established roles in cell signalling, the expression of p i 
integrin was analysed in the cell lines used in this study. Western blot analysis (Figure
80
3.34) showed that all four cell lines expressed the 116 kDa pi subunit with the 
metastatic SW620 cells expressing higher levels than any other cell line studied.
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Figure 3.34 E xp ression  o f  p i integrin in c e ll lin es u sed  in this study, p-actin  
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3.2.13 Effect of CD44 activation on cell invasion
To show that CD44-mediated upregulation of MMP-9 expression had an effect 
on cell invasion the in vitro invasion of the cells in the presence of HA was assayed. 
The presence of HA increased invasion of the SW480, SW620 and SW480M9 cells 
(Figure 3.35). The most dramatic increase was seen with the SW480M9 cells where 
three times as many cells (p < 0.005) invaded when treated with HA. Therefore, the 
effect of F10-44-2, a CD44 activating antibody on invasion was studied. CD44 
activation increased the in vitro invasion of SW620 and SW480M9 cells. SW480M9 
invasion increased two fold (p < 0.005) (Figure 3.35) when treated with F10-44-2 
antibody, in comparison with the invasion of the same cells treated with control mouse 
IgG. A CD44 blocking antibody (IM7.8.1) was then used to further confirm that the 
increased invasion was CD44-dependent. Blocking of CD44 with this antibody resulted 
in a significant suppression of invasion in all cells studied (p < 0.005) (Figure 3.35).
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Figure 3.35 The effect of CD44 on in vitro invasion. Cells were allowed to invade 
in the presence of hyaluronic acid (HA), CD44-stimulating antibody (F10442), 
CD44 blocking antibody (EVT7.8.1) or mouse IgG as a control.
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3.3 Discussion
Modern therapeutic approaches to eliminate or control metastasis are based on 
defining its critical events and the specific targets that regulate these events. Therefore, 
the identification and understanding of novel cellular and molecular determinants of 
metastasis is crucial. Both CD44 and MMPs have established roles in the process but 
there is little insight into how they interact in metastasis. Uncovering these interactions 
would help validate their use in the clinic as potential targets.
In this chapter, the interactions between CD44 and MMPs in regulating invasion 
and migration in human colorectal cancer cell lines were investigated. The non­
metastatic SW480 cell line established from a primary human colon adenocarcinoma 
was stably transfected with the cDNAs for MMP-7 and MMP-9. The effects of MMPs 
on cell invasion, adhesion and migration were assessed. Cells were grown on various 
ECM components to study the effect on MMP activity. CAM expression in these cell 
lines was analysed and the effects of CD44 activation through ligand binding and 
antibody treatment on MMP expression and invasion were investigated. This work 
aimed to demonstrate the importance of MMP and CD44 interactions in regulating 
colon tumour cell invasion.
MMP-7 and MMP-9 overexpression in SW480M7 and SW480M9 cells was 
shown by real time PCR and by western blot analysis. SW480 cells were used as a 
common control for both SW480M7 and SW480M9 experiments instead of SW480Neo 
cells which had been transfected with the empty pCMV vector used to transfect MMP-9 
cDNA. SW480 cells have previously been shown to be equal to SW480Neo cells in 
terms of in vitro invasiveness. The parental SW480 cells do not express MMP-7 or 
MMP-9, and transfection of the cDNAs for MMP-7 and MMP-9 into these cells 
increased their in vitro invasion. MMP secretion caused increased cell invasion most 
likely due to ECM turnover. Matrigel, which normally hinders the progression of cells, 
was degraded, allowing cells to pass freely to the lower chamber. Interestingly, the 
SW620 cells which were established from a lymph node metastasis from the same 
patient as the SW480 also did not express MMP-9 but were more invasive than the 
parental SW480 cells. Overexpression of MMP-9 in a rat transformed embryo cell line 
has been shown previously to increase the invasion and migration of these cells 
(Bernhard et al., 1994).
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The MMP transfected cells also showed increased migratory capacity. The 
parental SW480 cells were more migratory than the SW620 which has also been shown 
by Hewitt et al. (2000). A similar result has also been obtained by Kubens and Zanker 
(1998) using a three-dimensional collagen matrix and time-lapse video recording assay. 
It is possible that ECM components and indeed matrigel are acting as inducers of cell 
migration and that in the absence of matrigel the SW620 cells do not migrate or invade. 
It is also possible that ECM turnover and therefore the generation of soluble ECM 
components acted as stimuli for cell progression.
Adhesion of these cells on various matrices including, plastic, FN and HA was 
also investigated. The MMP-9 transfected cells were more adherent to FN and HA than 
any of the other cell lines. Examination of the levels of CD44 protein expressed in the 
cell lines showed that all cell lines expressed the standard 80 kDa form of CD44. An 
additional higher molecular weight band was seen in the metastatic SW620 and the 
MMP-9 transfected cell line. This band had a molecular weight of -120 kDa and could 
be CD44v6 which has been previously been shown to be involved in colon metastasis 
(Wielenga et al., 1993). A 120 kDa CD44v6 isoform has previously been identified in 
the serum of patients with metastatic breast disease using western blot analysis (Lackner 
et al., 1998). Although specific antibodies for CD44v3 and CD44v6 failed to identify 
this protein by western blot analysis, exon specific PCR was carried out to identify this 
band. CD44v6 specific PCR revealed that all cells expressed the CD44 isoform 
containing the v6 through v8 domains. Further analysis is therefore required to 
determine the identity of this 120 kDa isoform. Examination of (31 integrin expression 
showed that the SW620 cells expressed the highest amounts in comparison with the 
other cells used in this study, all of which expressed pi integrin.
The effect of growing cells on various ECM components on MMP-9 activity 
was then investigated. Cells were grown in the presence of a P1 integrin antibody, HA, 
fibronectin, and type IV collagen. MMP-9 activity was increased in SW480M9 cells 
grown on hyaluronic acid and on collagen. There was no effect in SW480, SW620 and 
SW480M7 cells. Real time MMP-9 PCR analysis of the SW480M9 cells showed that 
no difference occurred between any of the treatments at the mRNA level. The 
enhancing effect of the CD44-HA ligation interaction on MMP-9 activity was further 
investigated by the treatment of the SW480M9 cells with a CD44 activating monoclonal
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antibody. Increased levels of MMP-9 activity were observed after 24 hr of antibody 
treatment and this increase in activity was greater after 48 hr. Treatment with this 
antibody also had the effect of increasing MMP-2 activity after 24 hr. These 
observations were confirmed by western blot analysis. Real time MMP-9 PCR analysis 
proved no changes occurred at the mRNA level.
Since growth of the SW480M9 cells on HA and direct stimulation of CD44 
caused an increase in MMP activity, it was then investigated whether this increase in 
MMP-9 activity had a functional effect on cell invasion. Stimulation of CD44 by 
treatment with HA caused an increase in the invasion of the SW480, SW620 and 
SW480M9 cells when compared with control cells. Stimulation of CD44 using a 
monoclonal antibody increased the invasion of the SW620 and SW480M9 cells. 
SW480 cell invasion which was responsive to HA treatment showed no change when 
the cells were treated with the monoclonal antibody possibly due to the fact that HA has 
other receptors besides CD44. CD44 induced invasion was inhibited by treatment with 
a CD44 blocking antibody. SW480M7 cells, which were overall the most invasive 
cells, showed no difference in invasion upon CD44 ligation. Interestingly, the most 
responsive cells were the SW620 and SW480M9 cells both of which expressed higher 
levels of CD44 as well as the 120 kDa CD44 isoform. The presence of 120 kDa CD44 
alone was not sufficient for a large HA-induced increase in invasion and endogenous 
MMP-9 expression was also required. This was well displayed by the difference in cell 
invasion between the SW620 and SW480M9 cells in response to CD44 activation. 
However, regardless of the MMP expression profile, inhibition of CD44 function 
significantly reduced the invasion of all cells used in this study. This result shows the 
importance of CD44 in cell invasion, while all cell lines used were not equally 
responsive to CD44 activation, in terms of cell invasion they all behaved similarly when 
CD44 function was blocked. CD44 binds many components of the ECM and blocking 
this interaction completely, would result in complete loss of function thus both 
explaining the decrease in invasion as well as highlighting the importance of CD44 in 
this process. These observations suggest a dual role for CD44 in cell invasion, one, 
which involves MMP expression, and one, which is independent of MMP expression. 
Upon CD44 activation, endogenous MMP activity was enhanced resulting in increased 
invasion. In addition, blocking of CD44 even in cells that did not express MMP-9 still 
resulted in a reduction in cell invasion.
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Many studies have recently demonstrated the importance of MMP - CAM 
interactions in tumour cell invasion and metastasis. The importance of integrins in 
regulating MMP expression was highlighted by a study showing aV(36 integrin to 
promote squamous carcinoma cell invasion through up-regulation of MMP-9 (Thomas 
et al., 2001). a2p i integrin-mediated ligation of collagen by ovarian carcinoma cells 
results in tyrosine kinase signalling and the subsequent expression of MT1-MMP which 
activates latent MMP-2 resulting in enhanced cell surface MMP activity (Ellerbroek et 
al., 1999). Stimulation of CD44 has been shown to increase MMP-2 expression in 
human melanoma cells (Takahasi et al., 1999) and in lung carcinoma cells (Zhang et al., 
2002). Treatment of melanoma cells with the same CD44 stimulating antibody used in 
this study has been shown to upregulate MMP-2 expression and enhance their migratory 
ability (Takahashi et al., 1999). This type of use of monoclonal antibodies renders them 
superior to natural ligands, which often bind to multiple receptors. Blocking of CD44 
with a monoclonal antibody has previously been shown to significantly decrease the 
migration and invasion of murine mammary carcinoma cells (Ladeda et al., 1998). The 
CD44v3,8-10 isoform has been shown to be associated with MMP-9 at invadopodia of 
breast cancer cells and CD44v3 has been shown to recruit MMP-7 to the surface of 
neuroblastoma and lymphoma cells thus suggesting a collective role for MMPs and 
CD44 in tumour cell invasion and migration (Bourguignon et al., 1998). 
Overexpression of this isoform has also been shown to result in enhanced metastasis in 
mice (Barbour et al., 2003). The individual roles of CD44 isoforms in tumour 
metastasis are strengthened by a study showing that expression of antisense CD44v6 
inhibited colorectal metastasis in nude mice (Reeder et al., 1998). In contrast to this 
observation, CD44v6 expression has been shown to decrease in the advanced stages of 
colorectal metastasis suggesting a role for this variant in early colorectal neoplasia 
(Weg-Remers et al., 1998). MT1-MMP mediated cleavage and subsequent release of 
CD44 has been shown to promote cell migration in breast carcinoma cells (Kajita et al.,
2001). Such proteolytic cleavage of CD44 results in the translocation of the CD44 
intracellular domain to the nucleus where it activates transcription through the TP A 
responsive element (Okamoto et al., 2001). Inhibition of CD44 has been shown to 
inhibit the invasion of human glioma cells (Okada et al., 1996). Interestingly, Yu and 
Stamenkovic (2000) have shown that MMP-9 can associate with CD44 on the surface of 
mouse mammary carcinoma and human melanoma cells, mediating migration and 
invasion. This association may cause activation of signal transduction molecules, in the 
way that HA-CD44 binding has been shown to activate the ras-MEKl and the PI3
8 6
kinase-Akt signalling pathways in a human lung carcinoma cell line (Zhang et al., 
2002).
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3.4 Conclusion
In this chapter, it has been shown that culturing colon cancer cells on ECM 
components increased MMP-9 expression. HA, the major receptor for CD44 caused the 
greatest increase. In addition, direct stimulation of CD44 by treating with an activating 
antibody (F I0-44-2) caused an increase in MMP-2 and MMP-9 expression and caused 
activation of MMP-9. This is the first report to show up-regulation of MMP-9 
expression following CD44 stimulation in colon cancer cells (Murray et al., 2004). 
This upregulation was shown to be post-transcriptional as the levels of MMP-9 mRNA 
were unaffected. It is possible that CD44 activation directly triggers intracellular 
signals that result in MMP induction. Indeed ligation of CD44 on T cells has been 
shown to lead to tyrosine phosphorylation of intracellular proteins suggesting a role in 
signalling (Taher et al., 1996).
The interactions between CD44 and MMPs are diverse, and further studies 
would clarify exactly what mechanism underlies these observations. Figure 3.36 
summarises some known CD44-MMP interactions. This summary highlights how 
numerous these interactions are. The absence of any difference at the transcriptional 
level suggests that CD44 activation cannot induce MMP mRNA expression but it may 
affect post-transcriptional events. This explains why cell lines that did not express 
MMPs were not responsive to CD44 activation.
This study also highlights a specific interaction between MMP-9 and CD44. 
SW480M7 cells, which were stably transfected with the cDNA for MMP-7, were not as 
adherent to HA, did not express high levels of CD44 and their invasion was not 
responsive to CD44 activation. Expression of the 120 kDa isoform was also absent in 
SW480M7 cells. SW480M9 cells which were stably transfected with the cDNA for 
MMP-9 expressed a 120 kDa CD44 isoform, so too did the metastatic SW620 cells. 
There was a correlation between the expression of the 120 kDa CD44 and a CD44- 
responsive increase in invasion. Why cells overexpressing MMP-9 have differential 
splicing of CD44 remains to be elucidated. These cells were more adherent to HA and 
this adhesion interaction also resulted in enhanced MMP-9 activity.
Figure 3.36 Summary of interactions between CD44 and MMPs. (i) CD44 can 
dock MMP-9 (9) on the cell surface thus directing its ECM degrading activity as 
well as (ii) the MMP-9 mediated activation of latent cytokines or growth factors 
(LGF) to active growth factors (AGF). CD44v3 can dock MMP-7 (7) and heparin 
bound epidermal growth factor (hbEGF) allowing MMP-7 to activate hbEGF (iii). 
Activated cytokines or growth factors can then bind to their respective receptors in 
an autocrine (iv) or paracrine (v) manner where they then transduce intercellular 
signals (vi). As well as activating the latent pro form of secreted MMP-2 (p2) to its 
active form (a2). MT1-MMP (MT) can process CD44. The resulting intracellular 
domain can translocate to the nucleus (vii) and promote transcription through TPA- 
responsive elements (TRE), including transcription of CD44 itself.
Although the mechanism remains to be elucidated, CD44 activation clearly 
induces MMP-9 production. These results suggest that CD44 activation can directly 
increase the levels of MMP-9 and cause an increase in invasion in colon cancer cell 
lines.
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Chapter 4
Gene expression profiling of a panel of colorectal 
cancer cell lines using cDNA microarrays
4.1 Introduction
Microarray-based technologies have become the most widely used analytical 
technique for the study of gene-expression patterns on a genome-wide scale (Leung and 
Cavalieri, 2003 and Schena et al., 1995). Because cellular processes are governed by 
the repertoire of expressed genes, and the levels and timing of expression, it is 
important to have tools to monitor a large number of mRNAs in parallel. The collection 
of genomic information from two types of biological states and the ability to determine 
differences in mRNA expression profiles between these states using DNA microarray 
technology has become a powerful and valuable genomic tool to elucidating the 
molecular basis of almost every aspect of cancer biology as well as many other diseases. 
DNA array based technologies allow one to study expression levels of many genes in 
parallel, thus providing static (i.e. in which sample a gene of interest is expressed) and 
dynamic (i.e. how the expression pattern of one gene relates to those of others) 
information about gene expression (Schena et al., 1996 and Lockhart et al., 1996). 
Essentially, one can compare the expression level either of the same gene in different 
samples, or of different genes in the same sample, thus giving an insight into gene 
function and regulation.
Like many other molecular techniques, DNA microarrays exploit the sequence 
complementarity preferential binding features of the DNA duplex (Southern et al.,
1999). Because of mutual selectivity between complementary strands of nucleic acids, 
these techniques provide high sensitivity and specificity of detection. In many ways the 
path to array based methods began by binding DNA to solid supports such as 
nitrocellulose in ‘dot-blot’ methods (Southern, 1975). Briefly, this method typically 
involved mixtures of nucleotides attached to a solid support followed by incubation 
with a labelled gene-specific target.
Most of this section concerns cDNA microarrays, however other array 
technologies including oligonucleotide arrays have been developed. Affymetrix have 
developed an approach based on hybridisation to small but high-density arrays 
containing thousands of synthetic oligonucleotides. These arrays are synthesised in situ 
using a combination of photolithography and oligonucleotide chemistry (Lockhart et al.,
4.1.1 An introduction to microarray technology
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1996 and Lipshutz, et al., 1999). One advantage of Affymetrix chips over cDNA arrays 
is that every gene is represented at least 5 times with equally as many mismatch 
negative controls. Although these chips provide reliable and reproducible data, 
Affymetrix analysis is very expensive with one experiment costing at least €1,000.
With cDNA technology, the hybridisation strategy is altered in many ways 
(Figure 4.1). Firstly, with cDNA arrays impermeable rigid supports such as glass are 
used. As liquids cannot penetrate the support, the rate of hybridisation between target 
nucleic acids and the probes is enhanced. In array experiments, many gene-specific 
single-stranded polynucleotides are individually spotted on a single matrix. This matrix 
is then simultaneously probed with fluorescently tagged cDNA representations of total 
RNA pools from different samples, allowing the determination of the relative amount of 
transcript present in the pool by the intensity of fluorescent signal generated. Typical 
samples for analysis include cell lines and both clinical and laboratory animal derived- 
tissue biopsies. The quantitation of relative transcript abundance is based on the direct 
comparison between an ‘experimental’ cell state and a ‘control’ cell state.
Figure 4.1 cDNA microarray basics. Templates of interest are amplified 
from cDNA libraries and arrayed on a glass slide. mRNA from ‘test’ and 
‘reference’ samples are reverse transcribed and labelled with separate fluorescent 
dyes which are mixed and allowed to hybridise to the array. Slides are scanned by 
laser excitation of the incorporated targets and emission signals in both channels 
are compared. Figure adapted from Duggan et al., 1999.
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4.1.1.1 Array fabrication
Array fabrication begins with the selection of clones to be spotted onto the slide. 
These are often chosen from databases such as GenBank or UniGene 
(http://www.ncbi.nlm.nih.gov. 17 September 2004, and Bowtell, 1999). cDNA arrays 
are produced by robotically spotting or printing a few nanolitres (100 -  500 |J.g/ml) of 
purified PCR products of approximately 1 to 2 kb in size, representing specific genes 
onto a slide (Cheung et al., 1999). Most cDNA arrays are spotted on glass microscope 
slides that have been treated with poly-L-lysine, which enhances the hydrophobicity of 
the slide and the adherence of the printed DNA, thus limiting the spread of the spotted 
DNA droplet on the slide. DNA is then crosslinked to the matrix by UV irradiation.
4.1.1.2 Experim ental design
Proper planning of microarray experimental design is required to ensure that 
questions of interest can be answered accurately. Inadequate experimental design could 
result in either the loss of real biological data or the acquisition of false and 
untrustworthy information. Good microarray experimental designs should minimise the 
variation introduced at each stage of the experiment. The design of an array experiment 
has three layers (Figure 4.2).
Independent sources of variation are introduced at each of these layers. The top 
layer is subject to biological variance, which is unavoidable and intrinsic to all 
biological systems. Biological replication by using multiple animals or multiple flasks 
of cells in culture, is important in ensuring the end results are statistically significant, 
real and reproducible (Rosenbaum, 2001 and Lee et al., 2000). Pooling of labelled 
replicate RNA prior to hybridisation can reduce the biological component of variation 
but not the technical error due to sample handling or measurement.
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Figure 4.2 T h e three layers o f  tw o-co lou r m icroarray exp erim en ta l d esign  in a 
hypothetical experim ent that com pares the e ffec ts  o f  tw o  treatm ents, A  and B on 
gen e exp ression  in m ice. A t the top layer are the experim ental units, i.e. the tw o  
m ice and assign in g  tw o  m ice  to each  treatm ent ensures b io lo g ic a l replication. In 
the m iddle layer, obtain ing tw o  R N A  sam ples from  each  experim ental unit and 
assign in g  them  tw o  d ifferent co lour d ye labels ensures a tech n ica l replicate. T h ese  
techn ical replicates are paired (on e  red w ith on e green), m ixed  and co-h ybrid ised  to 
m icroarrays. T he lo w er  layer o f  a m icroarray experim ent in v o lv es  the array itse lf  
and the arrangem ent o f  the elem en ts on the array. T h is layer o f  design  includes 
d ecid in g  w hich  c D N A  probe sequ en ces to print, h ow  m any replicates to print, 
w hich  control seq u en ces to print and w here th ese  sh ou ld  b e  printed. F igure  
adapted from  C hurchill (2 0 0 2 ).
Technical variation is introduced in the middle layer by the processes of RNA 
extraction, labelling and hybridisation. Deciding which and how many technical 
replicates to pair and co-hybridise together can reduce the middle layer variability (Kerr 
and Churchill, 2001a and Yang and Speed, 2002). The dye-swap experiment is 
effective for the comparison of two samples (Kerr and Churchill 2001b). Using two 
arrays for the comparison of the two samples, this design also accounts for dye-bias 
with the dye assignments being reversed on the second array. Another measure used to 
minimise middle-layer variation is the use of a reference sample to which all samples in 
the array experiment are directly compared with, allowing subsequent sample to sample 
cross comparison. Reference samples are constructed using complex mixtures of tissue- 
or cell line -derived RNA (Quackenbush, 2002).
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Error associated with the measurement of fluorescence is introduced at the lower 
layer. This can be a result of dust on the slide or uneven background across the slide 
due to non-specific hybridisation. An important part of lower-layer design with a great 
impact on array data analysis is the arrangement of spots on a slide (Yang et al., 2002b). 
Important considerations here are which probes to spot on the slide, how many 
replicates of these should be spotted and where these replicates are distributed about the 
slide. Because array printing is subject to error and heterogeneous spot quality is 
common, replicate spot printing is advisable and increases precision. Negative controls 
(PCR mix with no template) and blanks (nothing printed) are often distributed about the 
slide to give an estimation of the background levels in the sub arrays.
4.1.1.3 Probe preparation
Microarrays assay differential gene expression by the co-hybridisation of 
fluorescently labelled probes prepared from different RNA sources. Labelled 
representations of cellular mRNA pools, usually reverse transcriptions, are used as 
targets for cDNA arrays. The purity and quality of the starting RNA is critical to the 
hybridisation performance, and therefore has a significant effect on the results of the 
assay. Contaminants such as cellular proteins, lipids and carbohydrates can mediate 
non-specific labelled cDNA binding. The commonly used fluorescent Cy dyes Cy3- 
dUTP and Cy5-dUTP are incorporated at the reverse transcription stage. Cy3 and Cy5 
dyes have good photostability and are widely separated in their excitation (550 and 650 
nm respectively) and emission spectra (570 and 670 nm respectively), which allows 
highly selective optical filtration.
4.1.1.4 Hybridisation
The main goal in the hybridisation step is to obtain high specificity while 
minimising background. The Institute of Genomic Research (TIGR) have developed 
protocols that yield reproducible, quality hybridisations while maximizing the measured 
fluorescence on the array (http://www.tigr.org/. 17 September 2004, and Hegde et al.,
2000). Pre-hybridisation in a 1 % BSA solution has the advantage of both blocking 
non-specific interactions between the probe and the slide as well as washing unbound 
DNA from the slide before the hybridisation step. This free DNA would otherwise 
compete with bound DNA for hybridisation.
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4.1.1.5 Image acquisition and image processing
The next step in assessing differential gene expression is scanning the hybridised 
slide using a confocal laser scanner capable of detecting both the Cy3- and Cy5-labeled 
probes and producing separate 16-bit greyscale tagged image file format (TIFF) images 
for each. However, most scanners are capable of distinguishing and detecting many 
other additional fluorescent dyes (Bowtell, 1999). Grids specifying target locations are 
overlaid on the images that are then analysed to calculate the relative expression level of 
each individual gene and hence identify differentially regulated genes. The hypothesis 
underlying microarray analysis is that the measured intensity for each arrayed gene 
represents its relative expression level. Local background is often sampled and 
subtracted from the signal and can be used to specify a threshold which the true signal 
must exceed (Chen et al., 1997). Local background sampling for each spot is preferred 
to global background sampling for the entire slide as uneven background across the 
array often arises during hybridisation. This can be due to non-specific hybridisations 
or artefacts such as dust on the slide surface. Local background-subtracted 
hybridisation intensities ( I l b s )  for each spot in both Cy3 and Cy5 channels are 
calculated and then used to calculate the Cy3 to Cy5 ratio of I Lb s  intensities for each 
individual spot (gene).
4.1.1.6 Data normalisation
Before biologically relevant patterns of expression are identified by comparing 
expression levels between samples on a gene-by-gene basis, it is appropriate to carry out 
normalisation on the data to eliminate questionable, low quality measurements and to 
adjust the measured intensities to make them comparable. The process of obtaining 
actual readings of expression levels from a cDNA microarray is subject to several 
sources of variability (biologic variability, printing of slides, preparation of fluorescent 
probes, measurement of the fluorescent light intensity etc) that will all be represented in 
the random fluctuations of observed expression levels (Schuchhardt et al., 2000). True 
differentially expressed genes need to be distinguished from differences generated by 
fluctuations in the data. The many sources of systematic variation in microarray 
experiments that affect the measured expression levels are best demonstrated in an 
experiment where two identical mRNA samples are labelled with different dyes and
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hybridised to the same slide (Yang et al., 2002c). In this example, it was rare to have 
the dye intensities equal across all spots. Although such systematic differences may be 
small, they may also have a confounding effect when assaying for subtle biological 
differences. Normalisation is a process that attempts to remove this variation. 
Normalisation of the individual hybridisation intensities in each of the two scanned 
channels is essential to adjust for label-specific differences such as incorporation and 
detection efficiencies thus facilitating channel-to-channel comparisons (Quackenbush,
2002). Normalisation is also necessary to adjust for differences in the starting RNA in 
the samples. All these issues can shift the average Cy3/Cy5 ratio if these intensities are 
not rescaled. Only by balancing these individual intensities appropriately can 
meaningful biological comparisons be made.
Total intensity normalisation considers all the genes in an array experiment and 
is based on the simple assumption that the total amount of RNA labelled with either 
Cy3 or Cy5 is equal. This form of global normalisation is a useful tool in instances of 
closely related samples where the transcription level of many genes will remain 
unchanged. While the intensity for one spot may be higher in one channel than the 
other, when averaged over thousands of spots in the array, these differences should 
average out. Therefore, the total fluorescence across all the spots in the array should be 
equal for both channels and a scatter plot of the measured Cy5 versus Cy3 intensities 
should have a slope of one. Using this approach, a normalisation factor (Ntofa/) is 
calculated by summing up the measured intensities in both channels;
Nx 1 array
Z*.
N  =  — ____total n
x '  array
E g ,
i=l
where R, and G, are the measured intensities (for the red and green colours commonly 
used to represent array data) of the z'th array element (gene) on an array that has from 1 
to NaW(y distinct elements. The ratio for the ith gene (T,) is then divided by this 
normalisation factor and becomes the normalised expression ratio;
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thus adjusting each ratio so that the mean ratio is equal to one.
Chen et al. (1997) have developed a normalisation method that makes use of a 
specific subset of genes as opposed to all elements on the slide. This method is useful 
for more divergent samples where the total intensity normalisation model would give a 
poorer estimation of normalisation. This method assumes that the distribution of 
transcription levels for a set of housekeeping genes that are expected to be unchanging 
have a mean value and standard deviation that are independent of the sample. In this 
case, the ratio of measured Cy5 to Cy3 ratios for these genes is used as a model to 
adjust the mean of ratios to one.
Locally weighted linear regression (LOWESS) analysis is a non-linear intensity 
dependent normalization procedure that is suited to two colour experiments where there 
are more than 100 elements on the chip (Cleveland, 1979 and Yang et al., 2002b). 
LOWESS normalisation is a technique that is used to eliminate dye-related artefacts in 
two-colour experiments that cause the Cy5/Cy3 ratio to be affected by the total intensity 
of the spot. The artefacts that LOWESS attempts to correct for include non-linear rates 
of dye incorporation as well as inconsistencies in the relative fluorescence intensity 
between the two dyes used.
4.1.1.7 Data Mining: the identification of differentially expressed genes
The extraction of biologically relevant information from large array generated 
gene lists still proves to be a serious bottleneck (Butte, 2002). Regardless of the nature 
of the experiment, the major interest in performing microarray analysis is in the 
identification of genes that are differentially expressed between samples in the data set. 
Therefore simply generating the data is not enough, one must be able to extract from it 
meaningful information about the system being studied. This currently requires the 
combined efforts of biologists, bioinformaticians, computer scientists, statisticians and 
software engineers.
A general two-fold cut off is often used to identify those genes that are most 
variable between samples (Yang et al., 2002a, Schena et al., 1995 and Schena et al., 
1996). Therefore, genes are taken to be differentially expressed if their expression 
under one condition is over two-fold greater or less than that under the other condition. 
The ‘fold’ change test is not a statistical one and does not provide any information on 
the level of confidence in the designation of genes as differentially expressed or not 
differentially expressed.
In order to distinguish genes that are significantly differentially expressed from 
random changes, independent microarray assays are often conducted starting from 
independent mRNA isolations and used to define differential expression based on their 
statistical consensus. As discussed in section 4.1.1.2, for statistical puiposes, biological 
replicates - RNA samples obtained from independent biological sources - are preferable 
to technical replicates - RNA samples from the one biological source, especially if 
conclusions are to be made regarding the significance of expression changes. Ideally, 
each biological condition for comparison should be represented by at least three 
independent biological samples (Lee et al., 2000). Obviously, this depends on the 
expense of the microarray experiment and the availability of samples and therefore 
RNA.
The t-test is one of many statistical methods suitable for detecting differentially 
expressed genes (Cui and Churchill, 2003). The t-test uses the error variance for a 
given gene over replicated experiments to determine if that gene is differentially 
expressed and if this difference is significant or not (Callow et al., 2000). A t-value for 
a given gene is computed as follows;
t  = ----- —
S E s
where Rg is the mean ratio of expression levels for that gene and SEg is its standard 
error. After a t-value is calculated it is converted to a p-value. Genes with p-values 
falling below a prescribed ‘nominal’ level may be regarded as significant.
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Several problems exist with this 2-fold approach to identifying significantly 
differentially expressed genes as genes of importance in the biology under investigation. 
The first is that not only changing genes but also the genes which are unchanged from 
one state to another (i.e. from normal to tumour or from primary to metastatic) may 
understandably have an important role in both states. The rudimentary analysis of 
picking changing genes at the top of a list may draw attention away from the biological 
importance of maintaining transcription of a gene from normal to disease state. Also 
real biological data might be lost when alterations in gene expression are more modest 
than two-fold. To address this problem Mootha et al (2003) have devised a powerful 
analytical approach termed gene set enrichment analysis (GSEA). GSEA studies the 
behaviour of genes as a group termed a ‘gene-set’. Biologically associated genes or 
genes involved in a similar cellular pathway or function are unified into gene-sets. The 
hypothesis being that subtle changes in these genes can have a profound effect on the 
biological pathway and when added together the relatively small changes in the genes of 
a ‘gene-set’ can reach extraordinary significance. This approach of data analysis aims 
to capture the real biology underlining the distinction of interest as apposed to 
subjectively cherry picking top ranking genes and creating hypotheses about pathway 
membership.
4.1.1.8 Post-analysis follow-up: validation of microarray data
Post-array verification of results using an independent laboratory approach 
provides experimental verification of gene-expression levels and ideally begins with the 
same biological samples that were compared in the array experiment. Common mRNA 
and protein methods used to validate array data include RT-PCR (Rajeevan et al.,
2001), northern analysis (Chaib et a l,  2001), ribonuclease protection assay (Taniguchi 
et al., 2001), in situ hybridisation (Mousses et al., 2002), immunoblot analysis (Al 
Moustafa et al., 2002) and immunohistochemistry (Mousses et al., 2002).
Before genes of interest are pursued for further investigation and validation, 
sequencing is required as a quality control measure. As many array experiments are 
carried out on the genome-wide scale the probability of error associated with spot 
identity and printing are also increasing. Array production is a high-throughput 
operation involving multiple steps of sample handling and processing, and is therefore
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understandably subject to  error. C onsequently , sequence verification is required to 
identify  and correct fo r such errors (Taylor et al., 2001).
For post-array  validation, real tim e RT-PCR is the m ost popular m ethod for 
quantitatively m easuring  specific m R N A  transcripts as it  is reproducible, rapid, 
inexpensive and requires little starting  tem plate (G iulietti et al., 2001 and W alker,
2002). H ow ever, R ajeevan  et al (2001) have show n that for m any genes studied there 
were significant quantitative d ifferences betw een array and R T -based data.
As w ell as validating array results at the m R N A  level it is also worth 
investigating the changes in  expression at the level o f the corresponding protein 
(C huaqui et al., 2002). The observed  changes at the m R N A  level m ay not always 
translate to the protein. This d iscrepancy  m ay be a factor o f  either the laboratory test 
used to determ ine protein  expression o r o f the b io logy  o f the protein , as protein function 
in the cell is affected b y  several factors besides abundance.
4.1.2 The application of microarray analysis in cancer studies
C ancer is a genetic d isease and as a pow erful genom ic tool, m icroarray analysis 
holds great prom ise in  the m olecular m edicine o f cancer research. This is because 
cancer is a com plex polygeneic and m ultifactorial disease, resulting  from  successive 
changes in  the genom e o f cells and from  the accum ulation o f m olecular alterations in 
both tum our and host cells (H anahan and W einberg, 2000). Such genetic alterations 
include expression suppression or enhancem ent as w ell as deletions, m utations, 
insertions and rearrangem ents o f  genes controlling  regulatory  pathw ays and cellular 
processes such as pro liferation , differentiation, cell cycle, D N A  repair and apoptosis. 
These genetic changes lead to genetic instability , tum ourigenesis, m alignancy, and an 
invasive and drug-resistant phenotype. Therefore, an understanding o f the m olecular 
behaviour o f  tum ours w ould aid their m olecular classification and the therapeutic 
decisions m ade (K han et al., 1998a). N ew  tools are required  to  predict the clinical 
behaviour and outcom e o f  individual tum ours and to ideally  prescribe individual 
tailored treatm ents.
D N A  m icroarray technology has the potential to identify  novel genes that have 
key roles in m ediating either sensitiv ity  or resistance to cancer drugs and
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chem otherapeutic agents. Such analysis o f  d rug-responsive genes w ill greatly assist the 
identification o f new biom arkers, novel therapeutic  targets and the developm ent o f 
logical and effective drug com binations. Several studies have investigated  the use of 
D N A  m icroarrays to pred ict the response o f  cancer cells to chem otherapies (Scherf et 
al., 2000, Zem butsu et al., 2002 and B low er et al., 2002). Such studies involve 
correlating gene expression w ith drug activity , thus providing the ability to group or 
cluster drugs based  on their activity. M icroarray-m ediated  identification o f the 
dow nstream  signalling pathw ays involved in tum our-cell response to  drugs w ill be a 
key step in  the future developm ent o f drug cytotoxicity. M ost current cancer 
m edications are relatively  non-specific cytotoxic agents that exert their effect on both 
norm al and tum our cells. N ew  selective agents are therefore needed to further im prove 
cure rates and reduce host toxicity. S tegm aier et al. (2004) have devised a novel 
approach for screening candidate sm all m olecules for their ability  to differentiate acute 
m yeloid leukaem ia (A M L) cells. This m ethod reduces the genes under scrutiny to a 
sm all subset, and assays the ability o f the drugs to  induce a characteristic signature of 
the transition  from  A M L  cells to  their differentiated  m yeloid  counterparts. Successful 
candidates can then  be investigated  on a genom e w ide scale, saving both  tim e and 
m oney.
M icroarray analysis has been used to investigate the underly ing biology o f m any 
cancers including A M L  (V irtaneva et al., 2001) breast (Sgroi et al., 1999), ovarian (Ono 
et al., 2000 and W elsh et a l,  2001), lung (A nbazhagan et al., 1999), and colon cancer 
(A lon et al., 1999). A rray analysis is applicable to any area or stage (e.g. initiation, 
p rogression, drug-resistance etc) o f  cancer b io logy  w here it is used to elucidate the 
underly ing m olecular m echanism s (B ertucci et al., 2001). A  better understanding o f the 
d isease at a m olecular level w ould  therefore allow  the design o f  therapies targeted to the 
specific m olecular cause o f  the disease. A rray technology provides an ideal tool for the 
investigation o f m etastasis as w ell as all areas o f  cancer, as the activity  o f  m any genes 
can be sim ultaneously m onitored, thus g iving an insight in to  the com plexity  o f cancer 
genetics. The control o f  m etastasis is an appealing target in cancer treatm ent as it is the 
m ain cause o f m ortality  in  cancer and it is com m only the reason for the failure of 
chem otherapy  to eradicate cancer. The m etastatic process has been described as an 
obstacle course in w hich rare cancer cells w ith appropriate com binations o f attributes 
survive to form  a m etastatic co lony  (Poste and Fidler, 1980 and F id ler and Kripke, 
1977). The challenge therefore, is to d iscover the m inim al set o f  genes that are
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functionally  necessary  for m etastasis. C onsequently , several studies using m icroarrays 
have focused on m etastasis by  com paring the expression profiles o f h ighly  m etastatic 
cells w ith less or non-m etastatic  paired  cells (C lark et al., 2000, H egde et al., 2001, 
B ittner et al., 2000 and M aniotis et al., 1999). B y using paired  or genetically  related 
cell lines, it can be p resum ed that the expression o f the m ajority  o f genes is shared with 
the exception o f  those prom oting  or related  to  m etastasis. This application o f 
m icroarray technology is ideal for the identification o f  biom arkers o f  m etastasis. Using 
array analysis, W eigelt et al. (2003) have show n that breast m etastases often  m aintain 
very sim ilar expression profiles to those o f  the prim ary breast tum ours from  the same 
patient. This study also show ed an inability  to  establish  a pattern in genetic expression 
changes betw een the prim ary  tum ours and m etastases. This stands in contrast w ith the 
custom ary m odel w here only a sub-set o f prim ary tum our cells gain m etastatic ability 
and that this is only a rare event in cancer progression (Fidler and Hart, 1982). These 
observations also differ from  a recent study using  m ultip le tum our types, w hich found a 
gene-expression signature that distinguished prim ary from  m etastatic adenocarcinom as 
(R am asw am y et al., 2003). H ow ever, the tissues used  in the R am asw am y study were 
not paired  which m ight explain  the differences nevertheless these gene-expression 
signatures m ay represent a com posite  o f  m ultiple, tissue-specific m etastasis program s.
4.1.3 The future of microarrays
The applications o f  m icroarrays to all areas o f investigative biology are endless. 
M icroarrays have becom e an accessible and com m on oncology research tool that will 
have a great im pact in the evolution o f the m olecular m edicine o f cancer. M ore and 
m ore cancers w ill be c lassified  into new previously  unrecognised subclasses based on 
their m olecular signatures thus facilitating  tailored treatm ents (Khan et al., 1998a, 
S cherf et al., 2000, G olub et al., 1999 and Su et al., 2001). For a young technique, 
m icroarray  analysis is already a key one to the investigation o f the com plexity  o f 
cancer.
As w ell as having a great im pact on the developm ent o f novel therapeutics, the 
recent com pletion o f the hum an genom e sequence will also spur a desire to carry out 
m icroarray  analysis on a w hole genom e level (The G enom e International Sequencing 
Consortium , 2001 and A ustin , 2004). Such genom e-w ide analysis is physically 
ham pered by  the problem s o f  m iniaturising arrays, such as cost, data acquisition and
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analysis. M odern m ethods o f printing arrays aim  to reduce the size o f arrays. B y 
reducing the size o f  the spots on a chip from  150 -  100 |im  to 30 -  25 (im, an entire
'y
100,000 spot array could  fit into the a 4 cm  area and such m iniaturisation m ay be 
com m onplace in fu ture array analysis (O kam oto et al., 2000). H ow ever, the current 
approach o f users selecting and prin ting sets o f genes to produce custom ised arrays is 
likely to rem ain attractive.
Further advances and im provem ents in array analysis w ill concern the care o f 
the biological sam ples under investigation. In particular, and o f clinical relevance, is 
the care o f  tissue sam ples, w hich is im portant in avoiding R N A  degradation. Stricter 
rules are needed for the collection, storage and processing o f  tissues. A nother m ajor 
issue in  need o f im provem ent is the purity  o f tissue sam ples. M ost biopsies are 
heterogeneous, contain ing m any different cell types including norm al surrounding cells 
such as epithelial, endothelial, adipose and strom al cells, infiltrating lym phocytes as 
w ell as tum our cells (R onnov-Jessen et al., 1996). A  pure hom ogenous sam ple is 
desirable in order to obtain  representative results. O ne solution to obtaining a pure 
sam ple is to use laser capture m icrodissection (LCM ). L C M  is used to harvest 
subpopulations o f cells, how ever, obtaining sufficient R N A  from  hom ogenous m aterial 
for m icroarray analysis usually  requires an am plification step (Em m ert-B uck et al.,
1996). A lthough it in troduces another variable in to  the process, R N A  am plification 
allow s array analysis to  be carried  out on 1 -  50 ng o f  m R N A  (W ang et al., 2000). 
Currently, the isolation o f  tum our cells from  surrounding cells is not critical w ith m any 
clinical studies on crude sam ples being published  (B ertucci et al., 2000, Perou et al., 
2000 and B ittner et al., 2000). O ne approach to estim ate the contribution o f each cell 
type is through parallel analysis o f  the expression profiles o f cell lines representing the 
different cell types (Perou et al., 1999).
The future o f arrays and the interpretation o f  the vast am ount o f  data generated 
revolve around the synergy  betw een different scientific cultures. M ultidisciplinary 
collaborations betw een m edical researchers, m athem aticians, com puter scientists and 
b ioinform aticians are requ ired  to carry studies forw ard to  the clinic. A  synergy is also 
required  betw een different types o f inform ation such as the transcriptional and 
translational data for the sam e sam ples. Such data  should  be com parable from  one 
laboratory  to another, thus p rovid ing  a platform  for connectivity .
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4.2 Results: analysis o f gene expression profiles in colon cancer cell lines
The expression profiles o f the fo llow ing co lorectal cancer cell lines were 
com pared by  cD N A  m icroarray  analysis; SW 480, SW 620, SW 480M 7 and SW 480M 9. 
A ll array analysis was carried  out at G M U , VA , U SA . Together, the SW 480 and 
SW 620 cell lines represented  a validated m odel o f  co lorectal m etastasis (H ew itt et al., 
2000). Both cell lines w ere derived  from  the sam e patien t at different stages o f tum our 
progression. The SW 480 cell line w as cultured from  a prim ary  lesion (D ukes stage B 
colon carcinom a) from  a 50-year-old  C aucasian m ale patien t and the SW 620 cell line 
was derived from  a lym ph node m etastasis in  the sam e patient a year later. The 
com parison o f  the expression  profiles o f  these isogenic cell lines therefore provided an 
insight into tum our m etastasis as the differences in expression  m ost likely represented 
changes that occurred w hen the cells acquired m etasta tic  potential. The increased 
invasion show n by the M M P transfected cell lines SW 480M 7 and SW 480M 9 was 
investigated by  array analysis w ith the aim  o f determ ining the dow nstream  effects of 
M M P-7 and M M P-9 overexpression and to identify  M M P-specific transcriptional
SW480 SW620 SW480M7 SW480M9
28 S 
18 S
events.
Figure 4.3 The integrity of RNA used in array analysis. It was crucial that the 
starting RNA for analysis was not degraded. The prominent bands of the 28 S and 
18 S ribosomal subunits indicated intact and good quality RNA. All RNA was 
prepared in triplicate.
4.2.1 RNA extraction, analysis and labelling
Prior to labelling  and hybrid isation (sections 2 .2 .16.4  and 2.2.14.6 respectively), 
RN A  was D N ase trea ted  and its quality and quantity  w ere then assessed by  gel
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electrophoresis and by  spectroscopy respectively  (section 2.2.2.1). It can be seen in 
Figure 4.3 that all R N A  sam ples w ere intact and not degraded. As the 39,360 elem ent 
experim ent was a tw o chip one, 8 [ig o f  D N ase treated  R N A  was required as opposed to 
h a lf that w hich w ould  norm ally  be required for a one chip experim ent (section 
2.2.16.4.2). R N A  w as therefore am plified to prov ide sufficient am ounts for all array 
experim ents including replicates (section 2.2.16.3). The initial concentrations o f  RN A 
sam ples plus the concentrations o f D N ase treated and am plified R N A  are listed in table 
4.1.
Table 4.1 Effects o f D N ase treatm ent and am plification on R N A  concentration and 
A 260/280 values.
RNA Sample A260/280 Yield 
(^g in 25 pi)
Yield: pg 
DNase 
treated RNA 
in 25 pi
Yield: pg aRNA 
in lOOpl
A260/280
SW480(1) 1.5 123.9 38.5 73 2.0
SW480(2) 1.7 87.9 25.8 67 1.6
SW480(3) 1.5 50.7 17.8 59 1.8
SW620(1) 1.5 95.9 37.5 46 1.4
SW620(2) 1.6 44.6 27.5 72 1.8
SW620(3) 1.4 121.2 38.5 106 1.6
SW480M7(1) 1.3 121.6 50.5 90 1.6
SW480M7(2) 1.6 90.8 34.8 67 1.7
SW480M7(3) 1.5 110.2 36.3 104 1.7
SW480M9(1) 1.5 132.8 39.0 91 1.6
SW480M9(2) 1.5 51.5 23.8 102 1.5
SW480M9(3) 1.5 96.8 35.5 84 1.6
4.2.2 Experimental design
Table 4.2 outlines the m icroarray experim ents carried out. In all array 
experim ents carried  out the SW 480 cell line w as used as a control. W here possible, 
experim ents w ere carried  out in triplicate to ensure statistically  significant expression 
changes could be identified . Experim ent 2 represents a technical replicate of 
experim ent 1, in w hich the sam e R N A  preparations from  SW 480 and SW 620 cells were 
com pared in both  experim ents. Experim ent 3 and 4 represent biological replicates, 
w here independent R N A  preparations o f SW 480 and SW 620 were used in each 
experim ent. G ene expression  in  tw o separate SW 480 preparations w ere com pared w ith
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the sam e SW 480M 7 preparation in experim ents 5 and 6. E xperim ent 7 represents a dye 
sw itch control for experim ent 6. T o investigate dye bias and uneven incorporation the 
SW 480 control norm ally  labelled  w ith  Cy3 w as labelled  w ith Cy5, w here the 
SW 480M 7 was labelled w ith Cy3.
Table 4.2 E xperim ental design for the com parison o f  gene expression in colorectal 
cancer cell lines by  cD N A  m icroarray  analysis. E ach num bered line represents an 
individual experim ent w here one sam ple w as labelled  w ith  Cy3 and one w ith Cy5. 
N um bers in brackets indicate the original R N A  preparation batch. C olour shading 
indicates the aR N A  am plification batch. D otted  borders indicate sam ples that were 
pooled  before hybridisations. Experim ent 7 and 10 represent sw itch dye controls for 
experim ents six and nine respectively. Experim ents 11 and 12 w ere ‘s e l f  vs. ‘se lf’ 
controls w here experim ent 12 com pares the expression o f  tw o separate aRN A  
am plifications.
Experiment Cy3 Cy5
1 SW480(1)
2 SW430(1)
m m m m m m mmm m m ■ a
3 J5W480(2}_
4 SW480(3)
SW620(1)
SW620(1)
SW620(3)
5 SW 480(2) SW480M7 (2)
6 V .-SW48 0 £ £ ‘  J  SW 480M7(2)
7 SW480M7(2) ! [S W 4 8 0 0 ‘ ]
8
9
10
SW480(2) SW480t' 1
i ! I  SW48Ö(2  ^‘ j  SW480M 
SW480M9(2) ! ‘  S W 4 8Ö 0 ] ]
11 l . . _ S.VYil § 9 ß L . . I  SW 480(2)
12 I * ~  SW480(2~ j SW480(2)
The expression o f SW 480 and SW 480M 9 cells w ere com pared in experim ents 8, 
9 and 10. Separate SW 480 R N A  preparations w ere com pared  w ith the sam e SW 480M 9
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preparation in experim ents 8 and 9. E xperim ent 10 acted as a dye switch control for 
experim ent 9. The ‘s e l f  vs. ‘s e l f  control experim ents, 11 and 12, w ere carried out in 
order to control the num ber o f false positive that the technique and data analysis 
generated. Experim ent 12 is a ‘se lf’ vs. ‘s e l f  com parison o f tw o separate aRN A 
batches.
4.2.3 Hybridisation and scanning
L abelled  cD N A s w ere hybrid ised and scanned according to T IG R  protocols.
T he arrays used in this experim ent w ere fabricated as outlined  in  section 2.2.16.1.
B riefly , 39,360 elem ents w ere spotted over tw o slides and spotted slides were stored at
room  tem perature under vacuum  until further use. Slides w ere hybridised as outlined in 
section 2.2.16.6, this op tim ised  T IG R  protocol b riefly  involved allow ing the labelled 
cD N A s to hybrid ise to the slide under hum id conditions at 42 °C for 15 hours. 
Follow ing w ashing, hybrid ised  slides w ere then scanned using a confocal laser scanner 
and the generated T IFF im ages w ere interpreted using Q uantarray softw are as outlined 
in section 2.2.16.7.
4.2.4 Data analysis
Follow ing scanning, the raw  data generated w as analysed using G enespring 6.0 
(S ilicon G enetics) softw are, a pow erful com m ercially  available expression data 
v isualization and analysis tool. The first step in the analysis o f  gene array data w ith this 
softw are was to install a gene key, a TX T file that describes the location o f  genes on the 
slide as well as a gene identifier (gene nam e or annotation num ber). The gene key used 
can be  found at the w eb address: h ttp ://w w w .dcu.ie/~biotech/dm urrav/C O M B IN E D - 
G E N E -K E Y .xls. June 25, 2004. D ata  was then im ported  and replicate and dye swap 
experim ents w ere identified. C ertain  data transform ations w ere then carried  out. The 
data w as norm alised using  the LO W ES S per-spot m ethod, w hich com pensates for non­
linear dye-bias. G enespring 6.0 softw are was used  as a data analysis tool, to sim ply 
identify  genes w ith  altered  expression  from  one state to another. T o carry the resulting 
lists o f  genes forw ard to the subsequent validation steps, detailed literature searches 
w ere required. This section describes the analysis o f  the data obtained from  the array 
experim ents.
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4.2.4.1 Data Analysis: comparison of SW480 and SW620 gene expression profiles
In all the data analysis carried  out, the colour bar in  F igure 4.4 was used to 
indicate the fo ld  changes in expression. F igure 4.5 is a scatter p lo t o f  the norm alised 
data for the SW 480 Vs SW 620 experim ent. This is a plot o f  the data obtained from  all 
replicates in  this experim ent including the dye sw itch control. Each data point or spot 
represents a gene and the colour o f that spot represents its expression  ratio.
0.1 0.5 1.0 2.0 5.0
Figure 4.4 Colour bar used to display fold changes in expression. Data points with 
red colouring indicated upregulation and data points with green colouring indicated 
downregulation.
G enes that are b lack in  co lour and generally  fall on the 45° line in the scatter plot 
are unchanged in  expression from  the SW 480 to the SW 620. G enes that are green and 
also generally  fall below  the low er 45° line have 2 fold m ore expression in the control 
SW 480 cells than the SW 620 cells. These genes are therefore dow n regulated at least 
two fold in the progression to m etastasis.
X-a>:is: SVWBQVs SW620 (Oefeuh Interpretation), SW 43G'/SM 520 Colored to'/: SYV-160 Vs SW620 (Apr 04) (DefaultInterpretation)
Y-axis: GW480V& SWS20 (A|ir 04) (Dftfaull IrltOfprfclaliOrt), GWQQ VSW62Q G«D «U C all genes (29933)
Figure 4.5 Scatter plot of normalised expression data for the comparison of 
SW480 with SW620 cells. This plot represents composite data from all replicates.
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G enes that are red in colour and fall above the upper 45° line have a m inim um  of 
2-fold increase in  expression in the m etastatic SW 620 cells in com parison to the non­
m etastatic SW 480 cells. It m ust also be  noted  that the darker the red  or green colouring, 
the greater the fo ld  difference, also, m ore trust is associated w ith the spots that are 
in tensely  coloured. These data points and therefore expression ratios are trustw orthy 
because there is a consensus and therefore little variance for that ratio betw een 
replicates. D ata  points o f little or unsaturated  intensity have less trust associated with 
them  and this is usually  because data is no t achieved in both channels for all replicates. 
T rust can also be lost if  the ratios are not sim ilar betw een replicates. This loss in trust 
can be due to  bad  hybridisation, dust on the array, h igh background, bad dye 
incorporation or uneven labelling. C onsidering  this, real bio logical data can be lost as a 
result o f  one ‘b a d ’ experim ent.
N evertheless, the next step was to  investigate the genes that w ere changing in 
expression. F igure 4.6 show s the selection o f genes (black in colour) w ith expression in 
the SW 620 at least tw o fold m ore than that in the SW 480 cells.
Tftl---- ....    »--> IT! ITrj  •--
1000 toooo lOOUOO
10000-
X-axis: SW480 Vs SVYS20 (Apr 04) (DefauH Interpretation), SW480 V 3WG20 Colored by SW480 Vs SW620 <Apr 04) (Default Interrelation)
Y-axis: SW480 Vs SVY620 (Apr 04) (Default lnle?prelalion), SW480 V SW620 Gene Lis!: all genes (39933). 418 genes selected
Figure 4.6 Selection of genes that are at least two fold up regulated in the SW620 
cells when compared with the SW480 cells. Selected genes are coloured black.
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It can be seen from Figure 4.6 that 418 genes were selected as having an 
increase in expression of at least 2-fold. These genes could be visualised as blocks, as 
demonstrated in Figure 4.7.
CotoiQd by &V4$9 Vs SW02C 04) (DflftcQ lnwf&niU»on> 
o* f l* u a r 2 foin op <«i^ >
Figure 4.7 Block représentai ion of the 418 genes with at least two-fold increase in 
expression in the SW620 cells when compared with SW480 cells.
T h is visualisation gives a good indication o f  the trust o f  these genes with the 
m ore trustw orthy, intensely coloured genes tow ards the bottom . G enes represented by 
blocks tow ards the bottom  o f figure 4.7 are darker in colour indicating a high level of 
trust associated w ith them. The expression  ratios for these genes are therefore sim ilar 
over replicates. B locks with unsaturated co louring represent genes with low levels o f 
trust associated w ith their expression changes. The expression ratios that represented 
significant changes in expression w ere selected next. For this a t-test w as perform ed on 
all o f the 4 18 genes. Expression ratios w ith a p-value lower than 0.005 were regarded 
as significant and are represented in Figure 4.8.
As can be seen from Figure 4.8, 233 out o f  418 genes were significantly 
upregulated at least 2-fold in the SW 620 cells in com parison w ith the SW 480 cells. 
B ecause this experim ent was carried  out in trip licate it can be concluded that these 233 
genes have statistically  significant changes o f  at least a two fold increase in expression 
in the SW 620 cell line in com parison w ith their expression in the parental SW 480 cell 
line.
I l l
Colored by: SW460 Vs SW62G (Apr 04) (Default Interrelation) 
Gone Li si SW620 significant 2 fold up (233)
Figure 4.8 Block representation of genes with 2-fold or more expression in SW620 
in comparison with SW480 cells. (p<0.005)
A selection o f  these 233 genes is listed  in table 4.3, and a full list can be found 
in appendix A  o f  this thesis.
T a b le  4 .3  Selection o f  genes w ith at least 2 -fo ld  increased expression in  SW 620 cells in 
com parison to SW 480 cells (p<0.005)
G m r N um ber Fold Change <;«n« Idtnlitv
A A 916325 21.624 aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)
AA608575 17.343 propionyl Coenzyme A  carboxylase, alpha polypeptide
AA I35152 11.576 glutathione peroxidase 2 (gastrointestinal)
R37743 5.089 T54 protein
R39239 4.897 tenascin C (hexabrachion)
R16134 4.069 transmembrane 4 superfamily member 11 (plasmolipin)
N70463 3.958 B-cell translocation gene 1, anti-proliferative
AA088420 3.588 peroxisome proliferative activated receptor, gamma
H79534 3.549 hemoglobin, epsilon 1
W 46900 3.436 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
AA779165 3.421 ADP-ribosylation factor-like 4
AA460463 3.416 cytokine-like protein C17
R60170 3.167 guanine deaminase
R98936 3.092 membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD 10)
AA478585 2.776 butyrophilin, subfamily 3, member A3
AA055835 2.725 caveolin 1, caveolae protein, 22kDa
A A 64408 8 2.676 cathepsin C
AA486220 2.670 lysyl-tRNA synthetase
A lso o f  in terest in this experim ent w ere the genes that w ere dow nregulated in 
the m etastatic SW 620 cells in com parison w ith the SW 480 cells. Therefore, all the 
above post-array  analysis w as carried out on the genes that w ere at least 2 fold 
dow nregulated, i.e. selection o f  genes and a t-test to determ ine significance. The genes 
that w ere significantly  at least tw o-fold dow nregulated  in com parison w ith the SW 480 
cells are represented  as b locks in F igure 4.9. G enes that are tw o fold  dow n regulated 
are represented as green blocks and the ‘m ore g reen’ these blocks are the m ore 
dow nregulated these genes are in the SW 620 cells. The m ore saturated in colour these 
blocks are also indicated  m ore trust associated w ith  their expression changes.
■ m SSPKSB* I I  i W M -Ji 0 I m m \ 1 V- V' ;! w ■ ■ ■
RNF6 LM02 KRT5 SBDS PSG3
BS&crJ — »11 ESC5S V'hztm
OIP2 THPO YKT6
.--I .^■H 'ill H U H mm m m im & J l H U . H D f d
AATF NEKS PPIG
FZD7
USP1 UBP1
MAOA PD2 OLRX PSOl NAPG AC01 PDP
MFN1 GUI TXTJL KMR1 OD81
DEK NPC2
STC2 TAZ
VMP1 IERS RAGD
BTG3 USP1 RARG RPS7
colored toy SW490 Vs s w m o  (Apr 04) (Default interpretation)
Garis List SW02O significants 2 fold dawn (206)
Figure 4.9 Block representation of genes down regulated in the SW620 cells in 
comparison with the SW480 cells (p<0.005).
It can be seen from  figure 4 .9  that the dow n regulation o f 208 genes in  SW 620 
cells was significant. A lso  visib le in figure 4 .9  next to each b lock  is the abbreviation 
for the gene that this b lock  represented. These abbreviations w ere not v isib le in  figure
4.8 due to the larger num ber o f  genes. A  selection  o f  these genes can be found in table 
4.4 and the fu ll list can be found in appendix A  o f this thesis.
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Table 4.4 Selection o f  genes w ith expression  ratios below  0.5 for the com parison of 
SW 620 w ith  SW 480 cells. (p<0.005)
i;en c  N um ber Fold C hung* Gene Identity
AA598601 0.148 insulin-like growth factor binding protein 3
AA406552 0.165 solute carrier family 2 (facilitated glucose transporter), member 3
AA487425 0.331 zinc finger protein 463
AA621315 0.344 catenin (cadherin-associated protein), alpha-like 1
A A 291163 0.351 glutaredoxin (thioltransferase)
AA486556 0.383 CD81 antigen (target of antiproliferative antibody 1)
AI439571 0.384 apoptosis antagonizing transcription factor
AA683077 0.400 mitogen-activated protein kinase 1
N67766 0.406 acetyl-Coenzyme A  synthetase 2 (AMP forming)-like
AAO17526 0.421 collagen, type IX, alpha 3
AA487486 0.433 cyclin D1 (PRAD1: parathyroid adenomatosis 1)
AA827551 0.445 Notch homolog 2 (Drosophila)
AI688757 0.464 cytochrome c oxidase subunit Vb
4.2.4.2 Data analysis: expression profiling of MMP transfected cell lines
T o investigate the dow nstream  effects o f individually  overexpressing M M P-7 
and M M P-9 on the expression profile o f  a colon cancer cell line, array analysis was 
used  to  com pare the SW 480M 7 and SW 480M 9 cells w ith  the parental SW 480 cells. By 
studying the global expression  o f these cells, cD N A  array technology provided  an ideal 
tool in  determ ining the transcrip tional effects o f M M P activity
4.2.4.2.1 Data analysis: protiling SW480M7 expression
Figure 4.10 is the scatter p lot o f norm alised data com paring the expression 
profile  o f  the M M P-7 transfected  cell line (SW 480M 7) w ith that o f the non-transfected 
cell line SW 480. A gain, the expression ratio  o f  each gene is represented by  a datapoint 
and the colour o f that data  poin t represents the nature o f that ratio. G reen data points 
represen t genes that are dow nregulated  in  cells transfected w ith  M M P-7 and red data 
poin ts represent genes w ith  up regulated  expression in the sam e cells. D ata points that 
are b lack  in colour indicate that these genes are unchanged from  one condition to 
another. B ecause altered gene expression resulting  from  M M P-7 overexpression was of 
interest, genes w ith  at least tw o-fold increase or decrease in expression w ere selected for 
further statistical analysis. G enes w ith at least 2-fold enhanced expression in  the M M P- 
7 transfected  cell line SW 480M 7 in com parison w ith  the SW 480 control are depicted in
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Figure 4.11. The changes in expression of these 147 genes reached significance with p 
values smaller than 0.005.
X-aids: SW460 Vs GW4BOM7 CDefauN Interpretation), 8W490 Vs 3W490M7 Colored toy: 8VM80V3 8W480M? (DsfaulHnlsmrelallon)
Yfflds: SW480 Vs 8W490M7 (DefeuH Interpretation). SW490 Vs SW490M7 Sens List all genes (3 9 9» )
Figure 4.10 S catter plot o f  norm alised  data  for the com parison  o f  S W 480M 7 cells 
w idi the control S W 480  cells. T h is plot rep resen ts data ob tained from  all replicates 
o f  th is experim ent including the dye sw itch  contro l.
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lesp GD47 C8X3
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■ ■ H  V  J B H H  M  ■ ■
LNK:
DPP7
CAV2
Colorad by: SW40O Vs SW490M7 (Default interpretation)
Gene List: M7 eiBniflcanWjr2foldup(H7)
Figure 4.11 S ign ifican tly  up regulated  genes in a cell line over expressing  M M P-7.
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T hese 147 genes are listed  in appendix A  o f  th is thesis, bu t a selection o f  them  
are listed  in  table 4.5.
Table 4.5 G enes w ith  at least 2 fo ld  increase in  expression  in cells transfected w ith
M M P-7 (p<0.005). The full list can be found in  appendix A  o f  this thesis.
Fnl.1 L'liange Gene Id
AI339434 2.750 caveolin 2
AI250799 2.676 defensin, alpha 4, corticostatin
AI276487 2.617 cytokeratin type II
AA669218 2.540 HB SI-like (S. cerevisiae)
AA916562 2.494 vacuolar protein sorting 4B (yeast)
H21892 2.492 Homo sapiens cDNA FLJ36638 fis, clone TRACH2018950.
AI288845 2.421 chemokine (C-C motif) receptor-like 2
AA479344 2.401 gap junction protein, beta 5 (connexin 31.1)
AA463462 2.384 Toll-interacting protein
AA778851 2.347 Human clone 137308 mRNA, partial cds.
AA953249 2.323 H factor 1 (complement)
AA977836 2.310 peroxisomal farnesylated protein
A A 410434 2.218 collagen triple helix repeat containing 1
AI198232 2.132 C-terminal PDZ domain ligand o f neuronal nitric oxide synthase
AA868008 2.042 histone 1, H4c
AA424562 2.017 tumor necrosis factor (ligand) superfamily, member 13
AAMM927
ASNS
AI552005 AA983892
CTSL2 DKFZP5B6J1624
AMI 0M6 
IARS
AA37B089
ECH1
W20G3O6
UGC0L2
AA970212 
L0C91 m
R36494 WiA-4-3-15-2
fL0T2
AIG15B79
PSA
Colored by: SW49QVs SW4&0M7 (Default Inlerprelalmn)
Gene List M7 significantly 2 fold dawn (12)
Figure 4.12 Block representation of genes that were at least 2-fold downregulated 
in SW480M7 cells in comparison with SW480 cells.
Figure 4.12 represents the genes that w ere significantly  dow nregulated in  the 
SW 480M 7 cells in  com parison w ith the parental SW 480. W hen tested for significance 
only  12 genes w ere statistically  dow nregulated  due to M M P-7 overexpression. L isted 
in  Table 4.6 is a selection o f  these genes as w ell as their fo ld  change in expression.
Table 4.6  Selection o f genes dow nregulated  in  cells overexpressing M M P-7 (p<0.005).
Gene Number____________ Fold Chunttc Gent Identify
AIO15679 0.304 phosphoserine aminotransferase
AI280306 0.341 UDP-glucose ceramide glucosyltransferase-like 2
AA894927 0.358 asparagine synthetase
AA410636 0.487 isoleucine-tRNA synthetase
R38494 0.493 flotillin 2
AI652005 0.515 cathepsin L2
As w ith  the SW 620 experim ent these genes w ere listed  for further investigation and for 
literature searches.
4.2.4.2.2 Analysis of SW480M9 expression data
The data obtained from  the array experim ents in  w hich the expression profile o f 
the SW 480M 9 cells, w hich  overexpress M M P-9, w as com pared w ith that o f the 
parental, non-transfected  SW 480 cells was analysed for genes that were significantly 
changing. F igure 4.13 is a scatter p lo t representing the norm alised data for the 
expression  ratios for all genes in  this experim ent. D ata from  all replicate experim ents 
including a dye sw itch control w ere considered in  this analysis and Figure 4.14 
represents genes w ith  at least 2 -fo ld  m ore expression in  the SW 480M 9 cells. The 
upregulation o f these 193 genes also reached statistical significance. H ighlighted in 
F igure 4.14 is M M P-9, w hich, as expected, was significantly  up-regulated  according to 
the array results.
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X-aas: SW480 vg SW48OW0 (Default Interpretation), SVVil0Q Va SW480M9 Colored by. SW40O vs SW4Q0M9 (Default Interpretation)
Y-axis: SW480 vs SW490M9 (Default (nteipretetton), s m e a  Vs s%V48QW9 Gene u s t  aU germ* 09933)
Figure 4.13 Scatter plot of data obtained from the array experiment comparing 
SW480 cells with MMP-9 overexpressing cells: SW480M9.
AQP9
RGML 8 m
KN$2 GOFI
colored by. SW480 vs SW480MS (Difauli Interpretation) 
Gene List Mi sign ifican t2 fold up (193), T72581 ealaeted
Figure 4.14 Overexpression of MMP-9 (highlighted in black) resulted in the 
upregulation of 193 genes (p<0.005).
The full list of all 193 genes that were significantly up regulated due to MMP-9 
overexpression is included in appendix A of this thesis. Table 4.7 lists a selection of 
these and also includes the fold changes in expression for these genes.
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As seen in F igure 4.15, 20 genes w ere significantly  dow nregulated  in  SW 480M 9 
cells w hen com pared w ith SW 480 cells. E ach  gene is identified  by  is accession num ber 
or its abbreviation.
T a b le  4.7 M M P-9 overexpression enhanced the expression o f  193 genes (p<0.005). 
A bove is a selection o f  those genes.
AA394240 6.417 X-box binding protein 1
T72581 4.686 matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)
AA479344 3.822 gap junction protein, beta 5 (connexin 31.1)
AA775447 3.433 aIpha-2-macroglobulin
AA676765 3.389 mitochondrial ribosomal protein 63
AA453796 3.2 tetraspanin similiar to uroplakin 1
AA733038 2.729 RNA polymerase I subunit
AA443193 2.698 homolog of yeast Sec5
AA479950 2.497 ATPase, Class II, type 9B
AA683578 2.377 Homo sapiens mRNA; cDNA DKFZp667G2419 (from clone DKFZp667G2419)
H29895 2.304 guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 2
AA700155 2.158 Crm, cramped-like (Drosophila)
AA706790 1.959 kinesin 2 60/70kDa
Al 3591 20 
CHD6
AAS94927 
ASN8
AAJ376466
A S S
AAA47M6
RTP801
AJ 0 1 5 6 7 9  
P S A
Colored by: SW480 vs SW490M9 ¿Default interpretation) 
Geno Usi: M9 significant 2 fold down (20)
AA278630
DDA3
AI080633
PDP
R 5 I 2 1 8
KIM0092
AJ675485
HERPUD1
AA449832 
AP1S2
A A S 0 8 4 0 6
IOG AP1
AA876405 
ASS
Figure 4.15 Genes downregulated in SW480M9 cells that met statistical 
significance (p<0.005).
Som e o f these 20 genes and their fo ld  change in  expression are listed  in Table 4.8.
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Table 4.8 Selection o f genes dow nregulated  as a result o f  M M P-9 overexpression in 
SW 480 cells.
O n e  Number Fold Change G ene Identity _____________________________
AI015679 0.298 phosphoserine aminotransferase
AA676466 0.393 argininosuccinate synthetase
AA894927 0.408 asparagine synthetase
AI080633 0.453 pyruvate dehydrogenase phosphatase
AA447746 0.460 HIF-1 responsive R TP801
AI359120 0.470 chromodomain helicase DNA binding protein 6
AA598496 0.473 IQ motif containing GTPase activating protein 1
AA278630 0.491 differential display and activated by p53
4.2.4.3 Data analysis of a ‘self’ vs. ‘self’ experiment
As outlined in Table 4 .2 , experim ents 11 and 12 represented replicates o f a ‘se lf’ 
Vs ‘se lf’ control experim ent w here the sam e sam ple was labelled  differently  and co­
hybridised. The ‘se lf’ vs. ‘se lf’ experim ent acts as a control to ru le out false results that 
m ight occur due to dye bias o r unequal incorporation.
X-axis: SVH80 Vs SVY480 (DefaultInterpretation), SW430 V3W480 Colored by: SW480V&SW480(Defaul1 Interrelation)
Y-axis: S w eO V s SVY480 (Default interpretation), SW*aO VSW480 Gene List all genes (59933)
Figure 4.16 Normalised data for the ‘self’ vs. ‘se lf control experiment where 
SW480 cDNA was labelled differently and cohybridised on the same slide.
T he norm alised data obtained  from  this experim ent is represented in Figure 4.16 
and w as analysed for genes that had changes in expression. O ut o f  all 39,365 genes on
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the array, no genes w ere sign ificantly  dow nregulated but 9 upregulated  genes m et 
statistical significance (figure 4.17).
PM 57433
R260B2
ZNF354A
AA76A328
CDK10
*A5MÈ65 
SROaPî
H74008
A A 7M 605
AA878391
GPC5
H06282
DCLRE1C
Colored tyjr S W  TO Vs SW180 (Default IntenorelgCKm)
Oene U st 460 v 480 2 Told up sia-nlfleant (0)
Figure 4.17 In a ‘self’ vs. ‘self’ control experiment 9 upregulated genes met 
statistical significance (p<0.005).
T hese genes are listed  in Table 4.9.
Table 4.9 G enes w ith 2 fo ld  o r m ore increased expression in  a ‘se lf’ vs. ‘s e lf  
experim ent.
AA057433 3.043 Data not found
AA878391 2.508 glypican 5
R26082 2.439 zinc finger protein 354A
AA7 89328 2.437 cyclin-dcpendent kinase (CDC2-like) 10
AA598665 2.374 SLIT-ROBO Rho GTPase activating protein 2
A A450351 2.290 protein inhibitor of activated STAT, 1
AA708605 2.196 Transcribed sequences
H74008 2.154 Data not found
H06282 2.014 suppressor of variegation 3-9 liomoiog 2 (Drosophila)
4.2.5 Post array analysis and validation of selected genes
A fter genes that w ere sign ificantly  up or dow n regulated  w ere identified, the 
next step was to carry  out detailed  literature searches and select genes for further
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validation and investigation. Table 4 .10 lists 5 genes that had expression changes that 
m et statistical significance in the array experim ents. The decision to further investigate 
and validate these genes is discussed later in this chapter.
Table 4.10 G enes selected for further analysis and validation.
Accession # Gene Name Fold Change Experiment
AA644088 Cathepsin C 3 up SW620
AA055835 Caveolin 1 3 up SW620
AA088420 Peroxisome Proliferative Activated Receptor 4 up SW620
R39239 Tenascin C 5 up SW620
AA894927 Asparagine Synthetase 3 down SW480M7 and SW480M9
4.2.5.1 Sequence validation
A s a quality  control m easure, the clones printed on the slides were also 
sequenced to confirm  their identity. The sequences o f the 5 genes chosen for further 
analysis w ere positively  identified  by their sequence using an A B I 377 DNA 
sequencing platform . The resulting  sequences are included in appendix B o f this thesis. 
F igure 4.18 is the resulting chrom atogram  for the sequencing o f the first 100 bases o f 
the tenascin  C clone and is show n as a representation  o f the 5 genes chosen for further 
validation.
10 20 30 40 $0 *0 70 10 90 13C
GCCGGGTT TCCUGTC^C ¿G T ttjT ,  CO CGCCC xGTG -  ATTCCC T 7CCGGCCGC IfiGtt . TTTTTTTTTTTTTT T7TTTTTT .C X A AC TC K * ¿AC
clone. Each coloured line represents a different base, (black: guanine, blue: 
cytosine, red: thymine, green: adenine. ‘N ’ is inserted when the identity of the 
base cannot be determined.
1 2 2
U sing the B L A ST  tool on the N ational Centre for B iotechnology Inform ation 
(NCBI) w ebsite  (h ttp ://w w w .ncbi.n lm .n ih .gov/b last/, 17 Septem ber 2004) the sequences 
o f the clones m atched their respective targets w ith the fo llow ing accuracy: Tenascin C 
95% , Caveolin  1 88% , PPA R y 96% , A sparagine Synthetase 98%  and C athepsin C 88%.
4.2.5.2 Quantitative real time PCR of target genes: validation of expression ratios
Q uantitative real tim e P C R  as outlined  in section 2.2.4 was used to confirm  the 
fold changes in expression. In com parison  to conventional PC R, real tim e PCR 
provides a m uch m ore accurate and quantitative representation o f  the differences in the 
expression o f a  gene from  one state to another.
4.2.5.2.1 Assessment of primers for use in real time PCR
Real T im e PC R  rem oves the  need to run products on an agarose gel, 
nevertheless the prim ers used m ust be specific and therefore the products o f control 
reactions w ere run on a gel to  confirm  the reaction yielded one product o f the desired 
size. S tandard R T -PC R  was carried  out as outlined in section 2.2.15.
R N A  extracted  from  the SW 620 cells was used to  test the prim ers for cathepsin 
C, tenascin  C, caveolin  1 and PPA Ry as their expression was show n to be increased in 
this cell line. R N A  from  SW 480 cells w as used to test the prim ers for asparagine 
synthetase. As can be seen in  F igure 4.19 the prim ers used  in the real tim e PC R  yielded 
only one p roduct o f the correct size w hen used in a standard PC R  reaction.
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Figure 4.19 Specificity of primers used in real time PCR. Separate RT-PCR 
reactions using primers for the five selected genes yielded only one product, each 
of the following sizes: (A) Cathepsin C 549 bp, (B) Caveolin 1 80 bp, (C) PPARy 
113 bp, (D) Asparagine Synthetase 202 bp and (E) Tenascin C 331 bp.
4.2.5.2.2 Real time PCR analysis of P-actin expression
A ll real tim e P C R  analysis was carried  out in  triplicate. The expression o f 0- 
actin was used  to norm alise the expression o f the target genes, thus m aking inter-sam ple 
com parisons possible. For com parative analysis, the outputted  real tim e fluorescent 
signal was d ifferen tiated  to  obtain  the curve in  F igure 4.20.
cf2/d2C
Figure 4.20 p-actin real time PCR analysis. The above curve was used to 
quantitate expression. Each colour represents a sample analysed in triplicate 
(Table 4.11).
The com parative quantitation  curve for (3-actin for all sam ples fall on one 
another, indicating, as expected, that there w as no m ajor d ifference in actin expression 
betw een the sam ples.
Table 4.11 Take o ff  and com parative quantitation values fo r p-actin real tim e PC R  for 
each sam ple in triplicate. T he units for take-o ff are cycle num ber.
Colour Name Takeoff Comparative Concentration
■ SW480 actin 13.1 1.00E+00
■ SW480 actin 13.3 9.07E-01
■ SW480 actin 12.7 1.22E+00
■ SW620 actin 11.8 1.88E+00
■ SW620 actin 12.9 1.10E+00
■ SW620 actin 11.7 1.98E+00
■ SW 480M9 actin 11.3 2.40E+00
■ SW 480M9 actin 13.5 8.23E-01
■ SW 480M9 actin 13.5 8.23E-01
■ SW 480M7 actin 11.2 2.52E+00
■ SW480M7 actin 11.1 2.65E+00
■ SW 480M7 actin 11.9 1.79E+00
C om parative quantita tion  is based on the take o ff point and it calculates the 
relative concentration o f  each sam ple com pared to the control sam ple chosen by the 
user. The num ber given is expressed  in  scientific notation.
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To further confirm  prim er specificity, a m elt curve was carried out at the end o f 
each reaction. F luorescence w as m easured as the com pleted  reaction tubes were heated 
from  50 °C to 99 °C. A  sharp drop in fluorescence ind icated  the m elting or denaturing 
o f the PCR product. T o determ ine there was only one product, this output signal was 
differentiated (F igure 4.21). O ne peak indicated  that there w as only PC R  product and 
that the prim ers used in the reaction w ere specific.
Figure 4.21 Melt curve analysis for [3-actin PCR reaction. One peak at 89 °C 
indicated there was only one PCR product and that the primers used were therefore 
specific.
The above fi-actin com parative quantitation  values w ere used to com pare the 
expression o f the five target genes betw een these sam ples.
4.2.5.2.3 Quantitative real time PCR analysis of cathepsin C expression
Real tim e PC R  analysis was used to investigate the levels o f C athepsin C 
expression in  the SW 480 and SW 620 cells. The com parative quantitation curve for the 
expression o f cathepsin  C (Figure 4.22) show s that the curves for both sam ples are well 
resolved indicating a d ifference in expression betw een SW 480 and SW 620 cells as seen 
in Table 4.12.
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dF2/d2C
Figure 4.22 Comparison of cathepsin C expression in SW480 and SW620 cells.
Each reaction was carried out in triplicate. Table 4.12 summarises colouring used.
T a b le  4 .12 C om parative quantitation  o f  cathepsin C (C ath C) expression in SW 480 and 
SW 620 cells.
Colour Name Takeoff Comparative Concentration
■ SW480 Cath C 25.3 1.00E+00
■ SW480 Cath C 25.1 1.13E+00
■ SW480 Cath C 25.9 6.98E-01
■ SW620 Cath C 21.0 1.31E+01
■ SW620 Cath C 21.4 1.03E+01
■ SW620 Cath C 21.0 1.31E+01
A  m elt curve (F igure 4 .23) was used to conclude that the cathepsin C prim ers 
used  were specific. The one resulting  peak indicated  there w as only one PC R  product 
was form ed. The PC R  p roduct was denatured at 85 °C.
F igure 4.23 Melt curve analysis, to determine specificity of PCR primers used in 
cathepsin C reaction.
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4.2.5.2A Caveolin 1 expression as determined by real time PCR
Figure 4.24 show s the real tim e data obtained  for the com parison o f  caveolin  1 
expression in the SW 480 and SW 620 cells. As can be seen from  Figure 4 .24 the curves 
obtained for caveolin  1 expression in the SW 480 and SW 620 cells did not fall on top of 
one another indicating differential expression.
dF2/d2C
Figure 4.24 Real time data for the analysis of caveolin 1 expression in the SW480 
and SW620 cell lines. Table 4.13 summarises colouring used.
Table 4.13 lists the com parative quantitation  values obtained from  the real tim e 
PC R  reaction. It can be  seen from  the raw  data in  Table 4.13 that the SW 620 caveolin 1 
PC R  reaction in  the SW 620 cells ‘to o k -o ff  in the exponential phase earlier, indicating a 
higher level o f  tem plate  and therefore expression. All raw  data w as subsequently 
norm alised using  the (3-actin data.
T a b le  4 .13 V alues obtained for the com parison o f  caveolin  1 expression in the SW 480 
and SW 620 cells by  real tim e PCR. Take o ff  indicated  the cycle in w hich the 
exponential phase was entered.
Colour Name Takeoff Comparative
Concentration
■ SW480 Cavi 19.7 1.00E+00
■ SW480 Cavi 19.8 9.44E-01
■ SW480 Cavi 19.9 8.91 E-01
■ SW620 Cavi 15.1 1.42E+01
■ SW620 Cavi 14.8 1.68E+01
■ SW620 Cavi 15.2 1.34E+01
As a quality  control step, m elt curve analysis w as carried out to h ighlight the 
specificity  o f the PC R  prim ers used (Figure 4.25). O ne peak at 82 °C indicated that the
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reaction  yielded only  one p roduct as desired. The m elting  tem perature o f PC R  products 
depends on the size o f  the p roduct and the GC content.
dF/dT
2
1_
0  _________________
Threshold
~ 150 Go I70 i o  l90 ®c
Figure 4.25 Melt curve analysis of the caveolin 1 PCR products. Table 4.13 
summarises colouring used.
4.2.5.2.5 Real time PCR analysis of PPARy expression
The expression o f  PPA R y in  the SW 480 and SW 620 cells was analysed using 
real tim e PCR. The resu lting  com parative quantitation curve (Figure 4.26) revealed  that 
the  individual curves fo r bo th  sam ples w ere w ell resolved, indicating a difference in  
PPA R y expression levels.
dF2A)X
PPARy in the SW480 and SW620 cells. Table 4.14 summarises colouring used.
The raw  data fo r th is real tim e PC R  reaction is lis ted  in  Table 4.14. A lthough 
th is is raw  un-norm alised  data, the  com parative concentration o f  PPA Ry was h igher in  
the SW 620 than  in  the S W 480 cells. P-actin expression levels w ere later used to 
norm alise  the data, and th is is d iscussed  later in  this chapter.
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Table 4.14 Raw  com parative concentration data obtained by  real-tim e PC R  for the 
expression o f  PPA Ry in SW 480 and SW 620 cells.
Colour Name Takeoff Comparative Concentration
r m m u j j u 19.0 1.00E+00
n B g j j 19.2 8.93E-01
n i 18.9 1.06E+00
n g p 16.0 5.42E+00
□ H 16.0 5.42E+00
□ B a a 15.7 6.42E+00
F ollow ing PC R, a m elt curve was carried  out to assure prim er specificity. The 
one resu lting  peak  (Figure 4.27) indicated there w as only one product form ed in the 
reaction.
product formed in all PPARy real time PCR reactions.
4.2.5.2.6 Confirmation of tenascin C expression by quantitative real time PCR
T enascin C expression  was chosen for further investigation as it had increased 
expression in  the SW 620 cells in com parison w ith  the SW 480 cells. Figure 4.28 
displays the tenascin C  real tim e PC R  data obtained.
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Figure 4.28 Tenascin C real time PCR comparative concentration data in the 
SW480 and SW620 cells. The raw data and colouring used are summarised in 
Table 4.15.
T a b le  4 .15 Tenascin  C expression  in  SW 480 and SW 620 cells.
Colour Name Takeoff Comparative Concentration
SW480 TenascinC 31.3 1.46E+00
■ SW480 TenascinC 30.1 1.70E+00
■ SW480 T enascinC 29.7 1.54E+00
■ SW620 T enascinC 21.6 I 4.30E+00
■ SW620 T enascinC 21.9 6.83E+00
■ SW620 TenascinC 22.1 5.99E+00
The raw  com parative concentration values for tenascin  C are higher in the 
SW 620 cells and the ‘take o f f  tim e is earlier indicating h igher expression levels. The 
m elt curve carried  out after the P C R  reaction show n in  F igure 4.29 had one peak 
indicating that on ly  one p roduct was form ed in  the reaction.
dF/dT
1.5
I
1 1 I
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Figure 4.29 The melt curve for tenascin C real time PCR indicated that only one 
PCR product was formed in both SW480 and SW620 reactions.
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4.2.5.2.7 Real tim e PCR analysis of asparagine synthetase expression
The expression o f  asparagine synthetase was investigated  in  the SW 480, 
SW 480M 7 and SW 480M 9 cell lines as it w as show n by  m icroarray  analysis to  be down 
regulated in SW 480M 7 and SW 480M 9 in com parison w ith SW 480.
cF2/d2C
Figure 4.30 Real time PCR asparagine synthetase comparative concentration data 
for SW480, SW480M7 and SW480M9 cells. Raw data and colouring used is 
summarised in Table 4.16.
T a b le  4 .16 R aw  data obtained from  the real tim e PC R  analysis o f asparagine synthetase 
expression. SW 480 cells had an earlie r take o ff tim e and higher com parative 
concentration values.
Colour Name Takeoff Comparative Concentration
■ SW480 AspSyn 13.6 1.00E+00
■ SW480 AspSyn 13.4 ■ I 1.13E+00
■ SW480 AspSyn 13.3 1.20E+00
■ SW480M7 AspSyn 16.4 2.03E-01
■ SW480M7 AspSyn «*6.7 2.77E-01
■ SW480M7 AspSyn 16.8 2.11E-01
■ SW480M9 AspSyn 16.6 1.06E-01
■ SW480M9 AspSyn 16.7 1.25E-01
■ SW480M9 AspSyn 17.3 1.45E-01
As can be seen from  the com parative concentration curve (F igure 4.30) and the raw  data 
obtained (Table 4.16) the SW 480 cells expressed m ore asparagine synthetase than the
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SW 480M 7 and SW 480M 9 cells. The m elt curve displayed in  F igure 4.31 show ed only 
one peak, ind icating  the PC R  reaction w as specific.
used were specific for one PCR product.
4.2.5.2.8 Normalisation of real time PCR data
T he raw  data  obtained  from  all P C R  reactions was norm alised using the P-actin 
expression levels. F igure  4 .32 is the norm alised real-tim e PC R  data for the genes o f 
interest. This data  w as obtained by  analysing three separate R N A  preparations for each 
cell line. This confirm ed that the data  obtained by  cD N A  m icroarray was real and could 
be validated  using  another technique.
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Cattiepsin C Caveolin 1 PPAR Tenascln C Asparagine
Synthetase
Figure 4.32 Real time PCR confirmation of fold changes in expression.
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4.2.5.3 Cathepsin C: validation of protein activity
As C athepsin  C is a proteolytic enzym e, its activity was assayed at the protein 
level using a specific  fluorescent substrate as outlined in section 2.2.18. A  specific 
peptide substrate for cathepsin C was coupled to  am ino-m ethylcoum arin (AM C). This 
com pound em itted  fluorescence w hen the  peptide was cleaved, thus allowing 
quantitation o f cathepsin  C activity by  com parison  to an A M C standard curve (Figure 
4.33).
IIM A M C
Figure 4.33 AMC standard curve.
To calculate the am ount o f  A M C  liberated  per jig protein the total protein 
concentration o f  cell lysates was determ ined by  B C A  assay. The raw  fluorescence and 
protein concentration  data for all four sam ples is listed  in Table 4.17.
T a b le  4 .17 The am ount o f  A M C  liberated p e r p.g total protein was calculated using the 
total protein concentration values. Note: 10 pi o f  each sam ple was used in each assay.
Sample
Protein
(ng/ni) uM AMC liberated
|iM AMC liberated 
per minute per fig 
Protein
SW480 1.4 1.35 0.097
SW620 2.4 5.08 0.212
SW480M7 1.5 0.63 0.043
SW480M9 1.4 1.11 0.077
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Figure 4 .34  displays the data obtained for the am ount o f A M C liberated per j^ ig 
total protein. This assay w as carried out in  triplicate.
0 25
SW480 SW620 SW480M7 SW480M9
Figure 4.34 Cathepsin C activity in colorectal cancer cell lines. Cathepsin C 
expression was assayed in total cell lysates and expressed as the amount of AMC 
liberated per |xg total protein.
4.2.5.4 Analysis of variant tenascin C  isoform expression
To further analyse the expression o f  Tenascin C in the SW 480 and SW 620 cell 
lines, specific PC R  prim ers w ere designed to investigate the m ultiple isoform s that exist 
due to alternative splicing (Figure 4.35).
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Figure 4.35 Design of primers used to investigate alternative splicing. The top 
part of this image is a graphic representation of the tenascin C protein. Exons 10 to 
16 are subject to variant exon splicing. The 8F/18R primer cassette was used to 
amplify all variants. The T9-17F/18R primer cassette was used to amplify the 
truncated isoform of tenascin C only. The T9-16F/18R primer cassette was used to 
amplify tenascin C isoforms with exon 16 only inserted. The T8F/T-14-16R 
cassette was used to amplify all isoforms where exons 14 and 16 were spliced 
together. Figure adapted from Adams et al., 2002.
F igure 4 .36 show s the expression profile  o f tenascin C in both  the SW 480 and 
SW 620 cell lines using an 8F/18R  PC R  prim er cassette, w hich am plified all tenascin C 
isoform s.
SW480 SW620
2345 bp full length 8 - 9 - ( + 7) - 17 - 18
+ 2 exons 985bp 8- 9 - ( + 2) - 17-18
+  1 exon 713bp 8 - 9 - ( + 1) - 17-18
Truncated 441 bp 8- 9 - 17-18500 bp
Actin 550 bp
Figure 4.36 Expression profile of all tenascin C isoforms in SW480 and SW620 
cells as determined by RT-PCR using 8F/18R primer cassette. P-actin was used as 
a loading control.
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As can be  seen from  figure 4.36 the SW 480 and SW 620 cells have different 
expression profiles and the SW 620 cells expressed m ore overall tenascin C. The 
SW 480 cells expressed  less truncated tenasin  C than  the SW 620 cells. B ecause all 
tenascin  C variant exons are 272 bp in  length, they  cannot be identified  using this PCR 
reaction. P C R  using  exon specific prim ers was therefore used.
SW480 SW620
431 bp 8- 9- 16- 17-18
Figure 4.37 Exon-16 specific tenascin C PCR using specific primer set to amplify 
the isoform with exons 8, 9, 16, 17 and 18 expressed in sequence.
PC R  using  exon 16-specific prim ers (figure 4.37) was used to show that the 
SW 620 cells expressed  this isoform , w here only exon 16 is spliced. SW 480 cells did 
not express m easurable levels o f this exon.
SW480 SW620
1665 bp 8 - 9- 10- 11- 12- 13- 14-16 
-1392  bp 8 - 9- ( + 3) - 14-16
- 1 1 1 8  bp 8- 9- ( + 2) - 14-16
572 bp 8-9-14-16
Figure 4.38 The expression of tenascin C isoforms where exons 14 and 16 are 
spliced together.
The SW 620 cells w ere also show n to express exons 14 and 16 side by  side 
(figure 4.38). T he SW 620 cells expressed 5 different variants all o f  w hich  om it exon 
15. SW 480 cells d id  no t express any 14/16 isoform s.
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4.3 Discussion
In this chapter, the m icroarray analysis o f a panel o f colorectal cancer cell lines 
was described. cD N A  arrays were used to com pare and contrast the expression profiles 
o f  tw o cell lines w hich  represented a m odel o f  hum an colorectal m etastasis. The non­
m etastatic SW 480 and m etastatic SW 620 cells lines w ere derived from  prim ary and 
secondary tum ours from  a single patient respectively  and therefore represent an ideal 
m odel for studying the later stages o f colorectal cancer progression (Leibovitz et al., 
1976 and H ew itt et al., 2000). Such analysis has the potential o f identifying genes o f 
im portance in  the m etastatic  process by  com parison o f expression profiles o f these 
isogenic cell lines and identify ing differentially  expressed genes. B ecause these cell 
lines share a com m on genetic background, studying their genetic differences was 
therefore sim plified  because background genetic variation was m inim ised and 
expression changes m ost likely  represented m etastasis specific as opposed to individual 
specific changes.
The aim  o f  this array study was to identify  m etastasis related genes or genes 
w hich conferred  a m etastatic potential or survival advantage on these cells and therefore 
gain an insight in to  this process. There was also the potential o f identifying novel genes 
as possib le therapeutic  targets or prognostic m arkers. The expression profiles o f cells 
stably  transfected  w ith  the cD N A s for M M P-7 and M M P-9, w hich have been term ed 
SW 480M 7 and SW 480M 9 respectively  w ere also com pared w ith that o f  the parental 
SW 480 cells. The M M Ps have established roles in  the m etastatic cascade (Curran and 
M urray, 1999) and the identification o f dow nstream  transcriptional events due to their 
activity  could  fu rther c larify  these roles. Cells were grow n in culture under standard 
conditions and R N A  w as prepared from  three independent culture flasks. This ensured 
biological replication.
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Table 4.18 Summary of results from cDNA microarray experiments.
E x p e r iin  en t > 2  fo ld  
up
< 2  fo ld  
dow n
SW 480 vs SW 620 233 208
S W 480 vs 
S W 480M 7
147 12
SW 480 vs 
S W 480M 9
193 20
Follow ing the array experim ents and subsequent data analysis, genes o f interest 
were chosen. As table 4 .18 sum m arises there w ere m any genes that were significantly 
tw o fold  up or dow n in each experim ent (e.g. 233 genes 2 fold up and 208 genes 2 fold 
dow n in SW 620 cells w hen com pared w ith SW 480 cells). This data alone is an 
im portan t collection o f  quality  inform ation. D ue to the experim ental design and the 
subsequent data analysis, these gene lists have use in further analysis and data m ining 
w here the potential to answ er m any biological questions regarding m etastasis is very 
real.
The overlapping genes w ith  expression changes that are com m on in all 
experim ents are represented  by  the V enn diagram s in  F igure 4.39. The full list o f  these 
com m on genes is included  in  appendix C to this thesis. In all experim ents the parental 
SW 480 cells w ere used  as the control. The gene changes represented in  Figure 4.39 all 
reach statistical significance. 44 genes w ere significantly  up regulated  in  both the 
SW 480M 7 and SW 480M 9 cells. Interestingly, there w ere no significant gene changes 
that w ere com m on to  all experim ents.
F igure 4.39 Number of genes with common changes in expression over all 
experiments.
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R ecently  the sam e SW 480 and SW 620 cell m odel has been used in an array 
study in to  the m echanism s o f  drug resistance (H uerta et al., 2003). A lthough different 
array technology to that described here  was em ployed, there are several differentially 
expressed genes that are com m on to bo th  studies including glutathione transferase, 
guanine nucleotide-binding pro tein  and cy c lin -D l. It m ust be noted that the H uerta et 
al. (2003) study reported  genes that m et tw o criteria: differentially  expressed as a result 
o f  treatm ent w ith  the chem otherapeutic  agent cisp latin  and differentially  expressed in 
the untreated  SW 480 versus SW 620 cells and this explains w hy so few  genes are in 
com m on. The R N A  w as not prepared  in  trip licate in the H uerta et al (2003) study plus 
the array used  had only 12,625 elem ents in com parison w ith the 39,365 used in  this 
study. In this study glutath ione transferase expression was 2.1 fold higher in  the 
SW 620 cells in  com parison w ith  the SW 480 cells. G lutathione transferase levels are 
e levated in patients w ith  a h igh risk  o f  developing colon cancer and its over expression 
leads to chem otherapeutic resistance in  ovarian cancer cell lines (G rubben et al., 2001 
and Z hang et al., 2001).
Serial analysis o f  gene expression  (SAG E) has also been used to study the same 
cell m odel to  identify  changes in  gene expression during colorectal cancer progression 
(Parle-M cD erm ott et al., 2000). 5 genes w ith d ifferential expression w ere reported in 
the Parle-M cD erm ott et al (2000) study bu t then only  5,000 tagged clones w ere studied. 
SA G E is an effective technique bu t does not allow  for the sam e statistical interpretation 
and analysis therefore it can be  argued that the results are less reliable. O nly one o f 
these 5 d ifferentially  expressed  genes is com m on to this study, keratin  5 (K5) was three 
fold dow n regulated  in  SW 620 cells in  com parison w ith SW 480 cells in  this study 
w hereas K5 was expressed in  SW 480 cells and undetected  in  SW 620 cells by SAGE 
analysis (Parle-M cD erm ott et al., 2000). K5 is a cytoskeletal filam ent protein  know n to 
p lay  a m ajor role in  cell m otility , invasion, proliferation, differentiation and in  the 
transduction o f  ex tracellu lar signals (Fuchs and W eber, 1994). The sam e cell m odel 
w as used, along w ith  tw o o ther cell m odels o f colorectal m etastasis in an elegant 19,000 
elem ent array  study (H edge et al., 2001). 1,569 genes w ere show n to be differentially 
regulated  betw een the SW 480 and SW 620 cells and 176 o f  these w ere differentially 
regulated  in all three m odels o f  colorectal m etastasis. O f the 176 reported  genes very 
few  w ere com m on to those iden tified  in  this study. Interestingly  caveolin  1 w hich was
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upregulated  in  this study w as detected as dow nregulated  in  the H edge et al (2001) study 
although its validation w as not reported.
F or the sake o f this study several genes o f in terest w ere chosen for further 
investigation and validation. These are listed  in  Table 4.10. The rationale for choosing 
these genes was based on detailed  literature searches that revealed  them  as good 
candidates for further investigation. G enes w ere short listed  because o f  the variety o f 
functions o f their respective protein products. These included a proteolytic enzym e 
(cathepsin C), an E C M  com ponent (tenascin C), a protein involved in cellular signalling 
(caveolin  1) and a transcrip tion  factor (PPARy) all o f  w hich represented classes o f 
m olecules w ith  know n roles in m etastasis. A sparagine synthetase was chosen for 
further investigation  because overexpression o f  both  M M P-7 and M M P-9 resulted  in its 
dow nregulation. T he differences in  the  expression o f these genes in the cell lines 
studies w as confirm ed using  real-tim e quantitative P C R  (Figure 4.32) as it is m ore 
quantitative and sensitive in  com parison to conventional R T-PC R . A lthough the exact 
fold changes as ju dged  by  m icroarray  and real-tim e are not equal, the trends are the 
sam e. T he reason  the fo ld  changes are no t m easured  to be equal betw een both  m ethods 
is possib ly  due to the d ifferences in  starting RN A . B oth  w ere carried out in  triplicate 
but d ifferent R N A  preparations w ere used.
C athepsin  C [EC 3.4.14.1] w as up regulated  2.7 fold in the SW 620 cells w hen 
com pared  to the parental SW 480 cells. A  m em ber o f the papain  superfam ily o f  cysteine 
p roteases, cathepsin  C is an oligom eric lysosom al protease capable o f  rem oving 
dipeptides from  the am ino term inus o f its protein  substrates (Paris et al., 1995). As well 
as a  d ipeptidyl am inopeptidase (DAP) activity, cathepsin  C has also been reported to 
have an endopeptidase activ ity  (K uribayashi et al., 1993). C athepsin C is expressed in a 
varie ty  o f  tissues w here its m ain functions are protein degradation and the activation o f 
pro-enzym es including serine proteases and granzym es (Rao et al., 1997). E levated 
cathepsin  C serum  activity  is associated w ith the pathogenesis o f  heart attacks, diabetes, 
and hepatitis  (D olenc et al., 1995). Cathepsins have been  particularly  w ell described for 
their abnorm al expression patterns during cancer developm ent (Iacobuzio-D onahue et 
al., 1997 and Leto et al., 1997). C ysteine proteases have know n roles in  apoptosis, the 
cell cycle and in the activation  o f  grow th factors (N itatori et al., 1996, Fu et al., 1998 
and M itho fer et al., 1998). The roles o f  cathepsin  C  in tum our progression have not 
been  investigated  thoroughly , m aking it a novel candidate. O ne study show ed that
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activity  o f  cathepsin  C was elevated in squam ous cell lung carcinom a (SCLC) when 
com pared to  norm al tissue (K repela et al., 1996). O ther cathepsins have im plicated 
roles in m alignancy. In m alignant co lorectal tum ours and prem alignant lesions, the 
expression o f  cathepsin  B w as highly  upregulated  (M urnane et al., 1991 and Em m ert- 
B uck et al., 1994). C athepsin  B activ ity  is thought to be a part o f  a proteolytic cascade 
leading to degradation o f  ex tracellu lar m atrices (K han et al., 1998b). Similarly, 
cathepsin  H  activ ity  was increased in colorectal cancers, especially  at the later stages 
involving invasion to lym ph nodes (del R e et al., 2000). The level o f cathepsin D  in 
prim ary breast cancer is a prognostic  m arker and correlates w ith  the incidence of 
clinical m etastasis and shorter survival (Foekens et al., 1999). In addition, the down 
regulation  o f cathepsin  D  activity  by  antisense technology resulted  in the inhibition of 
tum our grow th and lung m etastasis (G londu et al., 2002). The established roles o f other 
cathepsins in  cancer m akes cathepsin  C an in teresting target for further analysis. The 
roles o f proteolytic enzym es in m etastasis are broad and varied  but essential nonetheless 
(Liotta, 1990). Indeed, cathepsin  C  inhibitors have been designed w ith the aim  of 
suppressing m etastasis (K atunum a et al., 2002).
Follow ing  array analysis and confirm ation o f fo ld  change using real-tim e PCR, 
the d ifferences in cathepsin  C expression  at the protein level w ere investigated. For this 
study, a fluorescent conjugate that acted  as a cathepsin C specific substrate was used. 
Proteolysis o f  the substrate resulted  in an increase in m easurable fluorescence when 
excited  at 370 nm. Levels o f  fluorescence w ere therefore proportional to the levels o f 
specific cathepsin  C activity. As displayed in F igure 4.34, cathepsin C activity in  the 
SW 620 cells was tw ice that in the SW 480 cells. The differences observed at the 
transcrip tion level, w here SW 620 cells expressed m ore cathepsin  C m RN A  than the 
SW 480 cells, therefore translated  to sim ilar differences at the level o f m ature protein 
activity. C athepsin  C activ ity  w as not dram atically  affected  by overexpression o f 
M M P-7 or M M P-9. This w as expected  as neither SW 480M 7 nor SW 480M 9 cells 
show ed a statistical increase in cathepsin  C expression by  m icroarray analysis.
C aveolin  1 is a com ponent o f  the p lasm a m em brane. The caveolins are a three 
m em ber fam ily  and are the m ajo r structural proteins o f  specialised inner foldings on the 
p lasm a m em brane term ed  caveolae w here they  are involved in  signal transduction and 
sm all m olecule transport (M assim ino et al., 2002). E levated levels o f caveolin 1 have 
been  observed in  various cancers including pancreatic, oesophageal and colon cancer
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(Suzuoki et al., 2002, K ato et al., 2002 and Fine et al., 2001). U sing experim ental mice, 
increased caveolin  1 expression has been associated w ith increased m etastatic ability 
and prom otion  o f cell survival by  pro tection  from  apoptosis (Thom pson et al., 1999). 
H um an prostate cancers that are caveolin  1 positive have been show n to have a poor 
prognosis and increased m etastases and serum  caveolin 1 has been proposed as a 
potential prognostic  m arker o f  prostate cancer (Yang et al., 1998 and Tahir et al., 2003). 
C aveolin  1 has been show n to be overexpressed in colon adenocarcinom a where its 
expression w as directly associated w ith  tum our grow th rate (Patlolla et al., 2004). The 
role o f caveolin  1 in m alignancy is thought to  be in the coordination o f specific 
signalling m olecules including the S rc-fam ily  o f  tyrosine k inases, the ras fam ily and the 
EG F receptor (T ahir et al., 2001 and L i et al., 2001). In this study the expression of 
caveolin  1, as determ ined by  cD N A  m icroarray  analysis, w as 2.7 tim es higher in the 
m etastatic SW 620 cell line than  in the parental SW 480 cell line. Q uantitative real tim e 
PC R  analysis show ed a 9.5 fo ld  increase in caveolin  1 expression in  the SW 620 cells in 
com parison w ith  the SW 480 cells thus supporting this finding.
Peroxisom e Proliferative A ctivated  R eceptor gam m a (PPARy) is a nuclear 
horm one receptor (N H R ) that regulates the transcription o f  various genes (Rosen and 
Spiegelm an, 2001). PPA Ry is a ligand-activated  transcriptional factor that regulates 
cell p ro liferation , d ifferentiation and apoptosis in  both norm al and cancer cells. The 
PPA Ry receptor is targeted by  endogenous prostaglandins (Fajas et al., 2001) and it 
form s heterodim ers w ith the retenoid  X  receptor, w hich binds PPA Ry responsive 
elem ents thus m odulating the transcrip tion  o f the genes involved (Juge-A ubry et al.,
1997). H igh levels o f PPA Ry expression have been seen in m any cancers including 
liposarcom a, a m alignancy o f  the adipose lineage (Tontonoz et al., 1997). PPARy 
regulates the transcrip tion o f  genes involved in  epithelial d ifferentiation (Rosen and 
Spiegelm an, 2001) and has been show n to upregulate caveolin  1 expression 
(B ürgerm eister et al., 2003). PPA Ry expression has been found in various epithelial 
tissues including  colonic m ucosa (M ansen et al., 1996). PPA Ry expression is prim arily 
localized in  m ore differentiated  epithelial cells o f the colon and its expression and 
activation  therefore are associated  w ith  the differentiation o f in testinal cells (Lefebvre et 
al., 1999). W hile  PPARy ligands have been shown to reduce cell grow th in human 
colon cancers (Sarraf et al., 1998), paradoxically , PPARy ligands have also been shown 
to cause an increase in colon tum our num ber in  m ice suggesting the role o f  PPARy in 
the b io logy  o f  colon cancer m ay  be com plex (Saez et al., 1998). PPA Ry ligands have
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recently  been  show n to inhibit the in vitro invasion o f a h ighly  m etastatic hum an breast 
cell line (L iu et al., 2003). A lthough  the  com plete m echanism s o f PPA Ry are still 
unclear, the m odulation o f its activ ity  m ay  have therapeutic benefits. There are few 
reports exam ining  the expression o f PPA R y in m etastasis m aking it a novel candidate 
for further investigation in  this situation. In this study PPA Ry was upregulated  3.9 fold 
in  the SW 620 cells in com parison w ith  the SW 480 cells as determ ined by  cD N A  array 
analysis. R eal tim e PC R  data confirm ed  its upregulation and show ed that PPARy 
expression in SW 620 cells was 4 tim es that o f SW 480 cells.
T enascin  C is a large g lycopro tein  and a m ajor com ponent o f  the ECM. 
Tenascin  C expression is usually  lim ited  to  areas o f cell proliferation or m otility, and its 
expression  is therefore transient. T he pro tein  is re-expressed in  various m alignant 
neoplasm s, including colon and b reast cancers w here h igh expression has been 
associated  w ith  a poor prognostic outcom e and a high risk  o f  d istant m etastasis 
(H auptm ann et al., 1995, Ish ihara et al., 1995 and K ressner et al., 1997). Tenascin C 
expression is found in norm al surrounding  strom al and epithelial tissue as w ell as in the 
tum our itse lf w here its expression is often  concentrated  at the invasion front (Y oshida et 
al., 1997 and Jahkola et al., 1998). The linear arrangem ent o f  one tenascin C 
polypeptide can be seen in  F igure 4.35. Six tenascin C polypeptides can interact via 
their cysteine rich  am ino term ini to fo rm  hexam ers. A lternatively  spliced fibronectin 
type III dom ains follow  a series o f  E G F-like repeats. The structure and size o f tenascin 
C varies as a resu lt o f  this pre-m R N A  alternative splicing w hich gives rise to functional 
d iversity  o f the protein (Jones and Jones, 2000). The truncated form  o f tenascin C, in 
w hich no alternatively spliced exons are included, is generally found in  static tissues, 
and large variants contain ing alternatively  spliced FN III dom ains in various 
com binations are found in  developing tissues (M ackie and Tucker, 1992 and Joester and 
Faissner, 1999). Tenascin  C can in terac t w ith  cell surface receptors and w ith other 
E C M  com ponents for exam ple fibronectin  thus influencing cell behaviour (Jones and 
Jones, 2000 and C hiquet-E hrism ann et al., 1991). T enascin C can prom ote cell 
m igration, angiogenesis, cell p ro liferation , and act as a cell survival factor (Phillips et 
al., 1998, Schenk et al., 1999, Sw indle et al., 2001 and C ow an et al., 2000). Tenascin C 
can induce the expression o f  M M P-9, w hich  has also been show n to prom ote tum our 
grow th and progression (T rem ble et al., 1994 and K alem beyi et al., 2003). Tenascin C 
and M M P-2 are often coexpressed  during norm al processes such as w ound healing and 
in  the tum our strom a, suggesting their functions m ay be in ter-related (Sternlicht et al.,
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2000). E xpression  o f larger tenascin  C isoform s has also been  associated  w ith increased 
m igration and invasion o f carcinom as (Borsi et al., 1992) and a sw itch from  small to 
larger isoform s has been reported  in  co lorectal (D ueck et al., 1999) and breast cancers 
(A dam s et al., 2002). A n increase in  tenascin  C isoform s containing exons 10-13 has 
been show n to be  related  to the stage o f  colorectal cancer progression w hile an increase 
in exon 16 is associated  w ith a m etastatic  phenotype in colon cancer (D ueck et al., 
1999). A n increase in  the expression o f  tw o tenascin C isoform s has been associated 
w ith breast m alignancies, one contain ing  exon 16 only and another containing both 
exons 14 and 16 (A dam s et al., 2002). E xpression  o f  the 14/16 isoform  correlated w ith 
a m ore invasive phenotype. In this study, cD N A  array analysis show ed that the 
expression o f  tenascin  C in SW 620 cells was increased 4.9 fo ld  in  com parison with the 
SW 480 cells. R eal tim e PC R  show ed tenascin  C expression w as upregulated 4 fold in 
the m etastatic  SW 620 cells in  com parison  w ith the parental SW 480 cells, thus 
confirm ing the  cD N A  m icroarray data.
To exam ine the differences in  isoform  expression betw een these cell lines, PCR 
w ith  prim ers specific for various exons w as carried out. Firstly, all isoform s present in 
bo th  cell lines w ere revealed using  prim ers located  outside and at each end o f the 
a lternatively  spliced dom ain as illustrated  in  F igure 4.35. T hese prim ers annealed to 
exon 8 (forw ard) and exon 18 (reverse) neither o f w hich are subject to alternative 
splicing. T his resulted  in  a range o f  P C R  products w hich represented  different tenascin 
C isoform  transcrip ts that varied  in  length  due to exon splicing (Figure 4.36). This PC R  
reaction  w as not defin itive in term s o f in form ation  on specific isoform  expression as all 
the a lternatively  spliced tenascin  C exons w ere 272 bp in  size, therefore individual 
bands on a  gel could  represent any o f the possib le 5040 m athem atical com binations. 
T he only  conclusion  that could  be draw n from  this inform ation w as that a PC R  product 
o f 272 bp  represented  the truncated form  o f  tenascin  C w ith no exons spliced in and a 
band  o f  2345 represented the full length  isoform  w ith all 7 alternative exons spliced in. 
The bands in  betw een these tw o products represented  different com binations o f exons, 
and w hile the exact com bination could  not be deciphered, the num ber o f exons inserted 
could be  determ ined  by  the p roduct size. A s can be seen from  F igure 4.36 the overall 
total expression  o f  tenascin  C as show n b y  m icroarray and real tim e PC R  analysis was 
h igher in  the  SW 620 in  com parison w ith the SW 480 cells. It can also be  seen that the 
expression  profiles o f  both  cell lines w ere different. The cell lines expressed different 
isoform s and d ifferent am ounts o f isoform s. This was apparent from  the presence o f a
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713 bp product in  the SW 620 cells that w as absent in  the SW 480 cells. This was also 
apparent from  the d ifference in  the expression  o f truncated tenascin C and therefore the 
d ifference in  the in tensity  o f the 441 bp  p roduct w ith  the SW 620 cells expressing more. 
P-actin w as used  as a loading  control (F igure 4.36, low er panel) allow ing com parisons 
to be m ade betw een sam ples using  the in tensity  o f the 550 bp actin product to 
norm alise. P C R  using prim ers specific fo r d ifferent exons was then carried out. Using 
a forw ard prim er that spanned the 3 ’ end  o f  exon 9 and the 5 ’ start o f  exon 16 together 
w ith exon 18 specific reverse prim er (F igure 4.35) the tenascin C transcrip t w ith exon 
16 alone spliced in could  be specifically  am plified  and detected. This PC R  reaction 
therefore yielded only one product o f  431 bp  representing the expression o f tenascin C 
w ith exon 16 alone spliced in. As can be seen from  Figure 4.37 only the SW 620 cells 
expressed this isoform . E xon 16 expression  has been  associated w ith  pre-invasive 
breast d isease and a m etastatic  phenotype in  colorectal cancers (A dam s et al., 2002 and 
D ueck et al., 1999). The absence o f exon 16 tenascin  C expression in  SW 480 cells and 
its p resence in  SW 620 cells could indicate a key event in the progression to a m etastatic 
phenotype. A nother group o f  tenascin  C isoform s associated w ith m etastatic diseases 
are those in  w hich  exon 15 is not included  and therefore exons 14 and 16 are spliced 
next to each other. 14/16 Tenascin C  isoform s have been reported  to have increased 
expression in  m etastatic  breast and ovarian  tum ours (Adam s et al., 2002 and W ilson et 
al., 1996). P C R  using  a reverse prim er that spanned the 3 ’ end o f  exon 14 and the 5 ’ 
start o f  exon 16 and an exon 8 specific forw ard prim er (Figure 4.35) was carried out to 
determ ine expression  o f  14/16 tenascin  C isoform s in  the SW 480 and SW 620 cells. 
This PC R  reaction  w as specific for all isoform s containing exons 14 and 16 side by 
side, so m ultip le  products w ere therefore obtained (Figure 4.38). As seen in  Figure 4.38 
the SW 620 cells expressed a range o f  14/16 tenascin  C transcripts w hereas the non­
m etastatic SW 480 cells did not express any. As the alternatively spliced exons were the 
sam e size, only  the iden tity  o f  the 572 and 1665 bp products could be identified as the 
transcrip t into w hich  only  exons 14 and 16 w ere spliced and the transcrip t in to  w hich all 
exons except exon 15 w ere spliced respectively . A s expected from  the schem atic of 
tenascin  C  in F igure 4.35, there are five bands on the gel, each one representing an 
additional exon.
The expression  o f several genes w ere enhanced by  both  M M P-9 and M M P-7 
overexpression. P lasm inogen expression w as significantly  increased 2.8 and 2.4 fold in 
the SW 480 cells overexpressing M M P-9 and M M P-7 respectively. Aspargine
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synthetase w as chosen for further validation  and investigation as it w as 2.5 and 2.8 fold 
dow nregulated  in  both the SW 480M 9 and SW 480M 7 cell lines respectively. This gene 
was therefore o f in terest in  term s o f  identify ing genes that w ere responsive to M M P 
overexpression. O nly one o ther com m on gene w as dow nregulated as a resu lt o f  M M P- 
7 and M M P-9 overexpression. Phosphoserine am inotransferase 1 was 5 and 3.3 fold 
dow nregulated  in  the M M P-9 and M M P-7 transfected cells respectively. Asparagine 
synthetase catalyses the b iosynthesis o f  asparagine from  aspartic acid. A sparagine is a 
nonessential am ino acid that has been reported  as regulating the expression o f genes 
involved in  cell grow th (B arbosa-Tessm ann et al., 2000 and L eung-P ineda and Kilberg 
2002). U sing m icroarray  analysis, asparagine synthetase has recently  been  show n to be 
a target for transactivation  by  p53 in cancer cells and is associated w ith  an increase in 
the rate o f tum our cell grow th (Scian et al., 2004). A sparagine depletion can induce 
apoptosis, and the enzym e asparaginase w hen adm inistered in conjunction with 
chem otherapy has been  reported  to induce an apoptotic response due to  asparagine 
depletion (S tory  et al., 1993). A sparaginase has therefore long been  a standard 
com ponent o f  chem otherapy  against ch ildhood acute lym phoblastic leukaem ia (ALL) 
(O ettgen et al., 1967 and Sutow  et al., 1971). C onsidering this, it can be concluded that 
the expression  o f  asparagine synthetase supports cell growth. These roles for 
asparagine synthetase w ould  suggest that a decrease in its expression levels as seen in 
the m icroarray analysis o f SW 480M 7 and SW 480M 9 cells w ould not be beneficial to 
the cancer cell as it w ould  lead to increased apoptosis. H ow ever, it has been  show n that 
asparagine synthetase expression is responsive to  exogenous asparagine levels, and 
therefore form s part o f  a feedback m echanism  w here the end product o f the enzym atic 
reaction regulates the levels o f  the enzym e itself, thus suggesting asparagine levels are 
not depleted  in  the SW 480M 7 and SW 480M 9 cells (Greco et al., 1989). The levels of 
asparagine synthetase m R N A  expression and enzym atic activity  have been  show n to be 
decreased in  leukem ic cells and this has been hypothesised as the explanation for the 
effectiveness o f  asparaginase as a chem otherapeutic  agent in  ch ildhood leukaem ias 
(A slanian et al., 2001). A sparagine synthetase can therefore be thought o f  as an agonist 
for asparaginase. A ccum ulation  o f asparagine synthetase m R N A  is associated w ith a 
b lock and accum ulation  in the G1 phase o f the cell cycle o f asparagine deprived cells 
w hich can be reverted  b y  its addition (G reco et al., 1989).
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4.4 Conclusion
This chapter focused prim arily  on the identification o f m etastasis associated 
genes using  m icroarray  analysis to com pare the expression profiles o f a non-m etastastic 
cell line, SW 480 w ith  its m etastatic derivative, SW 620. 441 genes w ere show n to be 
differentially  expressed betw een these tw o cell lines. In other experim ents the 
expression profiles o f  tw o M M P overexpressing cell lines, SW 480M 7 and SW 480M 9, 
w hich have been  stably  transfected  w ith  the cD N A s for M M P-7 and M M P-9 
respectively, w ere com pared  w ith that o f  the parental non-transfected SW 480 cells, 
w hich d id  not express these M M Ps. The aim  o f these experim ents was to  identify  genes 
w hich are induced  or repressed as a dow nstream  effect o f excess M M P production and 
activity  and thus give a m olecular insight into their effects in colon cancer. M M P-7 
overexpression resulted  in  the differential expression  o f 159 genes and M M P-9 activity 
resulted  in the differential expression o f  213 genes. A ll analysis was carried out in 
triplicate allow ing these expression changes to be  identified  as statistically  significant. 
Several genes w ere chosen  for further validation  analysis. These genes w ere cathepsin 
C, caveolin  1, tenascin  C, asparagine synthetase and PPA Ry. A s quality  control steps, 
sequencing o f  the spotted cD N A  and real-tim e PC R  o f  the genes o f in terest confirm ed 
th en  iden tity  and changes in  expression respectively. A  proteolytic activity assay using 
a cathepsin  C specific fluorescent peptide revealed  its upregulation at the m R N A  level 
translated  in to  an increase in  enzym e activ ity  in  the SW 620 cells. Tenascin  C PCR 
revealed  differential expression o f various a lternatively  spliced transcripts in the SW 620 
in  com parison to  the SW 480 cells. U sing  exon specific PC R, the SW 620 cells were 
show n to express the m etastasis-associated  tenascin  C 14/16 and 16 isoform s.
This w ork  validated  the further investigation o f  these targets and other 
d ifferentially  regulated  genes as p layers in  the m etastatic process. It m ust be noted that 
although the SW 480 and SW 620 provide a good m odel o f colon to lym phatic system  
m etastasis they  only  represen t snapshots o f  this h ighly  com plex and m ultistage process. 
The occurrence o f m olecular alterations at stages betw een the establishm ent o f these 
tw o cell lines is very realistic  and m ay not be accounted for. Furtherm ore, contributions 
from  norm al strom al and surrounding tissue are also not accounted for and neither are 
the contribu tion  o f the various cells that form  the heterogeneous population o f  the 
tum our.
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Chapter 5
Expression of novel markers of colorectal metastasis 
in paired normal and tumour colon samples
5.1 Introduction
Colon cancers are com m on and account for about 15 % o f all cancers in western 
countries. In Ireland alone there are 2 ,000 new  cases each  year (N ational Cancer 
R egistry  o f  Ireland, 1997). C olon cancer occurs m ainly betw een the ages o f 55 and 70 
and m ales are at a slightly  h igher risk o f developing the disease. The 5-year survival 
rates for colon cancer patients is 80 % if  the cancer has not m etastasised and 40 % if  it 
has. Therefore, patien t survival depends on the degree o f spread or the stage o f the 
disease, w hich is discussed in m ore detail later in this section. N early  50 % o f patients 
d iagnosed w ith colon or rectal (referred to as colorectal) cancer develop m etastasis 
w ithin five years. M ost com m only, these tum ours m etastasise to the liver and lungs. 
C olon cancer can be either sporadic or inherited. H ereditary  form s o f colon cancer 
account for approxim ately  20 % o f cases and are further divided into tw o forms; 
fam ilial adenom atous polyposis (FAP) and hereditary  non-polyposis colon cancer 
(H N PCC). Both fam ilial types occur before the age o f 50, w hich is earlier than the 
sporadic cancers.
The origin o f colon cancer follow s a defined sequence o f events (Figure 5.1) 
w hereby a num ber o f genetic m utations are required for the progression o f  the disease 
(Fearon and V ogelstein , 1999). This progression from  norm al intestinal epithelium  to 
an invasive carcinom a is estim ated  to take 7 - 1 2  years. These D N A  m utations result in 
both  the loss o f function, usually  o f tum our suppressor genes and the gain o f function, 
usually  o f oncogenes.
5.1.1 The genetics o f human colon cancer
Figure 5.1 Gene changes occurring during colon carcinogenesis. The above flow 
diagram illustrates how colon tumourigenesis is a multistage process.
The adenom atous polyposis coli (APC) gene is located on chrom osom e 5 and 
codes for a protein that m ediates signal transduction from  E-cadherin. 70 % of colon 
cancers have A PC m utations, w hich play an im portant role in both sporadic and
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hereditary form s o f colon cancer due to  a loss in  A PC  function. W here w ild type A PC 
norm ally targets P-catenin for ubiquitination, a loss o f function  therefore results in  the 
translocation o f excess P-catenin to the nucleus w here it effects the transcription o f 
several target genes including  c-m yc, cyclin D and M M P-7 (He et al., 1998 and 
Craw ford et al., 1999).
In contrast, m utation o f  the K -R as gene on chrom osom e 11 typically  results in  a 
gain o f  function. The Ras pro tein  is a G TPase involved in the  transduction o f several 
cell signals in m any signalling  cascades including the M A PK  pathw ay. The activation 
o f the Ras protein is tightly  regu lated  how ever Ras m utation results in  its perm anent 
activation. Therefore, the cell is constan tly  stim ulated  w ith  m itogenic signals, thus 
enhancing tum ouri genesis.
O ne o f the m ost com m on regions o f  alleic loss is on chrom osom e 18, w hich is 
absent in 70 % o f  carcinom as and 50 % o f  late adenom as (V ogelstein  et al., 1989 and 
D elattre et al., 1989). SM A D  is located  in  this region and it is involved in the signalling 
pathw ay for TG Fp, a grow th inhibitory , differentiation-inducing cytokine. SM AD 
deletion results in  the cell ignoring  TG FP m ediated  cell p roliferation inhibition and 
results in a loss o f differentiation, increased proliferation and altered cell adhesion 
(Tarafa et al., 2000).
The loss o f large portions o f chrom osom e 17 has been  detected in  75 % of 
colorectal cancers (R isio et al., 2003). This loss is not apparent in  early adenom as, and 
it has been associated w ith  the progression o f the d isease (D iep et al., 2003 and Fearon 
et al., 1987). This region contains the p53 gene, the product o f  w hich is a repressor 
pro tein  that is essential for m ain tain ing  and regulating norm al cell cycle function. p53 
is the gene m ost frequently  altered  in  hum an cancers (Levine et al., 2004) and has been 
reported  to be m utated  in  colorectal cancers (Bos et al., 1987). p53 protects the cell 
from  various insults such as rad iation  or drugs by  co-ordinately  blocking cell 
proliferation, stim ulating D N A  repair and p rom oting  apoptotic cell death. In the 
proposed  m odel, p53 m utations are postulated  to  function late in colorectal 
carcinogenesis (Fearon and V ogelstein , 1990).
The genetic m utations m entioned  above take p lace during certain  stages o f colon 
tum ourigenesis, thus leading to  the hypothesis that colorectal carcinom a developm ent is
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a step w ise procedure, how ever the accum ulation o f these m utations is o f m ore 
im portance than the order in  w hich they  occur.
5.1.2 Staging of colorectal cancer
T um our staging is an extrem ely  im portant prognostic  param eter. In the staging 
o f colorectal cancer, w idely  accepted criteria  are used  to categorize the extent to w hich 
the cancer has advanced thus allow ing clinicians to discuss the cancer using the same 
language. Precise staging is critical fo r predicting disease free and overall survival 
outcom es and for planning treatm ents such as chem otherapy and rad iation  therapy. In 
colorectal cancers, stage is determ ined by: the extent to w hich  a cancer has penetrated 
the bow el wall; the presence or absence o f  lym ph node m etastases; or by  spread to 
d istant organs such as the lung, liver, bone or o ther sites. E ndoscopic m ethods are 
routinely  used as a preoperative staging technique for rectal cancers and biopsies are 
quite often taken for analysis. S taging involves inform ation  obtained from  
m icroscopical pathological analysis o f the surgically  rem oved tum our sam ple where all 
clin ical and pathologic findings are considered.
O ne o f  the m ost com m only  used  staging system  is the D ukes’ C lassification (Sir 
C uthbert D ukes), w hich has been  in use for over 70 years (D ukes, 1932). D ukes’ 
classification  originally  described three stages. D ukes’ A  tum ours are defined as those 
lim ited  to  the m ucosa w all o f  the colon. D ukes’ B tum ours are defined as those that 
have ex tended  and penetrated  through the w all and D ukes’ C tum ours are those w ith 
lym ph node m etastasis. D ukes’ C  tum ours w ere later div ided in to  tw o groups; C l 
tum ours are those w here on ly  regional lym ph nodes are positive and C 2 tum ours are 
those w here apical nodes are involved (G abriel et al., 1935). A  fourth stage, D ukes’ D 
was later added describ ing tum ours w ith  d istant m etastases, w hich w ere beyond the 
lim its o f surgical resection (D ukes 1949). These stages group together heterogeneous 
subsets o f  patients, therefore decreasing the ability o f D u k es’ classification as an 
ind icator o f  prognosis for individual patients. The pow er o f  D ukes’ classification to 
pred ict the behaviour o f  tum ours in individual patients is therefore lim ited. To 
overcom e these lim itations additional staging system s have been developed 
incorporating  m ore classification  param eters. In an effort to  add flexibility  to staging, 
o ther system s such as the tum our-node-m etastasis (TNM ) staging (G reene and Sobin,
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2002) have been used. H ow ever, the T N M  staging system  is only  a m odification o f the 
D ukes classification system  and is therefore not superior as a pred ictor o f prognosis.
M ore detailed  classification  param eters have been  explored  to allow for more 
reliable prediction o f tum our behaviour in  individual patients. These include tum our 
cell d ifferentiation (de B ruine et al., 1993) and proliferation status (al-Sheneber et al.,
1993). A ttention has also been paid  to  param eters that describe the invasive and 
m etastatic behaviour o f tum ours such  as, the expression o f proteases (A dachi et al., 
2001 and M ulcahy et al., 1994), the expression o f adhesion m olecules such as CD44 
variant isoform s (W ielenga et al., 1993), basem ent m em brane deposits (H avenith et al., 
1988), venous invasion (O uchi et al., 1996) and lym ph node m icrom etastasis (Greenson 
et al., 1994). The exploration o f  these param eters aim s to further sub classify colon 
tum ours for m ore precise prognosis.
As colon cancers are the m ost extensively  studied o f  all the solid tum ours in 
term s o f their genetic abnorm alities, detailed  m olecular analysis o f the underlying 
tum our cell genetics in search o f  prognostically  relevant param eters could  potentially 
yield h ighly valuable inform ation w hich  could be used in clinical m anagem ent. M any 
studies have been  based  on the Fearon and V ogelstein  (1990) m odel discussed earlier in 
this chapter. p53 and K-ras have been used as predictors o f an unfavourable outcom e in 
colorectal carcinom as (Bell et al., 1994 and M oerkerk  et al., 1994). C olorectal tum ours 
o f increasing stage have been  show n to have an increased frequency  o f  chrom osom e 18 
alleic losses, and it has therefore been proposed  as a prognostic  m arker (Jen et al.,
1994).
5.1.3 Assessing differential expression in matched tissues
Pathologists, clinicians and all involved in cancer m anagem ent are faced w ith a 
m ajor problem  because o f  the ex tensive heterogeneity  o f the disease. There is a lack o f 
histo logical and clin ical factors that can be used to reliably pred ict both  the evolution o f 
cancer and its sensitivity  to  therapies. As discussed earlier, new  prognostic and 
predictive factors are required  to  allow  effective individualised  m anagem ent o f 
treatm ent strategies and therapies.
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The availability  o f paired  ‘no rm al’ and tum our tissues provides a sim ple m odel 
for investigating  the com plexity  o f tum our biology. The com parison o f expression 
profiles has the  potential to reveal im portan t transcriptional differences underlying the 
developm ent o f  the disease. A s bo th  sam ples originate from  the sam e patient, the 
possib ility  o f generating false results is greatly  reduced and differences in  expression 
are therefore m ost likely to represent changes that contribute to the disease state. 
M atched tissue sam ples also represen t the biological state m ore so than  a hom ogenous 
culture o f  cells. They therefore, provide a  useful tool for the investigation o f potential 
targets or m arkers o f the disease. The expression o f m arkers identified  using cell lines 
can therefore be pursued in paired  tissue sam ples to assess the significance o f such 
expression.
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5.2 Results
In  this chapter, the expression  o f  novel m arkers o f colorectal m etastasis was 
investigated  in  paired  sam ples o f norm al and tum our colorectal tissue. As sum m arised 
in chapter 4, these genes w ere identified  by  cD N A  expression profiling  in  tw o cell lines, 
one derived from  a prim ary hum an colon adenocarcinom a and the o ther from  its lymph 
node m etastases. The genes iden tified  w ere the EC M  com ponent, Tenascin C, the 
transcrip tion factor, PPA Ry, the m em brane com ponent, C aveolin  1 and the protease, 
C athepsin  C. The differences in  expression  o f  these genes w ere thought to be o f 
im portance in colorectal tum our m etastasis.
T he colorectal tissue ban k  used  w as established in 1992 in  the M id-W estern 
R egional H ospital, L im erick, Ire land  by  D r M ary  M orrin. The bank  is com posed o f 
m atched tum our and norm al specim ens rem oved from  patients during surgery for 
colorectal cancer. T issues w ere frozen  in  liqu id  nitrogen and stored at -80 °C w ithin 30 
m inutes o f  rem oval at surgery. The corresponding dem ographic, pathological and 
follow -up records for each patien t w ere m aintained using an A ccess database. The 
tissue bank  contained 176 specim ens w hich  w ere com posed of, 5 % D ukes’ A, 54 % 
D ukes’ B, 19 % D ukes’ C and 22 % D u k es’ D  category tum ours. This tissue bank with 
its associated records represented a unique tool for analysis o f  gene expression.
5.2.1 Analysis of tissue RNA
O verall, 25 random ly chosen  sam ples, representing 12 pairs w ere cut, one pair 
also contained a polyp specim en. Inform ation  on these tissue sam ples was later 
collected  and is listed  in  Table 5.1. As can be seen from  Table 5.1 all D ukes’ 
classifications w ere represented.
R N A  was harvested as ou tlined  in section 2.2.19 and the yields obtained are 
sum m arised in Table 5.2. A s can be seen from  Table 5.2, R N A  was successfully 
extracted  from  all sam ples. T here w as a great variety in  the yield obtained w ith some 
sam ples e.g. the tum our sam ple T7 and the norm al sam ples N8 and N 12 being very 
dilute. The 260/280 absorbance ratio  values for all sam ples w ere close to  the desired 
value o f 1.8, although som e sam ples w ere a lo t higher, for exam ple T9 and N12. 
Sam ple set 6 was unique in  that it also included  a polyp sam ple.
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T a b le  5.1 Inform ation on tissue sam ples used  in this study, including  patient gender, 
age and 5 year survival history. Inform ation on the tum our includes its location and its 
D ukes’ classification.
Sample No Gender Age Location Dukes’
Classification
5-year survival
1 M 65 Left colon D No
2 F 69 Left colon B Yes
3 M 62 Rectal B Yes
4 M 59 Left colon B Yes
5 F 73 Right colon B No
6 F 76 Rectal B No
7 F 53 Right colon C Yes
8 M 59 Left colon A Yes
9 M 78 Left colon A Yes
10 M 57 Rectal C Yes
11 M 52 Left colon D Yes
12 M 31 Transverse C Yes
T a b le  5.2 R N A  concentration and A 260/280 values for paired  norm al (N), tum our (T) 
and polyp (P) specim ens.
Sample Concentration (jig/^1) A260/280 ratio
N1 1.416 1.8
T1 4.748 1.6
N2 2.512 1.7
T2 3.880 1.6
N3 2.220 1.7
T3 5.800 1.3
N4 2.448 1.6
T4 4.888 1.6
N5 2.920 1.8
T5 4.348 1.7
N6 1.996 1.7
T6 3.500 1.6
P6 0.468 1.9
N7 1.348 1.6
T7 0.244 2.1
N8 0.226 1.7
T8 0.356 1.6
N9 0.856 1.6
T9 0.324 2.2
N10 1.432 1.6
T10 1.236 1.7
N il 1.672 1.6
T il 3.736 1.6
N12 0.252 2.5
T12 5.944 1.4
R N A  integrity  in one pi o f each sam ple was assessed by  agarose gel 
electrophoresis as previously outlined in section 2.2.2.1. Figure 5.2 show s the resulting 
gel. The gel w as not loaded for equal am ounts o f  RN A. The m ajority  o f sam ples had
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visible 28 S and 18 S ribosom al bands. A lthough they  were not dilute, 2N  and 9T RN A  
were not v isible on the gel. 5N R N A  appeared to be degraded and 7T and 12N were not 
visible, although they  w ere quite dilute.
1 2 3 4 5 6 7 8 9 10 11 12
N T N  T N  T N  T N T N T P N T N T  N T N  T T N N T
Figure 5.2 Analysis of RNA from paired normal (N) and tumour (T) tissue 
samples. The presence of 28 S and 18 S ribosomal bands was indicative of RNA 
integrity.
To further assess the quality  o f R N A  and its usefulness in quantitative real tim e 
R T-PC R, a  standard P-actin R T -PC R , as outlined in  section 2.2.15, w as carried out on 
all sam ples. A  550 bp P C R  product w as obtained in all sam ples except sam ples T7, T9 
and N 12. T hese sam ples w ere om itted  from  further analysis and com parisons, however 
the o ther sam ples in  these pairings yielded PC R  products, and w ere therefore included 
for real tim e PC R  analysis. A lthough only  faint bands w ere observed for the R N A  from  
sam ples P6 and N 9 (F igure 5.2), P-actin PC R  on these sam ples yielded products (Figure 
5.3).
N1 T1 N2 T2 N3 T3 N4 T4 N5 T5 N6 T6 P6 N 7 T 7  N8 T8 N9 T9
Figure 5.3 P-Actin RT-PCR on paired normal (N) and tumour (T) samples. P- 
Actin expression was detected by the presence of a 550 bp product.
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5.2.2 Real tim e PCR analysis
A ll real tim e PC R  was carried out as outlined in section 2.2.4. As the Rotor- 
G ene 3000™  (Corbett R esearch) m ultip lex ing  system  used  could  only handle 36 
sam ples at any one tim e, the study w as divided in  two: Group one included the 
m atched norm al and tum our paired sam ples 1, 2, 3, 4, and 5 and Group two included 
the m atched norm al and tum our paired  sam ples 6, 8, 10, 11 plus N 7, N 9 and T12.
5.2.2.1 p-Actin expression
The com parative quantitation m ethod w as used to assess the levels o f |3-actin 
expression in all sam ples. (3-actin levels w ere then used to norm alise the expression 
levels o f the genes studied in  order to  m ake in ter sam ple com parisons. Figure 5.4 
show s the com parative quantitation curve obtained for the P-actin real tim e PCR 
reaction for G roup one tissue sam ples. The data  obtained is listed  in  Table 5.3. To 
confirm  the reaction conditions were specific for P-actin am plification a m elt curve was 
perform ed follow ing PC R. A s can be seen from  figure 5.5 each reaction resulted in 
only one peak  indicating that only one p roduct w as form ed.
dF2/d2C
Figure 5.4 Comparative quantitation of P-actin expression in Group one paired 
tissue samples. The colours used and values obtained are summarised in Table 5.3.
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Table 5.3 Raw real time PCR data obtained for (3-actin expression in Group one normal
(N) and tumour (T) tissue one samples.
Colour Name Takeoff Comparative Concentration
■ N1 20.6 1.00E+00
■ N1 19.8 7.43E-01
■ N1 19.5 7.88E-01
■ T1 22.1 4.62E-01
■ T1 22.3 5.52E-01
■ T1 23.7 4.35E-01
■ N2 22.3 7.31 E-02
■ N2 24.5 1.18E-01
■ N2 22.7 8.73E-02
■ T2 19.6 5.20E-01
T2 20.0 2.87E-01
T2 22.6 3.43E-01
■ N3 22.0 5.11 E-02
■ N3 22.1 1.25E-01
■ N3 22.3 2.99E-02
■ T3 22.3 1.78E-01
■ T3 21.9 5.43E-02
■ T3 21.7 8.23E-02
■ N4 22.1 2.87E-01
■ N4 21.8 1.89E-01
■ N4 20.0 1.49E-01
■ T4 19.1 4.35E-01
■ T4 22.1 5.52E-01
■ T4 20.3 4.62E-01
N5 22.1 6.01 E-03
N5 21.7 1.44E-03
N5 21.5 3.73E-03
■ T5 21.7 1.49E-01
■ T5 22.0 9.84E-02
■ T5 22.2 1.58E-01
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Figure 5.5 The melt curve for p-actin real time PCR of Group one tissue samples.
P-actin real tim e PC R  was also carried  out for G roup tw o tissue sam ples. The 
com parative quantitation m ethod was used and the resulting  curve is shown in Figure 
5.6.
Figure 5.6 The resulting comparative quantitation curve for the real time P-actin 
PCR in Group two tissue samples. The data obtained is summarised in Table 5.4.
Figure 5.7 The melt curve for p-actin real time PCR of Group two tissue samples.
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Table 5.4 Real time PCR data obtained for (3-actin expression in Group two normal (N),
polyp (P) and tumour (T) tissue samples.
I Colour Name Takeoff Comparative Concentration
■ N6 21.4 1.00E+00
■ N6 21.3 1.06E+00
■ N6 22.2 6.15E-01
■ T6 19.5 3.17E+00
■ T6 18.9 4.56E+00
■ T6 19.1 4.04E+00
■ P6 24.9 6.15E-01
■ P6 24.8 6.15E-01
■ P6 22.2 6.15E-01
N8 21.6 8.86E-01
■ N8 22.3 5.79E-01
■ N8 22.1 6.54E-01
■ T8 24.9 2.99E+00
■ T8 19.7 2.81 E+00
■ T8 19.5 3.17E+00
■ N10 20.9 1.35E+00
■ N10 22.6 1.13E+00
■ N10 25.8 9.16E-01
■ T10 20.9 1.35 E+00
■ T10 22.9 4.02E-01
■ T10 22.5 5.13E-01
■ N11 23.7 2.47E-01
■ N11 24.8 1.27E-01
■ N11 25.0 1.12E-01
T11 22.6 4.82E-01
T11 23.5 2.79E-01
T11 23.8 2.33E-01
■ N7 25.3 9.36E-02
■ N7 24.7 1.35E-01
■ N7 25.4 8.81 E-02
■ N9 25.5 8.29E-02
■ N9 25.7 7.34E-02
■ N9 25.6 7.80E-02
■ T12 25.4 8.81 E-02
■ T12 25.4 8.81 E-02
■ T12 24.3 1.72E-01
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As can be seen from  the m elt curve analysis o f  G roup tw o tissue sam ples 
(Figure 5.7) only one peak  occurred, this indicated that reaction  was specific for [3-actin 
am plification.
5.2.2.2 Cathepsin C expression
T he expression o f  cathepsin  C in  the tissue sam ples w as assessed using real tim e 
P C R  analysis. As before  the  analysis w as divided in  tw o groups. Figure 5.8 shows the 
com parative quantitation curve obtained for the real tim e PC R  analysis o f cathepsin C 
expression in G roup one tissue sam ples.
F igure 5.8 Comparative quantitation of cathepsin C expression in Group one 
paired tissue samples. The colours used and values obtained are summarised in 
Table 5.5.
T he raw  com parative quantita tion  data obtained for cathepsin  C  real tim e PC R  is 
listed  in Table 5.5. This data  was later norm alised using  the real tim e |3-actin data 
obtained in  section 5.2.2.1.
Figure 5.9 The melt curve for cathepsin C real time PCR of Group one tissue
samples.
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Following PCR, a melt curve was carried out to ensure specificity. The presence 
of only one peak indicated that no non-specific products were formed (Figure 5.9).
Table 5.5 Raw real time PCR data obtained for cathepsin C expression in Group one 
normal (N) and tumour (T) tissue samples.
I Colour Name Takeoff Comparative Concentration
■ N1 28.5 1.00E+00
■ N1 27.9 1.47E+00
■ N1 28.2 1.21E+00
■ T 1 25.8 5.62E+00
■ T1 27.5 4.20E+00
■ T1 26.9 2.78E+00
■ N2 28.5 7.74E-01
■ N2 28.9 7.74E-01
■ N2 28.4 7.74E-01
T2 27.4 2.02E+00
T2 28.8 8.26E-01
■ T2 29.9 4.09E-01
■ N3 29.8 4.36E-01
■ N3 29.6 4.95E-01
■ N3 29.5 5.28E-01
■ T3 28.0 1.38E+00
■ T3 28.4 1.07E+00
■ T3 28.7 8.80E-01
■ N4 29.3 6.00E-01
■ N4 29.4 5.63E-01
■ N4 28.8 8.26E-01
■ T4 27.5 1.89E+00
■ T4 27.6 1.78E+00
■ T4 27.6 1.78E+00
N5 29.3 6.00E-01
N5 30.0 3.83E-01
N5 28.4 1.07E+00
■ T5 29.2 6.39E-01
■ T5 28.9 7.74E-01
■ T5 28.1 1.29E+00
Cathepsin C expression was also assessed in Group two tissue samples using 
real time PCR. The resulting comparative quantitation data is represented in Figure
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5.10 and summarised in Table 5.6. This data was later normalised using (3-actin 
expression levels, thus allowing inter sample expression comparisons.
dF2AJ2C
Figure 5.10 Comparative quantitation of cathepsin C expression in Group two 
paired tissue samples. The colours used and values obtained are summarised in
Table 5.6.
Figure 5.11 The melt curve for cathepsin C real time PCR of Group two tissue 
samples.
Only one peak was obtained from the melt curve analysis of the PCR reactions, 
indicating reaction specificity (5.11).
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Table 5.6 Raw real time PCR data obtained for cathepsin C expression in Group two
normal (N), polyp (P) and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N6 28.0 1.00E+00
■ N6 28.6 6.98E-01
■ N6 28.9 5.83E-01
■ T6 28.9 5.83E-01
■ T6 28.2 5.17E-01
■ T6 28.2 8.87E-01
■ P6 28.0 1.00E+00
■ P6 28.1 9.42E-01
■ P6 27.9 1.06E+00
■ N8 27.4 1.43E+00
■ N8 26.7 2.18E+00
■ N8 27.8 1.13E+00
■ T8 27.2 1.62E+00
■ T8 27.5 1.35E+00
■ T8 27.3 1.52E+00
■ N10 30.2 2.67E-01
■ N10 27.9 3.83E-01
■ N10 27.8 1.06E+00
■ T10 28.4 1.13E+00
■ T10 27.9 7.87E-01
■ T10 27.9 1.06E+00
■ N11 25.7 3.98E+00
■ N11 26.6 2.32E+00
■ N11 25.8 3.74E+00
T11 25.2 5.37E+00
T11 25.1 5.70E+00
T11 24.5 8.17E+00
■ N7 29.0 5.49E-01
■ N7 27.4 1.43E+00
■ N7 29.0 5.49E-01
■ N9 29.3 4.58E-01
■ N9 29.8 3.40E-01
■ N9 30.1 2.84E-01
■ T12 29.0 5.49E-01
■ T12 28.4 7.87E-01
■ T12 27.9 1.06E+00
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P-actin expression levels were used to normalise the cathepsin C expression 
data. Figure 5.12 and 5.13 show the normalised cathepsin C expression values obtained 
for Group one and Group two tissue samples respectively.
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Figure 5.12 Normalised cathepsin C expression in Group one paired tissue 
samples.
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Figure 5.13 Normalised cathepsin C expression in Group two paired tissue 
samples.
Cathepsin C expression in tumours was compared with its expression in the 
normal samples. The comparative expression of cathepsin C is shown in Figure 5.14. 
Seven out of ten samples studied showed increased cathepsin C expression in tumour or
1 6 6
polyp tissue in comparison with normal tissue. Interestingly, the greatest increase in 
cathepsin C expression was observed in the Dukes’ D tumour sample T1 although 
another Dukes’ D tumour T il did not show a large increase in expression.
Cathepsin C
I I I 1 I 1 [ 1 I 1 , ,
T1 T2 T3 T4 T5 T6 P 6  T10 T11
Figure 5.14 Expression of cathepsin C in tumours (T) and polyp (P) samples in 
comparison with normal samples. A log scale was used to display up regulation 
(bars above axis) and down regulation (bars below axis).
5.2.2.3 Caveolin 1 expression
The expression of caveolin 1 in the colon tissue samples was assessed using real 
time PCR. The analysis was again divided in two groups. Comparative quantitation 
was used to assess the expression of caveolin 1 in Group 1 tissue samples and the data 
obtained is shown in Figure 5.15 and summarised in Table 5.7.
dF2/d2C
Figure 5.15 The expression of caveolin 1 in Group one paired tissue samples was 
determined using the comparative quantitation method. The colours used and 
values obtained are summarised in Table 5.7.
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Table 5.7 Raw real time PCR data obtained for caveolin 1 expression in Group one
normal (N) and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N1 17 1.00E+00
■ N1 17.8 6.51 E-01
■ N1 17.1 9.48E-01
■ T1 20.1 1.89E-01
■ T1 20.5 1.53E-01
■ T1 20.9 1.23E-01
■ N2 18.4 4.72E-01
■ N2 18.2 5.25E-01
■ N2 17.7 6.87E-01
T2 19.1 3.24E-01
R T2 18.3 4.98E-01
R T2 18.7 4.01 E-01
H N3 22.1 6.47E-02
R N3 20.2 1.79E-01
R N3 18.1 1.22E-01
R T3 21.1 1.11 E-01
R T3 21.1 1.11 E-01
R T3 21 1.17E-01
R N4 17.4 8.07E-01
R N4 17.3 8.51 E-01
N4 16.6 1.24E+00
T4 18.8 3.80E-01
T4 19.5 2.61 E-01
H T4 18.9 3.61 E-01
N5 19.7 2.35E-01
N5 19.7 2.35E-01
N5 20.2 1.79E-01
R T5 20.3 1.70E-01
R T5 20.8 1.30E-01
R T5 19.7 2.35E-01
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Figure 5.16 shows that a melt curve analysis of the PCR reactions yielded only 
one peak indicating the reactions were specific.
Figure 5.16 The melt curve for caveolin 1 real time PCR of Group one tissue 
samples.
Figure 5.17 shows the expression of caveolin 1 in Group two tissue samples 
determined using real time PCR. The data obtained is summarised in Table 5.8. The 
melt curve analysis of the PCR reactions yielded only one peak indicating the reactions 
were specific (Figure 5.16).
dF2/d2C
Figure 5.15 The expression of caveolin 1 in Group two paired tissue samples was 
determined using the comparative quantitation method. The colours used and 
values obtained are summarised in Table 5.8.
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Table 5.8 Raw real time PCR data obtained for caveolin 1 expression in Group two
normal (N), polyp (P) and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N6 17.5 1.00E+00
■ N6 17.3 1.11E+00
■ N6 18.0 7.65E-01
■ T6 17.9 8.07E-01
■ T6 17.9 8.07E-01
■ T6 18.2 6.87E-01
■ P6 19.1 4.24E-01
■ P6 18.4 6.17E-01
■ P6 17.8 8.51 E-01
■ N8 15.4 3.08E+00
■ N8 16.3 1.90E+00
■ N8 16.2 2.01 E+00
■ T8 16.7 1.54E+00
■ T8 17.6 9.48E-01
■ T8 17.1 1.24E+00
■ N10 18.3 6.51 E-01
■ N10 17.4 1.06E+00
■ N10 17.5 1.00E+00
■ T10 18.1 7.25E-01
■ T10 17.5 1.00E+00
■ T10 16.6 1.62E+00
■ N11 21.0 1.53E-01
■ N11 20.1 2.48E-01
■ N11 20.5 2.00E-01
■ T11 24.6 2.22E-02
■ T11 24.8 1.99E-02
■ T11 24.0 3.06E-02
■ N7 17.7 8.98E-01
■ N7 17.8 8.51 E-01
■ N7 18.3 6.51 E-01
N9 23.8 3.41 E-02
N9 24.0 3.06E-02
N9 24.0 3.06E-02
n T12 28.7 2.46E-03
T12 28.7 2.46E-03
m T12 26.9 6.47E-03
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Figure 5.16 The melt curve for caveolin 1 real time PCR of Group two tissue samples.
The normalised levels of caveolin 1 expression in both groups of tissue samples 
were calculated using the relative P-actin expression levels as determined in section 
5.2.2.1. Figures 5.17 and 5.18 show the normalised expression of caveolin 1 in Group 
one and two tissue samples respectively.
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Figure 5.17 Normalised caveolin 1 expression in Group one paired normal (N) and 
tumour (T) tissue samples.
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Figure 5.18 Normalised caveolin 1 expression in Group two paired normal (N), 
polyp (P) and tumour (T) tissue samples.
The level of caveolin 1 expression in tumours and polyp samples was compared 
with its expression in the normal tissue to which they were paired. Figure 5.19 shows 
the comparative expression of caveolin 1 in all paired tumour and polyp tissues studied. 
Interestingly, all tumour samples bar tumour sample 10, show decreased caveolin 1 
expression in comparison with normal tissue.
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Figure 5.19 Expression of caveolin 1 in tumours (T) and polyp (P) samples in 
comparison with normal samples. A log scale was used to display up regulation 
(bars above axis) and down regulation (bars below axis).
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5.2.2.4 Tenascin C expression
The expression of tenascin C in the colon tissue samples was determined using 
real time PCR. Figure 5.20 shows the comparative quantitation curve for tenascin C 
expression in Group one tissue samples. The raw data obtained is listed in Table 5.9.
dF2/dZC
Figure 5.20 Comparative quantitation of tenascin C expression in Group one tissue 
samples. The colours used and values obtained are summarised in Table 5.9.
The melt curve analysis of the above PCR reactions yielded only one peak per 
reaction, thus indicating that the conditions were specific (Figure 5.21).
Figure 5.21 The melt curve for tenascin C real time PCR of Group one tissue samples.
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Table 5.9 Raw comparative quantitation data obtained for tenascin C real time PCR in
Group one normal (N) and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N1 30.6 1.00E+00
■ N1 31.1 7.43E-01
■ N1 31.0 7.88E-01
■ T1 31.9 4.62E-01
■ T1 31.6 5.52E-01
■ T1 32.0 4.35E-01
■ N2 35.0 7.31 E-02
■ N2 34.2 1.18E-01
■ N2 34.7 8.73E-02
■ T2 31.7 5.20E-01
■ T2 32.7 2.87E-01
■ T2 32.4 3.43E-01
■ N3 35.6 5.11 E-02
■ N3 34.1 1.25E-01
■ N3 36.5 2.99E-02
■ T3 33.5 1.78E-01
■ T3 35.5 5.43E-02
■ T3 34.8 8.23E-02
■ N4 32.7 2.87E-01
■ N4 33.4 1.89E-01
■ N4 33.8 1.49E-01
■ T4 32.0 4.35E-01
■ T4 31.6 5.52E-01
■ T4 31.9 4.62E-01
■ N5 39.2 6.01 E-03
■ N5 41.6 1.44E-03
■ N5 11.3 3.73E-03
■ T5 33.8 1.49E-01
■ T5 34.5 9.84E-02
■ T5 33.7 1.58E-01
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Similarly, real time PCR was used to examine the expression of tenascin C in 
Group two tissue samples. Figure 5.22 shows the resulting comparative quantitation 
curve and Table 5.10 summarises the raw data obtained. Melt curve analysis was 
carried out following PCR. One peak indicated that only one product was formed 
(Figure 5.23).
dF2/d2C
Figure 5.22 Comparative quantitation of tenascin C expression in Group two tissue 
samples. The colours used and values obtained are summarised in Table 5.10.
Figure 5.23 The melt curve for tenascin C real time PCR of Group two tissue 
samples.
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Table 5.10 Raw comparative quantitation data obtained for tenascin C real time PCR in
Group two normal (N), polyp (P) and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N6 39.8 1.00E+00
■ N6 37.5 1.60E+00
■ N6 35.9 2.22E+00
■ T6 31.3 5.69E+00
■ T6 31.4 5.58E+00
■ T6 31.9 5.03E+00
■ P6 36.2 2.09E+00
■ P6 37.6 1.57E+00
■ P6 36.4 2.00E+00
■ N8 34.0 3.28E+00
■ N8 34.0 3.28E+00
■ N8 34.4 3.02E+00
T8 32.6 4.36E+00
■ T8 32.8 4.19E+00
■ T8 33.2 3.86E+00
■ N10 32.5 4.45E+00
■ N10 32.1 4.83E+00
■ N10 32.2 4.73E+00
■ T10 34.5 2.96E+00
■ T10 34.9 2.72E+00
■ T10 35.1 2.62E+00
■ N11 44.1 6.78E-01
■ N11 48.1 6.78E-01
■ N11 41.7 6.78E-01
■ T11 22.1 2.51 E-01
■ T11 44.9 3.52E-01
■ T11 49.1 1.49E-01
■ N7 38.6 1.28E+00
■ N7 39.8 1.00E+00
■ N7 36.0 2.18E+00
■ N9 48.1 1.83E-01
N9 45.9 2.87E-01
N9 13.1 2.35E-01
T12 48.1 1.83E-01
T12 33.9 2.00E-01
T12 24.3 1.92E-01
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Tenascin C expression was normalised using P-actin expression levels. Figures 
5.24 and 5.25 show the resulting normalised expression in Group one and Group two 
tissue samples respectively.
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Figure 5.24 Normalised tenascin C expression in Group one paired normal (N) and 
tumour (T) tissue samples.
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Figure 5.25 Normalised tenascin C expression in Group two paired normal (N), 
polyp (P) and tumour (T) tissue samples.
The expression of tenascin C in the tumour and polyp tissue samples was 
compared with its expression in the respective normal tissue sample. Figure 5.26 shows 
the comparative expression of tenascin C in all paired samples studied. There was no
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clear pattern of expression. Five out the ten tumour samples show increased tenascin C 
expression and the other five tumour samples show decreased expression in comparison 
with their normal tissue samples. These changes in expression do not seem to be related 
to Dukes’ staging as some Dukes’ B tumour samples show increased tenascin C 
expression (T5) and other Dukes’ B samples show decreased expression (T6).
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Figure 5.26 Expression of tenascin C in tumours (T) and polyp (P) samples in 
comparison with normal samples. A log scale was used to display up regulation 
(bars above axis) and down regulation (bars below axis).
5.2.2.5 PPARy expression
The expression of PPARy in paired colon tissue samples was analysed using 
quantitative real time PCR.
Figure 5.27 The expression of PPARy in Group one tissue samples. The data 
obtained and colours used are summarised in Table 5.11.
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PPARy expression in Group one tissue samples was determined using the 
comparative quantitation method (Figure 5.27). The raw data obtained is summarised 
in Table 5.11.
Table 5.11 Raw comparative quantitation data obtained for PPARy real time PCR in 
Group one normal (N), and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N1 24.8 1.00E+00
■ N1 24.2 1.47E+00
N1 25.0 8.79E-01
■ T1 23.9 1.79E+00
■ T1 24.9 9.37E-01
■ T1 24.0 1.68E+00
■ N2 23.9 1.79E+00
■ N2 24.0 1.68E+00
■ N2 24.3 1.38E+00
■ T2 21.0 1.16E+01
■ T2 21.1 1.09E+01
■ T2 21.4 8.98E+00
■ N3 23.5 2.31 E+00
■ N3 23.8 1.91 E+00
■ N3 23.7 2.03E+00
■ T3 20.6 1.50E+01
■ T3 20.3 1.83E+01
■ T3 20.7 1.41 E+01
■ N4 22.8 3.64E+00
■ N4 23.1 3.00E+00
■ N4 21.9 6.50E+00
■ T4 20.9 1.24E+01
■ T4 20.6 1.50E+01
■ T4 21.5 8.42E+00
N5 25.7 5.59E-01
N5 25.7 5.59E-01
N5 26.7 2.93E-01
■ T5 22.8 3.64E+00
■ T5 22.5 4.41 E+00
■ T5 21.9 6.50E+00
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Following PCR, melt curve analysis was carried out to ensure the reaction was 
specific, this was shown by the presence of only one peak in all reactions (Figure 5.28).
Figure 5.28 The melt curve for PPARy real time PCR of Group one tissue samples.
The expression of PPARy in Group two tissue samples was assessed using the 
same quantitative PCR (Figure 5.29). The raw data obtained is summarised in Table 
5.12. Melt curve analysis was carried out to ensure the reaction was specific (Figure 
5.30). No secondary peaks were detected.
dF2/'d2C
Figure 5.29 The expression of PPARy in Group two tissue samples. The data 
obtained and colours used are summarised in Table 5.12.
Figure 5.30 The melt curve for PPARy real time PCR of Group two tissue 
samples.
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Table 5.12 Raw comparative quantitation data obtained for PPARy real time PCR in
Group two normal (N), Polyp(P) and tumour (T) tissue samples.
Colour Name Takeoff Comparative Concentration
■ N6 24.1 1.00E+00
■ N6 24.1 1.00E+00
■ N6 23.5 1.51E+00
■ T6 20.8 9.72E+00
■ T6 20.7 1.04E+01
■ T6 20.8 9.72E+00
P6 24.9 5.76E-01
■ P6 25.3 4.37E-01
■ P6 25.6 3.56E-01
N8 22.4 3.23E+00
N8 22.5 3.01 E+00
■ N8 22.7 2.62E+00
■ T8 20.4 1.28E+01
■ T8 20.7 1.04E+01
■ T8 19.6 1.16E+01
■ N10 23.2 1.86E+00
■ N10 24.1 1.00E+00
■ N10 24.0 1.07E+00
■ T10 24.0 1.07E+00
■ T10 23.8 1.23E+00
■ T10 24.2 9.33E-01
■ N11 25.8 3.10E-01
■ N11 26.5 1.91 E-01
■ N11 26.7 1.67E-01
T11 26.5 1.91 E-01
T11 26.4 2.05E-01
T11 26.9 1.45E-01
N7 22.3 3.46E+00
■ N7 21.8 4.88E+00
■ N7 22.7 2.62E+00
■ N9 25.1 5.02E-01
■ N9 24.9 5.76E-01
■ N9 24.4 8.13E-01
■ T12 19.1 2.17E-03
■ T12 33.0 2.17E-03
■ T12 44.7 2.17E-03
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The normalised expression of PPARy in all tissues studied was calculated using 
the respective levels of P-actin expression determined in section 5.2.2.1. Figures 5.31 
and 5.32 show the normalised PPARy expression in Group one and Group two tissue 
samples respectively.
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Figure 5.31 Normalised PPARy expression in Group one paired normal (N) and 
tumour (T) tissue samples.
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Figure 5.32 Normalised PPARy expression in Group two paired normal (N), polyp 
(P) and tumour (T) tissue samples.
The expression of PPARy in paired samples was compared and the comparative 
expression is shown in Figure 5.33. Interestingly, seven out of the ten tumour samples
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studied showed increased PPARy expression in comparison with normal tissue and 
three showed decreased expression. The differences in expression did not appear to be 
related to Dukes’ staging as Dukes’ D tumour samples showed both increased PPARy 
expression (Tl) and decreased expression (T11) in comparison with normal tissue.
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Figure 5.33 Comparative expression of PPARy between tumour(T) or polyp (P) 
tissue and normal colon tissue samples. A log scale was used to display up 
regulation (bars above axis) and down regulation (bars below axis).
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5.3 Discussion
The identification of novel biomarkers of colorectal tumour metastasis is crucial 
to both the understanding and treatment of this disease. As described in chapter 4, 
cDNA microarray analysis was used to identify genes with significantly increased 
expression in a lymph node métastasés derived cell line when compared to the primary 
colon adenocarcinoma derived cell line. These selected genes have been identified as 
potential markers of colorectal metastasis. These genes were cathepsin C, tenascin C, 
PPARy and caveolin 1. To further validate the importance of these genes in the process 
their expression was monitored in a pilot study of paired normal and tumour colorectal 
biopsy specimens. RNA was extracted from samples and analysed for expression of 
these genes using RT and quantitative real time PCR. Following RNA analysis, nine 
paired samples were chosen for further scrutiny. The unpaired samples N7, N9 and T12 
were also analysed for expression of these genes.
Although the absolute levels of expression are of importance, the comparative 
expression of the above genes was also of interest. Quantitative real time PCR analysis 
allowed comparisons of gene expression to be made from one sample to another. 
Expression in tumours was compared with expression in the paired normal specimens.
Table 5.13 Expression ratios of selected genes in paired colorectal tissue. 
Increasing (red) or decreasing (green) expression of cathepsin C (CathC), 
PPAR, tenascin C (TenC) and caveolin 1 (Cavl) in tumour (T) or polyp (P) 
tissue samples in comparison with normal tissue.
Sample Cath C PPAR TenC Cav1
T1
T2
T3
T4
T5
T6
P6
T8
T10
T11
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Table 5.13 summarises the trend in expression of all four genes in the nine 
paired samples. Sample set six also included a polyp tissue specimen. Table 5.13 
shows the expression ratio of tumour/polyp : normal tissue. The most obvious trend is 
that caveolin 1 expression is decreased in all tumour samples in comparison with the 
normal tissue, with the exception of T10 where caveolin 1 expression is slightly 
increased in the tumour sample. Reduced caveolin 1 protein levels have been observed 
in a number of human tumours including ovarian (Bagnoli et al., 2000), colon (Bender 
et al., 2000) and lung (Racine et al., 1999). A reduction in caveolin 1 expression has 
also been associated with increased breast tumour cell invasion (Lu et al., 2004).
Cathepsin C expression was increased in tumour specimens Tl, T3, T4, T5, T10 
and T il in comparison with normal tissues. Cathepsin C expression was also elevated 
in the polyp sample (P6) but not in the corresponding tumour sample (T6). Although 
the roles of cathepsin C in colorectal tumour progression have not been fully 
investigated, elevated cathepsin C activity has been associated with the tumourigenesis 
of pancreatic B-cell carcinoma in RIPl-Tag2 mice (Joyce et al., 2004). Other 
cathepsins have been studied in colorectal cancer and increased cathepsin B expression 
has been associated with premalignant colorectal lesions where it is thought to be 
involved in ECM degradation (Murnane et al., 1991, Emmert-Buck et al., 1994 and 
Khan et al., 1998b).
PPARy expression was increased in tumour samples Tl, T2, T3, T4, T5, T6 and 
T10 and decreased in T8 and T il in comparison with their normal tissue samples. 
Interestingly, PPARy expression was decreased in the polyp tissue sample P6 where its 
expression was increased in the tumour sample T6 from the same patient. While the 
expression of PPARy in colonic mucosa has been previously reported, its roles in colon 
cancer remain undefined (Mansen et al., 1996).
Tenascin C expression was enhanced in tumour samples Tl, T3, T4 and T5 and 
polyp sample P6 in comparison with its expression in normal tissue. Tenascin C 
expression was decreased in tumour samples T2, T6 , T8 , T10 and Til .  Increased 
tenascin C expression has been associated with poor prognosis in colorectal and breast 
cancer (Dueck et al., 1999, Kressner et al., 1997 and Ishihara et al., 1995). In this 
study, tumour samples with increased tenascin C expression also had increased 
cathepsin C expression.
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Tumour tissue Tl, T3, T4 and T5 had the same trends in expression and while 
T1 was classified as Dukes’ D, T3, T4 and T5 were classified as Dukes’ B. T2 and T6 
were classified as Dukes’ B and have the same expression trends. Interestingly, tumour 
sample T8 , which was classified as Dukes’ A, was the only tumour sample in this study 
with decreased expression of all four genes.
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5.4 Conclusion
In this study the expression of four previously identified potential markers of 
colorectal metastasis was investigated in paired normal and tumour colorectal 
specimens. All Dukes’ classifications were represented and expression was monitored 
using real time PCR. The expression of PPARy, tenascin C, cathepsin C and caveolin 1 
was detected in all tissue samples studied. As this was a pilot study, expression in only 
a small number of paired tissue samples was investigated. No conclusive correlation 
could be made regarding expression trends, patient survival or tumour classification. 
The only notable trend was that caveolin 1 expression was decreased in all tumour 
tissue specimens in comparison with normal tissue, with the exception of tumour 
sample T10 where caveolin 1 expression was slightly elevated. Expression of all genes 
was both increased and decreased in tumour tissue in comparison with normal tissue. 
No correlation could be made between expression and Dukes’ staging as tumours with 
the same Dukes’ classification showed opposite trends in expression. Although this 
study is limited in terms of conclusions it may exemplify the limitations of the Dukes’ 
staging system, which groups together heterogeneous subsets of patients with diseases 
that often behave differently to identical therapies. This highlights the need for the 
development of new and effective prognostic markers and parameters for colorectal 
cancer.
A larger number of samples would be required to conclusively determine 
expression patterns. This study does not give information on the location of expression. 
Analysis was carried out on crude heterogeneous tissue samples. In future, 
immunohistochemical studies would clarify which cells were producing the proteins 
and also in which cellular location these proteins were being expressed.
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Chapter 6
Final conclusions and summary
6.1 Final conclusions and summary
While colorectal cancer is preventable if detected early, almost 50 % of patients 
with the disease develop metastasis within 5 years (Wagenaar-Miller et al., 2004). The 
ability of tumour cells to invade and spread to distant sites of the body is the cause of 
90 % of cancer deaths (Sporn, 1996). As metastasis is the cause of the high mortality 
rates associated with cancer, a better understanding of the process is required to either 
develop novel therapeutic strategies or improve on existing ones with the ultimate aim 
of ensuring longer patient survival. The key therefore, is to extend our knowledge of 
the metastatic process by identifying new interactions between existing markers and 
identifying novel biomarkers of the disease.
The cellular and molecular steps required for metastasis are generally similar for 
all solid tumour types and involve many key players including proteases and CAMs 
(Liotta and Kohn, 2003). The metastatic process involves intricate interplay between 
these molecules resulting in altered cell adhesion, proteolysis and migration 
(Bogenrieder and Herlyn, 2003). The ECM provides mechanical support for tumour 
cell migration and ECM remodelling is essential for tumour invasion (Chang and Werb, 
2001). Included in the many groups of molecules involved in metastasis are the MMPs. 
Enhanced MMP activity and therefore increased ECM turnover have been shown to aid 
tumour locomotion (Liotta et al., 1980 and Stetler-Stevenson et al., 1996). As well as 
degrading the ECM, MMPs can cleave and therefore activate latent growth factors as 
well as activating other MMPs (Wagenaar-Miller et al., 2004 and Yu and Stamenkovic, 
2000). MMPs contribute to all stages of tumour progression, including local area 
invasion, intravasation, extravasation and growth at distant sites (Chambers and 
Matrisian, 1997 and Sternlicht and Werb, 2001).
To investigate the effects of enhanced MMP activity on tumour cell behaviour, a 
colon adenocarcinoma cell line, SW480, which did not produce detectable amounts of 
MMP-9 or MMP-7, was stably transfected with the cDNAs for these MMPs. MMP 
overexpression was detected using real time PCR, zymography and western blot 
analysis. The transfected cells showed increased in vitro invasion through reconstituted 
basement membrane in comparison with the non-transfected parental cell line. The 
MMP-7 transfected cell line, SW480M7 was more invasive than the MMP-9 transfected 
cell line SW480M9. MMP inhibition has previously been shown to suppress tumour
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invasion (Agrez et al., 1999). Using in vitro migration assays, the MMP transfected cell 
lines were also shown to be more migratory than the parental SW480 cell line. 
Interestingly, the SW620 cells derived from a lymph node metastasis of the same 
patient from which the SW480 cell line was established, were more invasive yet less 
migratory than the parental SW480 cell line. The SW620 produce low levels of MMP-9 
and undetectable amounts of MMP-7 and it was not as invasive or migratory as the 
MMP transfected cells.
The function of CAMs are crucial to metastatis, as tumour cells must undergo 
changes in their adhesion properties throughout the process. CAMs with established 
roles in metastasis include the integrins and CD44. The integrins are a large family of 
adhesion molecules with roles in both cell-cell and cell-matrix interactions. Integrin- 
mediated signalling also occurs via these interactions. CD44 is another adhesion 
molecule with roles in both cell adhesion and signalling. CAM mediated signalling 
often requires successful adhesion to either ECM components or neighbouring cells 
(Rosales et al., 1995).
In this study cell adhesion assays were carried out to compare the adhesive 
properties of the cell lines and also to investigate the role of cell adhesion in the 
invasive process. Cell adhesion to plastic, HA and fibronectin was compared. The 
SW480 cells were equally as adhesive to plastic, HA and fibronectin. The SW620 cells 
were more adhesive to plastic than the parental SW480 cells however their adhesion to 
HA and fibronectin was the same as the SW480 cells. Although the MMP-7 transfected 
cell line SW480M7 was equally as adhesive to all matrices, overall it was more 
adhesive than the parental SW480 cells. The adhesion of the MMP-9 transfected cell 
line SW480M9 to plastic was similar to that of the parental SW480 cells however its 
adhesion to both HA and fibronectin was significantly increased.
Considering the individual roles of both CAMs and MMPs, the interactions 
between these groups of molecules were of extreme interest to this study. CAMs and 
MMPs are no longer thought of as acting in isolation in the metastatic process and more 
focus is being put on their collective roles. Furthermore, MMP-CAM interactions 
group the key metastatic steps of cell adhesion and proteolysis together. Both cell-cell 
and cell-matrix adhesion interactions have the ability to enhance MMP activity 
(Ellerbroek et al., 1999 and Yakubenko et al., 2000). CAMs have been shown to bind
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MMPs on the cell surface and target their proteolytic activity (Brooks et al., 1996 and 
Yu and Stamenkovic, 1999). As a result of MMP-mediatcd ECM turnover, tumour 
cells must adapt to the new ECM by varying CAM-ECM interactions which also effects 
CAM-mediated signal transduction (Cheresh, 1991).
For an insight into the influence of extracellular conditions on MMP activity 
cells were grown in the presence of various ECM components. SW480, SW620 and 
SW480M7 cells did not secrete MMP-9 and the presence of HA, fibronectin, type IV 
collagen or P-l integrin-stimulating antibody did not stimulate MMP-9 expression in 
these cells. SW480M9 cells showed enhanced MMP-9 activity when grown in the 
presence of ECM components and the greatest effect was observed when cells were 
grown in the presence of HA. This effect was shown to occur at the post-transcriptional 
level.
CD44 is the major cell surface receptor for HA in the ECM. CD44 mediates 
both cell-cell and cell-matrix adhesion interactions. Increased expression of 
alternatively spliced CD44 isoforms is associated with an invasive phenotype and has 
been observed in metastatic cancers including colorectal cancer (Wielenga et al., 1993, 
Jothy, 2003 and Gunthert et al., 1991). Expression of CD44 isoforms containing the v6 
alternatively spliced exon was increased during the progression of colorectal cancer 
(Herrlich et al., 1993 and Wielenga et al., 1993 and 1998).
CD44 and MMPs are both of importance in the metastatic process and it is 
thought that their roles are closely related. Stimulation of CD44 has been shown to 
increase MMP-2 expression (Takahasi et al., 1999 and Zhang et al., 2002). CD44 can 
also bind to MMP-2 and MMP-9 on the cell surface, linking cell adhesion and 
signalling with proteolytic activity (Yu and Stamenkovic, 1999 and Yu et al., 2002).
Since MMP-9 activity in the SW480M9 cells was responsive to treatment with 
HA, the cells were treated with a monoclonal antibody designed to stimulate CD44. 
CD44 activation enhanced MMP-9 activity in a time dependent manner and also 
resulted in the activation of pro-MMP-9. This increase in MMP-9 was shown to be 
post-transcriptional.
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The expression of CD44 and pi integrin was investigated in all four cell lines. 
All cells expressed similar amounts of the standard 80 kDa CD44 except SW480M9 
cells which showed increased expression. The SW480M9 and SW620 cells also 
expressed a 120 kDa CD44 isoform. All cell lines expressed the CD44 isoform 
containing the v6 through v8 sequence and all cell lines except the SW620 cells 
expressed isoforms containing the v6 through vlO sequence. The cell lines also 
expressed pi integrin with SW620 cells expressing the highest amount. These results 
may explain the differences in cell adhesion to various ECM components and the 
differences in response to ECM components in terms of MMP activity.
To show a functional role for CD44 crosslinking and activation, in vitro invasion 
assays were performed. Treatment of cell lines with HA increased their in vitro 
invasion. The most dramatic increase was observed in the SW480M9 cells. The 
activation of CD44 with a monoclonal antibody resulted in increased invasion of the 
SW620 and SW480M9 cells. Blocking of CD44 function resulted in decreased invasion 
in all cell lines studied.
Taken together, these results highlight the importance of CAM-MMP 
interactions in tumour cell invasion. The CD44-MMP-9 interactions reported here are 
of significance as they demonstrate the interplay between the ECM, CAMs and MMP 
activity in tumour cell invasion. CD44 activation was shown to enhance MMP-9 
activity which resulted in increased cell invasion that could be inhibited by blocking 
CD44 function. Similar increases in invasion were not observed in cell lines that did 
not express MMP-9 however blocking CD44 did reduce their invasion. This suggests 
that CD44 operates in cell invasion independently of MMP activity and that the 
combination of both molecules results in a cumulative effect.
Allowing one to study the expression levels of many genes in parallel, 
microarray analysis has become a powerful tool in the investigation of the molecular 
basis of metastasis. To identify metastasis related genes, cDNA microarray analysis 
was used to compare the gene expression profiles of the colorectal cancer cell lines. 
Using a 39,365 element microarray, genes with increased or decreased expression in the 
SW620, SW480M7 and SW480M9 cell lines were identified. In all experiments, the 
SW480 cell line was used as the control. 233 genes had increased expression of at least 
2 fold in the SW620 cells and 208 genes had decreased expression of at least 2 fold in
192
the SW620 cells when compared with the SW480 cells. 147 genes had increased 
expression of at least 2 fold in the SW480M7 cells and 208 genes had decreased 
expression of at least 2 fold in comparison to the SW480 cells. 193 genes had increased 
expression of at least 2 fold in the SW480M9 cells and 20 genes had decreased 
expression of at least 2 fold in the SW480M9 cells when compared with the SW480 
cells. The following genes were chosen for validation and further analysis: cathepsin C, 
tenascin C, PPARy and caveolin 1, which were all up regulated in the SW620 cell line. 
Asparagine synthetase was chosen for further analysis as its expression was decreased 
in both the SW480M7 and SW480M9 cell lines.
Cathepsin C is a cysteine protease, and its roles in colorectal metastasis have not 
yet been established (Rao et al., 1997). Caveolin 1 is a component of the plasma 
membrane and is involved in signal transduction (Massimino et al., 2002). Tenascin C 
is an ECM component involved in proliferation, and high expression has been reported 
in malignant colon cancers (Kressner et al., 1997). PPARy is a transcription factor 
involved in regulating the transcription of various genes involved in proliferation and 
differentiation (Rosen and Spiegelman, 2001). Asparagine synthetase is involved in the 
synthesis of asparagine and its levels have been shown to be decreased in leukaemic 
cells (Aslanian et al., 2001).
Sequencing confirmed the identity of the respective spotted cDNAs and real 
time PCR confirmed the changes in expression. A fluorescent substrate assay 
confirmed cathepsin C activity at the protein level. PCR was used to investigate the 
alternative splicing of tenascin C. SW620 cells expressed more tenascin C than the 
SW480 cells and it also expressed a tenascin C isoform containing exon 16 that the 
SW480 cells did not express. The SW620 cells also expressed tenascin C isoforms 
containing exons 14 and 16 which the SW480 cells did not express. These isoforms 
have previously been associated with malignancy in breast and colon (Wilson et al., 
1996, Adams et al., 2002 and Dueck et al., 1999). Further follow up investigation of 
these genes could potentially validate their use as prognostic markers of colorectal 
cancer or as therapeutic targets to control metastasis.
A pilot study investigating the expression of the four selected genes in paired 
samples of normal and tumour colon tissue was conducted. All Dukes’ classifications 
were represented in the nine paired specimens. Expression of all four genes was
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detected in all tissue samples although no conclusive trends in expression regarding 
Dukes’ classification or patient survival were observed. Tumour samples that had the 
same classification showed opposite trends in expression. The only notable trend was 
that Caveolin 1 expression was decreased in all tumour tissue in comparison with 
normal tissue, except tumour sample T10 where its expression was only slightly 
elevated. A reduction in caveolin 1 levels has been associated with increased invasion 
in various cancers including ovarian (Bagnoli et al., 2000), colon (Bender et al., 2000), 
breast (Lu et al., 2004) and lung (Racine et al., 1999). This finding contradicts the 
previous observation that caveolin 1 expression was upregulated in the SW620 cells in 
comparison with the SW480 cells. It is possible that the increase in caveolin 1 
expression in the SW620 cells is patient specific. The SW620 and SW480 cell lines are 
both of tumour origin and this study compared the gene expression of normal and 
tumour tissue. Therefore, the increase in caveolin 1 expression could be a key event in 
the development of metastasis whereas a decrease in caveolin 1 expression may 
represent an earlier event in tumour development. A larger sample set would be 
required to draw any conclusions regarding the expression of these genes in colorectal 
tumours of varying Dukes’ classification.
In conclusion, this data highlighted the role of many of the participants involved 
in tumour invasion and the need to consider the interplay and interactions between 
them. The first part of this thesis described a mechanism by which colorectal tumour 
cells interacted with the ECM resulting in an increase in MMP-9 activity. Crosslinking 
of CD44 resulted in a post-transcriptional enhancement of MMP-9 activity together 
with increased cell invasion. This mechanism could potentially be exploited by 
invading tumour cells, by either expressing MMP-9 themselves or by triggering MMP-9 
secretion in neighbouring stromal cells. Subsequently, invading tumour cells would 
benefit from the increased ECM turnover. Further investigation is required to elucidate 
the exact mechanism of activation. Nevertheless, this work described a mechanism, the 
intervention of which could lead to the development of new therapies.
Further insights were gained into the transcriptional events regulating colorectal 
metastasis using cDNA microarray analysis. Differentially regulated genes were chosen 
and their expression was validated and detected in matched colorectal tissue specimens. 
Further investigation of these genes will elucidate their underlying roles in colorectal 
metastasis and validate their use as prognostic markers of the disease. These genes
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were chosen from a large list of genes that were differentially regulated in a metastatic 
cell line. The other genes in this list are included as an appendix to this thesis and their 
investigation in the process is equally valid.
Analysis of the expression of these genes in a greater number of tissue samples 
would help to elucidate their roles in colorectal cancer. A larger sample set would also 
help correlate expression patterns with tumour stage. Analysis of tenascin C isoform 
expression in these tissues would define which tenascin C isoform(s) are expressed in 
colorectal tissues of varying Dukes’ classifications. Because the roles of these genes in 
colorectal cancer are undefined, loss of function and gain of function experiments 
would be required to elucidate them. The roles of these genes in in vitro invasion and 
migration could be monitored by overexpression in non-expressing cell lines and by 
diminishing their expression using small interfering RNA (siRNA) technology in 
expressing cell lines.
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Genes with significant 2 fold or more increased expression in SW620 cells in
comparison with SW480 cells
Gene ID Fold change (range) Gene Name
R32457 9.781 (4.585 to 45.874) hypothetical protein FLJ23516
R93124 9.323(4.377 to 20.716) aldo-keto reductase family 1, member C1
AA912032 6.749 (2.825 to 14.293) ESTs, Weakly similar to 2108276A ssDNA-binding protein
AA459407 6.015 (2.115 to 62.53) SWI/SNF related, matrix associated, actln dependent regulator of chromatin
AA862465 5.822 (5.355 to 6.681) alpha-2-glycoprotein 1, zinc
AA913480 5.708 (0.889 to 28.721) killer cell lectin-like receptor subfamily C, member 1
R37743 5.089 (3.208 to 7.518) T54 protein
H22922 5.041 (2.732 to 7.143) manic fringe homolog (Drosophila)
R39239 4.897 (3.667 to 9.456) tenascin C (hexabrachion)
AA495936 4.365 (3.02 to 6.401) microsomal glutathione S-transferase 1
R28294 4.097 (2.911 to 5.627) glycine cleavage system protein H (aminomethyl carrier)
R16134 4.069 (2.521 to 6.342) transmembrane 4 superfamily member 11 (plasmolipin)
H94063 4.052 (2.565 to 6.329) chromosome 13 open reading frame 1
AA451851 3.999 (2.551 to 8.188) single-stranded DNA binding protein 2
N70463 3.958 (2.664 to 6.885) B-cell translocation gene 1, anti-proliferative
AA436565 3.757 (2.196 to 8.12) pleckstrin homology-like domain, family A, member 1
R51331 3.74 (1.798 to 5.821) hypothetical protein DKFZp761B0514
R60981 3.6 (2.223 to 5.532) ESTs, Highly similar to T00343 hypothetical protein KIAA0584 - human (fragment)
AA088420 3.588 (2.81 to 5.428) peroxisome proliferative activated receptor, gamma
AA421048 3.578 (2.763 to 4.118) ESTs
H79534 3.549 (2.038 to 6.782) hemoglobin, epsilon 1
AA173755 3.526 (0.541 to 8.139) roundabout, axon guidance receptor, homolog 1 (Drosophila)
R59936 3.497 (2.325 to 4.735) Homo sapiens mRNAfull length insert cDNA clone EUROIMAGE 43101.
N48804 3.479 (2.663 to 6.234) ESTs
W46900 3.436 (2.319 to 4.711) chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
AA055052 3.427 (2.11 to 4.889) Homo sapiens cDNA FLJ11639 fls, clone HEMBA1004327.
AA779165 3.421 (2.237 to 5.184) ADP-ribosylation factor-like 4
AA460463 3.416 (1.328 to 7.632) cytokine-like protein C17
R15922 3.345 (1.963 to 6.949) ESTs
AA036952 3.302 (1.275 to 11.652) hypothetical protein FLJ30973
AA701963 3.288 (1.709 to 5.365) aldo-keto reductase family 1, member B1 (aldose reductase)
AA935273 3.279 (1.052 to 12.46) chemokine (C-X-C motif) ligand 3
AA487893 3.243 (1.567 to 5.931) transmembrane 4 superfamily member 1
AA113347 3.203 (2.328 to 5.949) tousled-like kinase 1
R68272 3.203 (1.475 to 6.679) KIAA1796 protein
R60170 3.167 (1.944 to 4.153) guanine deaminase
R98936 3.092 (2.104 to 4.458) membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10)
H16537 3.09 (2.88 to 3.328) ESTs
W42723 3.088 (2.247 to 4.818) chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)
N26928 3.072 (2.407 to 3.901) hypothetical protein from EUROIMAGE 588495
AA916325 21.624 (5.818 to 537.576) aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II)
AA521339 2.859 (2.332 to 3.427) Homo sapiens, clone IMAGE:4347271, mRNA
H56655 2.853 (1.961 to 3.73) KIAA1727 protein
N57754 2.819 (1.989 to 4.267) Data not found
R61847 2.785 (1.975 to 5.641) glutamate receptor, ionotropic, N-methyl-D-aspartate 3A
R67081 2.783 (2.318 to 3.899) hypothetical protein LOC115749
AA478585 2.776 (1.219 to 4.503) butyrophilln, subfamily 3, member A3
T62546 2.767 (1.857 to 4.538) KIAA0174 gene product
AA453759 2.739 (1.91 to 3.806) sprouty homolog 2 (Drosophila)
AA055835 2.725 (1.605 to 3.346) caveolin 1, caveolae protein, 22kDa
T74192 2.71 (2.272 to 4.094) protein S (alpha)
AA464605 2.701 (1.156 to 5.293) kidney ankyrin repeat-containing protein
AA434373 2.694(1.871 to 5.425) E74-llke factor 3 (ets domain transcription factor, epithelial-specific)
W37905 2.678 (1.333 to 6.587) hypothetical protein dJ462023.2
1
AA644088
AA486220
N28269
T66320
H69335
AA452270
AA598640
AA931725
R39446
W80482
AA115761
AA621155
W79301
AA018151
R63811
AA910218
AA707922
AA857364
AA454990
R40946
AA427719
AI014877
N49284
N71028
H08862
R95691
AA150263
AA131421
R71627
H65988
R61187
AA625979
H13623
N23606
AA449821
N75595
H93050
H22566
W37780
AA620867
R15911
AA778448
N57998
AA452113
AA449837
AA450336
AA679150
R42736
R41565
AA479978
W52386
R16241
AA469965
H16824
AI240593
AA283699
AA933890|
A1822026
AA666418
2.676 (1.991 to 3.645) cathepsln C
2.67 (2.118 to 3.791) lysyl-tRNA synthetase
2.665 (1.361 to 5.217) Homo sapiens mRNA; cDNA DKFZp564F112 (from clone DKFZp564F112)
2.648 (1.263 to 5.092) glutathione S-transferase A4
2.635 (1.411 to 5.18) Pirin
2.626 (1.894 to 4.892) ESTs
2.622 (1.783 to 3.324) midline 1 (Opitz/BBB syndrome)
2.622 (1.552 to 4.029) SPARC related modular calcium binding 2
2.605 (1.903 to 3.566) ATP-binding cassette, sub-family G (WHITE), member 1
2.602 (1.44 to 3.725) Homo sapiens cDNA FLJ13598 fis, clone PLACE1009921.
2.601 (1.501 to 3.791) Data not found
2.569 (1.748 to 3.852) mutS homolog 5 (E. coll)
2.569 (1.029 to 5.977) arylhydrocarbon receptor repressor
2.564 (1.734 to 3.353) ESTs
2.561 (1.621 to 4.576) LIM and cysteine-rich domains 1
2.544 (1.008 to 4.668) monogenic, audiogenic seizure susceptibility 1 homolog (mouse)
2.533 (1.435 to 4.141) phosphodiesterase 6H, cGMP-specific, cone, gamma
2.521 (1.375 to 4.721) Homo sapiens cDNA: FLJ22864 fis, clone KAT02164.
2.504 (2.082 to 2.767) BTB (POZ) domain containing 3
2.49 (1.953 to 5.041) crystallin, zeta (quinone reductase)
2.489 (1.469 to 4.285) KIAA1201 protein
2.483 (1.298 to 8.294) ESTs
2.48 (1.02 to 4.333) v-myb myeloblastosis viral oncogene homolog (avian)
2.465 (2.153 to 2.919) membrane-spanning 4-domains, subfamily A, member 6A
2.456 (1.21 to 4.691) chromosome 1 open reading frame 17
2.45 (2.25 to 2.836) Data not found
2.445 (0.916 to 3.947) placenta-specific 8
2.441 (1.624 to 3.536) Homo sapiens mRNA, 3'UTR, up-regulated by BCG-CWS.
2.434 (1.202 to 3.545) chromosome 6 open reading frame 37
2.387 (1.723 to 3.173) ESTs
2.381 (1.678 to 3.726) ESTs
2.378 (1.721 to 2.955) hypothetical protein FLJ20607
2.374 (1.331 to 4.696) epidermal growth factor receptor pathway substrate 8
2.37 (1.739 to 3.168) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1977059
2.369 (1.776 to 2.996) ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]
2.367 (1.72 to 3.181) nuclear transport factor 2
2.357 (1.68 to 3.567) ESTs, Weakly similar to hypothetical protein FLJ20378 [Homo sapiens] [H.sapiens]
2.352 (1.566 to 4.145) dachshund homolog (Drosophila)
2.35 (1.66 to 2.941) RNA-bindlng protein
2.341 (1.442 to 3.993) forkhead box P1
2.34 (1.503 to 5.621) Homo sapiens clone 24461 mRNA sequence
2.336 (1.724 to 3.307) protein kinase, X-linked
2.326 (1.256 to 3.432) ESTs
2.323 (1.656 to 3.216) KIAA1917 protein
2.322 (1.849 to 3.589) HTPAP protein
2.318 (1.139 to 3.749) neurexin 3
2.298 (1.502 to 2.943) BTB (POZ) domain containing 3
2.298 (1.064 to 3.238) myelin transcription factor 1
2.292 (1.32 to 3.185) ESTs
2.289 (1.648 to 2.95) Data not found
2.281 (1.217 to 3.742) Data not found
2.28 (1.669 to 4.622) ESTs
2.271 (1.378 to 4.575) lymphocyte-specific protein tyrosine kinase
2.27 (1.552 to 3.099) kinesin-associated protein 3
2.255 (1.968 to 2.618) ESTs
2.246 (1.315 to 4.034) Homo sapiens, clone IMAGE:5264268, mRNA
2.24 (1.491 to 3.072) Data not found
2.239 (1.682 to 2.734) ALEX1 protein
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AA937029 2.239 (1.326 to 3.92) nudix (nucleoside diphosphate linked moiety X)-type motif 4
AA152347 2.232 (1.644 to 2.765) glutathione S-transferase A4
AA452566 2.23 (1.801 to 2.491) peroxisomal membrane protein 3, 35kDa (Zellweger syndrome)
R98070 2.225 (1.301 to 3.276) ESTs
T50041 2.218 (1.409 to 3.794) DKFZP586A0522 protein
AA676945 2.206 (1.904 to 2.691) NPC1 (Niemann-PIck disease, type C1, gene)-like 1
R51524 2.202 (1.348 to 3.173) kelch-like 3 (Drosophila)
AA626156 2.201 (1.848 to 2.538) chromosome 1 open reading frame 28
A1023541 2.201 (1.402 to 3.18) carbonic anhydrase IX
H11987 2.189 (1.968 to 2.421) ESTs
N69672 2.189 (1.413 to 4.312) glycosylphosphatidylinositol specific phospholipase D1
H07920 2.188 (1.489 to 3.22) mitogen-activated protein kinase kinase 6
N34287 2.183 (1.956 to 2.425) unc-5 homolog B (C. elegans)
H25551 2.181 (1.215 to 3.788) Homo sapiens clone 161455 breast expressed mRNA from chromosome X.
AA452125 2.18 (1.672 to 2.902) LIM and cysteine-rich domains 1
H62473 2.178 (1.624 to 3.249) transforming growth factor, beta receptor III (betaglycan, 300kDa)
AA504777 2.177 (2.046 to 2.348) ESTs
R51494 2.175 (1.76 to 2.534) copine VIII
H12277| 
H12278 2.175 (1.28 to 4.744) Data not found
R41600 2.17 (1.597 to 2.574) hypothetical protein FLJ12688
AA448653 2.17(1.39 to 3.037) hypothetical protein LOC155435
AA620415 2.167 (1.482 to 2.964) vacuolar protein sorting 35 (yeast)
AA291486 2.167 (1.435 to 3.985) PTK2 protein tyrosine kinase 2
AA598548 | 
AI732161 2.164 (1.391 to 4.172) Data not found
AA457137 2.161 (1.571 to 3.026) hypothetical protein MGC2555
AA504618 2.156(1.791 to 2.691) tubulin-specific chaperone e
H05445 2.154 (1.233 to 3.273) growth associated protein 43
AA418907 2.152 (1.757 to 2.524) cytochrome P450, family 1, subfamily A, polypeptide 1
AA406320 2.152 (1.752 to 2.887) poliovirus receptor-related 3
T74688 2.15 (1.894 to 2.402) sulfide quinone reductase-like (yeast)
AA705069 2.146 (1.569 to 2.783) retinolc acid receptor, alpha
AA489069 2.146 (1.55 to 2.647) ESTs
R50775 2.133 (1.824 to 2.809) likely ortholog of mouse variant polyadenylation protein CSTF-64
AA663981 2.13 (1.518 to 3.783) immunoglobulin heavy constant gamma 3 (G3m marker)
AA704255 2.129 (1.335 to 2.708) spinocerebellar ataxia 7 (olivopontocerebellar atrophy with retinal degeneration)
AA428139 2.124 (1.895 to 2.339) intestinal cell kinase
A1347748 2.124 (1.744 to 2.372) DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 (DBP5 homolog, yeast)
N56995 2.123 (1.194 to 3.678) KIAA1706 protein
AA878391 2.121 (1.65 to 3.467) glyplcan 5
N47484 2.116 (1.125 to 3.185) glutathione S-transferase A4
N76084 2.111 (1.792 to 2.49) Homo sapiens cDNA FLJ12807 fis, clone NT2RP2002316.
AA706929 2.083 (1.395 to 2.709) protein phosphatase 1F (PP2C domain containing)
H26271 2.083 (1.056 to 4.079) pleckstrin homology-like domain, family A, member 1
AA446251 2.077 (1.392 to 3.085) laminin, beta 1
R60053 2.069 (1.68 to 2.44) hypothetical protein LOC155036
AA885311 2.069 (1.294 to 3.066) butyrylcholinesterase
AA457671 2.068 (1.343 to 3.09) procollagen-proline, 2-oxoglutarate 4-dioxygenase, alpha polypeptide I
AA454082 2.067 (1.447 to 2.95) Data not found
W84751 2.062 (1.548 to 3.26) KIAA1357 protein
R15832 2.059 (1.521 to 2.524) p21/Cdc42/Rac1 -activated kinase 1 (STE20 homolog, yeast)
H17022 2.057 (1.255 to 3.252) myosin VIIA and Rab interacting protein
AA521067 2.053 (1.681 to 2.616) inositol polyphosphate-5-phosphatase, 145kDa
R39765 2.043 (1.791 to 2.392) DC6 protein
AA425128 2.04 (1.63 to 2.469) ESTs
AA459956 2.039 (1.611 to 2.388) putative ribonuclease III
R64146 2.037 (1.703 to 2.31) Homo sapiens, clone IMAGE:5552108, mRNA
R73909 2.034 (1.83 to 2.178) pregnancy specific beta-1 -glycoprotein 2
R63647 2.033 (1.378 to 4.442) prolactin receptor
3
N53436
AA040742
AA418984
AA609149
H04230
AA449773
T95670
R06840
R55786
AA608575
AA135152
R40057
N66008
AA007597
N58065
AA479155
AA453750
R43604
AA709271
AA075722
T57241
AA452138
AA434090
AA779520
AA670390
R01211
AA775831
AA284528
AI033662
AA625673
AA417921
R24530
AA705229
R70685
R52703
AA455043
R40855
W15339
T74023
AA193381
R33363
AA610000
AA628230
AA399216
AA456642
AA449118
H73731
AI004245
AA478476
N66028
AA863471
R60014
AA701655
H05769
AA890663
AA777123
AA464196
AA873089
H18949
2.032 (1.758 to 2.306) homolog of rat orphan transporter v7-3
2.03 (1.451 to 2.776) poly(A) binding protein, nuclear 1
2.028 (1.687 to 2.499) sentrin/SUMO-specific protease SENP8
2.028 (1.463 to 2.809) Homo sapiens, Similar to hypothetical protein FLJ10058, clone MGC:34306
2.028 (1.32 to 2.682) fukutin-related protein
2.025 (1.25 to 2.899) CDC42 effector protein (Rho GTPase binding) 4
2.015 (1.011 to 2.765) Werner helicase interacting protein
2.013 (1.497 to 3.075) gamma-glutamyltransferase-like 3
2.005 (1.579 to 2.479) A kinase (PRKA) anchor protein 6
17.343 (4.64 to 293.5) propionyl Coenzyme A carboxylase, alpha polypeptide
11.576 (7.197 to 20.898) glutathione peroxidase 2 (gastrointestinal)
10.929 (3.612 to 32.266) prominin-like 1 (mouse)
10.31 (5.53 to 16.207) Putative prostate cancer tumor suppressor
1.997 (1.102 to 3.397) Homo sapiens, clone IMAGE:4347271, mRNA
1.994 (1.614 to 3.138) ESTs, Weakly similar to RIKEN cDNA 1110001019 [Mus musculus] [M.musculus]
1.994 (1.286 to 2.374) Homo sapiens, clone IMAGE:4826905, mRNA, partial cds
1.99 (1.347 to 2.35) hypothetical protein MGC14480
1.989 (0.995 to 3.909) Homo sapiens mRNA; cDNA DKFZp547E184 (from clone DKFZp547E184)
1.98 (1.844 to 2.422) neural cell adhesion molecule 2
1.957 (1.225 to 2.556) nuclear transport factor 2
1.954 (1.701 to 2.293) high mobility group nudeosomal binding domain 3
1.939 (1.362 to 2.964) leucine-rich repeat protein, neuronal 3
1.938 (1.215 to 3.653) fibroblast growth factor receptor-like 1
1.934 (1.543 to 2.359) ESTs
1.928 (1.751 to 2.373) ESTs
1.915 (1.286 to 2.574) microfibrillar-associated protein 1
1.903 (1.387 to 2.381) ESTs
1.901 (1.204 to 3.154) protease, serine, 2 (trypsin 2)
1.901 (1.093 to 2.759) Homo sapiens mRNA; cDNA DKFZp58600724 (from clone DKFZp58600724)
1.896 (1.632 to 2.157) amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 12
1.891 (1.221 to 3.19) C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member;
1.891 (1.17 to 2.533) folate receptor 1 (adult)
1.884 (1.172 to 2.616) hypothetical protein FLJ12270
1.883 (1.232 to 2.345) jagged 1 (Alagille syndrome)
1.878 (1.525 to 2.359) thymidine kinase 2, mitochondrial
1.877 (1.553 to 2.114) holocarboxylase synthetase
1.874 (1.377 to 2.407) ESTs
1.874 (1.011 to 3.264) hypothetical protein LOC161291
1.869 (0.91 to 3) tumor endothelial marker 6
1.866 (0.911 to 2.904) Homo sapiens cDNA FLJ37217 fis, clone BRALZ2008763.
1.865 (1.463 to 2.867) decidual protein induced by progesterone
1.864 (1.567 to 2.229) ESTs
1.86 (1.333 to 2.335) Data not found
1.86 (1.125 to 3.605) ESTs
1.859 (1.283 to 2.629) small proline-rich protein 2A
1.858 (1.13 to 2.53) transcription factor A, mitochondrial
1.857 (1.369 to 2.389) KIAA0601 protein
1.855 (1.513 to 2.32) hypothetical protein FLJ20449
1.854 (1.375 to 3.742) ESTs
1.849 (1.323 to 2.176) FKBP-associated protein
1.844 (1.232 to 2.38) KIAA1107 protein
1.827 (1.429 to 2.916) hypothetical protein DKFZp761N09121
1.826 (1 to 3.09) Data not found
1.821 (1.096 to 3.451) hypothetical protein MGC14254
1.82 (1.298 to 2.905) p21/Cdc42/Rac1 -activated kinase 1 (STE20 homolog, yeast)
1.812 (1.002 to 2.247) Homo sapiens, Similar to RIKEN cDNA 1110001019 gene, clone MGC:21689
1.807 (1.256 to 2.538) hyaluronoglucosaminidase 1
1.803 (1.192 to 2.786) cytochrome P450, family 3, subfamily A, polypeptide 5
1.79 (1.156 to 3.339) chromosome 6 open reading frame 33
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R49650
AA486738
R20755
R51210
1.773 (1.349 to 2.756) 
1.77 (1.276 to 2.636) 
1.748 (1.133 to 2.36) 
1.708 (1.17 to 2.239)
Fas apoptotic inhibitory molecule 2 
Bardet-Biedl syndrome 2 
Data not found
hypothetical protein FLJ22353
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Genes with significant 2 fold or more decreased expression in SW620 cells in
comparison with SW480 cells
Gene ID Fold change (range) Gene Name
AA452095 0.548 (0.401 to 0.862) SMC4 structural maintenance of chromosomes 4-like 1 (yeast)
AA190339 0.547 (0.408 to 0.693) dual specificity phosphatase 3 (vaccinia virus phosphatase VH1-related)
AA488177 0.543 (0.462 to 0.67) dynactin 4 (p62)
T46878 0.54 (0.377 to 0.683) eukaryotic translation initiation factor 3, subunit 1 alpha, 35kDa
AA443830 0.538 (0.388 to 0.873) chromosome 14 open reading frame 9
AA446021 0.537 (0.375 to 0.74) Homo sapiens cDNA FLJ11801 fis, clone HEMBA1006253,
AA454015 0.535 (0.41 to 0.644) HSPC126 protein
N95752 0.529 (0.385 to 0.657) Homo sapiens, Similar to RIKEN cDNA 1500009M05 gene, clone MGC:40370
AA431967 0.524 (0.375 to 0.703) LATS, large tumor suppressor, homolog 2 (Drosophila)
R51362 0.518 (0.364 to 0.825) mitochondrial ribosomal protein S31
AA485151 0.51 (0.362 to 0.756) heat shock 105kDa/110kDa protein 1
T64933 0.508 (0.384 to 0.8) KIAA1724 protein
AA437140 0.507 (0.393 to 0.694) hypothetical protein DKFZp434L0718
AA045083 0.506 (0.371 to 0.735) Homo sapiens, clone IMAGE:4402981, mRNA
AA609463 0.505 (0.428 to 0.594) hypothetical protein MGC19556
AA456968 0.505 (0.388 to 0.974) neurotrophic tyrosine kinase, receptor, type 2
R42699 0.505 (0.366 to 0.764) KIAA1387 protein
T55337 0.505 (0.343 to 0.617) Shwachman-Bodian-Diamond syndrome protein
AA398365 0.505 (0.329 to 0.935) Homo sapiens cDNA FLJ35589 fis, clone SPLEN2007498.
N74362 0.504 (0.344 to 0.623) serologically defined colon cancer antigen 3
AI333397 0.502 (0.354 to 0.703) Data not found
T67278 0.5 (0.43 to 0.573) hypothetical protein MGC46235
AA971738 0.499 (0.386 to 0.636) ESTs, Weakly similar to RTN2_HUMAN Reticulon protein 2
AA496796 0.498 (0.343 to 0.702) FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 (chondrocyte-derived)
AA134696 0.498 (0.32 to 0.726) Homo sapiens mRNA; cDNA DKFZp586E1120 (from clone DKFZp586E1120)
AA432085 0.497 (0.438 to 0.635) tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein
AA457731 0.497 (0.435 to 0.67) SNARE protein Ykt6
AA011211 0.496 (0.452 to 0.609) hypothetical protein FLJ10726
T70031 0.496 (0.35 to 0.66) solute carrier family 1 (neutral amino acid transporter), member 5
AA278402 0.495 (0.451 to 0.556) microtubule-actin crosslinking factor 1
AA115400 0.494 (0.365 to 0.694) hHDC for homolog of Drosophila headcase
H96654 0.494 (0.336 to 0.893) pp21 homolog
H96908 0.493 (0.4 to 0.752) hypothetical protein MGC10067
N73536 0.493 (0.341 to 0.713) hypothetical protein BM-002
T57834 0.49 (0.423 to 0.662) chromosome 20 open reading frame 108
N49581 0.488 (0.384 to 0.662) similar to CG6405 gene product
AA099034 0.487 (0.349 to 0.808) ubiqultin specific protease 1
A1289851 0.483 (0.393 to 0.668) Data not found
AA676749 0.483 (0.361 to 0.561) dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A
AA608632 0.482 (0.363 to 0.686) chromosome 14 open reading frame 35
AA598625 0.482 (0.314 to 0.607) solute carrier family 1 (glutamate/neutral amino acid transporter), member 4
T73780 0.481 (0.314 to 0.815) ESTs, Similar to hypothetical protein FLJ21617; erythroid differentiation-related factor 1
AA156946 0.481 (0.286 to 0.754) Data not found
AA126799 0.48 (0.395 to 0.582) uncharacterized hematopoietic stem/progenitor cells protein MDS031
H07934 0.478 (0.352 to 0.599) DKFZP564I1171 protein
N72265 0.476 (0.37 to 0.588) casein kinase 1, alpha 1
N51837 0.475 (0.369 to 0.65) DKFZP434A043 protein
H48097 0.475 (0.347 to 0.817) hypothetical protein FLJ20986
R94947 0.475 (0.321 to 0.871) Rho-associated, coiled-coil containing protein kinase 2
AA496884 0.474 (0.42 to 0.548) hypothetical protein FLJ 14564
AA195449 0.473 (0.375 to 0.534) hypothetical protein LOC130074
AI675707 0.472 (0.256 to 0.622) ribosomal protein S7
AA450334 0.471 (0.311 to 0.882) Homo sapiens cDNA FLJ13209 fis, clone NT2RP4000424.
AA417825 0.469 (0.315 to 0.577) hypothetical protein FLJ20643
N64494 0.468 (0.429 to 0.511) Homo sapiens cDNA FLJ37850 fis, clone BRSSN2013733,
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N74189 0.468 (0.37 to 0.685) WD domain, G-beta repeat-containing protein
AA446316 0.467 (0.383 to 0.534) ESTs
AA598504 0.467 (0.324 to 0.732) beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P)
R26732 0.466 (0.318 to 0.594) peripheral myelin protein 22
AI688757 0.464 (0.395 to 0.51) cytochrome c oxidase subunit Vb
AA293653 0.462 (0.331 to 0.608) phosphoprotein enriched in astrocytes 15
AA420992 0.46 (0.305 to 0.82) ESTs
AA630374 0.459 (0.36 to 0.634) dual specificity phosphatase 6
W76339 0.459 (0.354 to 0.637) nuclear factor (erythroid-derived 2)-like 3
R23738 0.459 (0.277 to 0.649) Homo sapiens cDNA FLJ30233 fis, clone BRACE2001971.
N32611 0.458 (0.408 to 0.571) hypothetical protein FLJ20481
AA970066 0.458 (0.288 to 0.726) ubiquitin specific protease 1
AA136133 0.455 (0.363 to 0.558) hypothetical protein FLJ14735
AA464694 0.454 (0.344 to 0.684) Human HeLa mRNA isolated as a false positive in a two-hybrid-screen,
AA629542 0.454 (0.3 to 0.683) WAS protein family, member 3
W49633 0.453 (0.352 to 0.571) mitofusin 1
N62924 0.452 (0.296 to 0.6) mitochondrial ribosomal protein S22
AA456437 0.452 (0.274 to 0.661) MKI67 (FHA domain) interacting nucleolar phosphoprotein
N62766 0.449 (0.359 to 0.583) neutral sphingomyelinase (N-SMase) activation associated factor
AA489626 0.448 (0.327 to 0.619) FYVE and coiled-coil domain containing 1
AA630449 0.448 (0.325 to 0.873) Niemann-Pick disease, type C2
AI340883 0.447 (0.352 to 0.613) tumor-associated calcium signal transducer 1
AA469953 0.446 (0.345 to 0.566) nucleoporin 50kDa
AA973097 0.446 (0.307 to 0.77) EST
AA827551 0.445 (0.327 to 0.899) Notch homolog 2 (Drosophila)
AA497040 0.445 (0.277 to 0.87) stanniocalcin 2
AA459690 0.445 (0.236 to 0.724) brain protein 44-like
N48319 0.444 (0.308 to 0.702) breast cancer anti-estrogen resistance 3
AI343879 0.442 (0.389 to 0.538) hypothetical protein FLJ11838
AA460731 0.442 (0.363 to 0.72) G protein-coupled receptor 107
AA293671 0.441 (0.297 to 0.584) CD8 antigen, beta polypeptide 1 (p37)
R42174 0.441 (0.286 to 0.678) sin3-associated polypeptide, 18kDa
AI263603 0.44 (0.398 to 0.478) EST
AA029312 0.439 (0.368 to 0.501) NIMA (never in mitosis gene a)- related kinase 9
H09322 0.438 (0.362 to 0.592) ESTs
AA447992 0.437 (0.379 to 0.583) ESTs
AA011096 0.437 (0.305 to 0.56) monoamine oxidase A
AA078976 0.435 (0.316 to 0.558) thioredoxin-like, 32kDa
W90381 0.434 (0.363 to 0.519) hypothetical protein LOC145622
AA487486 0.433 (0.382 to 0.497) cyclin D1 (PRAD1: parathyroid adenomatosis 1)
AA485349 0.433 (0.38 to 0.528) N-ethylmaleimide-sensitive factor attachment protein, gamma
N36176 0.433 (0.298 to 0.521) chromosome 1 open reading frame 9
AA004525 0.433 (0.267 to 0.601) hypothetical protein F23149_1
N80741 0.432 (0.235 to 0.741) ATP binding protein associated with cell differentiation
AA598573 0.429 (0.383 to 0.496) unc-84 homolog A (C. elegans)
H00589 0.427 (0.298 to 0.571) UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1
H15085 0.426 (0.304 to 0.584) ADP-ribosylation factor 4-like
Al 199321 0.426 (0.247 to 0.613) eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa
W72005 0.425 (0.322 to 0.557) adenomatosis polyposis coli down-regulated 1
AA443722 0.425 (0.321 to 0.52) upstream binding protein 1 (LBP-1a)
AA460716 0.425 (0.318 to 0.483) Data not found
R56870 0.425 (0.265 to 0.55) similar to RIKEN cDNA 2700047N05
AI056063 0.424 (0.305 to 0.545) ESTs
AA455235 0.423 (0.361 to 0.502) aldehyde dehydrogenase 1 family, member A3
AA488610 0.421 (0.393 to 0.439) MCM4 minichromosome maintenance deficient 4 (S. cerevisiae)
AA017526 0.421 (0.353 to 0.453) collagen, type IX, alpha 3
H10335 0.416 (0.292 to 0.636) Homo sapiens mRNA; cDNA DKFZp564L222 (from clone DKFZp564L222)
AA486445 0.415 (0.348 to 0.504) KIAA0563 gene product
N34466 0.415 (0.278 to 0.606) hypothetical protein DKFZp434H0820
N57005 0.412 (0.345 to 0.5) ring finger protein (C3H2C3 type) 6
7
Appendix A
W46944 0.411 (0.283 to 0.526) angiomotin like 2
H20809 0.41 (0.341 to 0.485) Homo sapiens cDNA FLJ33540 fis, clone BRAMY2007613.
T97762 0.41 (0.34 to 0.6) interferon-related developmental regulator 1
AA777187 0.41 (0.298 to 0.522) cysteine-rich, angiogenic inducer, 61
AA398356 0.41 (0.28 to 0.564) chromosome 11 open reading frame 14
N67766 0.406 (0.349 to 0.491) acetyl-Coenzyme A synthetase 2 (AMP forming)-like
H15549 0.405 (0.265 to 0.599) hypothetical protein FLJ32122
AI080633 0.405 (0.253 to 0.689) pyruvate dehydrogenase phosphatase
AA458502 0.404 (0.334 to 0.503) peptidyl-prolyl isomerase G (cyclophilin G)
AA608534 0.404 (0.288 to 0.523) Homo sapiens mRNA; cDNA DKFZp5S6C1019 (from clone DKFZp586C1019)
AA683077 0.4 (0.378 to 0.419) mitogen-activated protein kinase 1
AA283090 0.398 (0.324 to 0.456) Homo sapiens CD44 isoform RC (CD44) mRNA, complete cds
N51225 0.396 (0.287 to 0.597) Homo sapiens, clone IMAGE:4798592, mRNA
AA188789 0.395 (0.275 to 0.539) Homo sapiens, clone IMAGE:6057297, mRNA
AI215610 0.394 (0.337 to 0.506) ESTs
N93403 0.394 (0.333 to 0.523) hypothetical protein FLJ20707
R12808 0.39 (0.31 to 0.525) ESTs, Moderately similar to hypothetical protein, MGC:7199 [Mus musculus] [M.musculus
W65461 0.39 (0.229 to 0.553) dual specificity phosphatase 5
Al 095082 0.389 (0.249 to 0.605) Rag D protein
N29844 0.386 (0.32 to 0.655) peptidase (mitochondrial processing) beta
AI439571 0.384 (0.286 to 0.553) apoptosis antagonizing transcription factor
AM 46478 0.384 (0.273 to 0.482) hypothetical protein DKFZp761H0421
AA024832 0.384 (0.245 to 0.587) Homo sapiens mRNA; cDNA DKFZp586l0324 (from clone DKFZp586l0324)
AA486556 0.383 (0.374 to 0.392) CD81 antigen (target of antiproliferative antibody 1)
N32768 0.383 (0.271 to 0.656) pregnancy specific beta-1 -glycoprotein 3
N52496 0.382 (0.33 to 0.452) BTG family, member 3
AA479058 0.382 (0.318 to 0.488) thrombopoietin
AA460286 0.381 (0.207 to 0.563) guanine nucleotide binding protein (G protein), gamma 10
N46446 0.38 (0.229 to 0.564) Data not found
R55046 0.376 (0.303 to 0.505) MpV17 transgene, murine homolog, glomerulosclerosis
AI248758 0.376 (0.275 to 0.627) EST
R59697 0.373 (0.292 to 0.509) Homo sapiens mRNA fragment.
AA464544 0.368 (0.309 to 0.462) LIM domain only 2 (rhombotin-like 1)
R78530 | R78490 0.368 (0.22 to 0.636) Data not found
R67355 0.367 (0.201 to 0.715) angiomotin like 2
AA927761 0.365 (0.302 to 0.471) hypothetical protein LOC128977
R69622 0.362 (0.272 to 0.475) CGI-141 protein
N72878 0.361 (0.219 to 0.631) development and differentiation enhancing factor 1
AA459401 0.358 (0.246 to 0.542) kaliikrein 10
AA972654 0.353 (0.266 to 0.504) hypothetical protein MGC48972
N25987 0.352 (0.339 to 0.384) disrupted in renal carcinoma 2
AA723035 0.352 (0.265 to 0.582) zinc finger protein 36, C3H type-like 1
AA490044 0.351 (0.286 to 0.504) solute carrier family 5 (inositol transporters), member 3
AA291163 0.351 (0.251 to 0.521) glutaredoxin (thioltransferase)
AA479276 0.347 (0.331 to 0.375) ESTs
R66605 0.347 (0.287 to 0.412) hypothetical protein MGC20576
AA621315 0.344 (0.305 to 0.397) catenin (cadherin-associated protein), alpha-like 1
R25377 0.344 (0.29 to 0.412) DEK oncogene (DNA binding)
AA929006 0.343 (0.28 to 0.431) ESTs
AI347472 0.338 (0.235 to 0.573) ATP binding protein associated with cell differentiation
N48355 0.338 (0.221 to 0.485) fragile X mental retardation 1
N50079 0.336 (0.215 to 0.453) Opa-interacting protein 2
Al 088175 0.332 (0.255 to 0.557) hypothetical protein FLJ10120
AA487425 0.331 (0.225 to 0.44) zinc finger protein 463
AA135001 0.329 (0.246 to 0.437) hypothetical protein BC016153
AI383171 0.328 (0.191 to 0.799) Data not found
AA160507 0.327 (0.235 to 0.677) keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types)
N66178 0.326 (0.216 to 0.603) Homo sapiens cDNA FLJ23705 fis, clone HEP11066.
AI375330 0.325 (0.242 to 0.5) Homo sapiens cDNA: FLJ21243 fis, clone COLO1164.
N64734 0.324 (0.274 to 0.391) Data not found
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N25352 0.324 (0.228 to 0.42) coxsackie virus and adenovirus receptor
AA159669 0.323 (0.265 to 0.359) likely ortholog of rat vacuole membrane protein 1
AA496438 0.322 (0.155 to 0.499) retinoic acid receptor, gamma
AA165678 0.319 (0.275 to 0.448) ATP-binding cassette, sub-family C (CFTR/MRP), member 4
AA134595 0.317 (0.215 to 0.453) eukaryotic translation initiation factor 5A2
R43270 0.308 (0.281 to 0.346) protein phosphatase 1, regulatory (inhibitor) subunit 14C
AI264351 0.308 (0.233 to 0.414) Homo sapiens cDNA FLJ40926 fis, clone UTERU2006524.
H29268 0.302 (0.191 to 0.542) Homo sapiens, Similar to nuclear localization signals binding protein 1,
AA190626 0.298 (0.24 to 0.333) sentrin-specific protease
W37447 0.296 (0.199 to 0.501) ESTs
W69211 0.294 (0.211 to 0.364) chemokine (C-C motif) ligand 11
T62844 0.294 (0.174 to 0.545) hypothetical protein dJ473B4
AI334917 0.29 (0.148 to 0.91) LIM domain protein
AA187933 0.286 (0.224 to 0.376) transcriptional co-activator with PDZ-binding motif (TAZ)
AI096800 0.285 (0.251 to 0.33) immediate early response 5
AA010818 0.274 (0.22 to 0.315) myeloid/lymphoid or mixed-lineage leukemia
AA504265 0.273 (0.23 to 0.307) LIM and senescent cell antigen-like domains 1
N34799 0.271 (0.231 to 0.315) hypothetical protein FLJ23306
N54794 0.27 (0.241 to 0.304) Data not found
AI271884 0.258 (0.227 to 0.31) Wiskott-Aldrich syndrome-like
AA431753 0.252 (0.153 to 0.387) CED-6 protein
AA485677 0.252 (0.152 to 0.496) thyroid hormone receptor interactor 6
AA156988 0.249 (0.151 to 0.325) aconitase 1, soluble
N70078 0.248 (0.201 to 0.362) ziziminl
R32440 0.244 (0.152 to 0.357) Homo sapiens clone 23698 mRNA sequence
N63598 0.242 (0.164 to 0.317) Homo sapiens cDNA FLJ32453 fis, clone SKMUS2001703.
R96522 0.237 (0.137 to 0.329) pregnancy specific beta-1-glycoprotein 1
N69049 0.235 (0.158 to 0.295) frizzled homolog 7 (Drosophila)
AA457501 0.219 (0.12 to 0.288) duodenal cytochrome b
AA418036 0.211 (0.103 to 0.347) GLI-Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome)
AA406552 0.165 (0.118 to 0.204) solute carrier family 2 (facilitated glucose transporter), member 3
AA609556 0.162 (0.101 to 0.292) pinch-2
AA598601 0.148 (0.107 to 0.286) insulin-like growth factor binding protein 3
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Genes with significant 2 fold or more increased expression in SW480M7 cells in
comparison with SW480 cells
Gene ID Fold change (range) Gene Name
AI350438 9.704 (0.745 to 76.349) KIAA1966 protein
AA620619 3.29 (2.819 to 4.258) ESTs
AI192052 3.055 2.643 to 3.302) chromosome 14 open reading frame 28
H62199 2.985 1.43 to 6.286) ESTs
AA912874 2.813 1.568 to 4.216) Homo sapiens, clone IMAGE:5266192, mRNA
AI339434 2.75 ( .972 to 4.564) caveolin 2
AA418675 2.728 1.508 to 7.132) ADP-ribosylarginine hydrolase
AA424568 2.721 1.238 to 4.992) ESTs
AI250799 2.676 2.047 to 3.591) defensin, alpha 4, corticostatin
AM 25237 2.664 2.136 to 3.003) ESTs
AA933773 2.628 1.67 to 4.887) chromobox homolog 3 (HP1 gamma homolog, Drosophila)
AI276487 2.617 2.046 to 3.711) cytokeratin type II
AA609884 2.579 1.386 to 5.051) Data not found
AM 88068 2.565 1.208 to 4.913) parkin co-regulated gene protein
Al 125898 2.554 1.622 to 3.723) ESTs
AA464583 2.552 1.643 to 3.963) ESTs
AA437243 2.549 1.325 to 4.2) ESTs
R99080 2.541 1.819 to 4.839) Data not found
AA669218 2.54 (2.072 to 3.354) HBS1-like (S. cerevisiae)
Al 028163 2.534 1.689 to 3.592) ESTs
AA620642 2.518 2.31 to 2.942) hypothetical protein LOC51319
Al 140695 2.509 1.827 to 3.304) Data not found
AA916562 2.494 2.212 to 2.691) vacuolar protein sorting 4B (yeast)
N/A-2-1-15-4 2.493 2.224 to 2.961) Data not found
H21892 2.492 1.624 to 5.384) Homo sapiens cDNA FLJ36638 fis, clone TRACH2018950.
AA779228 2.476 2.031 to 3.043) ESTs
AI140566 2.433 1.888 to 2.968) ESTs,
AI288845 2.421 1.818 to 3.089) chemokine (C-C motif) receptor-like 2
AA634483 2.408 1.883 to 2.976) Homo sapiens, clone IMAGE:5266541, mRNA
AI204136 2.405 1.667 to 3.392) bromodomain containing 2
AI085068 2.404 1.802 to 2.929) ESTs
AA479344 2.401 1.679 to 3.437) gap junction protein, beta 5 (connexin 31.1)
Al 187832 2.398 1.629 to 3.185) ESTs
AA868748 2.393 1.966 to 2.676) ESTs
AA463462 2.384 1.852 to 3.85) Toll-interacting protein
AA676548 2.376 1.906 to 3.037) ESTs, Moderately similar to hypothetical protein FLJ20234
AA778851 2.347 1.881 to 2.748) Human clone 137308 mRNA, partial cds.
R38885 2.345 2.094 to 2.743) ESTs
Al 191761 2.339 1.823 to 2.875) serine protease inhibitor, Kazal type 4
AA953249 2.323 1.855 to 3.2) H factor 1 (complement)
AI022259 2.316 1.462 to 4.611) zinc finger protein 255
AA977836 2.31 ( .848 to 2.791) peroxisomal farnesylated protein
AA620670 2.307 1.392 to 4.403) ESTs
AI025808 2.274 1.735 to 3.098) Data not found
AA100957 2.266 1.086 to 3.754) DKFZP434C171 protein
AA609630 2.26 ( .921 to 2.529) Data not found
A A / / / / / 9 2.255 2.125 to 2.373) ESTs
N/A-3-1-14-6 2.253 1.869 to 2.744) Data not found
AA669367 AI732124 2.251 1.903 to 2.916) Data not found
AA921818 2.228 1.946 to 2.421) ESTs
Al 125351 2.228 1.498 to 3.926) ESTs
AA454949 2.227 2.177 to 2.312) hypothetical protein FLJ23468
AA410434 2.218 1.952 to 2.752) collagen triple helix repeat containing 1
Al 188006 2.218 1.775 to 3.075) ESTs
AM 25753 2.217 1.74 to 2.709) Homo sapiens, clone IMAGE:4822830, mRNA
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AA621004 2.217 1.374 to 3.394) ESTs
AA707094 2.211 1.617 to 4.113) ESTs
Al 187831 2.208 1.723 to 3.587) ESTs
AA504631 2.207 1.737 to 2.872) CDA14
AA868802 2.204 1.634 to 3.536) ESTs
AA677215 2.195 1.447 to 3.83) ESTs, Moderately similar to hypothetical protein FLJ20234
AA953254 2.181 1.629 to 2.658) collagen, type IV, alpha 5 (Alport syndrome)
AA778617 2.179 1.81 to 2.44) ESTs
AA694497 2.174 1.856 to 2.569) Data not found
AI032679 2.17 ( .587 to 2.749) ESTs
Ah 39912 2.165 1.708 to 2.781) Data not found
AA418896 2.165 1.489 to 4.332) ESTs, Weakly similar to hypothetical protein FLJ20489 [Homo sapiens] [H.sapiens]
AA706094 2.163 1.793 to 2.482) ESTs, Weakly similar to 2109260A B cell growth factor [Homo sapiens] [H.sapiens]
Al 138368 2.152 1.467 to 3.578) cytochrome c oxidase subunit Vllb2
AI139861 2.144 1.457 to 3.314) Data not found
AA437210 2.137 1.559 to 2.546) ESTs
AA609768 2.136 1.99 to 2.36) ESTs
AM 98232 2.132 1.945 to 2.41) C-terminal PDZ domain ligand of neuronal nitric oxide synthase
AA626942 2.131 1.647 to 2.883) ESTs
AA778577 2.13 ( .603 to 2.982) EST,
N63479 2.127 1.473 to 3) Data not found
AA682719 2.125 1.777 to 2.664) EST
AA921805 2.124 1.316 to 3.28) ESTs
AI278813 2.123 1.424 to 3.049) ESTs
H83116 2.117 1.574 to 3.141) origin recognition complex, subunit 6 homolog-like (yeast)
AI028784 2.107 1.602 to 2.755) Homo sapiens cDNA FLJ40501 fis, clone TESTI2045171.
AA465242 2.097 1.963 to 2.345) hypothetical protein MGC45400
AA629039 2.095 1.213 to 3.349) RNA binding motif protein 5
AI081823 2.093 1.908 to 2.376) chromosome 20 open reading frame 104
AI206318 2.089 1.814 to 2.446) gamma-aminobutyric acid (GABA) A receptor, beta 3
AM 25829 2.086 1.8 to 2.459) EST
AA773190 AI791127 2.086 1.712 to 2.432) Data not found
AA917956 2.085 1.866 to 2.334) Homo sapiens, clone IMAGE:3878708, mRNA
Al 142095 2.084 1.778 to 2.84) ESTs
AA418728 2.083 1.532 to 3.688) palmdelphin
AA479512 2.074 1.666 to 2.978) ESTs,
AI082726 2.073 1.639 to 2.45) Data not found
AA909246 2.072 1.221 to 2.986) Homo sapiens, clone IMAGE:4824710, mRNA
AA778839 2.068 1.624 to 2.66) ESTs
AA633769 2.068 1.454 to 4.049) dipeptidylpeptidase 7
R16676 2.067 1.663 to 2.569) NFS1 nitrogen fixation 1 (S. cerevisiae)
AA232895 2.065 1.3 to 3.606) Data not found
AA889865 2.063 1.75 to 2.712) EST
H77461 2.063 1.665 to 2.422) lymphocyte adaptor protein
AM 83541 2.063 1.241 to 3.607) Data not found
AI081607 2.061 1.822 to 2.615) ESTs
AA865729 2.059 1.191 to 3.18) ocular albinism 1 (Nettleship-Falls)
AA629924 2.056 1.763 to 2.414) Data not found
R07012 2.055 1.592 to 2.702) ESTs
AA425128 2.055 1.191 to 3.588) ESTs
AA625856 2.047 1.641 to 3.028) sorting nexin 5
AA626716 2.044 1.77 to 2.374) Data not found
AA868008 2.042 1.716 to 2.822) histone 1, H4c
R10885 2.04 ( .565 to 3.124) aspartoacylase-3
N22685 2.039 1.809 to 2.348) plexin C1
AI018280 2.039 1.742 to 2.746) Homo sapiens, clone MGC:34040 IMAGE:4829245, mRNA, complete cds
Al 140549 2.038 1.734 to 2.7) ESTs
AA677641 2.034 1.841 to 2.306) KIAA1910 protein
A1204635 2.034 1.644 to 2.418) Homo sapiens, clone IMAGE:5267179, mRNA
AA452255 2.034 1.224 to 3.395) integrln-binding sialoprotein (bone slaloproteln, bone sialoprotein II)
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AA993474
AA912886
AA437245
AI253652 |
AA625858
AM 24607
AI371323
AA424562
AA505111
AA455935
AA927182
AA778611
AA463483
AA719374
AA890153
AA479950
AA927951
AA778609
H45289
AA936776
AI341099
AA709162
AA923743
AA478606
H67514
AA398121
AI190411
AA911697
AI375330
AI131266
AI000726
AA496984
2.031 (1.692 to 2.456) Data not found
2.029 (1.57 to 2.433) ESTs
2.028 (1.968 to 2.125) Homo sapiens, clone IMAGE:5744200, mRNA
AI793206 2.028 (1.767 to 2.251) Data not found
2.025 (1.753 to 2.281) ESTs
2.021 (1.658 to 2.414) Data not found
2.019 (1.612 to 2.558) leukocyte immunoglobulin-like receptor, subfamily B
2.017 (1.111 to 2.734) tumor necrosis factor (ligand) superfamily, member 13
2.014 (1.327 to 2.823) copine III
2.012 (1.335 to 2.47) Homo sapiens mRNA; cDNA DKFZp564H1916 (from clone DKFZp564H1916)
2.009 (1.55 to 2.32) similar to rat nuclear ubiquitous casein kinase 2
2.006 (1.749 to 2.195) KIAA1086 protein
2.003 (1.354 to 3.717) CD47 antigen (Rh-related antigen, integrin-associated signal transducer)
2.002 (1.722 to 2.238) EST
1.994 (1.55 to 2.342) ESTs
1.984 (1.263 to 3.378) ATPase, Class II, type 9B
1.974 (1.126 to 3.346) fragile X mental retardation, autosomal homolog 1
1.973 (1.576 to 2.235) testis development protein NYD-SP26
1.955 (1.336 to 2.429) ESTs
1.954 (1.527 to 2.877) hypothetical protein FLJ38359
1.953 (1.52 to 2.688) Data not found
1.952 (1.5 to 3.161) Homo sapiens cDNA: FLJ22133 fis, clone HEP20529.
1.934 (1.178 to 3.197) ESTs
1.932 (1.423 to 2.419) x 006 protein
1.93 (1.529 to 2.946) ESTs
1.905 (1.496 to 2.452) ESTs
1.884 (1.243 to 2.593) tubby like protein 3
1.85 (1.488 to 2.733) hypothetical protein FLJ31349
1.846 (1.302 to 2.765) Homo sapiens cDNA: FLJ21243 fis, clone COLO1164.
1.835 (1.34 to 2.397) EST
1.798 (1.194 to 2.707) likely ortholog of mouse myocytic induction/differentiation originator
1.773 (1.34 to 2.898) angiomotin
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Genes with significant 2 fold or more decreased expression in SW480M7 cells in
comparison with SW480 cells
Gene ID Fold change (range) Gene Name
AI652005 0.515 (0.42 to 0.615) cathepsin L2
R38494 0.493 (0.468 to 0.515) flotillin 2
AA976089 0.488 (0.468 to 0.52) enoyl Coenzyme A hydratase 1, peroxisomal
AA410636 0.487 (0.384 to 0.656) isoleucine-tRNA synthetase
AA995233 0.477 (0.43 to 0.506) ESTs
AA983882 0.472 (0.356 to 0.668) DKFZP586J1624 protein
AA976212 0.439 (0.315 to 0.595) hypothetical protein BC013995
H59614 0.391 (0.286 to 0.62) Homo sapiens, clone MGC:52263 IMAGE:4123447, mRNA, complete cds
N/A-4-3-15-2 0.368 (0.251 to 0.481) Data not found
AA894927 0.358 (0.047 to 1.656) asparagine synthetase
AI280306 0.341 (0.225 to 0.584) UDP-glucose ceramide glucosyltransferase-like 2
AI015679 0.304 (0.275 to 0.324) phosphoserine aminotransferase
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Genes with significant 2 fold or more increased expression in SW480M9 cells in
comparison with SW480 cells
Gene ID Fold change (range) Gene Name
H05775
AA394240
T72581
N/A-2-1-15-4
AA778916
W80739
AA479344
AA598549
AA906569
AA934753 | AI733146 
AA775447
AI253652 | AI793206
AA676765
AA496949
AI288845
AA453796
AA634483
AI276487
AI285947
AA700141
AA777779
AA707545
AA937734
AA620619
AA933721
Al 125237
AI250799
AA626316
Al 140566
AI347622
AI340031
AA777308
AA733038
AA418698
AA495818
AA443193
AA912793
AI357236
AA778851
AA402915
A1024634
Al 125868
AA934618
Al 243367
AA779199
Al 188006
AA609630
AI206318
AI219893
7.081 (2.551 to 28.636) 
6.417 (4.968 to 8.801) 
4.686 (2.546 to 7.611) 
4.46 (2.382 to 13.241) 
4.134 (2.217 to 5.881)
4.038 (1.84 to 13.195)
3.822 (2.559 to 6.547) 
3.624 (2.02 to 10.901) 
3.482 (1.878 to 10.053) 
3.449(1.207 to 8.188) 
3.433 (1.27 to 8.108) 
3.426 (1.935 to 5.64) 
3.389 (3.031 to 3.83) 
3.318(2.061 to 8.036) 
3.265 (1.584 to 8.376)
3.2 (1.98 to 6.645) 
3.163 (2.347 to 5.209)
3.045 (1.767 to 5.447)
3.034 (2.024 to 4.721)
3.012 (1.644 to 4.481)
2.984 (1.804 to 7.067) 
2.984(1.433 to 7.845)
2.866 (1.949 to 3.643)
2.859 (2.287 to 3.893)
2.858 (1.432 to 5.858)
2.85 (2.088 to 4.203) 
2.778 (1.507 to 4.783) 
2.771 (1.682 to 3.918) 
2.767 (1.248 to 5.303) 
2.76 (2.068 to 3.556) 
2.74 (1.454 to 4.207) 
2.737 (2.14 to 3.727) 
2.729 (2.364 to 3.14) 
2.721 (1.74 to 5.203) 
2.699 (1.734 to 4.912) 
2.698 (2.098 to 3.381) 
2.696 (1.741 to 5.399) 
2.694 (2.044 to 3.962) 
2.692 (1.996 to 3.672) 
2.678 (1.677 to 6.066) 
2.667 (1.613 to 3.988) 
2.661 (1.414 to 6.057) 
2.66 (1.75 to 4.326) 
2.652 (2.527 to 2.83) 
2.647 (1.864 to 4.009) 
2.628 (1.624 to 5.214) 
2.619 (2.039 to 3.199) 
2.614 (1.717 to 5.806)
2.601 (1.453 to 5.182)
monoamine oxidase A 
X-box binding protein 1 
matrix metalloproteinase 9 
Data not found 
ESTs
Homo sapiens cDNA FLJ25106 fis, clone CBR01467. 
gap junction protein, beta 5 (connexin 31.1)
SMC2 structural maintenance of chromosomes 2-like 1 (yeast)
Data not found
Data not found
alpha-2-macroglobulin
Data not found
mitochondrial ribosomal protein 63
ESTs
chemokine (C-C motif) receptor-like 2
tetraspanln similiar to uroplakin 1
Homo sapiens, clone IMAGE:5266541, mRNA
cytokeratin type II
outer dense fiber of sperm tails 1
ESTs
ESTs
transition protein 1 (during histone to protamine replacement) 
Homo sapiens full length insert cDNA clone ZD16H11 
ESTs
myotubularin related protein 2
ESTs
defensin, alpha 4, corticostatin
likely ortholog of mouse kinesin light chain 2
ESTs,
tumor necrosis factor (ligand) superfamily, member 7 
ankyrin-like with transmembrane domains 1 
hypothetical protein FLJ13942 
RNA polymerase I subunit
Homo sapiens, similar to SHC, clone MGC:34023 IMAGE:4827789 
dudulin 2
homolog of yeast Sec5 
ESTs
protamine 1
Human clone 137308 mRNA, partial cds.
aminoacylase 1 
ESTs
Homo sapiens cDNA FLJ12032 fis, clone HEMBB1001880.
Homo sapiens mRNA fortMDC II, isoform [a]
ESTs
ESTs
ESTs
Data not found
gamma-aminobutyric acid (GABA) A receptor, beta 3 
ESTs
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AA016001 2.589 1.572 to 4.222) transposon-derived Busterl transposase-like protein
A1039422 2.577 1.885 to 4.27) hypothetical protein FLJ10770
AA907547 2.577 1.713 to 3.297) ESTs
Al 140549 2.556 1.329 to 6.064) ESTs
AI023853 2.554 1.558 to 4.084) ESTs, Weakly similar to hypothetical protein FLJ11531
AA927721 2.548 1.607 to 3.283) ESTs
AI269119 2.547 1.5 to 4.634) peroxisome receptor 1
AA778590 2.522 1.698 to 4.587) ESTs
AA778611 2.521 2.071 to 3.079) KIAA1086 protein
N22685 2.517 1.935 to 3.09) plexin C1
T91254 2.51 ( .803 to 3.846) ESTs, Weakly similar to neuronal thread protein
AA626716 2.509 1.973 to 2.985) Data not found
AA479950 2.497 2.11 to 2.989) ATPase, Class II, type 9B
Al 140695 2.474 2.078 to 3.144) Data not found
AA669367 | AI732124 2.474 1.743 to 4.704) Data not found
AA777837 2.47 ( .882 to 4.193) ESTs
H45289 2.458 1.724 to 2.988) ESTs
AA917956 2.455 2.312 to 2.671) Homo sapiens, clone IMAGE:3878708, mRNA
N/A-3-1-14-6 2.449 2.29 to 2.575) Data not found
AI002154 2.42 ( .61 to 4.38) zinc finger protein 106
AH 25425 2.419 1.804 to 3.5) Homo sapiens, clone IMAGE:5284350, mRNA
AA873143 2.409 2.162 to 2.897) pleckstrin homology domain containing, family B (evectins) member 1
AA704794 2.385 1.883 to 2.753) ESTs
AA705112 2.381 1.862 to 3.783) molybdenum cofactor synthesis 1
AA683578 2.377 1.962 to 2.859) Homo sapiens mRNA; cDNA DKFZp667G2419
AA884636 2.375 1.592 to 3.218) ESTs
AA455904 2.372 1.489 to 5.143) ESTs
AA707671 2.37 ( .643 to 4.191) Homo sapiens cDNA FLJ31598 fis, clone NT2RI2002549.
AA778617 2.366 1.929 to 2.81) ESTs
AH 98232 2.365 1.75 to 2.781) C-terminal PDZ domain ligand of neuronal nitric oxide synthase
AI091540 2.361 1.858 to 3.41) KIAA1376 protein
AA912886 2.357 1.745 to 3.057) ESTs
AA894577 2.35 .762 to 4.007) nucleolar protein 5A (56kDa with KKE/D repeat)
AA732931 2.35 ( .69 to 3.792) syntaxin 4A (placental)
AA279283 2.346 1.943 to 2.909) hypothetical protein FLJ20487
AA459690 2.335 1.355 to 4.084) brain protein 44-like
AA195276 2.334 1.837 to 3.437) ESTs, Weakly similar to L1 repeat, Tf subfamily, member 30
AA909002 2.333 1.628 to 2.974) ESTs
AI221641 2.331 1.498 to 4.45) potassium large conductance calcium-activated channel, subfamily M,
AA701664 2.329 1.992 to 2.667) ESTs
AA621132 2.327 1.479 to 3.875) aquaporin 9
AA437210 2.324 1.687 to 3.485) ESTs
AA669218 2.322 2.14 to 2.478) HBS1-like (S. cerevisiae)
AA778759 2.318 1.729 to 2.718) ESTs
H29895 2.304 1.753 to 3.113) guanine nucleotide binding protein (G protein)
AI339400 2.298 1.261 to 3.984) anti-Mullerian hormone receptor, type II
AA609992 2.297 1.822 to 2.916) NADP-dependent retinol dehydrogenase/reductase
AA479512 2.296 1.996 to 2.842) ESTs,
AM 40628 2.294 1.471 to 3.05) EDAR-associated death domain
AA664210 2.287 1.735 to 3.352) protein kinase (cAMP-dependent, catalytic) inhibitor gamma
AA719285 2.283 1.249 to 3.821) Data not found
R10890 2.278 1.518 to 4.861) ESTs
AA699307 2.275 1.281 to 4.157) ESTs,
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H73239 | AI821460 2.271 (1.356 to 3.454) Data not found
W70293 2.271 (1.089 to 3.787) Homo sapiens full length insert cDNA clone ZD58F01
AA884051 2.268(1.877 to 2.904) Data not found
AM 42095 2.266 (1.608 to 3.355) ESTs
Al 140706 2.262 (1.45 to 4.045) Homo sapiens cDNA FLJ11801 fis, clone HEMBA1006253
AA778646 2.257 (1.641 to 2.669) hypothetical protein FLJ25955
AA463454 2.247(1.955 to 2.842) hypothetical protein FLJ10849
N59790 2.246 (1.752 to 3.124) nuclear transcription factor, X-box binding 1
AA625858 2.245 (1.837 to 3.165) ESTs,
AA490464 2.237 (1.766 to 3.111) DKFZP564D116 protein
AA923758 2.233 (1.715 to 2.705) hypothetical protein MGC10796
R91397 2.231 (1.425 to 4.259) ESTs
H80879 2.225 (1.743 to 2.533) Data not found
AA936710 2.225 (1.649 to 3.421) COX15 homolog, cytochrome c oxidase assembly protein (yeast)
AA620642 2.224 (1.831 to 2.477) hypothetical protein LOC51319
AI139861 2.221 (1.609 to 2.98) Data not found
AA621332 2.22 (1.55 to 2.89) ESTs
AA913206 2.208 (1.37 to 4.681) G antigen 7B
AA706094 2.207 (1.747 to 2.87) ESTs, Weakly similar to 2109260A B cell growth factor
AA883722 2.207 (1.556 to 3.355) ESTs
AA668178 2.204 (1.785 to 2.812) karyopherin alpha 3 (importin alpha 4)
R89855 2.2 (1.85 to 2.707) ESTs, Highly similar to plakophilin 4 [Homo sapiens] [H.sapiens]
AM 25753 2.196 (1.655 to 3.297) Homo sapiens, clone IMAGE:4S22830, mRNA
AA910876 2.196 (1.495 to 2.967) KIAA0543 protein
AA625955 2.195 (1.812 to 3.188) EST
AA905044 2.192 (1.326 to 3.108) homeo box D8
AA4S5055 2.189 (1.972 to 2.338) sperm associated antigen 6
H77461 2.186 (1.627 to 2.732) lymphocyte adaptor protein
AA626152 2.178 (1.673 to 3.052) ESTs
Al 125490 2.176 (1.579 to 2.961) EST, Moderately similar to T42689 hypothetical protein DKFZp434J 1027.1
N63479 2.168 (1.807 to 2.504) Data not found
H78407 2.167 (1.899 to 2.482) ESTs
AA707468 2.163 (1.694 to 2.685) olfactory receptor, family 7, subfamily E, member 104 pseudogene
H84154 2.161 (1.883 to 2.549) cyciin D2
AA700155 2.158 (1.476 to 3.678) Crm, cramped-like (Drosophila)
AA906879 2.153 (1.525 to 2.826) hypothetical protein FLJ39441
AA897338 2.151 (1.298 to 2.936) Homo sapiens, clone IMAGE:5271578, mRNA
AA777043 2.15 (1.567 to 3.207) Data not found
AA598927 2.141 (1.747 to 2.7) Data not found
AA969184 2.136 (1.972 to 2.44) cardiac ankyrin repeat protein
AA877082 2.132 (1.98 to 2.284) Homo sapiens, Similar to hypothetical protein FLJ20378
AA707672 2.131 (1.921 to 2.255) membrane component, chromosome 11, surface marker 1
AA921818 2.129 (1.934 to 2.412) ESTs
AA677206 2.129 (1.859 to 2.582) ESTs
AA629344 2.123 (1.596 to 2.463) Data not found
R02826 2.119 (1.662 to 2.537) Data not found
AA63415B 2.119 (1.643 to 3.018) secretogranin III
AA909319 2.117 (1.506 to 3.332) ESTs
AI205822 2.114(1.095 to 3.093) ESTs
AA935694 2.112 (1.803 to 2.867) heparan sulfate (glucosamine) 3-O-sulfotransferase 2
AA158032 2.108(1.757 to 2.675) KIAA0783 gene product
H74017 2.107 (1.581 to 3.228) ESTs
AI339376 2.103 (1.542 to 3.323) crystallin, beta B1
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H01504 2.101 (1.653 to 2.511) Data not found
AA634425 2.1 (1.285 to 3.82) ESTs, Weakly similar to AD20_ HUMAN ADAM 20 precursor
R45255 2.099 1.764 to 2.515) EBNA1 binding protein 2
AA919087 | AI733140 2.097 1.7 to 2.574) Data not found
AI018179 2.094 1.968 to 2.166) ESTs
AA707503 2.092 1.347 to 2.729) DKFZP434I092 protein
W6S220 2.087 1.524 to 2.511) KIAA0101 gene product
AA626249 2.085 1.42 to 2.861) ESTs
AA773608 2.082 1.373 to 3.544) Homo sapiens, Similar to hypothetical protein FLJ14840
A1339089 2.081 1.788 to 2.522) syntaxin 6
AA456027 2.081 1.603 to 3.254) hypothetical protein FLJ13081
AA694497 2.076 1.739 to 2.408) Data not found
AA923730 2.065 1.583 to 2.909) ESTs
AA608845 2.061 1.445 to 3.729) ESTs
R42174 2.057 1.529 to 2.453) sin3-associated polypeptide, 18kDa
AA778577 2.056 1.72 to 2.671) EST,
AA055114 2.046 1.695 to 2.585) phosphoinositide-3-kinase, regulatory subunit, polypeptide 1 (p85 alpha)
AA702678 2.046 1.626 to 2.618) hypothetical protein FLJ 10204
AA454963 2.036 1.686 to 2.248) mitochondrial ribosomal protein L36
AH 87980 2.033 1.755 to 2.585) Data not found
AA676548 2.017 1.641 to 2.244) ESTs, Moderately similar to hypothetical protein FLJ20234
AA115742 2.013 1.864 to 2.193) procollagen C-endopeptidase enhancer 2
AA437245 2.01 .776 to 2.224) Homo sapiens, clone IMAGE:5744200, mRNA
N36948 2.005 1.286 to 3.023) ESTs, Weakly similar to hypothetical protein FLJ20294
W85710 2.002 1.808 to 2.261) carnitine palmitoyltransferase 1B (muscle)
AA126919 2 (1.4 3 to 2.442) tyrosylprotein sulfotransferase 1
AA496113 1.996 1.619 to 2.893) ESTs, Moderately similar to PR00478 protein
AA904562 1.988 1.719 to 2.278) Data not found
AA918288 1.987 1.591 to 2.758) Data not found
AI262978 1.981 1.61 to 2.372) methylenetetrahydrofolate dehydrogenase (NADP+ dependent)
AA706790 1.959 1.3 to 2.794) kinesin 2 60/70kDa
AI034168 1.955 1.308 to 3.552) ESTs
AA773190 | AI791127 1.95 ( .713 to 2.214) Data not found
AA490843 1.931 1.637 to 2.1) anaphase promoting complex subunit 5
AA071122 1.92 ( .379 to 3.312) Data not found
AA921738 1.869 1.48 to 2.487) Homo sapiens, clone IMAGE:5271140, mRNA
AA406388 1.863 1.622 to 2.32) hypothetical protein MGC10820
AA421300 1.806 1.451 to 2.562) zinc finger protein 261
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Genes with significant 2 fold or more decreased expression in SW480M9 cells in
comparison with SW480 cells
Gene ID Fold change (range) Gene Name
AA449832 0.531 (0.392 to 0.655) adaptor-related protein complex 1, sigma 2 subunit
AI061186 0.495 (0.35 to 0.683) Homo sapiens cDNA FLJ39845 fis, clone SPLEN2014452.
R51218 0.494 (0.397 to 0.685) KIAA0092 gene product
AI286236 0.492 (0.456 to 0.563) ESTs, Weakly similar to neuronal thread protein [Homo sapiens] [H.sapiens]
AA278630 0.491 (0.472 to 0.51) differential display and activated by p53
AI675465 0.473 (0.418 to 0.589) homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain
AA598496 0.473 (0.393 to 0.665) IQ motif containing GTPase activating protein 1
AI359120 0.47 (0.442 to 0.501) chromodomain helicase DNA binding protein 6
AI018218 0.464 (0.425 to 0.505) ESTs
AA447746 0.46 (0.367 to 0.517) HIF-1 responsive RTP801
AI080633 0.453 (0.42 to 0.497) pyruvate dehydrogenase phosphatase
AI053778 0.443 (0.344 to 0.505) ESTs, Weakly similar to hypothetical protein FLJ11267 [Homo sapiens] [H.sapiens]
H68542 0.442 (0.306 to 0.638) ESTs
AI300286 0.44 (0.31 to 0.629) Data not found
AI269079 0.439 (0.321 to 0.596) ESTs
AA894927 0.408 (0.133 to 1.378) asparagine synthetase
AA676405 0.402 (0.384 to 0.421) argininosuccinate synthetase
AA676466 0.393 (0.354 to 0.437) argininosuccinate synthetase
AA995233 0.365 (0.334 to 0.432) ESTs, Highly similar to ASSY_HUMAN Argininosuccinate synthase
AI015679 0.298 (0.21 to 0.409) phosphoserine aminotransferase
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Sequence verification
Appendix B
APPENDIX II: Results obtained for the sequencing of chosen clones. 
TENASCIN C
GCCGGGTTTCCNGTCACGACGTTGTAAAACGACGGCCAGTGAATTCCCTTGCGGCCGCAG
GNAATTTTTTTTTTTTTTTTTTTTTTAACAAACTCAAAAGTACTTGTGCTTTTATTTAAA
AAAAAAATACAATCAGGTACTGTCCAGAAATGTTTTGGAAAGAAAGATCTCTTGAAAAAT
CCTTAGTTTTCATCATCATCATCATCATTATTATATTAATAATATTAATCATATCCTTAA
AATGGAAACAGTATTGCTTTTCTGGTTTCTGTTGTATGAAATGTAAAAAAAGGGATGGCT
TCCAATGACACATTTAATCTTTGCTAACAAAAATAATGACAATTAATTATACAGCTTCAT
GTAAAATACGGCTGGTTCTAAAACAAACTACCCCTGTACATCCTACCCCTCTCCCATTCC
CAGAGCCACCTAANAGAAGTAAAAAACTATTGCGATGTTGTCACTGGGAGATTTTTGCTG
AATCAAACAACAAAACAGAAACATGTTGGAGACTGATGTCTTTGGTGCAAAGAAAGAAAT
CNCAGAGGAGGTGAGGCCCATGCTGTTGCCGTTGGCCCCANGGATCCATGGTCAGCTTTG
ACTCTCACCAAATGCCCAGGTGTGGACCGAGGGTTGGGCTGGTTGTATTGAGCTTTGGTA
AAACCTTTCCTCGCTCTGGGCCTTATTCCTCTCTCCCCAGNGGCCCTGGAATTTATGCCC
GTTTGCGCCTGCCTTCAAAAATTCCGNAAATTGCTTGGCCNCANCTTCCTCCTCANCAAA
ANTGGGATTGAANGGTTCNNGGGCCCTTCCCCGNGGGAAACNNNTTTAACNCCCTGGACN
GGGGGTTATTGGCCCCCNTATCCCCCCCNTCNNGGTTGAACCNGGGGGACNNNTTCCNN
CAVEOLIN 1
GCCGGGTTTCCAGTCACGACGTTGTAAACGACGGCCAGTGCCAAGCTAAAATTAACCCTC
ACTAAAGGGAATAAGCTTGCGGCCGCATCTTTTTTTTTTTTTTTTTTTCCTCCTCAGTTC
TTCATATTTCTCTCAAATTACCTTTCAACAATATGTTCATATCTCAGCCAATAAAGCGAT
GGTTGATCCACATGCAAATAAAAAGGTAAGGAAAAAAATTTAAATGGGTTTTAAAAATTC
AGACTGCCAAAAATAGATGAAATAGCTCAGAAGAGACATAATACTTATGAAAACTGAGAA
AGTGATCTTTTTATTTTCAACCAAGATAATTCAATTCATAAATTGTTGCTGTATTAGCAA
CTTGGAACTTGAAATTGGCACCAGGAAAATTAAAAGGAAAAAAAATCAGGTATACTTCTA
TCCTTGAAATGTCATTTATATTTCTTTCTGCAAGTTGATGCGGACATTGCTGAATATTTT
CCCAACAGCTTCAAANAGTGGGTCACAGACGGTGTGGACGTANATGGAATANACACGGCT
GATGCACTGAATCTCAATCAGGAAGCTCTTAATGCATGGTACAACTGCCCANATGTGCAG
GAAAGAGAGAATGGCGAAGTAAATGCCCCANATGAGTGCCATCGGGATGCCAAAGAGGGC
AGACAGCAAGCGGTAAAACCAGTATTTCGTCACAGTGAAGGTGGTGAAGCTGGCCTTCCA
AATGCCGTCAAAACTGTGTGTGCCTTCTGGTTCTGCAATCACATCTTCAAAGTCAATCTT
GACCACGTCCTCCTTGAAGTGTTTAAGGNCCCGGTTGGACCAANNCNATCCCTTGGGGGG
GNGCGTCNNAAACTTGGCTTCNCGCTCAACTNCGGCTGGNCANGGGCCN
PPAR-gamma
GCAGGGTTTCTCNTCACGGACGTTGTAANACGACGGCCAGTGNAATTGTAATACGACTCA
CTATAGGGCGAATTGGGTACCGGGCCCCCCCTCGAGTTTTTTTTTTTTTTTTTTCATAAT
ATGGTAATTTTTAATATTAAAAGTAAATTGTAAATGTGTCTTTATAAACAATATGCATAA
AATAGATCATATTCTAAAACCTTTTCTTTTTAAAATGCTTTTTCACAGTAAATTTCTTAG
GTGTCANATTTTCCCTCANAATAGTGCAACTGGAANAAGGGAAATGTTGGCAGTGGCTCA
GGACTCTCTGCTAGTACAAGTCCTTGTANATCTCCTGCAGGAGCGGGTGAANACTCATGT
CTGTCTCCGTCTTCTTGATCACCTGCAGTAGCTGCACGTGTTCCGTGACAATCTGTCTGA
GGTCTGTCATTTTCTGGAGCAGCTTGGCAAACAGCTGTGAGGACTCAGGGTGGTTCAGCT
TCAGCTGGAGCTCCAGGGCTTGTAGCAGGTTGTCTTGAATGTCTTCAATGGGCTTCACAT
TCAGCAAACCTGGGCGGTCTCCACTGAGAATAATGACAGCAATAAATATTGCCAAGTCGC
TGTCATCTAATTCCAGNGCATTGAACTTCACAGCAAACTCAAACTTGGGCTCCATAAAGT
CACCAAAAGGCTTTCGCAGGCTCTTTAAAAACCCCTTGTCATGAANCCTTGGCCCCCGGA
TATGAAAACCCCCATCTTTTATTCNTCAANGANGCCCGCNTTGGTGTAAATGACCTCGNG
GACCCCCCTNTTTGGANGAAAAGTTNCCTTGGCCCTTTCCAGTCNAGAATTNCNAAACCC
CGNAANGGCTTTNTGGCANAAANCCGGGAACNCCCCGGCNCNNCCCTCCCCCGGAANNGA
N
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ASPARAGINE SYNTHETASE
NNNNCNNNAANCATCATGACATGATTANGNATNTAATACGACTCACTATANGGAATNTGG
CCCTCGAGGCCAAGAATTCGGCACGAGGTTAATTTCCAAGTATATTCGGAAGAACACAGA
TAGCGTGGTGATCTTCTCTGGAGAAGGATCAGATGAACTTACGCAGGGTTACATATATTT
TCACAAGGCTCCTTCTCCTGAAAAAGCCGAGGAGGAGAGTGAGAGGCTTCTGAGGGAACT
CTATTTGTTTGATGTTCTCCGCGCAGATCGAACTACTGCTGCCCATGGTCTTGAACTGAG
AGTCCCATTTCTAGATCATCGATTTTCTTCCTATTACTTGTCTCTGCCACCAGAAATGAG
AATTCCAAAGAATGGGATAGAAAAACATCTCCTGAGAGAGACGTTTGAGGATTCCAATCT
GATACCCAAAGAGATTCTCTGGCGACCAAAAGAAGCCTTCAGTGATGGAATAACTTCAGT
TAAGAATTCCTGGTTTAAGATTTTACAGGAATACGTTGAACATCAGGTTGATGATGCAAT
GATGGCAAATGCAGCCCAGAAATTTCCCTTCAATACTCCTAAAACCAAAGAAGGATATTA
CTACCGTCCAAGTCTTTGAACGCCATTACCCAGGCCGGGCTGACTGGCTGANCCATTACT
GGATGCCCAAGTGGATCAATGCCACTGGACCTTCTGCCCGCACGCTGGACCACTACAAGT
CAGCCTGTCAAAGCTTAAGTGGGCTTTTTGCTGGTAATGNNGAAAGCCAAATATTTCCTC
CTGGTTGGGATGGGGGGACTGGGGGGGCANATAAGGGGNAACAATGGNNAGTCAACCTCC
AGGCTAACCTTGGGGNGNGAAAAAAAATNAAAGTCCCTAATCTAAAAAAAAAAAAAAAAA
ANCATTGGGGGCCCCAGCTTNTCCCTTNAAGGAGGGTAATTTACCTGGNCCTNGCCCCNT
TTCCACGCCNGGNNGGGAAACCTGGGNNTACCANTTTCCCCTTGGACCNC
CATHEPSIN C
GCCGGGTTTCCCTCACGACGTTGTAANACGACGGCCAGTGNAATTGTAATACGACTCACT
ATAGGGCGAATTGGGTACCGGGCCCCCCCTCGAGTTTTTTTTTTTTTTTTTTTTATTTTT
AAAACTTTATTTTAAAAATATGAGCATCTATTTTAAAAGTTTTGATAATTATTGCCATTA
TTTTCTTGTGATTGGTACAATTTAAAAATAAGTCTATGTTTTCACATTGATTTTAAAAAA
TATAGCATGTTTGAATTACAAATGATTAAGCAAACTCTATTACTTCATAGCTGACCATCT
TCCAGAAAATTCCCACTTAATTGAATACTTAGAAAAAAATGGCCAGTGGCCGATTGAAAG
GTATATTAAAATTAAGGGCAGTTTTAATTCTGAAGACAAATATCTTCATGGAAATCTATT
TGTAAGCTTCTGANATTGCTGCTGAAAGTCTACAGTCTGTGAATATACCAATTCCCCTTT
ACAACTGATGCAGATCATTATGAAATACTGGAAGGCATACCCTACAATTTAGGAATTGGT
GTGGCTGCCACTGCTATGCTCTCAATTGCACACTCATCAGTTCCTCTGCGGATCCGGAAG
TAGCCATTCTCACCCCAGCCGGTGCCCCAGCTGTTTTTAACAATCCAGTAATCCATCCCA
GANGCTGANTCAGTGCCNTAGCCCACAAGCANAACAGCATGATTAGTCAGCTCCAAGGGG
TTGAAAGGGTCTCTAAACCNGTGNGGNGGTANATCCCCCTTTTGTNGNGGGAGNAAGTCN
TCCTATACTTCCAAAAGCCACNGCCCTNGGGCCCATGAAGGGACCCAACCTCCAGGCTTC
CNTCAAGGNCTTCATTGGCNGCCCCCCCCAAAAAACCCNCCTNCNATAGGGGGNAACC
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Appendix C
Genes with common changes in expression over all 
experiments
Appendix C
Gene # Gene id
Genes with significant 2 fold or more increased expression in SW480M7 and
SW480M9 cells in comparison with SW480 cells
AA437210 
AA437245 
AA479344 
AA479512 
AA479950 
AA609630 
AA620619 
AA620642 
AA625858 
AA626716 
AA634483 
AA669218
AA669367 | AI732124 
AA676548 
AA694497 
AA706094
AA773190 | AI791127
AA777779
AA778577
AA778611
AA778617
AA778851
AA912886
AA917956
AA921818
Al 125237
Al 125753
Al 139861
Al 140549
Al 140566
Al 140695
Al 142095
Al 188006
AH 98232
Al 206318
AI250799
AI253652 | AI793206
AI276487
Al288845
H45289
H77461
N/A-2-1-15-4
N/A-3-1-14-6
N22685
N63479
ESTs
Homo sapiens, clone IMAGE:5744200, mRNA 
gap junction protein, beta 5 (connexin 31.1)
ESTs, Weakly similar to B36298 proline-rich protein PRB3S (cys) - human (fragment) [H.sapiens] 
ATPase, Class II, type 9B 
Data not found
ESTs
hypothetical protein LOC51319 
ESTs,
Data not found
Homo sapiens, clone IMAGE:5266541, mRNA 
HBS1-like (S. cerevisiae)
Data not found
ESTs, Moderately similar to hypothetical protein FLJ20234 [Homo sapiens] [H.sapiens]
Data not found
ESTs, Weakly similar to 2109260A B cell growth factor [Homo sapiens] [H.sapiens]
Data not found 
ESTs
EST
KIAA1086 protein 
ESTs
Human clone 137308 mRNA, partial cds.
ESTs
Homo sapiens, clone IMAGE:3878708, mRNA
ESTs
ESTs
Homo sapiens, clone IMAGE:4822830, mRNA
Data not found
ESTs
ESTs
Data not found
ESTs
ESTs
C-terminal PDZ domain ligand of neuronal nitric oxide synthase 
gamma-aminobutyric acid (GABA) A receptor, beta 3 
defensin, alpha 4, corticostatin 
Data not found 
cytokeratin type II
chemokine (C-C motif) receptor-like 2 
ESTs
lymphocyte adaptor protein 
Data not found 
Data not found 
plexin C1 
Data not found
Genes with significant 2 fold or more decreased expression in SW480M7 and 
SW480M9 cells in comparison with SW480 cells
Gene # Gene id
AA894927 asparagine synthetase
AA995233 ESTs, Highly similar to ASSY_HUMAN Argininosuccinate synthase (Citrulline-aspartate ligase) [H.sapiens] 
AI015679 phosphoserine aminotransferase
1
Appendix C
Gene # Gene id 
AA425128 ESTs
Genes with significant 2 fold or more decreased expression in SW480M9 and 
SW620 cells in comparison with SW480 cells
Gene # Gene id
AI080633 pyruvate dehydrogenase phosphatase
Genes with significant 2 fold or more increased expression in SW480M7 and
SW620 cells in comparison with SW480 cells
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Increased Invasion and Expression of MMP-9 in Human 
Colorectal Cell Lines by a CD44-dependent Mechanism
DAVID MURRAY1, MARY MORRIN2 and SUSAN MCDONNELL1
S c h o o l  o f  Biotechnology, N ational Institute fo r  Cellular Biotechnology, D ublin City University, D ublin 9; 
and 2L im erick Institute o f  Technology, L im erick, Ireland
bstract. Background: In order to investigate the interactions 
tween MMPs and CD44 we stably transfected a non-invasive 
Ion cell line, SW 480 with the cDNA fo r  M M P-9 and  
vestigated the effect on CD44 expression and in vitro 
vasion and migration. Materials and Methods: In vitro 
vasion and migration assays were carried out using Biocoat 
itrigel invasion chambers. M M P and CD44 expression was 
termined using zymography, Western blot analysis and RT- 
ZR. Results: Transfection o f  the parental SW 480 cells with 
e cDNA fo r  M MP-9 (SW480M9) caused increased invasion 
\d migration. M M P-9 expression increased when the 
V480M9 cells were grown on H A and collagen and cultured 
the presence o f  a CD44-activating antibody. Treatment o f  
s cells with HA and a CD44-activating antibody also resulted 
increased invasion, migration and attachment. Conclusion: 
tese results demonstrated that CD44 and M M P interactions 
e important in controlling tumour cell invasion and  
igration.
le matrix metalloproteinases (MMPs) are a family of highly 
inserved zinc-dependent endopeptidases which collectively 
e capable of degrading components of the extracellular 
atrix (ECM). The MMP family currently contains 23 
embers that can be divided into at least 5 classes based on 
bstrate specificity: gelatinases, collagenases, stromelysins, 
embrane-type MMPs and others (1). They have been shown 
rough numerous studies to be key role players in both 
jrmal and disease processes, but it is their role in tumour 
vasion and metastasis which has been most extensively 
udied (2). Metastasis is the spread of tumour cells from a 
•imary tumour to distant sites in the body and is the most 
thal aspect of cancer.
jrrespondence to: Susan McDonnell, PhD, School of Biotechnology, 
ublin City University, Glasnevin, Dublin 9, Ireland. Tel: 353-1- 
105244, e-mail: susan.mcdonnell@dcu.ie
zy Words: MMP-9, CD44, invasion, migration, colon tumour cell 
les.
MMP activity has been implicated at almost every stage 
of the metastatic cascade from local invasion at the primary 
tumour site to growth and development of a tumour at a 
secondary site (2). The substrate specificities of the two 
gelatinases, MMP-2 and MMP-9, differ from other MMPs 
in that they can degrade type IV collagen which is present in 
the basement membrane (1). They have been shown in 
several studies to function as independent predictors of 
disease outcome and recurrence (3).
CD44, the major cell surface receptor for hyaluronic acid 
(HA), is a multifunctional transmembrane adhesion 
molecule that also plays a key role in cell signalling (4). 
CD44 mediates cell-cell and cell-matrix interactions and is 
involved in adhesion, migration and invasion. It has been 
estimated that 45 CD44 variants exist as a result of 
alternative mRNA splicing (5). Abnormal CD44 variant 
expression has been associated with tumour progression and 
over-expression of CD44v6 has been observed more often 
in advanced colon cancers (Dukes’ stage C/D) compared 
with Dukes’ A/B, and it can therefore be used as a 
prognostic marker (6).
Both MMPs and CD44 are critical to the invasive process 
and several studies have recently begun to define how these 
molecules interact with each other. Stimulation of CD44 has 
been shown to increase MMP-2 expression in human 
melanoma cells (7) and in lung carcinoma cells (8). MMP-9 
has been shown to associate with CD44 on the surface of 
mouse mammary carcinoma and human melanoma cells (9). 
CD44v3 can anchor MMP-7 on the cell surface and target 
its activity (10). A recent paper has also shown that MT1- 
MMP can cleave CD44 and promote cell migration in a 
pancreatic tumour cell line (11).
Appreciating the importance of both attachment to and 
degradation of the ECM in tumour cell invasion, it is no 
longer appropriate to consider CD44 and MMPs as acting 
in isolation. In this study the interaction between CD44 and 
MMP-9 in regulating invasion and migration in colorectal 
tumour cell lines was examined. The non-metastatic SW480 
cell line was stably transfected with the cDNA for MMP-9. 
The effect of MMP-9 on cell adhesion and migration was
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assessed and cells were grown on various E C M  components 
to study the effect on MMP activity. Activation of CD44 
through ligand binding and antibody treatment caused 
increased MMP expression and invasion. Inhibition of 
CD44 activity by antibody treatment resulted in decreased 
invasion. These results demonstrated the importance of 
MMP and CD44 interactions in regulating colon tumour 
cell invasion.
Materials and Methods
C ell cu ltu re  a n d  tra n sfe c tio n  o f  S W 4 8 0  cells. T h e  cell lin e s  u s e d  in  
th is  s tu d y  w e re  S W 4 8 0 , ( A T C C #  C C L -2 2 8 ) e s ta b l i s h e d  f r o m  a 
p r im a ry  h u m a n  c o lo n  a d e n o c a rc in o m a ,  S W 6 2 0  ( A T C C #  C C L - 
2 2 7 ), e s ta b l i s h e d  f r o m  a  ly m p h  n o d e  m e ta s ta s is  f ro m  th e  s a m e  
p a t ie n t  a s  th e  S W 4 8 0  a n d  B H K 9 2  (B H K  cells  t r a n s fe c te d  w ith  th e  
c D N A  fo r  M M P -9 , a g ift f ro m  D y la n  E d w a rd s , U n iv e rs ity  o f  E a s t  
A n g lia ) . A ll c e ll lin e s  w e ie  n ia in la in e d  in  D u lb e c c o ’s m o d if ic a tio n  
o f  E a g le s ’ m e d iu m  (D M E M )  s u p p le m e n te d  w ith  5 %  f o e ta l  c a lf  
s e ru m  (F C S )  in a  h u m id  5 %  C 0 2  a tm o s p h e r e  a t  37  °C . T h e  S W 4 8 0  
ce lls  w e re  t r a n s fe c te d  w ith  lOjxg p C M V 9 2  (h u m a n  M M P -9  c D N A  
s u b -c lo n e d  in to  p C M V  e x p re ss io n  v e c to r )  as  p re v io u s ly  d e sc r ib e d
(1 2 ) a n d  2  jig p S V 2 n e o  u s in g  L ip o fe c ta m in e  ( In v i t ro g e n  P a is le y , 
U K ) fo llo w in g  th e  m a n u f a c tu r e r ’s in s tru c tio n s .  C e lls  w e re  s e le c te d  
in  600  |Ag/ml G e n e t ic in  (G -4 1 8 )  f o r  4 w e ek s . In d iv id u a l  c o lo n ie s  
w e re  s e le c te d  u s in g  c lo n in g  c y lin d e rs  (S ig m a , D u b lin ,  I r e la n d ) .
Z ym ography . C o n d itio n e d  m e d ia  (C M ) w as c o lle c te d  by in c u b a tin g  
8 0 %  c o n f lu e n t  c u l tu re s  fo r  7 2  h  in  s e r u m - f r e e  m e d ia .  C M  w as 
c o n c e n tr a te d  u s in g  M icrocon™  c e n tr ifu g a l f i l te r  d ev ices  (A m ic o n , 
C o rk , I r e la n d )  a n d  p r o te in  c o n c e n t r a t io n  d e te r m in e d  u s in g  th e  
b ic in c h o n in ic  ac id  (B C A ) assay  (P ie rc e , T a tte n h a ll ,  U K ). G e la t in a s e  
activ ity  w as a sse sse d  in  30  |xg to ta l  p ro te in  as  p re v io u s ly  d e sc r ib e d
(1 3 ). T o  in v e s t ig a te  th e  e f f e c t  o f  C D 4 4  s t im u la t io n  o n  M M P  
a c tiv ity , c e lls  w e re  in c u b a te d  w ith  50  (ig/m l C D 4 4  a c t iv a tin g  
a n tib o d y  F m .4 4 . 2  (B io d e s ig n , S aco , M E , U S A ) o r  w ith  m o u s e  Ig G  
(S ig m a) as c o n tro l  in  s e ru m -f re e  m e d ia . C ells  w e re  a lso  t r e a te d  w ith  
0 .2 5 m g /m l H A , O .O lm g/m l C o lla g e n  ty p e  IV  o r  0 .3  |xg/m l anti-(51- 
in te g r in  s tim u la tin g  a n tib o d y  (S ig m a ) in  s e ru m -f re e  m e d ia  fo r  72 h .
W estern  b lo t ana lysis. W e s te r n  b lo t  a n a ly s is  o f  c o n c e n t r a te d  C M  
(a s  p r e p a r e d  f o r  z y m o g ra p h y )  w a s  c a r r i e d  o u t  f o r  d e t e c t io n  o l  
M M P -2  a n d  M M P -9 . W e s te r n  b lo t  a n a ly s is  f o r  d e te c t io n  
o f  C D 4 4  w a s  c a r r ie d  o u t  o n  t o t a l  c e l l  ly s a te s  p r e p a r e d  as 
p re v io u s ly  d e s c r ib e d  (1 4 ) . E q u a l  a m o u n ts  o f  p r o te in  (5 0 |rg ) w e re  
s e p a r a t e d  o n  1 0 %  s o d iu m  d o d e c y l  s u lp h a t e - p o ly a c r y la m id e  ge l 
e le c tr o p h o re s is  (S D S -P A G E )  g e ls , t r a n s f e r r e d  a n d  b lo c k e d  in  5 %  
d r ie d  m ilk  in  T B S T  (0 .1 5 M  N a C l, 0 .0 1 M  T ris , 0 .0 5 %  (v /v ) T w e e n -  
2 0 ). P r im a ry  a n t ib o d ie s  w e re  d i lu te d ;  D 2 .1  m o u s e  p a n  s p e c if ic  
a n t i -C D 4 4  (a  g if t  f r o m  A id e e n  L o n g , R o y a l C o lle g e  o f  S u rg e o n s  
in  I r e la n d )  1 /1 0 0 0 , M A C 9 6  m o u s e  a n t i -M M P -9  (a  g if t  f ro m  
A n d re w  D o c h e r ty ,  C e l l te c h )  1 /5 0 0 , G L 8  m o u s e  a n t i -M M P -2  (a  
g if t  f ro m  A n d re w  D o c h e r ty ,  C e l l te c h , D u b lin , I r e la n d )  1 /2000  a n d  
m o u s e  a n t i - a c t in  (M e rc k  B io s c ie n c e s ,  N o tt in g h a m , U K )  1 /1 0 ,0 0 0  
in  t h e  s a m e  b lo c k in g  s o lu t io n  a n d  in c u b a te d  o v e r n ig h t  a t  4 ° C . 
T h e  b lo ts  w e re  w a s h e d ,  in c u b a te d  w ith  a n t i - m o u s e - h o r s e r a d i s h  
p e r o x id a s e  ( H R P )  ( A m e r s h a m ,  L i t t l e  C h a l f o n t ,  U K )  1 /5 0 0 0  in  
T B S T  f o r  2  h  a t  ro o m  t e m p e r a tu r e  a n d  th e n  d e v e lo p e d  u s in g  th e  
e n h a n c e d  c h e m o lu m in e s e n c e  (E C L )  sy s te m  (P ie rc e ) .
R N A  iso la tio n  a n d  reverse tr a n sc r ip tio n  p o ly m e r a s e  c h a in  ¡ea c iu  
(R T -P C R ).  T o ta l  R N A  w as  i s o la te d  f r o m  e q u a l c e ll n u m b e r s  u s i 
T R I  R E A G E N T  (S ig m a) fo llo w in g  th e  m a n u f a c tu r e r ’s in s tru c tio i 
R e v e r s e  t r a n s c r ip t io n  w as  a s  p re v io u s ly  d e s c r ib e d  a n d  5(il o f  tl 
r e s u l ta n t  c D N A  w as u s e d  as te m p la te  f o r  P C R  (13 ). T h e  s e q u e n c  
fo r  p r im e rs  w ith  a n n e a lin g  t e m p e r a tu r e s  in d ic a te d  in  b ra c k e ts  w e  
as fo llo w s: M M P - 9 -5 ’ A T G  A G T  T C G  G C C  A C G  C G C  T G  
G C T  T  3 ’: 3 ’ T  G C C  G G T  G A T  G A C  A C G  G A A  A C T  C A G  
(54  °C ); fi-A ct in -5 ’ T C A  G G A  G G A  G C A  A T G  A T C  T T G  A  : 
3 ’ T C  G A A  G A G  G A A  T T A  C A G  T G C  G T G  C T A  A A G  
(55 °C ). T h e  n u m b e r  o f  P C R  cy cles  u s e d  w as  3 0  a n d  th e  ex p ec ti 
p ro d u c t  size  a f te r  p r im e r  a m p lif ic a tio n  w as as fo llow s: M M P -9 : 3: 
b a se  p a ir s  (b p )  a n d  fi-ac tin : 6 8 2 b p .
In  v itro  in va sio n  a n d  m ig ra tio n  assays. B io co at™  m a tr ig e l  in v a sit 
c h a m b e r s  (B e c to n  D ic k in s o n  L a b w a re ,  U K ) w e re  u s e d  to  te s t  tl 
in  v itro  in v a s iv e  a c tiv ity  o f  t h e  c e l l  l in e s .  5 x 1 0 s ce lls  w e re  s e e d t  
in to  t h e  u p p e r  c h a m b e r  a n d  in c u b a te d  f o r  2 4  h  a t  37  
M e m b ra n e s  w e re  fix ed  a n d  s ta in e d  as p re v io u s ly  d e sc r ib e d  (1 3 ) ar 
in v asiv e  cells  c o u n te d  in  five  1 0 X  m a g n if ic a tio n  fie ld s . R e s u lts  w e 
e x p re s s e d  a s  a v e ra g e  ce ll c o u n t  p e r  f ie ld . T o  in v e s t ig a te  th e  e ffe  
o f  H A  o n  c e ll in v a s io n , c e lls  w e r e  s e e d e d  in  s e r u m - f r e e  m e d  
c o n ta in in g  0 .2 5 m g /m l H A  in  b o th  c h a m b e r s .  S W 4 8 0 M 9  c e lls  w e  
a llo w e d  to  in v a d e  in  t h e  p r e s e n c e  o f  5 0  u g /m l, C D 4 4 -a c tiv a ti i  
a n tib o d y  F | n . 4 4 _2 (B io d e s ig n ), C D 4 4 -b lo c k in g  a n tib o d y  IM 7 .8 .1  (gi 
f r o m  A id e e n  L o n g , R o y a l  C o lle g e  o f  S u r g e o n s ,  in  I r e la n d ) ,  c 
m o u s e  Ig G  (S ig m a ) as a  c o n tro l .  M ig ra t io n  assay s  w e re  c a r r ie d  o 
u n d e r  th e  s a m e  c o n d it io n s  e x c e p t in  t h e  a b s e n c e  o f  m a tr ig e l .  A  
e x p e r im e n ts  w e re  d o n e  in  d u p l ic a te  a n d  w e re  r e p e a t e d  th r e e  tim e
A d h e s io n  assays. T o  in v e s t ig a te  th e  a d h e s io n  o f  c e lls  to  v a r io i  
E C M  c o m p o n e n ts ,  a  f l a t - b o t to m e d  9 6 -w e ll p la te  w a s  co a te  
o v e rn ig h t  a t  4 ° C  w ith  e i th e r  Im g /m i H A  o r  50  |ig /m l f ib r o n e c t  
(F N ) . T h e  p la te  w as  w a s h e d  tw ic e  w ith  p h o s p h a te - b u f f e r e d  sa lii 
(P B S ), b lo c k e d  w ith  lm g /m l b o v in e  s e r u m  a lb u m in  (B S A ) fo r  2 
a t  4 ° C  a n d  th e n  1x10s ce lls  w e r e  a d d e d  a n d  a llo w e d  to  a d h e r e  f< 
90 m in  a t  4 °C . R e s id u a l m e d ia  w as  a s p ir a te d  a n d  th e  a d h e r e n t  cel 
w e re  in c u b a te d  in  m e d ia  c o n ta in in g  [3 - (4 ,5 -d im e th y lth ia z o l-2 -y l 
5 - ( 3 - c a r b o x y m e th o x y p h e n y l ) - 2 - ( 4 - s u l f o p h e n y l ) - 2 H - te t r a z o l iu n  
(M T S  r e a g e n t )  ( P ro m e g a ,  S o u th a m p to n ,  U K ) .  A b s o r b a n c e  w; 
re a d  a t  4 9 0 n m  a f te r  in c u b a t io n  a t  37  ° C  f o r  3 h . T h e  a b s o r b a m  
v a lu e  o b ta in e d  by  s e e d in g  u n t r e a t e d  w e lls  (i.e. m e d ia  w a s  n< 
a s p i r a t e d )  r e p r e s e n te d  1 0 0 %  a d h e s io n  a n d  a ll  o th e r  v a lu e s  w ei 
d iv id e d  by th is  to  c a lc u la te  p e rc e n ta g e  a d h e s io n . E x p e r im e n ts  w ei 
p e r f o r m e d  in  t r i p l i c a te  o n  th r e e  s e p a r a t e  o c c a s io n s  a n d  T - te s  
p e r f o r m e d  to  e n s u r e  s ig n if ic a n c e .
Results
Over-expression o f  M M P-9 in the SW 480 cells an 
characterisation o f  colon cell lines. Following transfection c 
the SW480 cells with the cDNA for MMP-9, a total of 2 
clones were selected and characterized. Clone 11 (referre 
to as SW480M9) was chosen for further analysis as 
secreted the highest levels of MMP-9 protein as shown b 
gelatin zymography (Figure 1A). SW480M9 showed 
marked increase in MMP-9 levels in comparison to th 
parental SW480 and its lymph node metastatic derivativ 
SW620. The identity of MMP-9 was confirmed by Wester
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F ig u re  2. T he e ffec t o f  C D 44 s tim u la tio n  on  M M P -9  expression. (A ) 
M M P -9  expression in SW 4S0  a nd  SW 480M 9 cells grown in the presence o f  
type I V  collagen, H A  a n d  fi ¡-integrin-activating antibody. (B) M M P -9  an d  
M M P -2  expression  in the  SW 4 8 0 M 9  cells treated w ith C D 44-activa ting  
an tibody  over 48  h by zym ography an d  W estern b lo t using  B H K 9 2  as a 
p o sitive  control. (C ) C om parison  o f  cell adhesion  to  plastic, TIA a n d  FN. 
T he asterisk deno tes t h a t p <0.005.
.gure  1. C haracterisation o f  co lon cell lines. (A ) M M P -9  expression in 
W480, S W 6 2 0  a n d  S W 4 8 0 M 9  cells w as a na lysed  by; (i) gela tin  
■mography, (ii) W estern blot, (iii) R T -P C R  w ith (iv) R T -P C R  fo r  fi actin  
: a control. (B ) C om parison  o f  in vitro invasion  o f  the SW 480, SW 620  
id  SW 480M 9 cells. (C ) C om parison  o f  in vitro m igra tion  o f  ce ll lines, 
he asterisk deno tes that p  <0.005.
lot analysis (Figure la) using an MMP-9 specific antibody. 
4MP-9 was not detected in either the SW480 or SW620 
ells by Western blot analysis. RT-PCR data (Figure 1A) 
onfirmed over-expression of MMP-9 in the SW480M9 cells 
t the mRNA level when compared to the SW480 and the 
1W620, which only showed faint bands. |3-actin was used as 
n equal loading control for RT-PCR.
Since ECM degradation is key to tumour cell invasion, 
the in vitro invasiveness of these cell lines through matrigel- 
coated membranes was compared. The SW480 cells showed 
little invasion (Figure IB) in comparison to the SW620 and 
SW480M9 cells, which were significantly (p< 0.005) more 
invasive. The SW620 and SW480M9 were respectively twice 
and three times more invasive. The migratory capacities of 
the cells were determined using the same procedure as the 
in vitro invasion assays in the absence of matrigel. Over­
expression of MMP-9 in the SW480M9 cells increased their 
migratory capacity in comparison to the parental SW480 
cells (Figure 1C). However, the parental SW480 cells were 
significantly (p<0.005) more migratory than the SW620, 
which were established from a lymph node metastasis from 
the same patient.
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F ig u re  3. CD 44 expression in  co lon  cell lines. C D 44 expression profiles o f  
the SW 480, SW 620 and  SW 480M 9 cell lines by Western blo t analysis using  
fi-actin  as an equal loading  control.
Effect o f E C M  components and CD44 activation on MMP-9 
expression and cell adhesion. To investigate the effect of 
ECM components and integrin signalling on MMP-9 
expression, cells were cultured in the presence of HA, type 
IV collagen and a pr integrin-activating antibody. After 
treatment, neither the SW480 or SW620 cells, which did not 
originally secrete measurable levels of MMP-9, showed any 
increase in MMP-9 expression levels (Figure 2A and data 
not shown). The SW480M9 cells showed no increase in 
MMP-9 activity in the presence of the Pj-integrin- 
stimulating antibody and a slight increase when grown on 
type IV collagen. Growth of the SW480M9 cells on HA 
greatly increased the levels of MMP-9. Since CD44 is the 
major cell surface receptor for HA, the SW480M9 were 
treated with an anti-CD44 monoclonal antibody (F10_4 4_2). 
Instead of blocking its activity, F10_4 4_2 activates CD44, 
mimicking its ligation of HA in the ECM and subsequently 
activating its associated intracellular signalling pathways. 
CM from antibody-treated cells was collected at timed 
intervals and analysed for MMP-9 expression. Within 6 h of 
treatment with the CD44-activating antibody, cells showed a 
slight increase in MMP-9 activity (Figure 2B) when 
compared with cells treated with a control mouse IgG. This 
difference in activity was more obvious after 24 and 48 h. 
Interestingly, activation of pro-MMP-9 to its active 88 kDa 
form occurred after 24 and 48 h. MMP-2 activity was also 
detected after 24 and 48 h of CD44 activation. These 
observations were confirmed by Western blot analysis 
(Figure 2B) with specific MMP-2 and MMP-9 antibodies.
To further investigate the behaviour of cells in the 
presence of ECM components, adhesion assays were carried 
out in the presence of HA and FN. Adhesion is a key event 
in the metastatic process where cells must first adhere to the 
ECM prior to its degradation. Increased cell-cell signalling 
and contact is also mediated by increased expression of cell
lfm
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F ig u re  4. The e ffect o f  en h a n ced  expression o f  M M P -9  via C D 44 on  i 
vitro invasion. (A ) In  vitro invasion o f  the SW 480, S W 620  a n d  SW 480M  
cells in the presence o f  H A . (B ) T he in  vitro invasion  o f  the  SW 480M  
cells in the  presence o f  H A , C D 44-activa ting  an tibody  (F iq_44_2), m o w  
IgG  (as a control) an d  C D 44-b locking  an tibody  (IM 7.8 .1 ). The astern  
denotes th a tp < 0 .0 0 5 .
adhesion molecules. The SW480M9 cells, which were th 
most responsive to HA treatment, also showed the mos 
adherence to FN and HA (Figure 2C). All percentag 
adhesion values were significant (/?<().005).
Expression and up-regulation o f  CD44 in M M P-9 transfectei 
cells. Due to the increased adhesion of the SW480M9 cell 
on HA and the enhancing effect of HA and CD4< 
stimulation on MMP-9 activity, the expression of CD4< 
protein was examined. All cell lines studied expressed th< 
80kDa CD44 (Figure 3), often referred to as CD44s o 
standard CD44. The SW480M9 cells expressed the highes 
levels of CD44s compared to the SW480 and SW620 cells 
Interestingly, the metastatic SW620 and the more invasivf 
SW480M9 showed expression of a 120kDa variant of CD4^ 
with SW480M9 showing highest levels of expression, Thest 
differences in CD44 expression may help explain the 
increased adhesion of SW480M9 to HA as well as the effeci 
HA had on MMP-9 activity in these cells.
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Effect o f  CD44 activation on in vitro invasion. To show that 
CD44-mediated up-regulation of MMP-9 expression had an 
effect on cell invasion, the in vitro invasion of the cells in the 
presence of HA was assayed. The presence of HA increased 
invasion in all cell lines tested (Figure 4A). The most 
dramatic increase was seen with the SW480M9 cells where 
twice as many cells (p< 0.005) invaded when treated with 
HA. Therefore, the effect of a CD44-activating antibody on 
invasion was studied. CD44 activation increased the in vitro 
invasion of SW480M9 cells two-fold (p<0.005) (Figure 4B) 
when compared with the invasion of the same cells treated 
with control mouse IgG. A CD44-blocking antibody 
(IM7.8.1) was used to further confirm that the increased 
invasion was CD44-dependent. Blocking of CD44 with this 
antibody resulted in a significant reduction (p < 0.005) in 
invasion (Figure 4B).
D iscu ssion
In this study the interactions between CD44 and MMP-9 in 
regulating invasion and migration in human colorectal 
cancer cell lines was investigated. The non-metastatic 
SW480 cell line, established from a primary human colon 
adenocarcinoma, was stably transfected with the cDNA for 
MMP-9. Over-expression of MMP-9 in a rat transformed 
embryo cell line has previously been shown to increase the 
invasion and migration of the cells (15). This paper was the 
first report of MMP-9 over-expression in a human colon cell 
line. The parental SW480 cells do not express MMP-9 and 
transfection of the cDNA for MMP-9 into these cells 
increased their invasion and migration. Interestingly, the 
SW620 cells, which were established from a lymph node 
metastasis from the same patient as the SW480, also did not 
express MMP-9. The MMP-9-transfected cells also showed 
increased migratory capacity. Surprisingly, the parental 
SW480 cells were more migratory than the SW620. A 
similar result was also obtained by Kubens and Zanker 
using a three-dimensional collagen matrix and time-lapse 
video recording assay (16).
Within the past few years, many researchers have 
demonstrated the importance of MMP interactions with cell 
adhesion molecules in regulating tumour cell invasion and 
metastasis. Several investigators have shown the importance 
of integrins in regulating MMP expression e.g. the aV(36 
integrin promotes invasion of squamous carcinoma cells 
through up-regulation of MMP-9 (17). Stimulation of CD44 
has been shown to increase MMP-2 expression in human 
melanoma cells (7) and in lung carcinoma cells (8). In this 
study we showed that culturing colon cells on ECM 
components increased MMP-9 expression. HA, the major 
receptor for CD44, caused the greatest increase. In addition, 
direct stimulation of CD44 by treating with an activating 
antibody (F10_4 4_2 ) caused an increase in MMP-2 and MMP-
9 expression and also caused activation of MMP-9 to its 
active form. This is the first report to show up-regulation of 
MMP-9 expression following CD44 stimulation in colon cells.
We also looked at adhesion of the cells on various 
matrices including, plastic, FN and HA. The MMP-9- 
transfected cells attached better to FN and HA than any of 
the other cell lines. Examination of the levels of CD44 
protein expressed in the cell lines showed that all three cell 
lines expressed the standard form of CD44. An additional 
higher molecular weight band was seen in the metastatic 
SW620 and the MMP-9-transfected cell line. This band had 
a molecular weight of ~ 120kDa and could be CD44v6, 
which has been previously been shown to be involved in 
colon metastasis (6). Exon-specific PCR would be needed 
to confirm the identity of this band.
Since we had shown that growth of the SW480M9 cells 
on HA and direct stimulation of CD44 caused an increase in 
MMP activity, we then looked at whether this increase in 
MMP-9 activity had a functional effect on cell invasion and 
migration. Stimulation of CD44 by treatment with HA and 
a CD44-activating antibody caused an increase in the 
invasion of the SW480M9 cells, which could be inhibited by 
treatment with a CD44-blocking antibody.
These results suggest that CD44 activation can directly 
increase the levels of MMP-9 and cause an increase in cell 
invasion in colon cell lines. Interestingly, Yu and 
Stamenkovic (9) have shown that MMP-9 can associate with 
CD44 on the surface of mouse mammary carcinoma and 
human melanoma cells. This association may cause 
activation of signal transduction molecules, e.g. HA-CD44 
binding activates the ras-MEKl and the PI3 kinase-Akt 
signalling pathways in a human lung carcinoma cell line (8). 
Future experiments will determine the signalling 
mechanisms involved in the up-regulation of MMP-9 
expression in these cells. In addition, using MMP-9 
promoter constructs, we will attempt to elucidate the 
transcriptional mechanisms involved in regulating MMP-9 
gene expression in these cells.
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